K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. (2002). Am J Kidney Dis, 39(2 Suppl 1), S1-266. 
Vitamin B6. (2003). Disease-a-Month, 49(11), 666-672. doi:10.1016/j.disamonth.2003.09.008
Summaries for patients. Associations of newer cardiac risk factors with chronic kidney disease. (2004). Annals of internal medicine, 140(1), I26. 
American Journal of Kidney Diseases: Foreword. (2005). American Journal of Kidney Diseases, 45(SUPPL. 3), 7-153. doi:10.1053/j.ajkd.2005.01.016
Homocysteine lowering does not improve survival in advanced CKD or ESRD. (2007). Nature Clinical Practice Nephrology, 3(12), 642-643. doi:10.1038/ncpneph0630
Reducing homocysteine not beneficial in advanced chronic kidney disease. (2008). Dialysis and Transplantation, 37(11), 462. doi:10.1002/dat.20449
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. (2020). Lancet, 395(10225), 709-733. doi:10.1016/s0140-6736(20)30045-3
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. (2020). Kidney Int, 98(4s), S1-s115. doi:10.1016/j.kint.2020.06.019
CONTENTS. (2021). Biochemical and Cellular Archives, 21(2), 1-2. 
A., R., C., D., & A., C. (2004). Agency for Healthcare Research and Quality; Rockville, MD. Evidence Reports/Technology Assessments. 
Abad, S., Vega, A., Quiroga, B., Arroyo, D., Panizo, N., Reque, J. E., & López-Gómez, J. M. (2016). Protein-bound toxins: added value in their removal with high convective volumes. Nefrologia, 36(6), 637-642. doi:10.1016/j.nefro.2016.05.013
Abbas, A. C., Alwaeli, A. Z., & Abass, E. C. (2021). Effect of serotonin concentration and some variables in the sera 6 hours before and after dialysis on chronic kidney patients with different ages in iraqi population. Indian Journal of Forensic Medicine and Toxicology, 15(1), 727-730. doi:10.37506/ijfmt.v15i1.13503
Abdel-Raheem, M. M., Hebert, B., Potti, A., Koka, V. K., & Danielson, B. D. (2002). Hyperhomocysteinemia and the risk of thromboembolic phenomenon in patients with chronic renal failure. Thrombosis Research, 105(4), 299-302. doi:10.1016/S0049-3848(02)00029-4
Abdel-Salam, M., Ibrahim, S., Pessar, S. A., & Al-Morsy, E. (2017). The relationship between serum homocysteine and highly sensitive C- reactive protein levels in children on regular hemodialysis. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 28(3), 483-490. doi:10.4103/1319-2442.206442
Abedi, S. A., Tarzamni, M. K., Nakhjavani, M. R., & Bohlooli, A. (2009). Effect of renal transplantation on coronary artery calcification in hemodialysis patients. Transplant Proc, 41(7), 2829-2831. doi:10.1016/j.transproceed.2009.07.037
Abedi, S. A., Tarzamni, M. K., Nakhjavani, M. R. J., & Bohlooli, A. (2009). Effect of Renal Transplantation on Coronary Artery Calcification in Hemodialysis Patients. Transplantation Proceedings, 41(7), 2829-2831. doi:10.1016/j.transproceed.2009.07.037
Abell, K., Kedar, A., Henry, O., Weatherly, B., Sunesara, I., Griswold, M., & Abell, T. L. (2011). High serum vitamin B12 levels are significantly associated with worsened gastric transit times in patients with diabetic gastroparesis, but not in patients with idiopathic gastroparesis. Gastroenterology, 140(5), S862. doi:10.1016/S0016-5085(11)63579-8
Abuauba, M. O., Grenda, R., Litwin, M., Roszkowska-Blaim, M., Wawer, Z., Pietraszek, E., . . . Brylska, U. (2009). Plasma total homocysteine, plasma folate, red blood cell folate and plasma vitamin B12 levels in chronic renal failure patients and renal transplant recipients. Pediatric Transplantation, 13, 153. 
Agarwal, R. (2008). The challenge of discovering patient-level cardiovascular risk factors in chronic kidney disease. Kidney International, 73(12), 1340-1342. doi:10.1038/ki.2008.124
Ahmad, A., Corban, M. T., Toya, T., Sara, J. D., Lerman, B., Park, J. Y., . . . Lerman, A. (2020). Coronary microvascular endothelial dysfunction in patients with angina and nonobstructive coronary artery disease is associated with elevated serum homocysteine levels. Journal of the American Heart Association, 9(19). doi:10.1161/JAHA.120.017746
Ajayi, O. I., Bwayo-Weaver, S., Chirla, S., Serlemitsos-Day, M., Daniel, M., Nouraie, M., . . . Gordeuk, V. R. (2013). Cobalamin status in sickle cell disease. International Journal of Laboratory Hematology, 35(1), 31-37. doi:10.1111/j.1751-553X.2012.01457.x
Akalın, N., Köroğlu, M., Harmankaya, Ö., Akay, H., & Kumbasar, B. (2015). Comparison of insulin resistance in the various stages of chronic kidney disease and inflammation. Ren Fail, 37(2), 237-240. doi:10.3109/0886022x.2014.982479
Akalin, N., Köroʇlu, M., Harmankaya, Ö., Akay, H., & Kumbasar, B. (2015). Comparison of insulin resistance in the various stages of chronic kidney disease and inflammation. Renal Failure, 37(2), 237-240. doi:10.3109/0886022X.2014.982479
Akgul, A., Bilgic, A., Sezer, S., Arat, Z., Ozdemir, F. N., & Haberal, M. (2008). Low Total Plasma Homocysteine Level in Relation to Malnutrition, Inflammation, and Outcome in Hemodialysis Patients. Journal of Renal Nutrition, 18(4), 338-346. doi:10.1053/j.jrn.2007.11.007
Akman, B., Afsar, B., Ataç, F. B., Ibis, A., Arat, Z., Sezer, S., . . . Haberal, M. (2006). Predictors of vascular access thrombosis among patients on the cadaveric renal transplantation waiting list. Transplantation Proceedings, 38(2), 413-415. doi:10.1016/j.transproceed.2006.01.022
Al Saeed, R. R., & Baraja, M. A. (2021). Vitamin B12 deficiency in patients with type 2 diabetes mellitus using metformin and the associated factors in Saudi Arabia. Saudi Medical Journal, 42(2), 161-165. doi:10.15537/SMJ.2021.2.25693
Al-Ahmad, A., Sarnak, M. J., Salem, D. N., & Konstam, M. A. (2001). Cause and management of heart failure in patients with chronic renal disease. Seminars in Nephrology, 21(1), 3-12. doi:10.1053/snep.2001.18367
Aldámiz-Echevarría, L., Sanjurjo, P., Vallo, A., Aquino, L., Pérez-Nanclares, G., Gimeno, P., . . . Rodríguez-Soriano, J. (2002). Hyperhomocysteinemia in children with renal transplants. Pediatric Nephrology, 17(9), 718-723. doi:10.1007/s00467-002-0894-2
Alfonso, A. I. Q., Castillo, R. F., Gallegos, R. F., & Jiménez, F. J. G. (2015). Study of serum albumin and bmi as nutritional markers in hemodialysis patients. Nutricion Hospitalaria, 31(3), 1317-1322. doi:10.3305/nh.2015.31.3.8084
Al-Jobory, O. H., Mohanakrishnan, B., Tasnim, S., Tawfeeq, Y., & Chandra, R. (2022). Homocysteinemia hiding in plain sight in a diabetic vasculopath. Journal of Investigative Medicine, 70(2), 706-707. doi:10.1136/jim-2022-SRMC.522
Almaiman, L., Allemailem, K. S., El-Kady, A. M., Alrasheed, M., Almatroudi, A., Alekezem, F. S., . . . Elshabrawy, H. A. (2021). Prevalence and significance of pyuria in chronic kidney disease patients in saudi arabia. Journal of Personalized Medicine, 11(9). doi:10.3390/jpm11090831
Al-Marafi, A., & Al-Ghuweri, A. (2006). Folic acid treatment of hyperhomocysteinemia in dialysis patients. Jordan Medical Journal, 40(3), 168-171. 
Alpert, M. A. (2013). Risk factors for cardiovascular disease in patients with chronic kidney disease. Cardiology (Switzerland), 125, 339. doi:10.1159/000354059
Alpert, M. A. (2014). Risk factors for cardiovascular disease in patients with chronic kidney disease. Cardiology (Switzerland), 128, 90. doi:10.1159/000365062
Altintas, E., & Sezgin, O. (2004). S-adenosylhomocysteine hydrolase, S-adenosylmethionine, S-adenosylhomocysteine: Correlations with ribavirin induced anemia. Medical Hypotheses, 63(5), 834-837. doi:10.1016/j.mehy.2004.03.031
Alvares Delfino, V. D., de Andrade Vianna, A. C., Mocelin, A. J., Barbosa, D. S., Mise, R. A., & Matsuo, T. (2007). Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients. Nutrition, 23(3), 242-247. doi:10.1016/j.nut.2007.01.002
Ambrosi, P., Barlatier, A., Habib, G., Garcon, D., Kreitman, B., Roland, P. H., . . . Luccioni, R. (1994). Hyperhomocysteinaemia in heart transplant recipients. European Heart Journal, 15(9), 1191-1195. 
Ambrost, P., Barlatier, A., Habib, G., Garcon, D., Kreitman, B., Roland, P. H., . . . Luccioni, R. (1994). Hyperhomocysteinaemia in heart transplant recipients. European Heart Journal, 15(9), 1191-1195. doi:10.1093/oxfordjournals.eurheartj.a060652
Amin, H. K., El-Sayed, M. I., & Leheta, O. F. (2016). Homocysteine as a predictive biomarker in early diagnosis of renal failure susceptibility and prognostic diagnosis for end stages renal disease. Ren Fail, 38(8), 1267-1275. doi:10.1080/0886022x.2016.1209382
Amin, H. K., El-Sayed, M. I. K., & Leheta, O. F. (2016). Homocysteine as a predictive biomarker in early diagnosis of renal failure susceptibility and prognostic diagnosis for end stages renal disease. Renal Failure, 38(8), 1267-1275. doi:10.1080/0886022X.2016.1209382
Aminzadeh, M. A., Gollapudi, P., & Vaziri, N. D. (2011). Effect of nephrotic syndrome on homocysteine metabolism. Nephrology Dialysis Transplantation, 26(4), 1244-1247. doi:10.1093/ndt/gfq551
Anan, F., Takahashi, N., Shimomura, T., Imagawa, M., Yufu, K., Nawata, T., . . . Yoshimatsu, H. (2006). Hyperhomocysteinemia is a significant risk factor for silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis. Metabolism: Clinical and Experimental, 55(5), 656-661. doi:10.1016/j.metabol.2005.12.007
Anand, N., Chandrasekaran, S. C., & Alam, M. N. (2013). The malnutrition inflammation complex syndrome-the micsing factor in the perio-chronic kidney disease interlink. Journal of Clinical and Diagnostic Research, 7(4), 763-767. doi:10.7860/JCDR/2013/5329.2907
Andreev, E., Tzontcheva, A., Lubomirova, M., & Kiperova, B. (2003). Hyperhomocysteinemia in patients with chronic kidney diseases. Nephrology, Hemodialysis and Transplantation, 9(4), 30-33. 
Anees, M., Mumtaz, A., Ibrahim, M., Shaheen, S. M., & Asghar, A. (2010). Effect of anemia and hyperhomocysteinemia on mortality of patients on hemodialysis. Iran J Kidney Dis, 4(1), 60-65. 
Angelini, A., Cappuccilli, M. L., Magnoni, G., Croci Chiocchini, A. L., Aiello, V., Napoletano, A., . . . Cianciolo, G. (2021). The link between homocysteine, folic acid and vitamin B12 in chronic kidney disease. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 38(4). 
Anurag, A. (2022). A Study on the Levels of Folic Acid, Vitamin B12 and Plasma Homocysteine in Patients with Chronic Kidney Disease. The Journal of the Association of Physicians of India, 70(4), 11-12. 
Anwar, W., Guéant, J. L., Abdelmouttaleb, I., Adjalla, C., Gérard, P., Lemoel, G., . . . Namour, F. (2001). Hyperhomocysteinemia is related to residual glomerular filtration and folate, but not to methylenetetrahydrofolate-reductase and methionine synthase polymorphisms, in supplemented end-stage renal disease patients undergoing hemodialysis. Clin Chem Lab Med, 39(8), 747-752. doi:10.1515/cclm.2001.124
Apeland, T., Mansoor, M. A., Seljeflot, I., Brønstad, I., Gøransson, L., & Strandjord, R. E. (2002). Homocysteine, malondialdehyde and endothelial markers in dialysis patients during low-dose folinic acid therapy. J Intern Med, 252(5), 456-464. doi:10.1046/j.1365-2796.2002.01056.x
Apeland, T., Tariq, A., Jonsson, G., Slettan, A., Weeraman, C. P. K., Marti, H. P., & Mansoor, M. A. (2017). Systemic redox imbalance in ADPKD and igan. Journal of the American Society of Nephrology, 28, 992. 
Arenas Jiménez, M. D. (2008). Updates in hemodialysis. Nefrologia, 28(SUPPL. 5), 71-76. 
Arik, G., Kara, Ö., Kuyumcu, M. E., Yeş il, Y., Cemal Kizilarslanoʇlu, M., Kilic¸, M. K., . . . Arioʇul, S. (2013). Inflammation and oxidative stress in elderly patients with atrial fibrillation. European Geriatric Medicine, 4, S25. doi:10.1016/j.eurger.2013.07.082
Armada, E., Pérez Melón, C., Otero, A., Gayoso, P., Rodríguez, M., & Esteban Morcillo, J. (2001). Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients. Nefrología : publicación oficial de la Sociedad Española Nefrologia, 21(2), 167-173. 
Armenta, A., Madero, M., & Rodriguez-Iturbe, B. (2022). Functional Reserve of the Kidney. Clinical Journal of the American Society of Nephrology, 17(3), 458-466. doi:10.2215/CJN.11070821
Arnadottir, M., Gudnason, V., & Hultberg, B. (2000). Treatment with different doses of folic acid in haemodialysis patients: effects on folate distribution and aminothiol concentrations. Nephrol Dial Transplant, 15(4), 524-528. doi:10.1093/ndt/15.4.524
Arnadottir, M., & Hultberg, B. (2003). The effect of vitamin B12 on total plasma homocysteine concentration in folate-replete hemodialysis patients. Clinical Nephrology, 59(3), 186-189. doi:10.5414/CNP59186
Arnadottir, M., Hultberg, B., Wahlberg, J., Fellström, B., & Dimény, E. (1998). Serum total homocysteine concentration before and after renal transplantation. Kidney Int, 54(4), 1380-1384. doi:10.1046/j.1523-1755.1998.00112.x
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., . . . Weitz, H. H. (2011). ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American college of cardiology foundation task force on clinical expert consensus documents. Journal of the American College of Cardiology, 57(20), 2037-2114. doi:10.1016/j.jacc.2011.01.008
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., . . . Weitz, H. H. (2011). ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology. Journal of the American Society of Hypertension, 5(4), 259-352. doi:10.1016/j.jash.2011.06.001
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., . . . Wesley, D. J. (2011). ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the american college of cardiology foundation task force on clinical expert consensus documents. Circulation, 123(21), 2434-2506. doi:10.1161/CIR.0b013e31821daaf6
Arora, S., & Belostotsky, V. (2013). Chronic kidney disease and thrombosis. Current Pediatric Reviews, 9(3), 200-204. doi:10.2174/1573396311309030004
Asfar, S., & Safar, H. A. (2007). Homocysteine levels and peripheral arterial occlusive disease: A prospective cohort study and review of the literature. Journal of Cardiovascular Surgery, 48(5), 601-605. 
Ashwanden, C. (2007). 35th EDTNA/ERCA Conference: Madrid, Spain, September 8-11, 2006. Dialysis and Transplantation, 36(3), 139-145. doi:10.1002/dat.20113
Aso, Y. (2008). Cardiovascular disease in patients with diabetic nephropathy. Current Molecular Medicine, 8(6), 533-543. doi:10.2174/156652408785747960
Assem, M., Lando, M., Grissi, M., Kamel, S., Massy, Z. A., Chillon, J. M., & Hénaut, L. (2018). The impact of uremic toxins on cerebrovascular and cognitive disorders. Toxins, 10(7). doi:10.3390/toxins10070303
Atamer, A., Kocyigit, Y., Ecder, S. A., Selek, S., Ilhan, N., Ecder, T., & Atamer, Y. (2008). Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. Journal of Nephrology, 21(6), 924-930. 
Ates, O., Keles, M., Uyanik, A., Bilen, H., Cetinkaya, R., & Turkeli, M. (2008). Central Retinal Vein Thrombosis and Hyperhomocysteinemia in a Young Patient With Renal Transplantation. Transplantation Proceedings, 40(10), 3755-3758. doi:10.1016/j.transproceed.2008.03.166
Athyros, V. G., Katsiki, N., & Mikhailidis, D. P. (2016). Statins, renal function and homocysteine. Pharmacological Reports, 68(5), 1093. doi:10.1016/j.pharep.2016.04.005
Attia, R. I., & Abed, N. A. N. (2021). EVALUATION OF SOME BIOCHEMICAL PARAMETERS AND THE EFFECT OF OXIDATIVE STREES DURING HEMODIALYSIS IN PATIENTS WITH CHRONIC RENAL DISEASE. Biochemical and Cellular Archives, 21(1), 405-410. 
Austen, S. K., Coombes, J. S., & Fassett, R. G. (2003). Homocysteine-lowering therapy in renal disease. Clin Nephrol, 60(6), 375-385. doi:10.5414/cnp60375
Austen, S. K., Fassett, R. G., Geraghty, D. P., & Coombes, J. S. (2006). Folate supplementation fails to affect vascular function and carotid artery intima media thickness in cyclosporin A-treated renal transplant recipients. Clinical Nephrology, 66(5), 373-379. doi:10.5414/cnp66373
Austin, G. (2016). Association of proton pump inhibitor use with serum biomarkers of inflammation, insulin resistance, and cardiovascular risk. American Journal of Gastroenterology, 111, S409. doi:10.1038/ajg.2016.360
Austin, G. L., Weiskopf, J. R., & Czwornog, J. L. (2018). Association of proton pump inhibitor use with serum biomarkers of inflammation, insulin resistance, cardiovascular risk, and renal function. Journal of Clinical Gastroenterology, 52(8), 691-695. doi:10.1097/MCG.0000000000000921
Avdelidou, A., Malindretos, P., Roma, V., Makedou, K., Makedou, A., & Grekas, D. (2010). Long term effect of vitamin E-coated dialysis membranes on oxidative stress and inflammation in hemodialysis patients. NDT Plus, 3, iii242. 
Avram, M. M. (2002). How can the cardiac death rate be reduced in dialysis patients? Seminars in dialysis, 15(1), 26-29. doi:10.1046/j.1525-139x.2002.0006e.x
Aykanat, B., Demircigil, G. C., Buyan, N., Baskin, E., Gulleroglu, K., Fidan, K., . . . Burgaz, S. (2016). Micronuclei and other nuclear anomalies in buccal epithelial cells of children with chronic kidney disease. Arhiv za Higijenu Rada i Toksikologiju, 67(4), 317-325. doi:10.1515/aiht-2016-67-2851
Aykanat, B., Qakmak, G., Fidan, K., Gülleroglu, K., Sepici, A., Bayrakći, U., . . . Burgaz, S. (2010). Detection of genomic damage in lymphocytes of children with chronic kidney disease by Comet Assay. Pediatric Nephrology, 25(9), 1913. doi:10.1007/s00467-010-1577-z
Aytaç, M. B., Deveci, M., Bek, K., Kayabey, Ö., & Ekinci, Z. (2016). Effect of cholecalciferol on local arterial stiffness and endothelial dysfunction in children with chronic kidney disease. Pediatric Nephrology, 31(2), 267-277. doi:10.1007/s00467-015-3220-5
Azhar, A., Hassan, N., Tapolyai, M., & Molnar, M. Z. (2021). Obesity, Chronic Kidney Disease, and Kidney Transplantation: An Evolving Relationship. Seminars in Nephrology, 41(2), 189-200. doi:10.1016/j.semnephrol.2021.03.013
Baaten, C. C. F. M. J., Sternkopf, M., Henning, T., Marx, N., Jankowski, J., & Noels, H. (2021). Platelet function in CKD: A systematic review and meta-analysis. Journal of the American Society of Nephrology, 32(7), 1583-1598. doi:10.1681/ASN.2020101440
Babaei, M., Dashti, N., Lamei, N., Abdi, K., Nazari, F., Abbasian, S., & Gerayeshnejad, S. (2014). Evaluation of plasma concentrations of homocysteine, IL-6, TNF-alpha, hs-CRP, and total antioxidant capacity in patients with end-stage renal failure. Acta Med Iran, 52(12), 893-898. 
Baber, U., De Lemos, J. A., Khera, A., McGuire, D. K., Omland, T., Toto, R. D., & Hedayati, S. S. (2008). Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney International, 73(5), 615-621. doi:10.1038/sj.ki.5002716
Baber, U., Toto, R. D., & de Lemos, J. A. (2007). Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. American Heart Journal, 153(4), 471-477. doi:10.1016/j.ahj.2006.10.042
Babińska, M., Chudek, J., Owczarek, A. J., Prochaczek, F., & Wiecek, A. (2005). Acute coronary syndrome in patients with chronic kidney disease--risk stratification. Polskie archiwum medycyny wewntrznej, 114(6), 1226-1235. 
Bacci, M. R., Adami, F., Figueiredo, F. W. S., Alves, B. C. A., Da Veiga, G. L., & Fonseca, F. L. A. (2018). Quality of life on hemodialysis and inflammation: A descriptive analysis. Brazilian Journal of Medical and Biological Research, 51(6). doi:10.1590/1414-431X20187355
Bachmann, J., Tepel, M., Raidt, H., Riezler, R., Graefe, U., Langer, K., & Zidek, W. (1995). Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. Journal of the American Society of Nephrology, 6(1), 121-125. 
Badiou, S., Morena, M., Bargnoux, A. S., Jaussent, I., Rodriguez, A., Leray-Moragues, H., . . . Cristol, J. P. (2011). Does hemodiafiltration improve the removal of homocysteine? Hemodial Int, 15(4), 515-521. doi:10.1111/j.1542-4758.2011.00610.x
Badiou, S., Terrier, N., Jaussent, I., Naudin, E., Maurice, F., Dupuy, A. M., . . . Cristol, J. P. (2006). Association of aminothiols with the clinical outcome in hemodialysis patients: comparison of chromatography and immunoassay for homocysteine determination. Clin Chem Lab Med, 44(8), 949-954. doi:10.1515/cclm.2006.184
Badri, S., Vahdat, S., Seirafian, S., Pourfarzam, M., Gholipur-Shahraki, T., & Ataei, S. (2021). Homocysteine-lowering interventions in chronic kidney disease. Journal of Research in Pharmacy Practice, 10(3), 114-124. doi:10.4103/jrpp.jrpp_75_21
Bagarolo, G. I., Stricker, L., Hemmers, C., Vondenhoff, S., Jankowski, V., Bruck, H., & Jankowski, J. (2021). Identification and validation of peptidic features in CKD patients and unravelling of a potential inflammation inducer. Nephrology Dialysis Transplantation, 36(SUPPL 1), i280. doi:10.1093/ndt/gfab088.006
Bai, Y., Yang, R., Song, Y., & Wang, Y. (2019). Serum 1,5-Anhydroglucitol Concentrations Remain Valid as a Glycemic Control Marker in Diabetes with Earlier Chronic Kidney Disease Stages. Experimental and Clinical Endocrinology and Diabetes, 127(4), 220-225. doi:10.1055/s-0043-122142
Bai, Y. H., Jiang, Y. F., & Jiang, Y. S. (2014). Lactobacillus bulgaricus mutants decompose uremic toxins. Renal Failure, 36(5), 790-794. doi:10.3109/0886022X.2014.890111
Baigent, C., Burbury, K., & Wheeler, D. (2000). Premature cardiovascular disease in chronic renal failure. Lancet, 356(9224), 147-152. doi:10.1016/s0140-6736(00)02456-9
Baigent, C., & Clarke, R. (2007). B vitamins for the prevention of vascular disease: Insufficient evidence to justify treatment. Journal of the American Medical Association, 298(10), 1212-1214. doi:10.1001/jama.298.10.1212
Baik, J. S., & Ma, H. I. (2020). Peripheral neuropathy in de novo patients with Parkinson's disease. Parkinsonism and Related Disorders, 79, e75. doi:10.1016/j.parkreldis.2020.06.273
Bakkaloglu, S. A., Saygili, A., Sever, L., Noyan, A., Akman, S., Ekim, M., . . . Kardelen, F. (2009). Assessment of cardiovascular risk in paediatric peritoneal dialysis patients: A Turkish Pediatric Peritoneal Dialysis Study Group (TUPEPD) report. Nephrology Dialysis Transplantation, 24(11), 3525-3532. doi:10.1093/ndt/gfp297
Balaskas, E. V., Grekas, D., Theodoridou, A., Makedou, A., Sioulis, A., & Tourkantonis, A. (2005). Comparing hyperhomocysteinemia in continuous ambulatory peritoneal dialysis and hemodialysis patients. Dialysis and Transplantation, 34(2), 90-97+115. 
Balbino, K. P., Juvanhol, L. L., Wendling, A. L., Marota, L. D., Costa, J. B. S., Bressan, J., & Hermsdorff, H. H. M. (2020). Dietary intake, clinical-nutritional status, and homocysteine in hemodialysis subjects: the mediating role of inflammation (NUGE-HD study). Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, 45(8), 845-850. doi:10.1139/apnm-2019-0800
Balla, S., Nusair, M. B., & Alpert, M. A. (2013). Risk factors for atherosclerosis in patients with chronic kidney disease: Recognition and management. Current Opinion in Pharmacology, 13(2), 192-199. doi:10.1016/j.coph.2012.12.001
Balta, S., Demirkol, S., Ay, S. A., Cakar, M., Sarlak, H., & Celik, T. (2013). Serum cystatin-C levels correlate with endothelial dysfunction in patients with the metabolic syndrome. Journal of Internal Medicine, 274(2), 200-201. doi:10.1111/joim.12078
Bamgbola, F. O., & Kaskel, F. J. (2003). Uremic malnutrition-inflammation syndrome in chronic renal disease: A pathobiologic entity. Journal of Renal Nutrition, 13(4), 250-258. doi:10.1053/S1051-2276(03)00114-6
Banks, J., Frykberg, R., Gifford, R., & Tierney, E. (2013). Limb salvage with transmetatarsal amputations (TMA) at the carl T. Hayden VA medical center. Diabetes, 62, A619. doi:10.2337/db13-2297-2440
Baptista, A. P., Cacdocar, S., Palmeiro, H., Faísca, M., Carrasqueira, H., Morgado, E., . . . Neves, P. L. (2008). Inflammation, homocysteine and carotid intima-media thickness. Revista Portuguesa de Cardiologia, 27(1), 39-48. 
Baragetti, I., Raselli, S., Stucchi, A., Terraneo, V., Furiani, S., Buzzi, L., . . . Buccianti, G. (2007). Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration. Nephrology, dialysis, transplantation, 22(11), 3292‐3297. doi:10.1093/ndt/gfm402
Barbieri, L., Verdoia, M., Schaffer, A., Niccoli, G., Perrone-Filardi, P., Bellomo, G., . . . Luca, G. D. (2015). Elevated homocysteine and the risk of contrast-induced nephropathy: A cohort study. Angiology, 66(4), 333-338. doi:10.1177/0003319714533401
Barrett, K. M. (2011). Neurologic manifestations of acute and chronic renal disease. CONTINUUM Lifelong Learning in Neurology, 17(1), 45-55. doi:10.1212/01.CON.0000394673.82619.24
Barsalou, J., Bradley, T. J., & Silverman, E. D. (2013). Cardiovascular risk in pediatric-onset rheumatological diseases. Arthritis Research and Therapy, 15(3). doi:10.1186/ar4212
Baskin, E., Gulleroglu, K., Bayrakci, U. S., Uslu, N., Altun, E., Cengiz, N., . . . Haberal, M. (2009). The value of gamma-glutamyltransferase in cardiovascular risk prediction in pediatric renal transplant recipients. Pediatric Transplantation, 13, 96. 
Bastami, M., Masotti, A., Saadatian, Z., Daraei, A., Farjam, M., Ghanbariasad, A., . . . Nariman-Saleh-Fam, Z. (2021). Critical roles of microRNA-196 in normal physiology and non-malignant diseases: Diagnostic and therapeutic implications. Experimental and Molecular Pathology, 122. doi:10.1016/j.yexmp.2021.104664
Baya, W., Anoun, J., Ben Hassine, I., Mzabi, A., Karmani, M., Ben Fredj Ismail, F., . . . Laouani Kechrid, C. (2019). Cardiovascular risk factors in systemic lupus erythematosus with hypertension. Journal of Hypertension, 37, e169. 
Bayés, B., Cruz Pastor, M., Bonal, J., Juncà, J., Hernandez, J. M., Riutort, N., . . . Romero, R. (2003). Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrology Dialysis Transplantation, 18(1), 106-112. doi:10.1093/ndt/18.1.106
Bayés, B., Pastor, M. C., Bonal, J., Juncà, J., Hernandez, J. M., Riutort, N., . . . Romero, R. (2003). Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant, 18(1), 106-112. doi:10.1093/ndt/18.1.106
Bayés, B., Pastor, M. C., Bonal, J., & Romero, R. (2005). "New" cardiovascular risk factors in patients with chronic kidney disease: Role of folic acid treatment. Kidney International, Supplement, 67(93), S39-S43. doi:10.1111/j.1523-1755.2005.09309.x
Beaulieu, A. J., Gohh, R. Y., Han, H., Hakas, D., Jacques, P. F., Selhub, J., & Bostom, A. G. (1999). Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arteriosclerosis, thrombosis, and vascular biology, 19(12), 2918‐2921. doi:10.1161/01.atv.19.12.2918
Beavers, K. M., Beavers, D. P., Bowden, R. G., Wilson, R. L., & Gentile, M. (2008). Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients. Nephrology (Carlton, Vic.), 13(4), 284‐288. doi:10.1111/j.1440-1797.2008.00934.x
Bednarek-Skublewska, A., Buraczyńska, M., Wawrzycki, S., Baranowicz-Gaszczyk, I., & Ksiazek, A. (2002). [Some aspects of homocysteine metabolism in hemodialysis patients]. Pol Arch Med Wewn, 108(5), 1041-1047. 
Beg, M., Sharma, V., Akhtar, N., Gupta, A., & Mohd, J. (2011). Role of antioxidants in hypertension. Journal, Indian Academy of Clinical Medicine, 12(2), 122-127. 
Behera, B. P. (2020). Comparative study of lipid profile in patients of non-diabetic chronic kidney disease in relation to its severity. International Journal of Pharmacy and Pharmaceutical Sciences, 12(8), 142-148. doi:10.22159/ijpps.2020v12i8.38221
Bełtowski, J. (2010). Hypoxia in the renal medulla: Implications for hydrogen sulfide signaling. Journal of Pharmacology and Experimental Therapeutics, 334(2), 358-363. doi:10.1124/jpet.110.166637
Bełtowski, J., & Kedra, A. (2006). Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacological Reports, 58(2), 159-178. 
Benito, S., Sánchez-Ortega, A., Unceta, N., Jansen, J. J., Postma, G., Andrade, F., . . . Barrio, R. J. (2018). Plasma biomarker discovery for early chronic kidney disease diagnosis based on chemometric approaches using LC-QTOF targeted metabolomics data. Journal of Pharmaceutical and Biomedical Analysis, 149, 46-56. doi:10.1016/j.jpba.2017.10.036
Bennett, P. C., Silverman, S., Gill, P. S., & Lip, G. Y. (2009). Ethnicity and peripheral artery disease. Qjm, 102(1), 3-16. doi:10.1093/qjmed/hcn140
Bennett, P. C., Silverman, S., Gill, P. S., & Lip, G. Y. H. (2009). Ethnicity and peripheral artery disease. QJM, 102(1), 3-16. doi:10.1093/qjmed/hcn140
Bennett-Richards, K., Kattenhorn, M., Donald, A., Oakley, G., Varghese, Z., Rees, L., & Deanfield, J. E. (2002). Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure? Circulation, 105(15), 1810-1815. doi:10.1161/01.CIR.0000014417.95833.1D
Benoit, S. W., Ciccia, E. A., & Devarajan, P. (2020). Cystatin C as a biomarker of chronic kidney disease: latest developments. Expert Rev Mol Diagn, 20(10), 1019-1026. doi:10.1080/14737159.2020.1768849
Bereczki, D. (2008). [Stroke in chronic renal failure]. Orv Hetil, 149(15), 691-696. doi:10.1556/oh.2008.28292
Bergesio, F., Monzani, G., Guasparini, A., Ciuti, R., Gallucci, M., Cristofano, C., . . . Salvadori, M. (2005). Cardiovascular risk factors in severe chronic renal failure: the role of dietary treatment. Clin Nephrol, 64(2), 103-112. doi:10.5414/cnp64103
Bergesio, F., Monzani, G., Guasparini, A., Ciuti, R., Gallucci, M., Cristofano, C., . . . Salvadori, M. (2005). Cardiovascular risk factors in severe chronic renal failure: The role of dietry treatment. Clinical Nephrology, 64(2), 103-112. doi:10.5414/cnp64103
Bernasconi, A. R., Liste, A., Del Pino, N., Rosa Diez, G. J., & Heguilén, R. M. (2006). Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure. Nephrology, 11(2), 137-141. doi:10.1111/j.1440-1797.2006.00536.x
Bertoni, E., Rosati, A., Larti, A., Merciai, C., Zanazzi, M., Rosso, G., . . . Salvadori, M. (2006). Chronic Kidney Disease Is Still Present After Renal Transplantation With Excellent Function. Transplantation Proceedings, 38(4), 1024-1025. doi:10.1016/j.transproceed.2006.03.059
Best, P. J., Reddan, D. N., Berger, P. B., Szczech, L. A., McCullough, P. A., & Califf, R. M. (2004). Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J, 148(2), 230-242. doi:10.1016/j.ahj.2004.04.011
Best, P. J. M., Reddan, D. N., Berger, P. B., Szczech, L. A., McCullough, P. A., & Califf, R. M. (2004). Cardiovascular disease and chronic kidney disease: Insights and an update. American Heart Journal, 148(2), 230-242. doi:10.1016/j.ahj.2004.04.011
Beto, J. A., & Bansal, V. K. (1998). Interventions for other risk factors: Tobacco use, physical inactivity, menopause, and homocysteine. American Journal of Kidney Diseases, 32(5 SUPPL. 3), S172-S183. doi:10.1053/ajkd.1998.v32.pm9820474
Bhalla, V. (2011). In diabetic nephropathy, high doses of vitamin B decrease glomerular filtration rate and increase risk of the composite outcome of a vascular event or all-cause mortality compared with placebo. Evidence-Based Medicine, 16(1), 14-15. doi:10.1136/ebm1141
Bhandari, S. (2011). Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. Frontiers in bioscience : a journal and virtual library, 16, 1364-1387. doi:10.2741/3794
Bhattacharya, P., Shah, B., Sarmah, D., Datta, A., Kalia, K., & Yavagal, D. R. (2021). The involvement of mitochondrial dysfunction in exacerbation of ischemic stroke pathology in chronic kidney disease. Neurology, 96(15 SUPPL 1). 
Bhowmik, D., Gupta, A., Kumar, R., Lakshmy, R., Guleria, S., & Agarwal, S. (2017). Evaluation of physiological and biochemical parameters in living kidney donors-pre and post donation. Nephrology Dialysis Transplantation, 32, iii134. doi:10.1093/ndt/gfx140
Biasioli, S., & Schiavon, R. (2000). Homocysteine as a cardiovascular risk factor. Blood Purif, 18(3), 177-182. doi:10.1159/000014416
Biasioli, S., Schiavon, R., Petrosino, L., Cavallini, L., Cavalcanti, G., & De Fanti, E. (1998). Dialysis kinetics of homocysteine and reactive oxygen species. ASAIO Journal, 44(5), M423-M432. doi:10.1097/00002480-199809000-00020
Biasioli, S., Schiavon, R., Petrosino, L., Cavallini, L., De Fanti, E., Zambello, A., . . . Targa, L. (2001). Do different dialytic techniques have different atherosclerotic and antioxidant activities? Asaio j, 47(5), 516-521. doi:10.1097/00002480-200109000-00024
Bilginer, Y., Ozaltin, F., Basaran, C., Aki, T. F., Karabulut, E., Duzova, A., . . . Bakkaloglu, A. (2007). Carotid intima-media thickness in children and young adults with renal transplant: Internal carotid artery vs. common carotid artery. Pediatric Transplantation, 11(8), 888-894. doi:10.1111/j.1399-3046.2007.00760.x
Billion, S., Tribout, B., Cadet, E., Queinnec, C., Rochette, J., Wheatley, P., & Bataille, P. (2002). Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12. Nephrol Dial Transplant, 17(3), 455-461. doi:10.1093/ndt/17.3.455
Birn, H. (2008). Should patients with chronic renal insufficiency be treated with folic acid, vitamin B6 and vitamin B12? Ugeskrift for laeger, 170(11), 933-937. 
Blacher, J., Demuth, K., Guerin, A. P., Safar, M. E., Moatti, N., & London, G. M. (1998). Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol, 18(4), 535-541. doi:10.1161/01.atv.18.4.535
Blacher, J., Demuth, K., Guerin, A. P., Vadez, C., Moatti, N., Safar, M. E., & London, G. M. (1999). Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol, 12(4), 248-255. 
Blinc, A., & Poredos, P. (2007). Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. Eur J Clin Invest, 37(3), 157-164. doi:10.1111/j.1365-2362.2007.01767.x
Blinc, A., & Poredoš, P. (2007). Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. European Journal of Clinical Investigation, 37(3), 157-164. doi:10.1111/j.1365-2362.2007.01767.x
Bochud, M., Burnier, M., & Guessous, I. (2011). Top three pharmacogenomics and personalized medicine applications at the nexus of renal pathophysiology and cardiovascular medicine. Current Pharmacogenomics and Personalized Medicine, 9(4), 299-322. doi:10.2174/187569211798377135
Böger, C. A., Stubanus, M., Haak, T., Götz, A. K., Christ, J., Hoffmann, U., . . . Krämer, B. K. (2007). Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy. Nephrol Dial Transplant, 22(1), 154-162. doi:10.1093/ndt/gfl512
Böger, R. H. (2003). The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovascular Research, 59(4), 824-833. doi:10.1016/S0008-6363(03)00500-5
Böger, R. H. (2006). Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond. Annals of Medicine, 38(2), 126-136. doi:10.1080/07853890500472151
Bolignano, D., Pettinato, G., Lacquaniti, A., Coppolino, G., Romeo, A., & Buemi, M. (2010). Neutrophil gelatinase-associated lipocalin (NGAL) reflects early renal damage in kidney transplant recipients. NDT Plus, 3, iii267. 
Borazan, A., Aydemir, S., Sert, M., & Yilmaz, A. (2004). The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels. Mediators Inflamm, 13(5-6), 361-364. doi:10.1080/09629350400008786
Borazan, A., & Binici, D. N. (2010). Relationship between insulin resistance and inflamation markers in hemodialysis patients. Ren Fail, 32(2), 198-202. doi:10.3109/08860220903491232
Borba, E. F., Prokopowitsch, A. S., Andrade, D. C. O., Gonc¸ alves, C. R., Bortolotto, L. A., & Bonfa, E. (2013). Evaluation of arterial stiffness by pulse wave velocity in active lupus patients. Lupus, 22(1), 154. doi:10.1177/0961203313476777
Borges, N. A., Stenvinkel, P., Bergman, P., Qureshi, A. R., Lindholm, B., Moraes, C., . . . Mafra, D. (2019). Effects of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Levels in Hemodialysis Patients: a Pilot Study. Probiotics and Antimicrobial Proteins, 11(2), 648-654. doi:10.1007/s12602-018-9411-1
Bostom, A., Brosnan, J. T., Hall, B., Nadeau, M. R., & Selhub, J. (1995). Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis, 116(1), 59-62. doi:10.1016/0021-9150(95)05522-x
Bostom, A., Steubl, D., Garimella, P. S., Franceschini, N., Roberts, M. B., Pasch, A., . . . Eaton, C. B. (2018). Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure. American Journal of Nephrology, 47(4), 275-282. doi:10.1159/000489095
Bostom, A. G. (2000). Homocysteine: "expensive creatinine" or important modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients? J Am Soc Nephrol, 11(1), 149-151. doi:10.1681/asn.V111149
Bostom, A. G., Carpenter, M. A., Hunsicker, L., Jacques, P. F., Kusek, J. W., Levey, A. S., . . . Selhub, J. (2009). Baseline Characteristics of Participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. American Journal of Kidney Diseases, 53(1), 121-128. doi:10.1053/j.ajkd.2008.08.010
Bostom, A. G., Carpenter, M. A., Kusek, J. W., Hunsicker, L. G., Pfeffer, M. A., Levey, A. S., . . . McKenney, J. (2006). Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. American Heart Journal, 152(3), 448-453. doi:10.1016/j.ahj.2006.03.004
Bostom, A. G., Carpenter, M. A., Kusek, J. W., Levey, A. S., Hunsicker, L., Pfeffer, M. A., . . . et al. (2011). Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation, 123(16), 1763‐1770. doi:10.1161/CIRCULATIONAHA.110.000588
Bostom, A. G., Carpenter, M. A., Kusek, J. W., Levey, A. S., Hunsicker, L., Pfeffer, M. A., . . . Weir, M. (2011). Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: Primary results from the folic acid for vascular outcome reduction in transplantation trial. Circulation, 123(16), 1763-1770. doi:10.1161/CIRCULATIONAHA.110.000588
Bostom, A. G., & Culleton, B. F. (1999). Hyperhomocysteinemia in chronic renal disease. Journal of the American Society of Nephrology, 10(4), 891-900. 
Bostom, A. G., Gohh, R. Y., Tsai, M. Y., Hopkins-Garcia, B. J., Nadeau, M. R., Bianchi, L. A., . . . Selhub, J. (1997). Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler Thromb Vasc Biol, 17(10), 1894-1900. doi:10.1161/01.atv.17.10.1894
Bostom, A. G., Kronenberg, F., Gohh, R. Y., Schwenger, V., Kuen, E., König, P., . . . Selhub, J. (2001). Chronic renal transplantation: a model for the hyperhomocysteinemia of renal insufficiency. Atherosclerosis, 156(1), 227-230. doi:10.1016/s0021-9150(00)00613-4
Bostom, A. G., Kronenberg, F., Gohh, R. Y., Schwenger, V., Kuen, E., König, P., . . . Selhub, J. (2001). Chronic renal transplantation: A model for the hyperhomocysteinemia of renal insufficiency. Atherosclerosis, 156(1), 227-230. doi:10.1016/S0021-9150(00)00613-4
Bostom, A. G., Kronenberg, F., Jacques, P. F., Kuen, E., Ritz, E., König, P., . . . Selhub, J. (2001). Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate. Atherosclerosis, 159(1), 219-223. doi:10.1016/s0021-9150(01)00502-0
Bostom, A. G., Kronenberg, F., Jacques, P. F., Kuen, E., Ritz, E., König, P., . . . Selhub, J. (2001). Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: Critical impact of true glomerular filtration rate. Atherosclerosis, 159(1), 219-223. doi:10.1016/S0021-9150(01)00502-0
Bostom, A. G., & Lathrop, L. (1997). Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int, 52(1), 10-20. doi:10.1038/ki.1997.298
Bostom, A. G., Shemin, D., Gohh, R. Y., Beaulieu, A. J., Bagley, P., Massy, Z. A., . . . Selhub, J. (2001). Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney International, Supplement, 59(78), S246-S252. 
Bostom, A. G., Shemin, D., Gohh, R. Y., Beaulieu, A. J., Jacques, P. F., Dworkin, L., & Selhub, J. (2000). Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation, 69(10), 2128-2131. doi:10.1097/00007890-200005270-00029
Bostom, A. G., Shemin, D., Gohh, R. Y., Verhoef, P., Nadeau, M. R., Bianchi, L. A., . . . Rosenberg, I. H. (1998). Lower fasting total plasma homocysteine levels in stable renal transplant recipients versus maintenance dialysis patients. Transplantation Proceedings, 30(1), 160-162. doi:10.1016/S0041-1345(97)01219-0
Bostom, A. G., Shemin, D., Lapane, K. L., Miller, J. W., Sutherland, P., Nadeau, M., . . . et al. (1995). Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis, 114(1), 93-103. doi:10.1016/0021-9150(94)05470-4
Bostom, A. G., Shemin, D., Lapane, K. L., Nadeau, M. R., Sutherland, P., Chan, J., . . . Rosenberg, I. H. (1996). Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis, 123(1-2), 193-202. doi:10.1016/0021-9150(96)05809-1
Bostom, A. G., Shemin, D., Lapane, K. L., Sutherland, P., Nadeau, M. R., Wilson, P. W., . . . Rosenberg, I. H. (1996). Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis, 125(1), 91-101. doi:10.1016/0021-9150(96)05865-0
Bostom, A. G., Shemin, D., Lapane, K. L., Sutherland, P., Nadeau, M. R., Wilson, P. W. F., . . . Rosenberg, I. H. (1996). Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study. Atherosclerosis, 125(1), 91-101. doi:10.1016/0021-9150(96)05865-0
Bostom, A. G., Shemin, D., Nadeau, M. R., Shih, V., Stabler, S. P., Allen, R. H., & Selhub, J. (1995). Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation. Atherosclerosis, 113(1), 129-132. doi:10.1016/0021-9150(94)05466-v
Bostom, A. G., Shemin, D., Yoburn, D., Fisher, D. H., Nadeau, M. R., & Selhub, J. (1996). Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis, 120(1-2), 241-244. doi:10.1016/0021-9150(95)05705-6
Bottiglieri, T., Williams, M., Arning, E., Filardo, G., Fenves, A. Z., & East, C. (2013). S-adenosylhomocysteine levels may better differentiate between normal control, subjects with ckd stages 3 and 4, and subjects on hemodialysis. Circulation, 128(22). 
Bowden, R. G., Wyatt, F. B., & Wilson, R. (2002). Homocysteine and vascular access thrombosis in end-stage renal disease patients: a retrospective study. J Nephrol, 15(6), 666-670. 
Bowden, R. G., Wyatt, F. B., Wilson, R., Wilborn, C., & Gentile, M. (2004). Homocysteine and vascular access thrombosis in a cohort of end-stage renal disease patients. Ren Fail, 26(6), 709-714. doi:10.1081/jdi-200037117
Bradran, A., & Nasri, H. (2006). Association between white blood cell count and levels of serum homocysteine in end-stage renal failure patients treating with hemodialysis. Journal of Ayub Medical College, Abbottabad : JAMC, 18(1), 22-26. 
Brady, C. B., Gaziano, J. M., Cxypoliski, R. A., Guarino, P. D., Kaufman, J. S., Warren, S. R., . . . Jamison, R. L. (2009). Homocysteine Lowering and Cognition in CKD: The Veterans Affairs Homocysteine Study. American Journal of Kidney Diseases, 54(3), 440-449. doi:10.1053/j.ajkd.2009.05.013
Brattström, L., & Wilcken, D. E. (2000). Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr, 72(2), 315-323. doi:10.1093/ajcn/72.2.315
Brattstrom, L., & Wilcken, D. E. L. (2000). Homocysteine and cardiovascular disease: Cause or effect? American Journal of Clinical Nutrition, 72(2), 315-323. doi:10.1093/ajcn/72.2.315
Bravo-Soto, G. A., & Madrid, T. (2016). Is folic acid supplementation useful for chronic kidney disease? Medwave, 16, e6591. doi:10.5867/medwave.2016.6591
Bro, S. (2009). Cardiovascular effects of uremia in apolipoprotein E-deficient mice. Danish Medical Bulletin, 56(4), 177-192. 
Bro, S., Bentzon, J. F., Falk, E., Andersen, C. B., Olgaard, K., & Nielsen, L. B. (2003). Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. Journal of the American Society of Nephrology, 14(10), 2466-2474. doi:10.1097/01.ASN.0000088024.72216.2E
Brondino, N., Fusar-Poli, L., Miceli, E., Di Stefano, M., Damiani, S., Rocchetti, M., & Politi, P. (2019). Prevalence of Medical Comorbidities in Adults with Autism Spectrum Disorder. Journal of General Internal Medicine, 34(10), 1992-1994. doi:10.1007/s11606-019-05071-x
Brosnan, J. T., Hall, B., Selhub, J., Nadeau, M. R., & Bostom, A. G. (1995). Renal metabolism of homocysteine in vivo. Biochem Soc Trans, 23(3), 470s. doi:10.1042/bst023470s
Bross, M. H., Soch, K., & Smith-Knuppel, T. (2010). Anemia in older persons. American Family Physician, 82(5), 480-487. 
Bross, R., Zitterkoph, J., Pithia, J., Benner, D., Rambod, M., Kovesdy, C. P., . . . Kalantar-Zadeh, K. (2009). Association of serum total iron-binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients. American Journal of Nephrology, 29(6), 571-581. doi:10.1159/000191470
Brox-Torrecilla, N., Arhip, L., Miguélez-González, M., Castellano-Gasch, S., Contreras-Chicote, A., Rodríguez-Ferrero, M. L., . . . Cuerda Compes, C. (2021). Acidemia metilmalónica y homocisteinemia de inicio tardío. Nutricion hospitalaria, 38(4), 871-875. doi:10.20960/nh.03623
Brox-Torrecilla, N., Arhip, L., Miguélez-González, M., Castellano-Gasch, S., Contreras-Chicote, A., Rodríguez-Ferrero, M. L., . . . Cuerda Compes, C. (2021). Late-onset methylmalonic acidemia and homocysteinemia. Nutr Hosp, 38(4), 871-875. doi:10.20960/nh.03623
Brox-Torrecilla, N., Arhip, L., Miguélez-González, M., Castellano-Gasch, S., Contreras-Chicote, A., Rodríguez-Ferrero, M. L., . . . Compes, C. C. (2021). Late-onset methylmalonic acidemia and homocysteinemia. Nutricion Hospitalaria, 38(4), 871-875. doi:10.20960/nh.03623
Brulez, H. F., van Guldener, C., Donker, A. J., & ter Wee, P. M. (1999). The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant, 14(1), 154-159. doi:10.1093/ndt/14.1.154
Brunelli, S. M., Meyers, K. E. C., Guttenberg, M., Kaplan, P., & Kaplan, B. S. (2002). Cobalamin C deficiency complicated by an atypical glomerulopathy. Pediatric Nephrology, 17(10), 800-803. doi:10.1007/s00467-002-0895-1
Brunetti, M., Terracina, L., Timio, M., Saronio, P., & Capodicasa, E. (2001). Plasma sulfate concentration and hyperhomocysteinemia in hemodialysis patients. J Nephrol, 14(1), 27-31. 
Brzósko, S., Hryszko, T., Małyszko, J., & Myśliwiec, M. (2001). Homocysteine--new risk factor for progression of atherosclerosis and its complications. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 10(55), 56-59. 
Bucsa, C. A., Tacu, D., Kerezsy, E., Bucsa, A., Deleanu, D., Hirza, M., . . . Sinescu, I. (2010). The outcome of the renal transplant patients with primary coronary angioplasty for acute myocardial infarction. Transplantation, 90, 869. 
Bundy, J. D., Chen, J., Yang, W., Budoff, M., Go, A. S., Grunwald, J. E., . . . He, J. (2018). Risk factors for progression of coronary artery calcification in patients with chronic kidney disease: The CRIC study. Atherosclerosis, 271, 53-60. doi:10.1016/j.atherosclerosis.2018.02.009
Bundy, J. D., Chen, J., Yang, W., Budoff, M., Go, A. S., Grunwald, J. E., . . . the, C. S. I. (2018). Risk factors for progression of coronary artery calcification in patients with chronic kidney disease: The CRIC study. Atherosclerosis, 271, 53-60. doi:10.1016/j.atherosclerosis.2018.02.009
Buscemi, S., Corleo, D., Buscemi, C., & Giordano, C. (2018). Does iris(in) bring bad news or good news? Eating and Weight Disorders, 23(4), 431-442. doi:10.1007/s40519-017-0431-8
Busch, M., Franke, S., Müller, A., Wolf, M., Gerth, J., Ott, U., . . . Stein, G. (2004). Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney International, 66(1), 338-347. doi:10.1111/j.1523-1755.2004.00736.x
Busch, M., Göbert, A., Franke, S., Ott, U., Gerth, J., Müller, A., . . . Wolf, G. (2009). Vitamin B6 Metabolism in Chronic Kidney Disease - Relation to Transsulfuration, Advanced Glycation and Cardiovascular Disease. Nephron - Clinical Practice, 114(1), c38-c46. doi:10.1159/000245068
Busch, M., Göbert, A., Franke, S., Ott, U., Gerth, J., Müller, A., . . . Wolf, G. (2010). Vitamin B6 metabolism in chronic kidney disease--relation to transsulfuration, advanced glycation and cardiovascular disease. Nephron. Clinical practice, 114(1), c38-46. doi:10.1159/000245068
Buyan, N., Akçaboy, M., Göktaş, T., Kula, S., Nazliel, B., Çakar, N., . . . Erbaş, D. (2017). Effects of whole blood viscosity and plasma NOx on cardiac function and cerebral blood flow in children with chronic kidney disease. Turkish Journal of Medical Sciences, 47(5), 1482-1491. doi:10.3906/sag-1609-33
Cabarkapa, V., Stosić, Z., Zeravica, R., & Ilincić, B. (2007). The importance of homocysteinemia measurement in chronic renal failure. Medicinski pregled, 60 Suppl 2, 81-83. 
Čabarkapa, V., Stošić, Z., Žeravica, R., & Ilinčić, B. (2007). Hyperhomocysteinemia in chronic renal insufficiency. Journal of Medical Biochemistry, 26(1), 42-45. doi:10.2478/v10011-007-0008-6
Cabrera, S., Alvo, M., & Ferro, C. (2017). The Nephroprotective Effect of Folic Acid-Only a Matter of Homocysteine? [2]. JAMA Internal Medicine, 177(2), 286. doi:10.1001/jamainternmed.2016.8583
Cadnapaphornchai, M. A., & Teitelbaum, I. (2014). Strategies for the preservation of residual renal function in pediatric dialysis patients. Pediatric Nephrology, 29(5), 825-836. doi:10.1007/s00467-013-2554-0
Cai, Q., Mukku, V. K., & Ahmad, M. (2013). Coronary artery disease in patients with chronic kidney disease: A clinical update. Current Cardiology Reviews, 9(4), 331-339. doi:10.2174/1573403X10666140214122234
Campistol, J. M. (2003). Sirolimus: A potential option for the prevention of chronic allograft nephropathy. Transplantation Reviews, 17(1), 11-19. 
Campos, B., Lee, T., & Roy-Chaudhury, P. (2013). Arteriovenous Fistula Failure: Is There a Role for Epigenetic Regulation? Seminars in Nephrology, 33(4), 400-406. doi:10.1016/j.semnephrol.2013.05.012
Canaud, B., Lévesque, R., Krieter, D., Desmeules, S., Chalabi, L., Moragués, H., . . . Cristol, J. P. (2004). On-line hemodiafiltration as routine treatment of end-stage renal failure: why pre- or mixed dilution mode is necessary in on-line hemodiafiltration today? Blood Purif, 22 Suppl 2, 40-48. doi:10.1159/000081874
Canepa, A., Carrea, A., Caridi, G., Dertenois, L., Minniti, G., Cerone, R., . . . Perfumo, F. (2003). Homocysteine, folate, vitamin B12 levels, and C677T MTHFR mutation in children with renal failure. Pediatric Nephrology, 18(3), 225-229. doi:10.1007/s00467-002-1058-0
Cantaluppi, V., Medica, D., Quercia, A. D., Dellepiane, S., Gai, M., Leonardi, G., . . . Camussi, G. (2014). Circulating extracellular vesicles in patients with end stage chronic kidney disease: New uremic toxins involved in inflammation, endothelial dysfunction and vascular calcification. Nephrology Dialysis Transplantation, 29, iii151. doi:10.1093/ndt/gfu148
Canton, C. G., Bosch, E., Ramirez, A., Auyanet, I., Gonzalez, Y., Rossique, P., . . . Checa, M. D. (2010). Vascular calcifications and cardiovascular risk factors in chronic kidney disease. NDT Plus, 3, iii394. 
Capelli, I., Cianciolo, G., Gasperoni, L., Zappulo, F., Tondolo, F., Cappuccilli, M., & La Manna, G. (2019). Folic acid and vitamin B12 administration in CKD, why not? Nutrients, 11(2). doi:10.3390/nu11020383
Cappuccilli, M., Bergamini, C., Giacomelli, F. A., Cianciolo, G., Donati, G., Conte, D., . . . Capelli, I. (2020). Vitamin B supplementation and nutritional intake of methyl donors in patients with chronic kidney disease: A critical review of the impact on epigenetic machinery. Nutrients, 12(5). doi:10.3390/nu12051234
Cárdenas, V. M., Boller, F., & Román, G. C. (2019). Helicobacter pylori, vascular risk factors and cognition in U.S. older adults. Brain Sciences, 9(12). doi:10.3390/brainsci9120370
Cardona Portela, P., & Escrig Avellaneda, A. (2018). Small vessel cerebrovascular disease. Hipertension y Riesgo Vascular, 35(4), 185-194. doi:10.1016/j.hipert.2018.04.002
Carluccio, F., Siems, W., Stefanelli, G., Sommerburg, O., Grune, T., Riedel, E., & Hampl, H. (2002). Homocysteine in chronic renal failure in relation to renal anemia and to oxidative stress parameters 4-hydroxynonenal and malondialdehyde. Clinical nephrology, 58 Suppl 1, S26-30. 
Carluccio, F., Siems, W., Stefanelli, G., Sommerburg, O., Grune, T., Riedel, E., & Hampl, H. (2002). Hyperhomocysteinemia in chronic renal failure in relation to renal anemia and to oxidative stress parameters 4-hydroxynonenal and malondialdehyde. Nieren- und Hochdruckkrankheiten, 31(SUPPL. 1), S28-S33. 
Carpenter, M., Bostom, A., Hunsicker, L., Ivanova, A., Kasiske, B., Kusek, J., . . . Weir, M. (2011). Higher systolic blood pressure is associated with increased cardiovascular risk in patients with hypertension in the folic acid for vascular outcome reduction in transplantation trial. American Journal of Transplantation, 11, 375. doi:10.1111/j.1600-6143.2011.03534.x
Carpenter, M. A., Weir, M. R., Adey, D. B., House, A. A., Bostom, A. G., & Kusek, J. W. (2012). Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the favorit study. Clinical Transplantation, 26(4), E438-E446. doi:10.1111/j.1399-0012.2012.01676.x
Carral-Santander, I. E., Santos-Palacios, A., Martínez-Baez, B. E., Cernichiaro-Espinosa, L., Elizondo-Camacho, J. M., Valdés-Lara, C. A., . . . Velez-Montoya, R. (2019). Secondary hyperhomocysteinemia-related occlusive retinal vasculopathy: A case report. American Journal of Ophthalmology Case Reports, 13, 41-45. doi:10.1016/j.ajoc.2018.11.005
Cases, A. (2004). New cardiovascular risk factors and chronic kidney disease. Hypertrophy of the left ventricle. Atrial fibrillation. Smoking. Obesity. Emerging cardiovascular risk factors: homocysteine, Reactive C protein. Fibrinogen. Nefrología : publicación oficial de la Sociedad Española Nefrologia, 24 Suppl(6), 62-72, 187-72235. 
Casserly, L. F., & Dember, L. M. (2003). Thrombosis in end-stage renal disease. Seminars in dialysis, 16(3), 245-256. 
Cattaneo, M. (2000). Hyperhomocysteinaemia and atherothrombosis. Ann Med, 32 Suppl 1, 46-52. 
Cavalcanti Sette, L. H. B., & Lopes, E. P. A. (2014). Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: A comprehensive review. Clinics, 69(4), 271-278. doi:10.6061/clinics/2014(04)09
Cavalier, E., Delanaye, P., Collette, J., Krzesinski, J. M., & Chapelle, J. P. (2006). Evaluation of different bone markers in hemodialyzed patients. Clinica Chimica Acta, 371(1-2), 107-111. doi:10.1016/j.cca.2006.02.029
Cavalier, E., Lukas, P., Carlisi, A., & Delanaye, P. (2013). Impact of vitamin K antagonists on the plasma levels of dephosphouncarboxylated Matrix Gla Protein (dp-ucMGP) in hemodialysis patients. Clinical Chemistry, 59(10), A92. 
Cepeda, J., Tranche-Iparraguirre, S., Marín-Iranzo, R., Fernández-Rodríguez, E., Riesgo-García, A., García-Casas, J., & Hevia-Rodríguez, E. (2010). Cystatin C and Cardiovascular Risk in the General Population. Revista Espanola de Cardiologia, 63(4), 415-422. doi:10.1016/S0300-8932(10)70062-2
Cesari, M., Rossi, G. P., & Pessina, A. C. (2005). Homocysteine-lowering treatment in coronary heart disease. Curr Med Chem Cardiovasc Hematol Agents, 3(4), 289-295. doi:10.2174/156801605774322319
Cetın, N., Sav, N. M., Karabel, D., Yildirim, A., & Yıldız, B. (2016). Serum albumin and von Willebrand factor: possible markers for early detection of vascular damage in children undergoing peritoneal dialysis. Clinical and investigative medicine. Medecine clinique et experimentale, 39(4), E111-E119. 
Cetin, O., Bekpinar, S., Unlucerci, Y., Turkmen, A., Bayram, C., & Ulutin, T. (2006). Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation. Clin Nephrol, 65(2), 97-102. doi:10.5414/cnp65097
Cetin, O., Bekpinar, S., Ünlucerci, Y., Turkmen, A., Bayram, Ç., & Ulutin, T. (2006). Hyperhomocysteinemia in chronic renal failure patients: Relation to tissue factor and platelet aggregation. Clinical Nephrology, 65(2), 97-102. doi:10.5414/CNP65097
Chaitanya, V., Devi, N., Suchitra, M., Rao, P. V. L. N., Lakshmi, B., & Kumar, V. (2018). Osteopontin, cardiovascular risk factors and carotid intima-media thickness in chronic kidney disease. Indian Journal of Nephrology, 28(5), 358-364. doi:10.4103/ijn.IJN_321_17
Chalmers, L., Kaskel, F. J., & Bamgbola, O. (2006). The Role of Obesity and Its Bioclinical Correlates in the Progression of Chronic Kidney Disease. Advances in Chronic Kidney Disease, 13(4), 352-364. doi:10.1053/j.ackd.2006.07.010
Chan, N. N., Chan, W. B., & Chan, J. C. (2003). Reduction of total homocysteine levels by oral folic acid fails to improve endothelial function in children with chronic renal failure. Circulation, 107(1), e6-7; author reply e6-77. 
Chao, M. C., Hu, S. L., Hsu, H. S., Davidson, L. E., Lin, C. H., Li, C. I., . . . Lin, W. Y. (2014). Serum homocysteine level is positively associated with chronic kidney disease in a Taiwan Chinese population. Journal of Nephrology, 27(3), 299-305. doi:10.1007/s40620-013-0037-9
Chapman, J. (2006). Guest editor's introduction. Nephrology Dialysis Transplantation, 21(SUPPL. 3), iii1-iii2. doi:10.1093/ndt/gfl297
Chauveau, P., Chadefaux, B., Coude, M., Aupetit, J., Hannedouche, T., Kamoun, P., & Jungers, P. (1992). Increased plasma homocysteine concentration in patients with chronic renal failure. Mineral and Electrolyte Metabolism, 18(2-5), 196-198. 
Chauveau, P., Chadefaux, B., Coudé, M., Aupetit, J., Hannedouche, T., Kamoun, P., & Jungers, P. (1992). Increased plasma homocysteine concentration in patients with chronic renal failure. Miner Electrolyte Metab, 18(2-5), 196-198. 
Chauveau, P., Chadefaux, B., Coude, M., Aupetit, J., Kamoun, P., & Jungers, P. (1996). Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Mineral and Electrolyte Metabolism, 22(1-3), 106-109. 
Chauveau, P., Chadefaux, B., Coudé, M., Aupetit, J., Kamoun, P., & Jungers, P. (1996). Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Mineral and electrolyte metabolism, 22(1‐3), 106‐109. 
Chavalitdhamrong, D., Danovitch, G. M., & Bunnapradist, S. (2007). Is there a reversal of reverse epidemiology in renal transplant recipients? Seminars in Dialysis, 20(6), 544-548. doi:10.1111/j.1525-139X.2007.00351.x
Chaykovska, L., Tsuprykov, O., & Hocher, B. (2011). Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy. Clin Lab, 57(7-8), 455-467. 
Chen, C. H., Yang, W. C., Hsiao, Y. H., Huang, S. C., & Huang, Y. C. (2016). High homocysteine, low vitamin B-6, and increased oxidative stress are independently associated with the risk of chronic kidney disease. Nutrition, 32(2), 236-241. doi:10.1016/j.nut.2015.08.016
Chen, C. H., Yeh, E. L., Chen, C. C., Huang, S. C., & Huang, Y. C. (2017). Vitamin B-6, Independent of Homocysteine, Is a Significant Factor in Relation to Inflammatory Responses for Chronic Kidney Disease and Hemodialysis Patients. BioMed research international, 2017, 7367831. doi:10.1155/2017/7367831
Chen, C. W., Jaffe, I. Z., & Karumanchi, S. A. (2014). Pre-eclampsia and cardiovascular disease. Cardiovascular Research, 101(4), 579-586. doi:10.1093/cvr/cvu018
Chen, J., & Sun, N. (2018). Study on correlation between plasma homocysteinemia level and target organ damage in patients with primary hypertension. Journal of Hypertension, 36, e221-e222. doi:10.1097/01.hjh.0000548905.41602.ea
Chen, J. Y., Tsai, Y. W., Chen, S. Y., Ho, C. I., Weng, Y. M., Hsiao, C. T., & Li, W. C. (2015). The association of leptin and homocysteine with renal function impairment in a population of Taiwanese adults. Clinical Nutrition, 34(5), 943-950. doi:10.1016/j.clnu.2014.10.001
Chen, J. Y., Ye, Z. X., Wang, X. F., Chang, J., Yang, M. W., Zhong, H. H., . . . Yang, S. L. (2018). Nitric oxide bioavailability dysfunction involves in atherosclerosis. Biomedicine and Pharmacotherapy, 97, 423-428. doi:10.1016/j.biopha.2017.10.122
Chen, T., Li, Y., Wang, J., & Wang, J. (2021). Correlation among cystatin C, homocysteine and arteriosclerosis indexes in patients with chronic kidney disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 46(12), 1338-1345. doi:10.11817/j.issn.1672-7347.2021.210059
Chen, T. C., Wang, I. K., Lee, C. H., Chang, H. W., Chiou, T. T., Lee, C. T., . . . Chuang, F. R. (2006). Hyperhomocysteinaemia and vascular access thrombosis among chronic hemodialysis patients in Taiwan: a retrospective study. Int J Clin Pract, 60(12), 1596-1599. doi:10.1111/j.1742-1241.2006.00848.x
Chen, W., Feng, J., Ji, P., Liu, Y., Wan, H., & Zhang, J. (2023). Association of hyperhomocysteinemia and chronic kidney disease in the general population: a systematic review and meta-analysis. BMC Nephrol, 24(1), 247. doi:10.1186/s12882-023-03295-y
Cheng, S., Feng, J., & Wang, X. (2011). [Research advances in the treatment of hyperhomocysteinemia]. Sheng li ke xue jin zhan [Progress in physiology], 42(5), 329-334. 
Cheng, X. (2013). Updating the relationship between hyperhomocysteinemia lowering therapy and cardiovascular events. Cardiovascular Therapeutics, 31(4), e19-e26. doi:10.1111/1755-5922.12014
Cheung, K. W. K., Hsueh, C. H., Zhao, P., Meyer, T. W., Zhang, L., Huang, S. M., & Giacomini, K. M. (2017). The Effect of Uremic Solutes on the Organic Cation Transporter 2. Journal of Pharmaceutical Sciences, 106(9), 2551-2557. doi:10.1016/j.xphs.2017.04.076
Chi, Y. W., & Jaff, M. R. (2008). Optimal risk factor modification and medical management of the patient with peripheral arterial disease. Catheterization and Cardiovascular Interventions, 71(4), 475-489. doi:10.1002/ccd.21401
Chiarello, P. G., Vannucchi, M. T., Moysés Neto, M., & Vannucchi, H. (2003). Hyperhomocysteinemia and oxidative stress in hemodialysis: effects of supplementation with folic acid. Int J Vitam Nutr Res, 73(6), 431-438. doi:10.1024/0300-9831.73.6.431
Chiarello, P. G., Vannucchi, M. T., & Vannucchi, H. (2003). Hyperhomocysteinemia and oxidative stress during dialysis treatment. Ren Fail, 25(2), 203-213. doi:10.1081/jdi-120018721
Chien, S. J., Lin, I. C., Hsu, C. N., Lo, M. H., & Tain, Y. L. (2015). Homocysteine and arginine-to-asymmetric dimethylarginine ratio associated with blood pressure abnormalities in children with early chronic kidney disease. Circulation Journal, 79(9), 2031-2037. doi:10.1253/circj.CJ-15-0412
Chiriac, S., Stanciu, C., Girleanu, I., Cojocariu, C., Sfarti, C., Singeap, A. M., . . . Trifan, A. (2021). Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Canadian Journal of Gastroenterology and Hepatology, 2021. doi:10.1155/2021/6696857
Chiu, N. Z., & Shyu, K. G. (2007). Deep vein thrombosis associated with marked hyperhomocysteinemia and active pulmonary tuberculosis. Acta Cardiologica Sinica, 23(3), 186-191. 
Chmielewski, M., Carrero, J. J., Stenvinkel, P., & Lindholm, B. (2009). Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. Current Opinion in Lipidology, 20(1), 3-9. doi:10.1097/MOL.0b013e32831ef234
Cho, B. J., Bae, S. H., Park, S. M., Shin, M. C., Park, I. W., Kim, H., & Kwon, S. (2019). Comparison of systemic conditions at diagnosis between central retinal vein occlusion and branch retinal vein occlusion. PLoS ONE, 14(8). doi:10.1371/journal.pone.0220880
Cho, B. J., Bae, S. H., Park, S. M., Shin, M. C., Park, I. W., Kim, H. K., & Kwon, S. (2019). Comparison of systemic conditions at diagnosis between central retinal vein occlusion and branch retinal vein occlusion. PLoS One, 14(8), e0220880. doi:10.1371/journal.pone.0220880
Cho, J., Jun, K. W., Kim, M. H., Hwang, J. K., Moon, I. S., & Kim, J. I. (2017). Coagulation profile in patients with chronic kidney disease before and after kidney transplantation: A retrospective cohort study. Clinical Transplantation, 31(9). doi:10.1111/ctr.13051
Choi, S. T., Kim, J. S., & Song, J. S. (2014). Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients. Journal of Korean medical science, 29(6), 788-792. doi:10.3346/jkms.2014.29.6.788
Choi, S. T., Song, J. S., Kim, J. S., Kang, E. J., Lee, K. H., & Ha, Y. J. (2012). Elevated serum homocysteine levels were related not with serum uric acid levels but with decreased renal function in chronic gouty patients. Arthritis and Rheumatism, 64, S813. doi:10.1002/art.37735
Chuang, C. H., Lee, Y. Y., Sheu, B. F., Hsiao, C. T., Loke, S. S., Chen, J. C., & Li, W. C. (2013). Homocysteine and C-reactive protein as useful surrogate markers for evaluating CKD risk in adults. Kidney and Blood Pressure Research, 37(4-5), 402-413. doi:10.1159/000355722
Chuang, F. R., Fang, J. T., Chen, J. B., Lin, C. L., Chen, H. Y., Lee, C. N., . . . Lee, C. H. (2003). Hyperhomocystinemia and the prevalence of symptomatic atherosclerotic vascular disease in Taiwanese chronic hemodialysis patients: A retrospective study. Renal Failure, 25(5), 765-774. doi:10.1081/JDI-120024292
Ciaccio, M., & Bellia, C. (2010). Hyperhomocysteinemia and cardiovascular risk: Effect of vitamin supplementation in risk reduction. Current Clinical Pharmacology, 5(1), 30-36. doi:10.2174/157488410790410551
Cianciolo, G., Cappuccilli, M., & La Manna, G. (2017). The Hydrogen Sulfide-Vitamin B12-Folic Acid Axis: An Intriguing Issue in Chronic Kidney Disease. A Comment on Toohey JI: "Possible Involvement of Hydrosulfide in B12-Dependent Methyl Group Transfer". Molecules 2017, 22, 582, pii: E582. Molecules (Basel, Switzerland), 22(7). doi:10.3390/molecules22071216
Cianciolo, G., De Pascalis, A., Di Lullo, L., Ronco, C., Zannini, C., & La Manna, G. (2017). Folic acid and homocysteine in chronic kidney disease and cardiovascular disease progression: Which comes first? CardioRenal Medicine, 7(4), 255-266. doi:10.1159/000471813
Cianciolo, G., La Manna, G., Colì, L., Donati, G., D'Addio, F., Persici, E., . . . et al. (2008). 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients. American journal of nephrology, 28(6), 941‐948. doi:10.1159/000142363
Cianciolo, G., La Manna, G., Colì, L., Donati, G., D'Addio, F., Persici, E., . . . Stefoni, S. (2008). 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients. Am J Nephrol, 28(6), 941-948. doi:10.1159/000142363
Cibulka, R., & Racek, J. (2007). Metabolic disorders in patients with chronic kidney failure. Physiological research / Academia Scientiarum Bohemoslovaca, 56(6), 697-705. 
Clarke, H., Kim, D. H., Meza, C. A., Ormsbee, M. J., & Hickner, R. C. (2020). The evolving applications of creatine supplementation: Could creatine improve vascular health? Nutrients, 12(9), 1-23. doi:10.3390/nu12092834
Clementi, A., Virzì, G. M., Goh, C. Y., Cruz, D. N., Granata, A., Vescovo, G., & Ronco, C. (2013). Cardiorenal syndrome type 4: A review. CardioRenal Medicine, 3(1), 63-70. doi:10.1159/000350397
Clements, L., & Ashurst, I. (2006). Dietary strategies to halt the progression of chronic kidney disease. EDTNA/ERCA journal (English ed.), 32(4), 192-197. 
Clothier, J. C., Simpson, J. M., Turner, C., Dalton, R. N., Rasmussen, P., Rawlins, D., . . . Sinha, M. D. (2013). Investigating the role of cardiovascular biomarkers in children with pre-dialysis chronic kidney disease: A substitute to echocardiography to detect increased left ventricular mass? Nephron - Clinical Practice, 124(3-4), 191-201. doi:10.1159/000356385
Cobo, G., Hecking, M., Port, F. K., Exner, I., Lindholm, B., Stenvinkel, P., & Carrero, J. J. (2016). Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. Clin Sci (Lond), 130(14), 1147-1163. doi:10.1042/cs20160047
Cohen, B. D. (2003). Methyl group deficiency and guanidino production in uremia. Mol Cell Biochem, 244(1-2), 31-36. 
Cohen, E., Margalit, H., Shochat, T., Goldberg, E., & Krause, H. (2021). Sex differences in folate levels: A cross sectional study of a large cohort from Israel. Israel Medical Association Journal, 23(1), 17-22. 
Cohen, E., Margalit, I., Shochat, T., Goldberg, E., & Krause, I. (2019). The relationship between the concentration of plasma homocysteine and chronic kidney disease: a cross sectional study of a large cohort. J Nephrol, 32(5), 783-789. doi:10.1007/s40620-019-00618-x
Cohen, G., & Hörl, W. H. (2012). Immune dysfunction in Uremia-An update. Toxins, 4(11), 962-990. doi:10.3390/toxins4110962
Coleman, J. E., Watson, A. R., Chowdhury, S., Thurlby, D., & Wardell, J. (2002). Comparison of two micronutrient supplements in children with chronic renal failure. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 12(4), 244-247. 
Colman, S., Bross, R., Benner, D., Chow, J., Braglia, A., Arzaghi, J., . . . Kalantar-Zadeh, K. (2005). The Nutritional and Inflammatory Evaluation in Dialysis patients (NIED) study: overview of the NIED study and the role of dietitians. J Ren Nutr, 15(2), 231-243. doi:10.1053/j.jrn.2005.01.003
Connolly, G. M., Cunningham, R., McNamee, P. T., Young, I. S., & Maxwell, A. P. (2010). Elevated homocysteine is a predictor of all-cause mortality in a prospective cohort of renal transplant recipients. Nephron. Clinical practice, 114(1), c5-11. doi:10.1159/000242443
Coresh, J., Astor, B., & Sarnak, M. J. (2004). Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 13(1), 73-81. doi:10.1097/00041552-200401000-00011
Coresh, J., Longenecker, J. C., Miller 3rd, E. R., Young, H. J., & Klag, M. J. (1998). Epidemiology of cardiovascular risk factors in chronic renal disease. Journal of the American Society of Nephrology : JASN, 9(12 Suppl), S24-30. 
Corredor, Z., Filho, M. I. S., Rodríguez-Ribera, L., Velázquez, A., Hernández, A., Catalano, C., . . . Pastor, S. (2020). Genetic Variants Associated with Chronic Kidney Disease in a Spanish Population. Scientific Reports, 10(1). doi:10.1038/s41598-019-56695-2
Corte, Z., & Venta, R. (2020). Biological variation of metabolic cardiovascular risk factors in haemodialysis patients and healthy individuals. Annals of Translational Medicine, 8(6). doi:10.21037/atm.2020.03.26
Coskunfirat, N., Hadimioglu, N., Ertug, Z., Akbas, H., Davran, F., Ozdemir, B., . . . Arici, G. (2015). Homocysteine levels after nitrous oxide anesthesia for living-related donor renal transplantation: a randomized, controlled, double-blind study. Transplantation proceedings, 47(2), 313‐318. doi:10.1016/j.transproceed.2014.10.014
Cosola, C., Rocchetti, M. T., Marzocco, S., Di Micco, L., De Simone, E., Dal Piaz, F., . . . Di Iorio, B. R. (2017). Dietary regimens poor in animal proteins decrease cyanates production through urea reduction in chronic kidney disease. Nephrology Dialysis Transplantation, 32, iii252-iii253. doi:10.1093/ndt/gfx148
Couper, C., Doriot, A., Siddiqui, M. T. R., & Steiger, E. (2021). Nutrition Management of the High-Output Fistulae. Nutrition in Clinical Practice, 36(2), 282-296. doi:10.1002/ncp.10608
Covic, A., Gusbeth-Tatomir, P., & Goldsmith, D. (2008). Negative outcome studies in end-stage renal disease: How dark are the storm clouds? Nephrology Dialysis Transplantation, 23(1), 56-61. doi:10.1093/ndt/gfm706
Covic, A., & Voroneanu, L. (2018). Chronic kidney disease and stroke: More observations but no trials. Nephrology Dialysis Transplantation, 33(3), 367-370. doi:10.1093/ndt/gfx363
Coylewright, M., Rice, K., Budoff, M. J., Blumenthal, R. S., Greenland, P., Kronmal, R., . . . Post, W. S. (2011). Differentiation of severe coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 219(2), 616-622. doi:10.1016/j.atherosclerosis.2011.08.038
Criqui, M. H., & Aboyans, V. (2015). Epidemiology of Peripheral Artery Disease. Circulation Research, 116(9), 1509-1526. doi:10.1161/CIRCRESAHA.116.303849
Cross, J. M., Donald, A., Vallance, P. J., Deanfield, J. E., Woolfson, R. G., & MacAllister, R. J. (2001). Dialysis improves endothelial function in humans. Nephrology Dialysis Transplantation, 16(9), 1823-1829. doi:10.1093/ndt/16.9.1823
Cui, H., Wang, F., Fan, L., Hu, Y. X., Hu, G. L., Liu, L., & Hong, C. M. (2011). Association factors of target organ damage: Analysis of 17 682 elderly hypertensive patients in China. Chinese Medical Journal, 124(22), 3676-3681. doi:10.3760/cma.j.issn.0366-6999.2011.22.014
Cunard, R. (2017). Endoplasmic Reticulum Stress, a Driver or an Innocent Bystander in Endothelial Dysfunction Associated with Hypertension? Current Hypertension Reports, 19(8). doi:10.1007/s11906-017-0762-x
Curtis, B. M., & Parfrey, P. S. (2005). Congestive heart failure in chronic kidney disease: Disease-specific mechanisms of systolic and diastolic heart failure and management. Cardiology Clinics, 23(3), 275-284. doi:10.1016/j.ccl.2005.04.002
Cuspidi, C., Tadic, M., & Sala, C. (2015). Aldosterone and abnormal left ventricular geometry in chronic kidney disease. Hypertension Research, 38(5), 314-316. doi:10.1038/hr.2015.34
Cutler, M. J., Urquhart, B. L., Freeman, D. J., Spence, J. D., & House, A. A. (2009). Mesna for the treatment of hyperhomocysteinemia in hemodialysis patients. Blood purification, 27(3), 306‐310. doi:10.1159/000207197
Czekalski, S., Oko, A., & Pawlaczyk, K. (2006). Early development and rapid progression of atherosclerosis in patients with chronic kidney disease. Advances in Clinical and Experimental Medicine, 15(2), 227-232. 
Czupryniak, A., Kałuzyńska, A., Nowicki, M., Wiecek, B., Bald, E., & Owczarek, D. (2005). Raynaud's phenomenon and endothelial dysfunction in end-stage renal disease patients treated with hemodialysis. Kidney Blood Press Res, 28(1), 27-31. doi:10.1159/000081059
da Matta, S. M., Janaina Matos, M., Kummer, A. M., Barbosa, I. G., Teixeira, A. L., & Silva, A. C. (2014). Cognitive alterations in chronic kidney disease: an update. Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia, 36(2), 241-245. 
Dad, T., Tighiouart, H., Joseph, A., Bostom, A., Carpenter, M., Hunsicker, L., . . . Weiner, D. E. (2016). Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. American Journal of Kidney Diseases, 68(2), 277-286. doi:10.1053/j.ajkd.2016.01.019
Dad, T., & Weiner, D. E. (2015). Stroke and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management Across Kidney Disease Stages. Seminars in Nephrology, 35(4), 311-322. doi:10.1016/j.semnephrol.2015.06.003
Dai, J., Fang, P., Saredy, J., Xi, H., Ramon, C., Yang, W., . . . Wang, H. (2017). Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation. Journal of Hematology and Oncology, 10(1). doi:10.1186/s13045-017-0504-1
Dandana, A., Gammoudi, I., Chalghoum, A., Chahed, H., Addad, F., Ferchichi, S., & Miled, A. (2014). Clinical utility of serum cystatin C in predicting coronary artery disease in patients without chronic kidney disease. Journal of Clinical Laboratory Analysis, 28(3), 191-197. doi:10.1002/jcla.21665
Daskalopoulou, S. S., Daskalopoulos, M. E., Liapis, C. D., & Mikhailidis, D. P. (2005). Peripheral arterial disease: A missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Current Medicinal Chemistry, 12(4), 443-452. doi:10.2174/0929867053363009
David, S., Kümpers, P., Lukasz, A., Fliser, D., Martens-Lobenhoffer, J., Bode-Böger, S. M., . . . Kielstein, J. T. (2010). Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrology Dialysis Transplantation, 25(8), 2571-2576. doi:10.1093/ndt/gfq060
Davis, I. D. (2003). Indications for renal transplantation and post-transplantation management. Annales Nestle, 61(1), 32-42. doi:10.1086/377672
de Bruijn, R. F. A. G., & Ikram, M. A. (2014). Cardiovascular risk factors and future risk of Alzheimer's disease. BMC Medicine, 12(1). doi:10.1186/s12916-014-0130-5
De Gómez Dumm, N. T., Giammona, A. M., & Touceda, L. A. (2003). Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine. Lipids in Health and Disease, 2, 1-6. doi:10.1186/1476-511X-2-1
De Gómez Dumm, N. T., Giammona, A. M., & Touceda, L. A. (2003). Variations in the lipid profile of patients with chronic renal failure, treated with folic acid. International Journal for Vitamin and Nutrition Research, 73(3), 215-220. doi:10.1024/0300-9831.73.3.215
de jaeger, C., Fraoucene, N., Voronska, E., & Cherin, P. (2010). Role of homocysteine in pathology. Medecine et Longevite, 2(2), 73-86. doi:10.1016/j.mlong.2010.03.002
de Koning, L., & Hu, F. B. (2010). Homocysteine lowering in end-stage renal disease: is there any cardiovascular benefit? Circulation, 121(12), 1379-1381. doi:10.1161/CIR.0b013e3181daa7c9
De Lorenzo, A., Noce, A., Bigioni, M., Calabrese, V., Della Rocca, D. G., Di Daniele, N., . . . Di Renzo, L. (2010). The effects of Italian Mediterranean Organic Diet (IMOD) on health status. Current Pharmaceutical Design, 16(7), 814-824. doi:10.2174/138161210790883561
de Meer, K., van den Akker, J. T., Smulders, Y., Stam, F., Stehouwer, C. D., & Finglas, P. (2002). In vivo stable isotope measurements of methyl metabolism: applications in pathophysiology and interventions. Food Nutr Bull, 23(3 Suppl), 113-119. 
De Meer, K., van den Akker, J. T., Smulders, Y., Stam, F., Stehouwer, C. D. A., & Finglas, P. (2002). In vivo stable isotope measurements of methyl metabolism: Applications in pathophysiology and interventions. Food and Nutrition Bulletin, 23(3 SUPP), 113-119. 
de Menezes, F. L., Koch-Nogueira, P. C., do Val, M. L. D. M., Pestana, J. O. M., Jorgetti, V., dos Reis, M. A., . . . Leite, H. P. (2019). Is arterial calcification in children and adolescents with end-stage renal disease a rare finding? Nephrology, 24(7), 696-702. doi:10.1111/nep.13480
De Santo, N. G., Cirillo, M., Perna, A., Iacono, G., & Capasso, G. (2006). Candidate risk factors for cardiovascular disease in CKD. Seminars in Nephrology, 26(1), 1-2. doi:10.1016/j.semnephrol.2005.06.001
De Santo, N. G., & Perna, A. F. (2006). Do elevated homocysteine levels predict mortality in chronic kidney disease stages 3-4? Nature Clinical Practice Nephrology, 2(11), 614-615. doi:10.1038/ncpneph0314
De Vecchi, A. F., Catena, F. B., Accinni, R., & Patrosso, C. (1999). Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis. Kidney Int, 56(4), 1604-1605. doi:10.1046/j.1523-1755.1999.00713-4.x
de Vecchi, A. F., Novembrino, C., Patrosso, M. C., Cresseri, D., Ippolito, S., Rosina, M., . . . Bamonti Catena, F. (2003). Effect of incremental doses of folate on homocysteine and metabolically related vitamin concentrations in nondiabetic patients on peritoneal dialysis. Asaio j, 49(6), 655-659. doi:10.1097/01.mat.0000094486.12329.6b
De Vriese, A. S., Langlois, M., Bernard, D., Geerolf, I., Stevens, L., Boelaert, J. R., . . . Matthys, E. (2003). Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients. Nephrol Dial Transplant, 18(12), 2596-2600. doi:10.1093/ndt/gfg437
De Vriese, A. S., Verbeke, F., Schrijvers, B. F., & Lameire, N. H. (2002). Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure? Kidney Int, 61(4), 1199-1209. doi:10.1046/j.1523-1755.2002.00249.x
Debreceni, B., & Debreceni, L. (2014). The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease. Cardiovascular Therapeutics, 32(3), 130-138. doi:10.1111/1755-5922.12064
Deebukkhum, S., Pingmuangkaew, P., Tangvarasittichai, O., & Tangvarasittichai, S. (2012). Estimated creatinine clearance, homocysteine and high sensitivity-C- reactive protein levels determination for early prediction of nephropathy and atherosclerosis risk in type 2 diabetic patients. Indian Journal of Clinical Biochemistry, 27(3), 239-245. doi:10.1007/s12291-012-0192-0
Deferrari, G., Cipriani, A., & La Porta, E. (2021). Renal dysfunction in cardiovascular diseases and its consequences. Journal of Nephrology, 34(1), 137-153. doi:10.1007/s40620-020-00842-w
Delanaye, P., Krzesinski, J. M., Warling, X., Moonen, M., Smelten, N., Médart, L., . . . Cavalier, E. (2014). Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron - Clinical Practice, 128(1-2), 127-134. doi:10.1159/000366449
Delanaye, P., Krzesinski, J. M., Warling, X., Smelten, N., & Cavalier, E. (2013). Vitamin k antagonists in hemodialysis patients: Impact on the plasma levels of dephospho-uncarboxylated matrix GLA-protein. Nephrology Dialysis Transplantation, 28, i12. doi:10.1093/ndt/gft141
Delanaye, P., Mariat, C., & Glassock, R. J. (2015). Safety of living kidney donation: Another brick in the wall...and a solid (Physiologic) One. American Journal of Kidney Diseases, 66(1), 1-3. doi:10.1053/j.ajkd.2015.04.005
Demir, M., Köse, K., Yazici, C., ÖZŞahin, A., Tokgöz, B., & Utaş, C. (2014). Cardiovascular risk factors in patients with hemodialysis: Paraoxonase and hyperhomocysteinemia. Clinical Chemistry, 60(10), S161. 
Demuth, K., & Germain, D. P. (2002). Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatrica, International Journal of Paediatrics, Supplement, 91(439), 57-61. doi:10.1111/j.1651-2227.2002.tb03112.x
Deng, X., Jiang, N., Guo, L., Wang, C., Li, J., Liu, X., . . . Liu, L. (2020). Protective Effects and Metabolic Regulatory Mechanisms of Shenyan Fangshuai Recipe on Chronic Kidney Disease in Rats. Evidence-based Complementary and Alternative Medicine, 2020. doi:10.1155/2020/5603243
Dennis, V. W., Nurko, S., & Robinson, K. (1997). Hyperhomocysteinemia: Detection, risk assessment, and treatment. Current Opinion in Nephrology and Hypertension, 6(5), 483-488. doi:10.1097/00041552-199709000-00013
Dennis, V. W., & Robinson, K. (1996). Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl, 57, S11-17. 
Derić, M., & Čabarkapa, V. S. (2010). Cardiovascular biomarkers in chronic kidney disease. Journal of Medical Biochemistry, 29(4), 298-303. doi:10.2478/v10011-010-0033-8
Derosa, G., Libetta, C., Esposito, P., Borettaz, I., Tinelli, C., D'Angelo, A., & Maffioli, P. (2017). Effects of two different dialytic treatments on inflammatory markers in people with end-stage renal disease with and without type 2 diabetes mellitus. Cytokine, 92, 75-79. doi:10.1016/j.cyto.2016.12.026
Dervisoglu, E., Kozdag, G., Etiler, N., & Kalender, B. (2012). Association of glomerular filtration rate and inflammation with left ventricular hypertrophy in chronic kidney disease patients. Hippokratia, 16(2), 137-142. 
Descombes, E., Boulat, O., Bersier, L. F., & Fellay, G. (2001). Difference in the homocysteine-lowering effect of folic acid in haemodialysis patients with and without occlusive vascular disease. Nephrol Dial Transplant, 16(3), 585-589. doi:10.1093/ndt/16.3.585
Dessì, M., Di Giovamberardino, G., Pieri, M., Noce, A., Zenobi, R., Di Daniele, N., & Pastore, A. (2015). Influence of dialysis techniques and alternate vitamin supplementation on homocysteine levels in patients with known MTHFR genotypes. Clinical and experimental nephrology, 19(1), 140‐145. doi:10.1007/s10157-014-0961-6
Dessì, M., Noce, A., Dawood, K. F., Galli, F., Taccone-Gallucci, M., Fabrini, R., . . . Ricci, G. (2012). Erythrocyte glutathione transferase: A potential new biomarker in chronic kidney diseases which correlates with plasma homocysteine. Amino Acids, 43(1), 347-354. doi:10.1007/s00726-011-1085-x
Dharnidharka, V. R., Kwon, C., & Stevens, G. (2002). Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis, 40(2), 221-226. doi:10.1053/ajkd.2002.34487
Di Daniele, N. (2019). The role of preventive nutrition in chronic non-communicable diseases. Nutrients, 11(5). doi:10.3390/nu11051074
Di Daniele, N., Di Renzo, L., Noce, A., Iacopino, L., Ferraro, P. M., Rizzo, M., . . . De Lorenzo, A. (2014). Effects of Italian Mediterranean organic diet vs. low-protein diet in nephropathic patients according to MTHFR genotypes. Journal of Nephrology, 27(5), 529-536. doi:10.1007/s40620-014-0067-y
Di Giuseppe, D., Di Simplicio, P., Capecchi, P. L., Lazzerini, P. E., & Pasini, F. L. (2003). Alteration in the redox state of plasma in heart-transplant patients with moderate hyperhomocysteinemia. J Lab Clin Med, 142(1), 21-28. doi:10.1016/s0022-2143(03)00057-x
Di Iorio, B. R., Bellasi, A., Raphael, K. L., Santoro, D., Aucella, F., Garofano, L., . . . Vitale, F. (2019). Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. Journal of Nephrology, 32(6), 989-1001. doi:10.1007/s40620-019-00656-5
Di Lullo, L., Rivera, R., Barbera, V., Bellasi, A., Cozzolino, M., Russo, D., . . . Ronco, C. (2016). Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies. International Journal of Cardiology, 217, 16-27. doi:10.1016/j.ijcard.2016.04.170
Di Minno, M. N., Tremoli, E., Coppola, A., Lupoli, R., & Di Minno, G. (2010). Homocysteine and arterial thrombosis: Challenge and opportunity. Thromb Haemost, 103(5), 942-961. doi:10.1160/th09-06-0393
Di Minno, M. N. D., Tremoli, E., Coppola, A., Lupoli, R., & Di Minno, G. (2010). Homocysteine and arterial thrombosis: Challenge and opportunity. Thrombosis and Haemostasis, 103(5), 942-961. doi:10.1160/TH09-06-0393
Diaz, E., Vanhaecke, C., Sanchez, J., Durlach, A., Gusdorf, L., & Viguier, M. (2020). Multifocal diffuse dermal angiomatosis: A reflection of high cardiovascular risk. Acta Dermato-Venereologica, 100(14), 1-2. doi:10.2340/00015555-3546
Dichgans, M., & Zietemann, V. (2012). Prevention of vascular cognitive impairment. Stroke, 43(11), 3137-3146. doi:10.1161/STROKEAHA.112.651778
Dierkes, J., Domröse, U., Ambrosch, A., Bosselmann, H. P., Neumann, K. H., & Luley, C. (1999). Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol, 51(2), 108-115. 
Dierkes, J., Domröse, U., Ambrosch, A., Schneede, J., Guttormsen, A. B., Neumann, K. H., & Luley, C. (1999). Supplementation with vitamin B12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Metabolism, 48(5), 631-635. doi:10.1016/s0026-0495(99)90062-8
Dierkes, J., Domröse, U., Bosselmann, K. P., Neumann, K. H., & Luley, C. (2001). Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 11(2), 67-72. 
Dierkes, J., Domröse, U., Westphal, S., Ambrosch, A., Bosselmann, H. P., Neumann, K. H., & Luley, C. (2000). Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation, 102(16), 1964-1969. doi:10.1161/01.cir.102.16.1964
Ding, N., Xie, L., Ma, F., Ma, S., Xiong, J., Lu, G., . . . Jiang, Y. (2022). miR-30a-5p promotes glomerular podocyte apoptosis via DNMT1-mediated hypermethylation under hyperhomocysteinemia. Acta biochimica et biophysica Sinica, 54(2), 1-11. doi:10.3724/abbs.2021005
Ditscheid, B., Fünfstück, R., Busch, M., Schubert, R., Gerth, J., & Jahreis, G. (2005). Effect of L-methionine supplementation on plasma homocysteine and other free amino acids: a placebo-controlled double-blind cross-over study. European journal of clinical nutrition, 59(6), 768‐775. doi:10.1038/sj.ejcn.1602138
Dobry, A., Ko, L., St. John, J., Sloan, M., Nigwekar, S., & Kroshinsky, D. (2018). Evaluating the association between hypercoagulable conditions and calciphylaxis in patients with renal disease: A retrospective case-control study. Journal of the American Academy of Dermatology, 79(3), AB134. doi:10.1016/j.jaad.2018.05.560
Dobry, A. S., Ko, L. N., John, J. S., Sloan, J. M., Nigwekar, S., & Kroshinsky, D. (2018). Association between hypercoagulable conditions and calciphylaxis in patients with renal disease a case-control study. JAMA Dermatology, 154(2), 182-187. doi:10.1001/jamadermatol.2017.4920
Domenici, F. A., Vannucchi, M. T., Simões-Ambrósio, L. M., & Vannucchi, H. (2007). Hyperhomocysteinemia and polymorphisms of the methylenetetrahydrofolate gene in hemodialysis and peritoneal dialysis patients. Mol Nutr Food Res, 51(11), 1430-1436. doi:10.1002/mnfr.200700114
Domenici, F. A., Vannucchi, M. T. I., Simões-Ambrósio, L. M. C., & Vannucchi, H. (2007). Hyperhomocysteinemia and polymorphisms of the methylenetetrahydrofolate gene in hemodialysis and peritoneal dialysis patients. Molecular Nutrition and Food Research, 51(11), 1430-1436. doi:10.1002/mnfr.200700114
Dong, Q., Tang, G., He, M., Cai, Y., Cai, Y., Xing, H., . . . Huo, Y. (2012). Methylenetetrahydrofolate reductase C677T polymorphism is associated with estimated glomerular filtration rate in hypertensive Chinese males. BMC Medical Genetics, 13. doi:10.1186/1471-2350-13-74
Doroszewski, W., Włodarczyk, Z., Strózecki, P., Manitius, J., Grabarczyk, E., Rość, D., & Odrowaz-Sypniewska, G. (2007). [Assessment of plasminogen activator inhibitor-1 and von Willebrand factor as a markers of endothelial function in patients with end-stage kidney disease after allotransplantation during a one-year follow-up]. Pol Arch Med Wewn, 117(5-6), 213-220. 
Doroszewski, W., Włodarczyk, Z., Strózecki, P., Manitius, J., Grabarczyk, E., Rość, D., & Odrowa̧z-Sypniewska, G. (2007). Assessment of plasminogen activator inhibitor-1 and von Willebrand factor as a marers of endothelial function in patients with end-stage kidney disease after allotransplantation during a one-year follow-up. Polskie Archiwum Medycyny Wewnetrznej, 117(5-6), 213-220. doi:10.20452/pamw.134
Dou, C., Xia, D., Zhang, L., Chen, X., Flores, P., Datta, A., & Yuan, C. (2005). Development of a novel enzymatic cycling assay for total homocysteine. Clinical Chemistry, 51(10), 1987-1989. doi:10.1373/clinchem.2005.053421
Dow, E. R., Tsui, I., & Sarraf, D. (2020). Macular Infarction in a Patient with Sickle Cell Trait. Retinal cases & brief reports. doi:10.1097/ICB.0000000000001014
Drewil, A. H., Al-Bayati, M. A., & Malik, A. S. (2020). Evaluation of indoxyl sulfate in chronic kidney disease associated with left ventricular hypertrophy. International Journal of Research in Pharmaceutical Sciences, 11(Special Issue 4), 3073-3079. doi:10.26452/IJRPS.V11ISPL4.4608
Dronca, M., Paşca, S. P., Nemeş, B., Vlase, L., & Vladutiu, D. (2008). Serum paraoxonase 1 activities and homocysteinemia in hemodialysis patients. Clinical Chemistry and Laboratory Medicine, 46(6), 880-881. doi:10.1515/CCLM.2008.164
Drut, A., Soetart, N., Bertin, C., Le Corff, E., Berder, C., Thorin, C., . . . Mallem, M. Y. (2020). Plasma homocysteine concentration in privately owned healthy adult cats: assessment of biological determinants and establishment of a reference interval. Journal of Feline Medicine and Surgery, 22(7), 623-630. doi:10.1177/1098612X19868549
Ducloux, D., Bresson-Vautrin, C., & Chalopin, J. M. (1999). Ocular venous occlusion and hyperhomocysteinemia. Ann Intern Med, 131(7), 548-549. doi:10.7326/0003-4819-131-7-199910050-00033
Ducloux, D., Motte, G., & Chalopin, J. M. (2000). Homocysteine in renal disease. Clinical Laboratory, 46(3-4), 141-151. 
Dukkipati, R., Adler, S., & Mehrotra, R. (2008). Cardiovascular implications of chronic kidney disease in older adults. Drugs and Aging, 25(3), 241-253. doi:10.2165/00002512-200825030-00006
Dülger, H., Gür, T., Sayarlioǧlu, H., Şekeroǧlu, M. R., Erkoç, R., & Beǧenik, H. (2007). Homocysteine levels and lipid profile in hemodialysis patients. Turkiye Klinikleri Journal of Medical Sciences, 27(4), 491-495. 
Dumler, F., & Kilates, C. (2007). Metabolic and Nutritional Complications of Renal Transplantation. Journal of Renal Nutrition, 17(1), 97-102. doi:10.1053/j.jrn.2006.10.017
Dupuis, L., Brown-Tortorici, A., Kalantar-Zadeh, K., & Joshi, S. (2021). A Mini Review of Plant-Based Diets in Hemodialysis. Blood Purification, 50(4-5), 672-677. doi:10.1159/000516249
Duranton, F., Cohen, G., De Smet, R., Rodriguez, M., Jankowski, J., Vanholder, R., & Argiles, A. (2012). Normal and pathologic concentrations of uremic toxins. Journal of the American Society of Nephrology, 23(7), 1258-1270. doi:10.1681/ASN.2011121175
Dursun, B., Yaʇi, B., Toraman, A., & Rota, S. (2015). Comparison of asymmetric dimethlyarginine levels and coronary artery calcifications in different stages of chronic kidney diseae and kidney transplantation. Transplant International, 28, 833. doi:10.1111/tri.12702
Dwivedi, R. S., Herman, J. G., McCaffrey, T. A., & Raj, D. S. C. (2011). Beyond genetics: Epigenetic code in chronic kidney disease. Kidney International, 79(1), 23-32. doi:10.1038/ki.2010.335
Eastell, R., Newman, C., & Crossman, D. C. (2010). Cardiovascular disease and bone. Archives of Biochemistry and Biophysics, 503(1), 78-83. doi:10.1016/j.abb.2010.06.008
Eaton, C. B. (2005). Traditional and emerging risk factors for cardiovascular disease. Primary Care - Clinics in Office Practice, 32(4), 963-976. doi:10.1016/j.pop.2005.09.009
Echouffo-Tcheugui, J. B., & Kengne, A. P. (2012). Risk Models to Predict Chronic Kidney Disease and Its Progression: A Systematic Review. PLoS Medicine, 9(11). doi:10.1371/journal.pmed.1001344
Edwards, D. G., & Martens, C. R. (2011). Peripheral vascular dysfunction in chronic kidney disease. Cardiology Research and Practice, 1(1). doi:10.4061/2011/267257
Efstratiadis, G., Tziomalos, K., Mikhailidis, D. P., Athyros, V. G., & Hatzitolios, A. (2008). Atherogenesis in renal patients: A model of vascular disease? Current Vascular Pharmacology, 6(2), 93-107. doi:10.2174/157016108783955374
Einollahi, B., Lessan-Pezeshki, M., Kalantar, E., Rostami, Z., Khalili, N., Ghadiani, M. H., & Ahmadi, J. (2011). Hyperhomocysteinemia after kidney transplantation. Transplant Proc, 43(2), 586-587. doi:10.1016/j.transproceed.2011.01.061
Eiselt, J., Rajdl, D., Racek, J., Vostrý, M., Rulcová, K., & Wirth, J. (2014). Asymmetric dimethylarginine and progression of chronic kidney disease - A one-year follow-up study. Kidney and Blood Pressure Research, 39(1), 50-57. doi:10.1159/000355776
Ekström, T. J., & Stenvinkel, P. (2009). The epigenetic conductor: A genomic orchestrator in chronic kidney disease complications? Journal of Nephrology, 22(4), 442-449. 
El Husseini, N., Kaskar, O., & Goldstein, L. B. (2014). Chronic kidney disease and stroke. Advances in Chronic Kidney Disease, 21(6), 500-508. doi:10.1053/j.ackd.2014.09.001
Elbaz, O., & Elagroudi, A. (2009). Elevated serum homocysteine in hemodialysis patients. Journal of Thrombosis and Haemostasis, 7(S2), 1188. doi:10.1111/j.1538-7836.2009.03473-3.x
Elfimova, E., Aksenova, A., Galitsin, P., Rvacheva, A., Zykov, K., Litvin, A., & Chazova, I. E. (2015). Effect of therapy on inflammatory risk factors of cardiovascular complications in patients with obstructive sleep apnea. Journal of Hypertension, 33, e476. doi:10.1097/01.hjh.0000468883.21778.cd
Elian, K. M., & Hoffer, L. J. (2002). Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease. Metabolism: clinical and experimental, 51(7), 881‐886. doi:10.1053/meta.2002.32800
Elias, M. F., Crichton, G. E., & Abhayaratna, W. P. (2015). Interactions between plasma homocysteine and arterial stiffness in chronic kidney disease in community-dwelling individuals: The Maine-syracuse study. Journal of Human Hypertension, 29(12), 726-731. doi:10.1038/jhh.2015.17
Elliott, M. K., McCaughan, J. A., & Fogarty, D. G. (2014). Do patients with chronic kidney disease get optimal cardiovascular risk reduction? Current Opinion in Nephrology and Hypertension, 23(3), 267-274. doi:10.1097/01.mnh.0000444913.78536.b1
Elmariah, S., Farrell, L. A., Daher, M., Shi, X., Keyes, M. J., Cain, C. H., . . . Gerszten, R. E. (2016). Metabolite Profiles Predict Acute Kidney Injury and Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement. J Am Heart Assoc, 5(3), e002712. doi:10.1161/jaha.115.002712
El-Mesallamy, H. O., Abdel Hamid, S. G., & Gad, M. Z. (2008). Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: Improvements by L-arginine intake. Kidney and Blood Pressure Research, 31(3), 189-195. doi:10.1159/000135655
El-Shafey, E. M. (2014). Reply to letter to the editor: Adiponectin levels in hemodialysis patients. Therapeutic Apheresis and Dialysis, 18(2), 216-217. doi:10.1111/1744-9987.12184
Emna, T., Ahlem, B., Kahena, B., Sana, H., Lilia, Z., Afef, B., & Jaouida, A. (2014). Risk factors of diabetic nephropathy. Clinical Chemistry and Laboratory Medicine, 52, S659. doi:10.1515/cclm-2014-4019
Emrich, I. E., Zawada, A. M., Rogacev, K. S., Seiler, S., Obeid, R., Geisel, J., . . . Heine, G. H. (2014). S-adenosylhomocysteine in CKD associated cardiovascular diesase. Nephrology Dialysis Transplantation, 29, iii375. doi:10.1093/ndt/gfu165
Emrich, I. E., Zawada, A. M., Seiler, S., Obeid, R., Geisel, J., Fliser, D., & Heine, G. H. (2016). S-Adenosylhomocysteine-a novel non-traditional cardiovascular risk factor in CKD. Perfusion (Germany), 29(3), 109. 
Emrich, I. E., Zawada, A. M., Seiler-Mußler, S., Obeid, R., Geisel, J., Fliser, D., & Heine, G. H. (2016). S-adenosylhomocysteine: A novel non-traditional cardiovascular risk factor in ckd. Nephrology Dialysis Transplantation, 31, i424. doi:10.1093/ndt/gfw188.7
Ensrud, K. E. (2013). Fracture risk in CKD. Clinical Journal of the American Society of Nephrology, 8(8), 1282-1283. doi:10.2215/CJN.06300613
Erdem, S. S., Hümeyra Yerlikaya, F., Tonbul, Z., Türkmen, K., Erdur, M. F., Taner, A., . . . Mehmetoʇlu, I. (2012). Asymmetric dimethylarginine and homocysteine levels in dialysis patients. Turkish Journal of Biochemistry, 37. 
Erdem, S. S., Yerlikaya, F. H., Tonbul, Z., Türkmen, K., Erdur, F. M., Taner, A., . . . Mehmetoglu, I. (2013). Asymmetric dimethylarginine and homocysteine levels in dialysis patients. European Journal of General Medicine, 10(2), 90-95. doi:10.29333/ejgm/82285
Errakonda, P. R., Paladugu, R., Bitla, A. R., Musturu, S. M., Lakshman, J., Pemmaraju, S. R., & Vishnubhotla, S. (2011). Effect of a single hemodialysis session on endothelial dysfunction. J Nephrol, 24(1), 83-90. doi:10.5301/jn.2010.4926
Ertek, S., Torun, A. N., & Ates, K. (2010). The factors that affect plasma homocysteine levels, pulse wave velocity and their relationship with cardiovascular disease indicators in peritoneal dialysis patients. Int Urol Nephrol, 42(1), 211-218. doi:10.1007/s11255-009-9625-y
Estrada-Veras, J., Alvarado-Enriquez, J., & Gahl, W. (2014). Cerebellar hypometabolism in erdheim chester disease: Histiocytic infiltration, early neurodegeneration or underlying metabolic deficit? Molecular Genetics and Metabolism, 111(3), 291. 
Etgen, T. (2015). Kidney disease as a determinant of cognitive decline and dementia. Alzheimer's Research and Therapy, 7(1). doi:10.1186/s13195-015-0115-4
Etgen, T., Bickel, H., & Förstl, H. (2010). Metabolic and endocrine factors in mild cognitive impairment. Ageing Research Reviews, 9(3), 280-288. doi:10.1016/j.arr.2010.01.003
Fabregate-Fuente, R., Andres-Castillo, A., Tello-Blasco, S., Barrio-Carreras, D., Rodriguez-Guerrero, A., Cano-Tebar, S., . . . Saban-Ruiz, J. (2015). Methylene tetrahydrofolate reductase genes mutations in resistant hyperhomocysteinemia. Atherosclerosis, 241(1), e215. 
Fabrizi, F., Messa, P., & Martin, P. (2014). Update to hepatitis C review. Kidney International, 85(5), 1238-1239. doi:10.1038/ki.2014.50
Fadel, F. I., Elshamaa, M. F., Essam, R. G., Elghoroury, E. A., El-Saeed, G. S. M., El-Toukhy, S. E., & Ibrahim, M. H. (2014). Some amino acids levels: Glutamine, glutamate, and homocysteine, in plasma of children with chronic kidney disease. International Journal of Biomedical Science, 10(1), 36-42. 
Fanning, J. P., Wong, A. A., & Fraser, J. F. (2014). The epidemiology of silent brain infarction: A systematic review of population-based cohorts. BMC Medicine, 119. doi:10.1186/PREACCEPT-3620022701268369
Farid, F., Faheem, M., El-Hakim, I., Abd El-Aziz, M., Rayan, M., & Mostafa, H. (2010). Adiponectin, dyslipidemia and cardiovascular events among pediatric patients with chronic kidney disease. NDT Plus, 3, iii546. 
Farid, F. A., Faheem, M. S., Heshmat, N. M., Shaheen, K. Y., & Saad, S. S. (2004). Study of the homocysteine status in children with chronic renal failure. American Journal of Nephrology, 24(3), 289-295. doi:10.1159/000077855
Farouk, H., Kandil, D., Kamel, S., Elghoroury, E. A., Elshamaa, M. F., Sabry, S., & Galal, A. (2013). Effect of GSTM1 and GSTT1 deletions in the development of oxidative stress in children with chronic kidney disease. Journal of Clinical and Basic Cardiology, 16(1-4), 1-5. 
Faure, V., Dou, L., Sabatier, F., Cerini, C., Sampol, J., Berland, Y., . . . Dignat-George, F. (2006). Elevation of circulating endothelial microparticles in patients with chronic renal failure. Journal of Thrombosis and Haemostasis, 4(3), 566-573. doi:10.1111/j.1538-7836.2005.01780.x
Feinstein, S., Sela, B. A., Drukker, A., Becker-Cohen, R., Raveh, D., Gavendo, S., & Frishberg, Y. (2002). Hyperhomocysteinemia in children on renal replacement therapy. Pediatr Nephrol, 17(7), 515-519. doi:10.1007/s00467-002-0901-7
Feix, A., Winkelmayer, W. C., Eberle, C., Sunder-Plassmann, G., & Födinger, M. (2004). Methionine synthase reductase MTRR 66A > G has no effect on total homocysteine, folate, and Vitamin B12 concentrations in renal transplant patients. Atherosclerosis, 174(1), 43-48. doi:10.1016/j.atherosclerosis.2003.12.036
Feldt-Rasmussen, B., & El Nahas, M. (2009). Potential Role of Growth Factors With Particular Focus on Growth Hormone and Insulin-Like Growth Factor-1 in the Management of Chronic Kidney Disease. Seminars in Nephrology, 29(1), 50-58. doi:10.1016/j.semnephrol.2008.10.007
Feliers, D., Lee, H. J., & Kasinath, B. S. (2016). Hydrogen Sulfide in Renal Physiology and Disease. Antioxidants and Redox Signaling, 25(13), 720-731. doi:10.1089/ars.2015.6596
Fellah, H., Feki, M., Feki, H., Souissi, M., Kaabachi, N., Ben Abdallah, T., . . . Mebazaa, A. (2004). Classical and "non-classical" cardiovascular risk factors in Tunisian patients with end stage renal disease: prevalence and association with cardiovascular events. Clin Lab, 50(7-8), 447-453. 
Fellah, H., Feki, M., Hsairi, M., Sanhaji, H., Kaabachi, N., Abdallah, T. B., . . . Mebazaa, A. (2003). Hyperhomocysteinemia and end-stage renal disease: Determinants and association with cardiovascular disease in Tunisian patients. Clinical Chemistry and Laboratory Medicine, 41(5), 675-680. doi:10.1515/CCLM.2003.102
Fellah, H., Feki, M., Hsairi, M., Sanhaji, H., Kaabachi, N., Ben Abdallah, T., . . . Mebazaa, A. (2003). Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients. Clin Chem Lab Med, 41(5), 675-680. doi:10.1515/cclm.2003.102
Fellah, H., Hammami, M. B., Feki, M., Boubaker, K., Abdallah, T. B., Lacour, B., . . . Kaabachi, N. (2009). Predictors for cardiovascular morbidity and overall mortality in Tunisian ESRD patients: a six year prospective study. Clin Biochem, 42(7-8), 648-653. doi:10.1016/j.clinbiochem.2008.12.023
Fellström, B., Holdaas, H., Jardine, A. G., Svensson, M. K., Gottlow, M., Schmieder, R. E., & Zannad, F. (2009). Cardiovascular disease in patients with renal disease: The role of statins. Current Medical Research and Opinion, 25(1), 271-285. doi:10.1185/03007990802622064
Feng, J., Lu, X., Wang, S., & Li, H. (2021). The assessment of cognitive impairment in maintenance hemodialysis patients and the relationship between cognitive impairment and depressive symptoms. Seminars in dialysis. doi:10.1111/sdi.13031
Feng, Y., Liang, W., Liang, W., Xiao, X., & Zhang, Y. (2022). Effects of XueZhiTong capsules on chronic kidney disease patients with dyslipidemia. Tropical Journal of Pharmaceutical Research, 21(1), 177-183. doi:10.4314/tjpr.v21i1.26
Ferechide, D., & Radulescu, D. (2009). Hyperhomocysteinemia in renal diseases. Journal of medicine and life, 2(1), 53-59. 
Fernández-Andrade, C. (2002). [Renal markers and predictors, and renal and cardiovascular risk factors]. Nefrologia, 22 Suppl 1, 2-29. 
Ferramosca, E., Burke, S., Chasan-Taber, S., Ratti, C., Chertow, G. M., & Raggi, P. (2005). Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J, 149(5), 820-825. doi:10.1016/j.ahj.2004.07.023
Fiedler, R., Mall, M., Wand, C., & Osten, B. (2005). Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. J Ren Nutr, 15(2), 253-256. doi:10.1053/j.jrn.2005.01.007
Filiopoulos, V., Hadjiyannakos, D., Takouli, L., Metaxaki, P., Sideris, V., & Vlassopoulos, D. (2009). Inflammation and oxidative stress in end-stage renal disease patients treated with hemodialysis or peritoneal dialysis. Int J Artif Organs, 32(12), 872-882. doi:10.1177/039139880903201206
Filiopoulos, V., & Vlassopoulos, D. (2009). Inflammatory syndrome in chronic kidney disease: Pathogenesis and influence on outcomes. Inflammation and Allergy - Drug Targets, 8(5), 369-382. doi:10.2174/1871528110908050369
Fischer, D. C., Nissel, R., Puhlmann, A., Mitzner, A., Tieß, M., Schmidt, R., & Haffner, D. (2009). Differential effects of short-term growth hormone therapy on the cardiovascular risk profile in patients with chronic kidney disease: A pilot study. Clinical Nephrology, 72(5), 344-352. doi:10.5414/cnp72344
Fischer, D. C., Nissel, R., Puhlmann, A., Mitzner, A., Tieß, M., Schmidt, R., & Haffner, D. (2010). Differential effects of short-term growth hormone therapy on the cardiovascular risk profile in patients with chronic kidney disease: A pilot study. Nieren- und Hochdruckkrankheiten, 39(8), 312-321. doi:10.5414/nhp39312
Flisinski, M., Brymora, A., Elminowska-Wenda, G., Bogucka, J., Walasik, K., Stefanska, A., . . . Manitius, J. (2014). Morphometric analysis of muscle fibre types in rat locomotor and postural skeletalmuscles in different stages of chronic kidney disease. Journal of Physiology and Pharmacology, 65(4), 567-576. 
Flisiński, M., Brymora, A., Stefańska, A., Strózecki, P., & Manitius, J. (2013). The impact of dietary fructose increase on markers of kidney injury and inflammation in uninephrectomized rats. Nephrology Dialysis Transplantation, 28, i162-i163. doi:10.1093/ndt/gft111
Flisinski, M., Wisniewska-Chudy, E., Brymora, A., Stefanska, A., Strozecki, P., & Manitius, J. (2017). Chronic kidney disease leads to hypoxia inducible factor-1alpha to hypoxia inducible factor-2alpha switch in the gastrocnemius muscle. Journal of Physiology and Pharmacology, 68(3), 419-425. 
Florentin, M., Liberopoulos, E. N., Kei, A., Mikhailidis, D. P., & Elisaf, M. S. (2011). Pleiotropic effects of nicotinic acid: Beyond high density lipoprotein cholesterol elevation. Current Vascular Pharmacology, 9(4), 385-400. doi:10.2174/157016111796197279
Florian, T., Tepel, M., Ying, L., Katharina, K., Nora, F., Antje, W., & Alexandra, S. (2012). Cysteine residues regulate transient receptor potential canonical type 6 channel PROTEIN EXPRESSION. Nephrology Dialysis Transplantation, 27, ii79. doi:10.1093/ndt/gfs213
Flynn, J. T. (2006). Cardiovascular disease in children with chronic renal failure. Growth Hormone and IGF Research, 16(SUPPL.), 84-90. doi:10.1016/j.ghir.2006.03.014
Födinger, M., Buchmayer, H., Heinz, G., Papagiannopoulos, M., Kletzmayr, J., Perschl, A., . . . Sunder-Plassmann, G. (2001). Association of two MTHFR polymorphisms with total homocysteine plasma levels in dialysis patients. Am J Kidney Dis, 38(1), 77-84. doi:10.1053/ajkd.2001.25197
Födinger, M., Dierkes, J., Skoupy, S., Röhrer, C., Hagen, W., Puttinger, H., . . . Sunder-Plassmann, G. (2003). Effect of glutamate carboxypeptidase II and reduced folate carrier polymorphisms on folate and total homocysteine concentrations in dialysis patients. J Am Soc Nephrol, 14(5), 1314-1319. doi:10.1097/01.asn.0000064949.67401.d3
Födinger, M., Mannhalter, C., Wölfl, G., Pabinger, I., Müller, E., Schmid, R., . . . Sunder-Plassmann, G. (1997). Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int, 52(2), 517-523. doi:10.1038/ki.1997.362
Födinger, M., Veitl, M., Skoupy, S., Wojcik, J., Röhrer, C., Hagen, W., . . . Sunder-Plassmann, G. (2003). Effect of TCN2 776C>G on vitamin B12 cellular availability in end-stage renal disease patients. Kidney Int, 64(3), 1095-1100. doi:10.1046/j.1523-1755.2003.00173.x
Foidart, J. M., Seak-San, S., Emonts, P., & Schaaps, J. P. (2003). Vascular placental pathology in high-risk groups: Definition and synopsis. Annales de Medecine Interne, 154(5-6), 332-339. 
Fomin, V. V., Rogova, I. V., Damulin, I. V., & Mukhin, N. A. (2015). Cognitive impairment in predialysis stages of chronic kidney disease. Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova, 2015(12), 25-30. doi:10.17116/jnevro201511511225-30
Fort, J. (2005). Chronic renal failure: a cardiovascular risk factor. Kidney international. Supplement(99), S25-29. 
Foucher, C., Brugère, L., & Ansquer, J. C. (2010). Fenofibrate, homocysteine and renal function. Current Vascular Pharmacology, 8(5), 589-603. doi:10.2174/157016110792006987
Fox, C. S., Gona, P., Larson, M. G., Selhub, J., Tofler, G., Hwang, S. J., . . . Vasan, R. S. (2010). A multi-marker approach to predict incident CKD and microalbuminuria. Journal of the American Society of Nephrology, 21(12), 2143-2149. doi:10.1681/ASN.2010010085
Francis, M. E., Eggers, P. W., Hostetter, T. H., & Briggs, J. P. (2004). Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney International, 66(1), 303-312. doi:10.1111/j.1523-1755.2004.00732.x
Francisco, L. V., Deminice, R., Jordão, A. A., & Da Silva, L. E. (2012). Creatine supplementation and homocysteine metabolism in rats fed choline-deficient diet. Journal of Nutrigenetics and Nutrigenomics, 5(4-5), 248-249. doi:10.1159/000343955
Franco, Á., Starosta, R. T., & Roriz-Cruz, M. (2019). The specific impact of uremic toxins upon cognitive domains: a review. Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia, 41(1), 103-111. doi:10.1590/2175-8239-JBN-2018-0033
Franco Á, O., Starosta, R. T., & Roriz-Cruz, M. (2019). The specific impact of uremic toxins upon cognitive domains: a review. J Bras Nefrol, 41(1), 103-111. doi:10.1590/2175-8239-jbn-2018-0033
Franke, S., Müller, A., Sommer, M., Busch, M., Kientsch-Engel, R., & Stein, G. (2003). Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. Clin Nephrol, 59(2), 88-97. doi:10.5414/cnp59088
Frick, B., Neurauter, G., & Fuchs, D. (2002). Moderate hyperhomocysteinemia and oxidative stress [4]. Kidney International, 61(5), 1910. doi:10.1046/j.1523-1755.2002.00345.x
Friedman, A. N. (2002). Pharmacologic B-vitamin therapy for hyperhomocysteinemia in dialysis patients: has the time come? Nutrition in clinical care : an official publication of Tufts University, 5(1), 20-24. 
Friedman, A. N., Rosenberg, I. H., Selhub, J., Levey, A. S., & Bostom, A. G. (2002). Hyperhomocysteinemia in renal transplant recipients. American Journal of Transplantation, 2(4), 308-313. doi:10.1034/j.1600-6143.2002.20404.x
Friedman, J. A., & Dwyer, J. T. (1995). Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis. Nutr Rev, 53(7), 197-201. doi:10.1111/j.1753-4887.1995.tb01551.x
Fu, W., Dudman, N. P., Perry, M. A., Young, K., & Wang, X. L. (2000). Interrelations between plasma homocysteine and intracellular S-adenosylhomocysteine. Biochem Biophys Res Commun, 271(1), 47-53. doi:10.1006/bbrc.2000.2587
Fu, W., Dudman, N. P. B., Perry, M. A., Young, K., & Wang, X. L. (2000). Interrelations between plasma homocysteine and intracellular S-adenosylhomocysteine. Biochemical and Biophysical Research Communications, 271(1), 47-53. doi:10.1006/bbrc.2000.2587
Fukasawa, M., Matsushita, K., Kamiyama, M., Mikami, Y., Araki, I., Yamagata, Z., & Takeda, M. (2003). The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis, 41(3), 637-642. doi:10.1053/ajkd.2003.50125
Fukuzawa, J., Hasebe, N., Yao, N., Koyama, S., & Kikuchi, K. (2006). Homocysteine. Nippon rinsho. Japanese journal of clinical medicine, 64 Suppl 5, 173-176. 
Fung, M. M., Salem, R. M., Lipkowitz, M. S., Bhatnagar, V., Pandey, B., Schork, N. J., & O'Connor, D. T. (2012). Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC). Nephrology, dialysis, transplantation, 27(1), 197‐205. doi:10.1093/ndt/gfr257
Gade, K., Blaschke, S., Rodenbeck, A., Becker, A., Anderson-Schmidt, H., & Cohrs, S. (2013). Uremic restless legs syndrome (RLS) and sleep quality in patients with end-stage renal disease on hemodialysis: Potential role of homocysteine and parathyroid hormone. Kidney and Blood Pressure Research, 37(4-5), 458-463. doi:10.1159/000355727
Gaitonde, D. Y., Cook, D. L., & Rivera, I. M. (2017). Chronic Kidney Disease: Detection and Evaluation. Am Fam Physician, 96(12), 776-783. 
Galli, F., Benedetti, S., Buoncristiani, U., Piroddi, M., Conte, C., Canestrari, F., . . . Floridi, A. (2003). The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney international, 64(2), 748‐755. doi:10.1046/j.1523-1755.2003.00134.x
Galli, F., Piroddi, M., Bartolini, D., Ciffolilli, S., Buoncristiani, E., Ricci, G., & Buoncristiani, U. (2014). Blood thiol status and erythrocyte glutathione-S-transferase in chronic kidney disease patients on treatment with frequent (daily) hemodialysis. Free Radical Research, 48(3), 273-281. doi:10.3109/10715762.2013.861901
Gallo, M. (2019). The real-life study on expanded hemodialysis (HDX): 9 months experience of a single hemodialysis unit. Nephrology Dialysis Transplantation, 34, a226. doi:10.1093/ndt/gfz106.FP539
Galosi, S., Nardecchia, F., & Leuzzi, V. (2020). Treatable Inherited Movement Disorders in Children: Spotlight on Clinical and Biochemical Features. Movement Disorders Clinical Practice, 7(2), 154-166. doi:10.1002/mdc3.12897
Ganda, A., Weiner, S. D., Chudasama, N. L., Valeri, A. M., Jadoon, A., Shimbo, D., & Radhakrishnan, J. (2012). Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction. Clinical Nephrology, 77(5), 366-375. doi:10.5414/CN107169
García-Bello, J. A., Gómez-Díaz, R. A., Contreras-Rodríguez, A., Sánchez-Barbosa, L., Mondragón-González, R., Gallardo-Montoya, J. M., & Wacher, N. H. (2021). Endothelial dysfunction in children with chronic kidney disease. Nefrologia, 41(4), 436-445. doi:10.1016/j.nefroe.2020.10.002
Garcia-Bello, J. A., Gómez-Díaz, R. A., Contreras-Rodríguez, A., Talavera, J. O., Mondragón-González, R., Sanchez-Barbosa, L., . . . Wacher, N. H. (2014). Carotid intima media thickness, oxidative stress, and inflammation in children with chronic kidney disease. Pediatric Nephrology, 29(2), 273-281. doi:10.1007/s00467-013-2626-1
Garg, A. X. (2013). Living kidney donation: Biochemical changes and patient outcomes. American Journal of Kidney Diseases, 62(3), 448-449. doi:10.1053/j.ajkd.2013.06.006
Garibotto, G., Fiorini, F., Sala, M. R., Marchelli, M., Verzola, D., Rossi, D., & Sofia, A. (2003). Amino acid loss with polyethersulfone. Contributions to nephrology(138), 59-67. 
Garibotto, G., Sofia, A., Valli, A., Tarroni, A., Di Martino, M., Cappelli, V., . . . Procopio, V. (2006). Causes of hyperhomocysteinemia in patients with chronic kidney diseases. Seminars in Nephrology, 26(1), 3-7. doi:10.1016/j.semnephrol.2005.06.002
Garibotto, G., Valli, A., Anderstam, B., Eriksson, M., Suliman, M. E., Balbi, M., . . . Lindholm, B. (2009). The kidney is the major site of S-adenosylhomocysteine disposal in humans. Kidney Int, 76(3), 293-296. doi:10.1038/ki.2009.117
Garibotto Giacomo, G., Sofia, A., Saffioti, S., Bonanni, A., Mannucci, I., & Verzola, D. (2010). Amino acid and protein metabolism in the human kidney and in patients with chronic kidney disease. Clinical Nutrition, 29(4), 424-433. doi:10.1016/j.clnu.2010.02.005
Gastrich, M. D., Bachmann, G., Balica, A., & Lasser, N. L. (2008). A review of randomized controlled trials showing the benefits of nutritional and pharmacological treatments to reduce carotid intima media thickness. Topics in Clinical Nutrition, 23(2), 158-186. doi:10.1097/01.TIN.0000318912.61982.87
Gavriilaki, E., Paschou, E., Kalaitzoglou, A., Papaioannou, G., & Sabanis, N. (2015). B12 deficiency in chronic kidney disease: Early recognition matters. Internal Medicine Journal, 45(11), 1195-1196. doi:10.1111/imj.12892
Gebhart, F. (2005). New hypertension definition could boost drug utilization. Drug Topics, 149(12). 
Gentil, M. A., Cabello, V., Campistol, J. M., Gomez, C., Polo, J., & Ortega, F. (2010). Causal factors of anaemia in Kidney Transplant (KT) patients with stage 3-4 Chronic Kidney Disease (CKD). American Journal of Transplantation, 10, 247-248. doi:10.1111/j.1600-6143.2010.03108.x
George, T., Abraham, G., Ezhilan, J., Manickam, K., & Ramkumar, S. R. (2011). Coronary artery disease and its management in chronic kidney disease patients-a south indian study. Catheterization and Cardiovascular Interventions, 77, S93-S94. doi:10.1002/ccd.23089
Ghanbari, Y., Munshi, M. U. A., & Nagaraju, K. (2016). Effect of folic acid, pyridoxine and cyanocobalamin in reducing the elevated level of homocysteine in advance chronic kidney disease and end-stage renal disease. International Research Journal of Pharmacy, 7(5), 24-28. doi:10.7897/2230-8407.07546
Ghandour, H., Bagley, P. J., Shemin, D., Hsu, N., Jacques, P. F., Dworkin, L., . . . Selhub, J. (2002). Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid. Kidney international, 62(6), 2246‐2249. doi:10.1046/j.1523-1755.2002.00666.x
Ghoshal, S., Allred, N. D., & Freedman, B. I. (2020). The Contribution of Kidney Disease to Cognitive Impairment in Patients with Type 2 Diabetes. Current Diabetes Reports, 20(10). doi:10.1007/s11892-020-01333-9
Gill, S. S., & Alibhai, S. M. H. (2003). Folate deficiency, homocysteine and dementia. Geriatrics and Aging, 6(4), 24-28. 
Giraldi, M., Paltrinieri, S., Curcio, C., & Scarpa, P. (2019). Serum concentration of homocysteine in spontaneous feline chronic kidney disease. Veterinary Journal, 254. doi:10.1016/j.tvjl.2019.105358
Gluba, A., Mikhailidis, D. P., Lip, G. Y. H., Hannam, S., Rysz, J., & Banach, M. (2013). Metabolic syndrome and renal disease. International Journal of Cardiology, 164(2), 141-150. doi:10.1016/j.ijcard.2012.01.013
Goldenstein, H., Levy, N. S., Lipener, Y. T., & Levy, A. P. (2013). Patient selection and vitamin E treatment in diabetes mellitus. Expert Review of Cardiovascular Therapy, 11(3), 319-326. doi:10.1586/erc.12.187
Goldsmith, D. (2008). Negative outcome studies in end-stage renal disease. Blood Purification, 26(1), 63-66. doi:10.1159/000110567
Goldsmith, D., & Covic, A. (2014). The EVOLVE study is negative, so what does this 'bitter pill' of disappointment mean now for renal patients? International Journal of Clinical Practice, 68(3), 286-289. doi:10.1111/ijcp.12261
Goldsmith, D. J. A., & Covic, A. (2008). Calcium and the saga of the binders: Accumulating controversy, or building consensus? International Urology and Nephrology, 40(4), 1009-1014. doi:10.1007/s11255-008-9477-x
Goligorsky, M. S. (2000). Endothelial cell dysfunction and nitric oxide synthase. Kidney International, 58(3), 1360-1376. doi:10.1046/j.1523-1755.2000.00292.x
Goligorsky, M. S. (2005). Endothelial cell dysfunction: Can't live with it, how to live without it. American Journal of Physiology - Renal Physiology, 288(5 57-5), F871-F880. doi:10.1152/ajprenal.00333.2004
Goligorsky, M. S. (2015). Pathogenesis of endothelial cell dysfunction in chronic kidney disease: A retrospective and what the future may hold. Kidney Research and Clinical Practice, 34(2), 76-82. doi:10.1016/j.krcp.2015.05.003
Golubev, R. V., Blashko, E. L., Dobronravov, V. A., Zhloba, A. A., & Smirnov, A. V. (2005). Elevated plasma homocysteine and glutathione level in patients with renal failure. Biomeditsinskaya Khimiya, 51(5), 549-551. 
Gómez-Díaz, R. A., García-Bello, J. A., Mondragón-González, R., Díaz-Flores, M., Valladares-Salgado, A., Gallardo, J. M., . . . Wacher, N. H. (2013). Metabolic syndrome in children with chronic kidney disease: PON1 and treatment modality. Archives of Medical Research, 44(8), 645-649. doi:10.1016/j.arcmed.2013.10.014
Gonçalves, D. L. N., Moreira, T. R., & da Silva, L. S. (2022). A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease. Sci Rep, 12(1), 6251. doi:10.1038/s41598-022-10118-x
Gonin, J. M. (2005). Folic acid supplementation to prevent adverse events in individuals with chronic kidney disease and end stage renal disease. Current Opinion in Nephrology and Hypertension, 14(3), 277-281. doi:10.1097/01.mnh.0000165896.98372.f4
Gonin, J. M., Nguyen, H., Gonin, R., Sarna, A., Michels, A., Masri-Imad, F., . . . Wilcox, C. S. (2003). Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. J Nephrol, 16(4), 522-534. 
Gonin, J. M., Nguyen, H., Gonin, R., Sarna, A., Michels, A., Masri-Imad, F., . . . et al. (2003). Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. Journal of nephrology, 16(4), 522‐534. 
Goodnough, L. T., & Schrier, S. L. (2014). Evaluation and management of anemia in the elderly. American Journal of Hematology, 89(1), 88-96. doi:10.1002/ajh.23598
Gorin, Y. (2013). Nox4 as a potential therapeutic target for treatment of uremic toxicity associated to chronic kidney disease. Kidney International, 83(4), 541-543. doi:10.1038/ki.2012.434
Goto, S., Yoshiya, K., Kita, T., Fujii, H., & Fukagawa, M. (2011). Uremic Toxins and Oral Adsorbents. Therapeutic Apheresis and Dialysis, 15(2), 132-134. doi:10.1111/j.1744-9987.2010.00891.x
Graboski, A. L., & Redinbo, M. R. (2020). Gut-Derived Protein-Bound Uremic Toxins. Toxins, 12(9). doi:10.3390/toxins12090590
Grabowska-Polanowska, B., Skowron, M., Miarka, P., Pietrzycka, A., & Śliwka, I. (2017). The application of chromatographic breath analysis in the search of volatile biomarkers of chronic kidney disease and coexisting type 2 diabetes mellitus. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1060, 103-110. doi:10.1016/j.jchromb.2017.05.030
Grant, W. B. (2016). Using Multicountry Ecological and Observational Studies to Determine Dietary Risk Factors for Alzheimer's Disease. Journal of the American College of Nutrition, 35(5), 476-489. doi:10.1080/07315724.2016.1161566
Gu, Y., Chen, M., Zhu, B., Pei, X., Yong, Z., Li, X., . . . Zhao, W. (2020). A risk scoring system for the decreased glomerular filtration rate in Chinese general population. Journal of Clinical Laboratory Analysis, 34(4). doi:10.1002/jcla.23143
Gu, Z., Huang, Y., Yang, F., Tang, S., Sun, J., Chen, T., . . . Wang, J. (2021). The application of neutrophil gelatin-related lipid delivery protein in evaluation of renal function, nutrition, anemia and inflammation in patients with CKD. Nephrologie et Therapeutique, 17(1), 35-41. doi:10.1016/j.nephro.2020.10.006
Guay, D. R. P. (2010). Geriatric pharmacotherapy updates. American Journal Geriatric Pharmacotherapy, 8(6), 599-609. doi:10.1016/S1543-5946(10)80009-1
Guerraty, M. A., Chai, B., Hsu, J. Y., Ojo, A. O., Gao, Y., Yang, W., . . . Mohler, E. R. (2015). Relation of aortic valve calcium to chronic kidney disease (from the Chronic Renal Insufficiency Cohort Study). American Journal of Cardiology, 115(9), 1281-1286. doi:10.1016/j.amjcard.2015.02.011
Guerrot, D., & Humalda, J. K. (2020). Blood pressure targets in chronic kidney disease: an update on the evidence. Curr Opin Nephrol Hypertens, 29(3), 327-332. doi:10.1097/mnh.0000000000000601
Guessous, I., Ponte, B., Marques-Vidal, P., Paccaud, F., Gaspoz, J. M., Burnier, M., . . . Bochud, M. (2014). Clinical and biological determinants of kidney outcomes in a population-based cohort study. Kidney and Blood Pressure Research, 39(1), 74-85. doi:10.1159/000355779
Gugliucci, A., Kotani, K., & Kimura, S. (2012). Paraoxonase 1 in chronic kidney failure. Journal of Lipids, 2012. doi:10.1155/2012/726048
Guimarães, A. C. (2006). Hyperhomocysteinemia as a risk factor for coronary atherosclerotic disease in the elderly. Arquivos Brasileiros de Cardiologia, 86(2), 83-84. 
Güngör, Y., Kayataş, M., Yıldız, G., Özdemir, Ö., & Candan, F. (2011). The presence of PAI-1 4G/5G and ACE DD genotypes increases the risk of early-stage AVF thrombosis in hemodialysis patients. Ren Fail, 33(2), 169-175. doi:10.3109/0886022x.2011.552151
Gupta, A., & Robinson, K. (1997). Hyperhomocysteinaemia and end stage renal disease. J Nephrol, 10(2), 77-84. 
Gupta, R., Birnbaum, Y., & Uretsky, B. F. (2004). The renal patient with coronary artery disease: Current concepts and dilemmas. Journal of the American College of Cardiology, 44(7), 1343-1353. doi:10.1016/j.jacc.2004.06.058
Guttormsen, A. B., Ueland, P. M., Svarstad, E., & Refsum, H. (1997). Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney International, 52(2), 495-502. doi:10.1038/ki.1997.359
Hachinski, V., Ganten, D., Lackland, D., Kreutz, R., Tsioufis, K., Hacke, W., & World Stroke Organization, t. W. H. F. t. W. H. L. t. E. S. o. H. (2018). Implementing the proclamation of stroke and potentially preventable dementias. Journal of Clinical Hypertension, 20(10), 1354-1359. doi:10.1111/jch.13382
Hadi, H. A., Carr, C. S., & Al Suwaidi, J. (2005). Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vascular health and risk management, 1(3), 183-198. 
Hage, F. G., Venkataraman, R., Zoghbi, G. J., Perry, G. J., DeMattos, A. M., & Iskandrian, A. E. (2009). The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 53(23), 2129-2140. doi:10.1016/j.jacc.2009.02.047
Hagen, W., Födinger, M., Hörl, W. H., & Sunder-Plassmann, G. (2001). Therapy of hyperhomocysteinemia in end-stage renal disease patients. Minerva Urologica e Nefrologica, 53(3), 159-170. 
Hagen, W., Födinger, M., Hörl, W. H., & Sunder-Plass-Mann, G. (2001). Therapy of hyperhomocysteinemia in end-stage renal disease patients. Minerva Urol Nefrol, 53(3), 159-170. 
Hages, M., & Pietrzik, K. (1996). Vitamin therapy of hyperhomocysteinaemia in chronic renal failure. Nephrology Dialysis Transplantation, 11(9), 1933. doi:10.1093/oxfordjournals.ndt.a027724
Hajhosseiny, R., Khavandi, K., & Goldsmith, D. J. (2013). Cardiovascular disease in chronic kidney disease: Untying the Gordian knot. International Journal of Clinical Practice, 67(1), 14-31. doi:10.1111/j.1742-1241.2012.02954.x
Halabi, G., Gauthier, T., Darioli, R., Mooser, V., Vogel, G., & Wauters, J. P. (1998). Hyperhomocysteinemia in chronic renal failure: Prevalence, mechanisms and therapeutic possibilities. Medecine et Hygiene, 56(2197), 376-379. 
Halimi, J. M., & Lebranchu, Y. (2000). Regulation and dysfunction of endothelium-dependent vasomotricity: Applications in clinical practice. Presse Medicale, 29(38), 2109-2115. 
Hamdouni, H., Achour, O., Naija, S., Aounallah, M., Mhiri, M., Ben Rejeb, N., . . . Bouslama, A. (2016). Dementia genetic and environmental risk factors in a Tunisian population. Clinical Chemistry and Laboratory Medicine, 54(10), eA278. doi:10.1515/cclm-2016-0657
Hamed, S. A. (2019). Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies. Expert Review of Clinical Pharmacology, 12(1), 61-90. doi:10.1080/17512433.2019.1555468
Han, C., Xu, K., Wang, L., Zhang, Y., Zhang, R., Wei, A., . . . Cong, H. (2022). Impact of persistent subclinical hypothyroidism on clinical outcomes in non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. Clinical Endocrinology, 96(1), 70-81. doi:10.1111/cen.14613
Han, H., Dwyer, J. T., Selhub, J., Jacques, P. F., Park, J. H., Kim, Y. S., . . . Bostom, A. G. (2000). Determinants of plasma total homocysteine levels in Korean chronic renal transplant recipients. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 10(4), 202-207. 
Han, H., Wang, Y., Li, X., Wang, P. A., Wei, X., Liang, W., . . . Yi, F. (2013). Novel role of NOD2 in mediating Ca2+ signaling: evidence from NOD2-regulated podocyte TRPC6 channels in hyperhomocysteinemia. Hypertension, 62(3), 506-511. doi:10.1161/hypertensionaha.113.01638
Han, Q. X., Zhang, D., Zhao, Y. L., Liu, L., Li, J., Zhang, F., . . . Zhu, H. Y. (2019). Risk factors for hyperuricemia in Chinese centenarians and near-centenarians. Clinical Interventions in Aging, 14, 2239-2247. doi:10.2147/CIA.S223048
Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., . . . Wyne, K. L. (2020). Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm-2020 executive summary. Endocrine Practice, 26(10), 1196-1224. doi:10.4158/CS-2020-0490
Hankey, G. J. (2018). B vitamins for stroke prevention. Stroke and Vascular Neurology, 3(2), 51-58. doi:10.1136/svn-2018-000156
Hannedouche, T. P., Kunz, K., Muller, S., & Chantrel, F. (1998). Homocysteine and chronic renal failure. Advances in nephrology from the Necker Hospital, 28, 287-310. 
Haraki, T., Takegoshi, T., Kitoh, C., Kajinami, K., Wakasugi, T., Hirai, J., . . . Mabuchi, H. (2001). Hyperhomocysteinemia, diabetes mellitus, and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease. Clin Nephrol, 56(2), 132-139. 
Hasselwander, O., & Young, I. S. (1998). Oxidative stress in chronic renal failure. Free Radical Research, 29(1), 1-11. doi:10.1080/10715769800300011
Hasuike, Y., Hama, Y., Nonoguchi, H., Hori, K., Tokuyama, M., Toyoda, K., . . . Nakanishi, T. (2012). Persistent Homocysteine Metabolism Abnormality Accelerates Cardiovascular Disease in Hemodialyzed Patients-the Nishinomiya Study. Journal of Renal Nutrition, 22(1), 12-18.e11. doi:10.1053/j.jrn.2011.04.005
Hasuike, Y., Hama, Y., Nonoguchi, H., Hori, K., Tokuyama, M., Toyoda, K., . . . Nakanishi, T. (2012). Persistent homocysteine metabolism abnormality accelerates cardiovascular disease in hemodialyzed patients--the Nishinomiya Study. J Ren Nutr, 22(1), 12-18.e11. doi:10.1053/j.jrn.2011.04.005
Haviv, Y. S., Shpichinetsky, V., Goldschmidt, N., Atta, I. A., Ben-Yehuda, A., & Friedman, G. (2002). The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients. Nephron, 92(1), 120-126. doi:10.1159/000064485
Hawwa, N., Schreiber Jr, M. J., & Tang, W. H. W. (2013). Pharmacologic management of chronic reno-cardiac syndrome. Current Heart Failure Reports, 10(1), 54-62. doi:10.1007/s11897-012-0122-8
Hayden, M. R., Tyagi, S. C., Kolb, L., Sowers, J. R., & Khanna, R. (2005). Vascular ossification - Calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - Calcific uremic arteriolopathy: The emerging role of sodium thiosulfate. Cardiovascular Diabetology, 4. doi:10.1186/1475-2840-4-4
Haynes, R., & Clarke, R. (2012). Homocysteine, the kidney, and vascular disease. BMJ (Online), 344(7863). doi:10.1136/bmj.e3925
Haynes, W. G. (2002). Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther, 16(5), 391-399. doi:10.1023/a:1022130217463
He, J., Reilly, M., Yang, W., Chen, J., Go, A. S., Lash, J. P., . . . Budoff, M. (2011). Novel risk factors for coronary artery calcification among patients with chronic kidney disease: The CRIC study. Circulation, 124(21). 
He, J., Reilly, M., Yang, W., Chen, J., Go, A. S., Lash, J. P., . . . Budoff, M. (2012). Risk factors for coronary artery calcium among patients with chronic kidney disease (from the chronic renal insufficiency cohort study). American Journal of Cardiology, 110(12), 1735-1741. doi:10.1016/j.amjcard.2012.07.044
He, J., Shlipak, M., Anderson, A., Roy, J. A., Feldman, H. I., Kallem, R. R., . . . Townsend, R. R. (2017). Risk factors for heart failure in patients with chronic kidney disease: The CRIC (Chronic Renal Insufficiency Cohort) study. Journal of the American Heart Association, 6(5). doi:10.1161/JAHA.116.005336
He, J., Shlipak, M., Anderson, A., Roy, J. A., Feldman, H. I., Kallem, R. R., . . . for the, C. I. (2017). Risk factors for heart failure in patients with chronic kidney disease: The CRIC (Chronic Renal Insufficiency Cohort) study. Journal of the American Heart Association, 6(5). doi:10.1161/JAHA.116.005336
Healy, H., Reith, D., Morgan, C., Clague, A., & Westhuyzen, J. (2000). Are metalloproteins and acute phase reactants associated with cardiovascular disease in end-stage renal failure? Ann Clin Lab Sci, 30(3), 295-304. 
Heinz, J., Domröse, U., Luley, C., Westphal, S., Kropf, S., Neumann, K. H., & Dierkes, J. (2009). Influence of a supplementation with vitamins on cardiovascular morbidity and mortality in patients with end-stage renal disease: design and baseline data of a randomized clinical trial. Clinical nephrology, 71(3), 363‐365. doi:10.5414/cnp71363
Heinz, J., Domröse, U., Westphal, S., Luley, C., Neumann, K. H., & Dierkes, J. (2008). Washout of water-soluble vitamins and of homocysteine during haemodialysis: effect of high-flux and low-flux dialyser membranes. Nephrology (Carlton), 13(5), 384-389. doi:10.1111/j.1440-1797.2008.00946.x
Heinz, J., Kropf, S., Domröse, U., Westphal, S., Borucki, K., Luley, C., . . . Dierkes, J. (2010). B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation, 121(12), 1432‐1438. doi:10.1161/CIRCULATIONAHA.109.904672
Heinz, J., Kropf, S., Luley, C., & Dierkes, J. (2009). Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Am J Kidney Dis, 54(3), 478-489. doi:10.1053/j.ajkd.2009.01.266
Helal, I., Smaoui, W., Hamida, F. B., Ouniss, M., Aderrahim, E., Hedri, H., . . . Kheder, A. (2010). Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 21(1), 59-62. 
Hénaut, L., Candellier, A., Boudot, C., Grissi, M., Mentaverri, R., Choukroun, G., . . . Massy, Z. A. (2019). New insights into the roles of monocytes/macrophages in cardiovascular calcification associated with chronic kidney disease. Toxins, 11(9). doi:10.3390/toxins11090529
Henning, B. F., Riezler, R., Tepel, M., Langer, K., Raidt, H., Graefe, U., & Zidek, W. (1999). Evidence of altered homocysteine metabolism in chronic renal failure. Nephron, 83(4), 314-322. doi:10.1159/000045423
Henning, B. F., Tepel, M., Graefe, U., & Zidek, W. (2000). Homocystein metabolites in patients with chronic renal failure. Medizinische Klinik, 95(9), 477-481. doi:10.1007/pl00002136
Henning, B. F., Tepel, M., Graefe, U., & Zidek, W. (2000). [Homocysteine and its metabolites in chronic renal insufficiency and the effect of a vitamin replacement]. Med Klin (Munich), 95(9), 477-481. doi:10.1007/pl00002136
Henning, B. F., Zidek, W., Riezler, R., Graefe, U., & Tepel, M. (2001). Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate. Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie, 200(3), 155‐168. 
Hermans, M. M. H., Kooman, J. P., & Stehouwer, C. D. A. (2008). Chronic renal disease as cardiovascular risk factor. Nederlands Tijdschrift voor Geneeskunde, 152(29), 1614-1618. 
Hernandez, G. T., Sippel, M., & Mukherjee, D. (2013). Interrelationship between chronic kidney disease and risk of cardiovascular diseases. Cardiovascular and Hematological Agents in Medicinal Chemistry, 11(1), 38-43. doi:10.2174/1871525711311010007
Herrmann, W., Herrmann, M., & Obeid, R. (2007). Hyperhomocysteinaemia: A critical review of old and new aspects. Current Drug Metabolism, 8(1), 17-31. doi:10.2174/138920007779315008
Herrmann, W., Quast, S., Ellgass, A., Wolter, K., Kiessig, S. T., Molinari, E., & Riegel, W. (2000). An increased serum level of free Apo(a) in renal patients is more striking than that of Lp(a) and is influenced by homocysteine. Nephron, 85(1), 41-49. doi:10.1159/000045628
Herrmann, W., Schorr, H., Obeid, R., Makowski, J., Fowler, B., & Kuhlmann, M. K. (2005). Disturbed homocysteine and methionine cycle intermediates S-adenosylhomocysteine and S-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes. Clinical Chemistry, 51(5), 891-897. doi:10.1373/clinchem.2004.044453
Herzog, A. L., Kalogirou, C., Wanner, C., & Lopau, K. (2019). Comparison of different algorithms for the assessment of cardiovascular risk after kidney transplantation by the time of entering waiting list. Clinical Kidney Journal, 13(2), 150-158. doi:10.1093/ckj/sfz041
Hewitson, C. L., Whiting, M. J., Barbara, J. A., & Mangoni, A. A. (2007). Acute effects of haemodialysis on biochemical modulators of endothelial function. J Intern Med, 262(5), 571-580. doi:10.1111/j.1365-2796.2007.01848.x
Higashimoto, T., Kim, A. Y., Ogawa, J. T., Sloan, J. L., Almuqbil, M. A., Carlson, J. M., . . . Wang, T. (2020). High-dose hydroxocobalamin achieves biochemical correction and improvement of neuropsychiatric deficits in adults with late onset cobalamin C deficiency. In (Vol. 51, pp. 17-24).
Higgins, J. P., & Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21(11), 1539-1558. doi:10.1002/sim.1186
Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O'Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. (2016). Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One, 11(7), e0158765. doi:10.1371/journal.pone.0158765
Himmelfarb, J. (2005). Hemodialysis complications. American Journal of Kidney Diseases, 45(6), 1122-1131. doi:10.1053/j.ajkd.2005.02.031
Himmelfarb, J., McMenamin, E., & McMonagle, E. (2002). Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int, 61(2), 705-716. doi:10.1046/j.1523-1755.2002.00151.x
Hirose, S., Kim, S., Matsuda, A., Itakura, Y., Matsumura, O., Tamura, H., . . . Isoda, K. (1998). [Effects of folic acid supplementation on hyperhomocysteinemia in CAPD patients: effects on unsaturated fatty acids]. Nihon Jinzo Gakkai Shi, 40(1), 8-16. 
Hirose, S., Kono, R., Mitarai, T., Isoda, K., Kim, S., & Shimoyama, H. (1999). Hyperhomocysteinemia in CAPD patients: peritoneal transport of total homocysteine at peritoneal equilibration test and daily elimination of total homocysteine. Nippon Jinzo Gakkai shi, 41(8), 778-786. 
Hishida, A., Okada, R., Guang, Y., Naito, M., Wakai, K., Hosono, S., . . . Hamajima, N. (2013). MTHFR, MTR and MTRR polymorphisms and risk of chronic kidney disease in Japanese: Cross-sectional data from the J-MICC Study. International Urology and Nephrology, 45(6), 1613-1620. doi:10.1007/s11255-013-0432-0
Hoffer, L. J. (1999). Optimum protein intake in chronic renal failure. Diabetes, Nutrition and Metabolism - Clinical and Experimental, 12(6), 435-439. 
Hoffer, L. J. (2002). Editorial: Renal failure, homocysteine and the pharmacology of vitamin B12. Metabolism, 51(4), 399-402. doi:10.1053/meta.2002.32517
Hoffer, L. J. (2002). Methods for measuring sulfur amino acid metabolism. Current Opinion in Clinical Nutrition and Metabolic Care, 5(5), 511-517. doi:10.1097/00075197-200209000-00009
Hoffer, L. J. (2006). Testing the homocysteine hypothesis in end-stage renal disease: Problems and a possible solution. Kidney Int, 69(9), 1507-1510. doi:10.1038/sj.ki.5000279
Hoffer, L. J., Bank, I., Hongsprabhas, P., Shrier, I., Saboohi, F., Davidman, M., . . . Barré, P. E. (2000). A tale of two homocysteines--and two hemodialysis units. Metabolism, 49(2), 215-219. doi:10.1016/s0026-0495(00)91351-9
Hoffer, L. J., Djahangirian, O., Bourgouin, P. E., Eid, J., & Saboohi, F. (2005). Comparative effects of hydroxocobalamin and cyanocobalamin on plasma homocysteine concentrations in end-stage renal disease. Metabolism: clinical and experimental, 54(10), 1362‐1367. doi:10.1016/j.metabol.2005.04.027
Hoffer, L. J., & Elian, K. M. (2004). Parenteral vitamin B12 therapy of hyperhomocysteinemia in end-stage renal disease. Clin Invest Med, 27(1), 10-13. 
Hoffer, L. J., Robitaille, L., Elian, K. M., Bank, I., Hongsprabhas, P., & Mamer, O. A. (2001). Plasma reduced homocysteine concentrations are increased in end-stage renal disease. Kidney International, 59(1), 372-377. doi:10.1046/j.1523-1755.2001.00500.x
Hoffer, L. J., Saboohi, F., Golden, M., & Barré, P. E. (2005). Cobalamin dose regimen for maximum homocysteine reduction in end-stage renal disease. Metabolism: clinical and experimental, 54(6), 835‐840. doi:10.1016/j.metabol.2005.01.034
Hoffman, M. (2011). Hypothesis: Hyperhomocysteinemia is an indicator of oxidant stress. Medical Hypotheses, 77(6), 1088-1093. doi:10.1016/j.mehy.2011.09.009
Hojs, R., Gorenjak, M., Ekart, R., Dvorsak, B., & Pecovnik-Balon, B. (2002). Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail, 24(2), 215-222. doi:10.1081/jdi-120004098
Holdt, B., Korten, G., Knippel, M., Lehmann, J. K., Claus, R., Holtz, M., & Hausmann, S. (1996). Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Perit Dial Int, 16 Suppl 1, S246-249. 
Holubarsch, C. J. F. (2007). Cardiovascular diseases in patients with renal disease: Epidemiology, pathophysiology and therapy. Clinical Research in Cardiology Supplements, 2(SUPL.1), S9-S14. doi:10.1007/s11789-006-0030-0
Hong, S. Y., Yang, D. H., & Chang, S. K. (1998). Plasma homocysteine, vitamin B6, vitamin B12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid. American Journal of Nephrology, 18(5), 367-372. doi:10.1159/000013378
Hong, S. Y., Yang, D. H., & Chang, S. K. (1998). The relationship between plasma homocysteine and amino acid concentrations in patients with end-stage renal disease. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 8(1), 34-39. 
Horie, T., Kimura, T., & Ono, K. (2016). Emerging novel biomarkers for arteriosclerosis obliterans. Journal of Atherosclerosis and Thrombosis, 23(2), 171-172. doi:10.5551/jat.ED028
Hörl, W. (2006). Sequela of hypertension: Kidney disease. Internist, 47(3), 226-232. doi:10.1007/s00108-005-1575-6
Horl, W. H. (1999). Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrology Dialysis Transplantation, 14(SUPPL. 2), 50-60. 
Hörl, W. H. (2003). [Atherosclerosis and uremia: signifance of non-traditional risk factors]. Wien Klin Wochenschr, 115(7-8), 220-234. doi:10.1007/bf03040320
Hörl, W. H. (2003). Atherosclerosis and uremia: The importance of non-traditional risk factors. Wiener Klinische Wochenschrift, 115(7-8), 220-234. doi:10.1007/bf03040320
Hörl, W. H., Cohen, J. J., Harrington, J. T., Madias, N. E., & Zusman, C. J. (2004). Atherosclerosis and uremic retention solutes. Kidney Int, 66(4), 1719-1731. doi:10.1111/j.1523-1755.2004.00944.x
Horlings, C. G. C., Rath, J., Finsterer, J., Wanschitz, J. V., & Löscher, W. N. (2020). Laboratory Tests for Neuropathies: What to do and to Avoid. Journal of Neuromuscular Diseases, 7(3), 279-286. doi:10.3233/JND-200488
Hörster, F., & Hoffmann, G. F. (2004). Pathophysiology, diagnosis, and treatment of methylmalonic aciduria - Recent advances and new challenges. Pediatric Nephrology, 19(10), 1071-1074. doi:10.1007/s00467-004-1572-3
Hotoleanu, C., Dronca, M., & Chouky, E. (2012). Hyperhomocysteinemia is associated with venous thromboembolism. Clinical Chemistry and Laboratory Medicine, 50(2), A53. doi:10.1515/cclm-2012-0032
Hou, F. F., & Xu, X. (2017). The Nephroprotective Effect of Folic Acid-Only a Matter of Homocysteine?-Reply. JAMA Internal Medicine, 177(2), 286-287. doi:10.1001/jamainternmed.2016.8593
House, A. A., & Donnelly, J. G. (1999). Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis. ASAIO journal (American Society for Artificial Internal Organs : 1992), 45(1), 94‐97. doi:10.1097/00002480-199901000-00021
House, A. A., Eliasziw, M., Urquhart, B. L., Freeman, D. J., & Spence, J. D. (2004). Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial. American journal of kidney diseases, 44(4), 689‐694. 
House, A. A., & Ronco, C. (2007). Cardiovascular risk in hemodialysis patients: A mechanistic approach. International Journal of Artificial Organs, 30(11), 1020-1027. doi:10.1177/039139880703001112
Houze, P., Gamra, S., Madelaine, I., Bousquet, B., & Gourmel, B. (2001). Simultaneous determination of total plasma glutathione, homocysteine, cysteinylglycine, and methionine by high-performance liquid chromatography with electrochemical detection. Journal of Clinical Laboratory Analysis, 15(3), 144-153. doi:10.1002/jcla.1018
Hsu, C. Y., Sun, C. Y., Lee, C. C., Wu, I. W., Hsu, H. J., & Wu, M. S. (2012). Global DNA methylation not increased in chronic hemodialysis patients: A case-Control study. Renal Failure, 34(10), 1195-1199. doi:10.3109/0886022X.2012.723280
Hu, J., Juan, W., & Sahyoun, N. (2015). Associations between folate biomarker levels and renal function among adults in the U.S. FASEB Journal, 29(1). 
Huemer, R. P. (2006). Chronic renal disease: Orthomolecular ramifications. Journal of Orthomolecular Medicine, 21(1), 48-54. 
Hultberg, B., Andersson, A., & Arnadottir, M. (1995). Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron, 70(1), 62-67. doi:10.1159/000188545
Hultberg, B., Andersson, A., & Sterner, G. (1993). Plasma homocysteine in renal failure. Clinical Nephrology, 40(4), 230-235. 
Hung, K. C. (2015). Echocardiographic characteristics of chronic kidney disease: The Taiwanese experience. Journal of Medical Ultrasound, 23(1), 14-16. doi:10.1016/j.jmu.2015.03.003
Hunter, T. (2005). CE: The clinical significance of elevated homocysteine. Drug Topics, 149(17). 
Hurabielle, C., Sebille, G., Barrou, B., Moguelet, P., Francès, C., & Barete, S. (2016). Livedoid vasculopathy associated with HIV infection in two patients: A causal relationship? Acta Dermato-Venereologica, 96(6), 844-845. doi:10.2340/00015555-2338
Huysmans, K., Lins, R. L., Daelemans, R., Zachée, P., & De Broe, M. E. (1998). Hypertension and accelerated atherosclerosis in endstage renal disease. Journal of Nephrology, 11(4), 185-195. 
Hwang, S. Y., Siow, Y. L., Au-Yeung, K. K., House, J., & O, K. (2011). Folic acid supplementation inhibits NADPH oxidase-mediated superoxide anion production in the kidney. Am J Physiol Renal Physiol, 300(1), F189-198. doi:10.1152/ajprenal.00272.2010
Hwang, S. Y., Siow, Y. L., Au-Yeung, K. K. W., House, J., & O, K. (2011). Folic acid supplementation inhibits NADPH oxidase-mediated superoxide anion production in the kidney. American Journal of Physiology - Renal Physiology, 300(1), F189-F198. doi:10.1152/ajprenal.00272.2010
Hwang, S. Y., Woo, C. W., Au-Yeung, K. K., Siow, Y. L., Zhu, T. Y., & O, K. (2008). Homocysteine stimulates monocyte chemoattractant protein-1 expression in the kidney via nuclear factor-kappaB activation. Am J Physiol Renal Physiol, 294(1), F236-244. doi:10.1152/ajprenal.00331.2007
Hwang, S. Y., Woo, C. W. H., Au-Yeung, K. K. W., Siow, Y. L., Zhu, T. Y., & O, K. (2008). Homocysteine stimulates monocyte chemoattractant protein-1 expression in the kidney via nuclear factor-κB activation. American Journal of Physiology - Renal Physiology, 294(1), F236-F244. doi:10.1152/ajprenal.00331.2007
Hyánek, J., Pehal, F., Dubská, L., Pejznochová, H., Hoffmann, R., Balasz, J., . . . Jenčová, H. (2002). Methylmalonic acidaemia estimation and its diagnostic significance. Klinicka Biochemie a Metabolismus, 10(2), 77-82. 
Hyndman, M. E., Manns, B. J., Snyder, F. F., Bridge, P. J., Scott-Douglas, N. W., Fung, E., & Parsons, H. G. (2003). Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease. Metabolism: clinical and experimental, 52(2), 168‐172. doi:10.1053/meta.2003.50022
Ibrahim, S., & El Dessokiy, O. (2009). Prevalence of methylenetetrahydrofolate gene (MTHFR) C677T polymorphism among chronic hemodialysis patients and its association with cardiovascular disease: A cross-sectional analysis. Clinical and Experimental Nephrology, 13(5), 501-507. doi:10.1007/s10157-009-0194-2
Ikee, R., Toyoyama, T., Endo, T., Tsunoda, M., & Hashimoto, N. (2016). Clinical factors associated with constipation in hemodialysis patients. Int Urol Nephrol, 48(10), 1741-1742. doi:10.1007/s11255-016-1363-3
Iki, M., Fujita, Y., Tamaki, J., Kouda, K., Yura, A., Kadowaki, E., . . . Kurumatani, N. (2011). GFR estimated with serum creatinine may be misleading in association between subclinical decline in renal function and bone mass in community-dwelling elderly men: FORMEN Study. Bone, 48, S195-S196. doi:10.1016/j.bone.2011.03.692
Ikizler, T. A. (2013). A patient with CKD and poor nutritional status. Clinical Journal of the American Society of Nephrology, 8(12), 2174-2182. doi:10.2215/CJN.04630513
Imani, H., Tabibi, H., Atabak, S., Rahmani, L., Ahmadinejad, M., & Hedayati, M. (2009). Effects of Soy Consumption on Oxidative Stress, Blood Homocysteine, Coagulation Factors, and Phosphorus in Peritoneal Dialysis Patients. Journal of Renal Nutrition, 19(5), 389-395. doi:10.1053/j.jrn.2009.01.020
Inagi, R., Nangaku, M., Onogi, H., Ueyama, H., Kitao, Y., Nakazato, K., . . . Miyata, T. (2005). Involvement of endoplasmic reticulum (ER) stress in podocyte injury induced by excessive protein accumulation. Kidney Int, 68(6), 2639-2650. doi:10.1111/j.1523-1755.2005.00736.x
Ingrosso, D., & Perna, A. F. (2009). Epigenetics in hyperhomocysteinemic states. A special focus on uremia. Biochimica et Biophysica Acta - General Subjects, 1790(9), 892-899. doi:10.1016/j.bbagen.2008.11.010
Ingrosso, D., & Perna, A. F. (2019). Derangements of sulfur metabolism in chronic kidney disease. FEBS Open Bio, 9, 26. doi:10.1002/2211-5463.12674
Ingrosso, D., & Perna, A. F. (2020). Dna methylation dysfunction in chronic kidney disease. Genes, 11(7), 1-21. doi:10.3390/genes11070811
Inker, L. A., Astor, B. C., Fox, C. H., Isakova, T., Lash, J. P., Peralta, C. A., . . . Feldman, H. I. (2014). KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis, 63(5), 713-735. doi:10.1053/j.ajkd.2014.01.416
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., . . . Levey, A. S. (2012). Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med, 367(1), 20-29. doi:10.1056/NEJMoa1114248
Iossa, D., Molaro, R., Andini, R., Parrella, A., Ursi, M. P., Mattucci, I., . . . Durante-Mangoni, E. (2016). Clinical significance of hyperhomocysteinemia in infective endocarditis A case-control study. Medicine (United States), 95(39). doi:10.1097/MD.0000000000004972
Isbel, N. M., Haluska, B., Johnson, D. W., Beller, E., Hawley, C., & Marwick, T. H. (2006). Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. American Heart Journal, 151(3), 745-753. doi:10.1016/j.ahj.2005.06.017
Ishikawa, M., Namiki, A., Kubota, T., Fukazawa, M., Joki, N., Moroi, M., . . . Yamaguchi, T. (2001). Effect of hyperhomocysteinemia on endothelial activation and dysfunction in patients with end-stage renal disease. Am J Cardiol, 88(10), 1203-1205. doi:10.1016/s0002-9149(01)02064-1
Ivanovski, N., Stojceva-Taneva, O., Grozdanovski, R., Boskovska, M., Drueke, T. B., & Massy, Z. A. (2004). Short-term effect of folic acid supplementation in renal transplant recipients and chronic kidney disease patients with comparable renal function impairment. Nephrologie, 25(7), 301-303. 
Iwamoto, J. (2012). Effects of raloxifene on bone metabolism in hemodialysis patients. International Journal of Endocrinology and Metabolism, 10(3), 573-575. doi:10.5812/ijem.5367
Ix, J. H., Katz, R., Bansal, N., Foster, M., Weiner, D. E., Tracy, R., . . . Shlipak, M. G. (2017). Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial. American Journal of Kidney Diseases, 69(3), 410-419. doi:10.1053/j.ajkd.2016.10.019
Iyer, H., Abraham, G., Reddy, Y. N., Pandurangi, U. M., Kalaichelvan, U., Gomathi, S. B., . . . Santhosham, R. (2013). Risk factors of chronic kidney disease influencing cardiac calcification. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 24(6), 1189-1194. doi:10.4103/1319-2442.121279
Jaar, B. G., Plantinga, L. C., Astor, B. C., Fink, N. E., Longenecker, C., Tracy, R. P., . . . Coresh, J. (2007). Novel and Traditional Cardiovascular Risk Factors for Peripheral Arterial Disease in Incident-Dialysis Patients. Advances in Chronic Kidney Disease, 14(3), 304-313. doi:10.1053/j.ackd.2007.04.005
Jacobsen, D. W. (1998). Acquired hyperhomocysteinemia in heart transplant recipients. Clin Chem, 44(11), 2238-2239. 
Jacobsen, D. W. (2006). Homocysteine targeting of plasma proteins in hemodialysis patients. Kidney Int, 69(5), 787-789. doi:10.1038/sj.ki.5000235
Jagadeswaran, D., Indhumathi, E., Hemamalini, A. J., Sivakumar, V., Soundararajan, P., & Jayakumar, M. (2019). Inflammation and nutritional status assessment by malnutrition inflammation score and its outcome in pre-dialysis chronic kidney disease patients. Clinical Nutrition, 38(1), 341-347. doi:10.1016/j.clnu.2018.01.001
Jagieła, J., Bartnicki, P., & Rysz, J. (2020). Selected cardiovascular risk factors in early stages of chronic kidney disease. International Urology and Nephrology, 52(2), 303-314. doi:10.1007/s11255-019-02349-1
Jain, D., Aggarwal, H. K., Goyal, S., Sen, J., & Seth, S. (2017). Evaluation of serum homocysteine level and its relation with carotid intima-media thickness in patients of chronic kidney disease. Medical Studies/Studia Medyczne, 33(4), 247-253. doi:10.5114/ms.2017.72476
Jaisson, S., Desmons, A., Braconnier, A., Wynckel, A., Rieu, P., Gillery, P., & Garnotel, R. (2020). An unusually high plasma concentration of homocysteine resulting from a combination of so-called “secondary” etiologies. Clinical Biochemistry, 80, 52-55. doi:10.1016/j.clinbiochem.2020.03.010
Jakubowski, H. (2019). Homocysteine Modification in Protein Structure/Function and Human Disease. Physiol Rev, 99(1), 555-604. doi:10.1152/physrev.00003.2018
Jalal, D., Chonchol, M., Etgen, T., & Sander, D. (2012). C-reactive protein as a predictor of cardiovascular events in elderly patients with chronic kidney disease. Journal of Nephrology, 25(5), 719-725. doi:10.5301/jn.5000047
Jamal, S. A., Leiter, R. E., & Bauer, D. C. (2005). Hyperhomocysteinaemia and aortic calcification are associated with fractures in patients on haemodialysis. Qjm, 98(8), 575-579. doi:10.1093/qjmed/hci092
Jamison, R. L., Hartigan, P., Gaziano, J. M., Fortmann, S. P., Goldfarb, D. S., Haroldson, J. A., . . . Robinson, K. (2004). Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study. Clinical trials (London, England), 1(5), 451-460. 
Jamison, R. L., Hartigan, P., Gaziano, M., Kaufman, J., Goldfarb, D. S., & Warren, S. (2004). Cardiovascular disease in patients with advanced chronic kidney disease (ACKD) and hyperhomocysteinemia. The VA Coop. Studies Program Homocysteine Study (HOST). Journal of the American Society of Nephrology : JASN, 15(Oct), 132A. 
Jamison, R. L., Hartigan, P., Kaufman, J. S., Goldfarb, D. S., Warren, S. R., & Guarino, P. (2007). Homocysteine lowering effect on mortality and vascular disease in advanced chronic kidney disease and end stage renal disease. 4th world congress of nephrology.19th international congress of the international society of nephrology (ISN); 2007 apr 21-25; rio de janeiro, brazil, 211. 
Jamison, R. L., Hartigan, P., Kaufman, J. S., Goldfarb, D. S., Warren, S. R., Guarino, P. D., & Gaziano, J. M. (2007). Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. Journal of the American Medical Association, 298(10), 1163-1170. doi:10.1001/jama.298.10.1163
Jamison, R. L., Shih, M. C., Humphries, D. E., Guarino, P. D., Kaufman, J. S., Goldfarb, D. S., . . . Lavori, P. (2009). Effect of the MTHFR C677T and A1298C Polymorphisms on Survival in Patients With Advanced CKD and ESRD: A Prospective Study. American Journal of Kidney Diseases, 53(5), 779-789. doi:10.1053/j.ajkd.2008.12.023
Jan, M., Cueto, R., Jiang, X., Lu, L., Sardy, J., Xiong, X., . . . Wang, H. (2021). Molecular processes mediating hyperhomocysteinemia-induced metabolic reprogramming, redox regulation and growth inhibition in endothelial cells. Redox Biology, 45. doi:10.1016/j.redox.2021.102018
Janda, K., Aksamit, D., Krzanowski, M., Kuzniewski, M., & Sułowicz, W. (2013). [Evaluation of the interdependence between homocystein and folic acid levels in patients after kidney transplantation during a 2 year observation period]. Przegla̧d lekarski, 70(4), 175-179. 
Jang, E. H., Kim, M. K., Baek, K. H., Song, K. H., Cha, B. Y., & Kwon, H. S. (2013). Beta 2 microglobulin and subclinical atherosclerosis in normoalbuminuric type 2 diabetes mellitus. Diabetes, 62, A110. doi:10.2337/db13-388-679
Janssen, M. J., van den Berg, M., Stehouwer, C. D., & Boers, G. H. (1995). Hyperhomocysteinaemia: a role in the accelerated atherogenesis of chronic renal failure? Neth J Med, 46(5), 244-251. doi:10.1016/0300-2977(94)00100-6
Janssen, M. J., van den Berg, M., van Guldener, C., Boers, G. H., & Stehouwer, C. D. (1994). Withdrawal of folic acid supplementation in maintenance hemodialysis patients. Clin Nephrol, 42(2), 136-137. 
Janssen, M. J. F. M., Van den Berg, M., Stehouwer, C. D. A., & Boers, G. H. J. (1995). Hyperhomocysteinaemia: A role in the accelerated atherogenesis of chronic renal failure? Netherlands Journal of Medicine, 46(5), 244-251. doi:10.1016/0300-2977(94)00100-6
Janssen, M. J. F. M., Van Guldener, C., De Jong, G. M. T., Van den Berg, M., Stehouwer, C. D. A., & Donker, A. J. M. (1996). Folic acid treatment of hyperhomocysteinemia in dialysis patients. Mineral and Electrolyte Metabolism, 22(1-3), 110-114. 
Jardine, M. J., Kang, A., Zoungas, S., Navaneethan, S. D., Ninomiya, T., Nigwekar, S. U., . . . Perkovic, V. (2012). The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: Systematic review and meta-analysis. BMJ (Online), 344(7863). doi:10.1136/bmj.e3533
Ji, A., Pan, C., Wang, H., Jin, Z., Lee, J. H., Wu, Q., . . . Cui, L. (2019). Prevalence and associated risk factors of chronic kidney disease in an elderly population from eastern China. International Journal of Environmental Research and Public Health, 16(22). doi:10.3390/ijerph16224383
Ji, Y., Tan, S., Xu, Y., Chandra, A., Shi, C., Song, B., . . . Gao, Y. (2013). Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: A meta-analysis. Neurology, 81(15), 1298-1307. doi:10.1212/WNL.0b013e3182a823cc
Jia, G., Di, F., Wang, Q., Shao, J., Gao, L., Wang, L., . . . Li, N. (2015). Non-alcoholic fatty liver disease is a risk factor for the development of diabeticnephropathy in patients with type 2 diabetes mellitus. PLoS ONE, 10(11). doi:10.1371/journal.pone.0142808
Jiang, C., Wang, B., Li, Y., Xie, L., Zhang, X., Wang, J., . . . Qin, X. (2020). U-shaped association between serum albumin and development of chronic kidney disease in general hypertensive patients. Clinical Nutrition, 39(1), 258-264. doi:10.1016/j.clnu.2019.02.002
Joannides, R., Bellien, J., & Thuillez, C. (2006). Clinical methods for the evaluation of endothelial function - A focus on resistance arteries. Fundamental and Clinical Pharmacology, 20(3), 311-320. doi:10.1111/j.1472-8206.2006.00406.x
Johnson, D. W., Armstrong, K., Campbell, S. B., Mudge, D. W., Hawley, C. M., Coombes, J. S., . . . Isbel, N. M. (2007). Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology, 12(4), 391-398. doi:10.1111/j.1440-1797.2007.00804.x
Johnson, D. W., Craven, A. M., & Isbel, N. M. (2007). Modification of cardiovascular risk in hemodialysis patients: An evidence-based review. Hemodialysis International, 11(1), 1-14. doi:10.1111/j.1542-4758.2007.00146.x
Joosten, E. (2004). Strategies for the Laboratory Diagnosis of Some Common Causes of Anaemia in Elderly Patients. Gerontology, 50(2), 49-56. doi:10.1159/000075555
Jourde-Chiche, N., Dou, L., Cerini, C., Dignat-George, F., & Brunet, P. (2011). Vascular Incompetence in Dialysis Patients-Protein-Bound Uremic Toxins and Endothelial Dysfunction. Seminars in Dialysis, 24(3), 327-337. doi:10.1111/j.1525-139X.2011.00925.x
Jourde-Chiche, N., Dou, L., Cerini, C., Dignat-George, F., & Brunet, P. (2011). Vascular incompetence in dialysis patients--protein-bound uremic toxins and endothelial dysfunction. Semin Dial, 24(3), 327-337. doi:10.1111/j.1525-139X.2011.00925.x
Jourde-Chiche, N., Dou, L., Sabatier, F., Calaf, R., Cerini, C., Brunet, P., & Dignat-George, F. (2009). Progenitor cells are related to vascular injury and uremic toxins in hemodialysis patients. Journal of Thrombosis and Haemostasis, 7(S2), 916-917. doi:10.1111/j.1538-7836.2009.03473-2.x
Jovanovich, A., Chonchol, M., Cheung, A. K., Kaufman, J. S., Greene, T., Roberts, W. L., . . . Kendrick, J. (2012). Racial differences in markers of mineral metabolism in advanced chronic kidney disease. Clinical Journal of the American Society of Nephrology, 7(4), 640-647. doi:10.2215/CJN.07020711
Jovanovich, A. J., Chonchol, M., Brady, C. B., Kaufman, J. D., Kendrick, J., Cheung, A. K., & Jablonski, K. L. (2014). 25-vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: A veteran population. Clinical Nephrology, 82(5), S1-S4. doi:10.5414/CN108365
Jovanovich, A. J., Chonchol, M. B., Sobhi, A., Kendrick, J. B., Cheung, A. K., Kaufman, J. S., . . . Jablonski, K. L. (2015). Mineral Metabolites, Angiotensin II Inhibition and Outcomes in Advanced Chronic Kidney Disease. American Journal of Nephrology, 42(5), 361-368. doi:10.1159/000441684
Jun, M., & Perkovic, V. (2015). Fibrates: Risk benefits and role in treating dyslipidemias. In (Vol. 1, pp. 423-438).
Jungers, P., Chauveau, P., Bandin, O., Chadefaux, B., Aupetit, J., Labrunie, M., . . . Kamoun, P. (1997). Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Mineral and Electrolyte Metabolism, 23(3-6), 170-173. 
Jungers, P., Joly, D., Massy, Z., Chauveau, P., Nguyen, A. T., Aupetit, J., & Chadefaux, B. (1999). Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients. Nephrology Dialysis Transplantation, 14(12), 2903-2906. doi:10.1093/ndt/14.12.2903
Jungers, P., Massy, Z. A., Nguyen Khoa, T., Fumeron, C., Labrunie, M., Lacour, B., . . . Man, N. K. (1997). Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrology Dialysis Transplantation, 12(12), 2597-2602. doi:10.1093/ndt/12.12.2597
Jungers, P., Oualim, Z., Nguyen-Khoa, T., Massy, Z., & London, G. (2003). Cardioprotection: An essential component of the treatment of chronic renal failure patients. Nephrologie, 24(2), 79-88. 
Kahvecioglu, S., Ersoy, A., Gullulu, M., & Dirican, M. (2014). Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant. Experimental and Clinical Transplantation, 12(4), 334-342. doi:10.6002/ect.2013.0110
Kai, W., Kun, L., Lin, X., Guanjun, L., Shengchao, M., Guizhong, L., . . . Yinju, H. (2021). Mechanism of hyperhomocysteinemia induced renal injury in CBS+/- mice. Chinese Journal of Tissue Engineering Research, 25(11), 1728-1732. doi:10.3969/j.issn.2095-4344.3084
Kaisar, M., Isbel, N., & Johnson, D. W. (2007). Cardiovascular disease in patients with chronic kidney disease a clinical review. Minerva Urologica e Nefrologica, 59(3), 281-297. 
Kaisar, M. O., Isbel, N. M., & Johnson, D. W. (2008). Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. Reviews on Recent Clinical Trials, 3(2), 79-88. doi:10.2174/157488708784223853
Kaji, E., Kato, J., Saito, S., Harada, K., Kuwaki, K., Tatsukawa, M., . . . Yamamoto, K. (2011). Serum folate and homocysteine levels are associated with colon tumorigenesis in end-stage renal disease patients. Nutr Cancer, 63(2), 202-211. doi:10.1080/01635581.2011.523501
Kalantari, S., Chashmniam, S., Nafar, M., Samavat, S., Rezaie, D., & Dalili, N. (2020). A Noninvasive Urine Metabolome Panel as Potential Biomarkers for Diagnosis of T Cell-Mediated Renal Transplant Rejection. OMICS A Journal of Integrative Biology, 24(3), 140-147. doi:10.1089/omi.2019.0158
Kalantar-Zadeh, K., Abbott, K. C., Salahudeen, A. K., Kilpatrick, R. D., & Horwich, T. B. (2005). Survival advantages of obesity in dialysis patients. American Journal of Clinical Nutrition, 81(3), 543-554. doi:10.1093/ajcn/81.3.543
Kalantar-Zadeh, K., & Balakrishnan, V. S. (2006). The kidney disease wasting: Inflammation, oxidative stress, and diet-gene interaction. Hemodialysis International, 10(4), 315-325. doi:10.1111/j.1542-4758.2006.00124.x
Kalantar-Zadeh, K., Block, G., Humphreys, M. H., & Kopple, J. D. (2003). Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney International, 63(3), 793-808. doi:10.1046/j.1523-1755.2003.00803.x
Kalantar-Zadeh, K., Stenvinkel, P., Bross, R., Khawar, O. S., Rammohan, M., Colman, S., & Benner, D. (2005). Kidney insufficiency and nutrient-based modulation of inflammation. Current Opinion in Clinical Nutrition and Metabolic Care, 8(4), 388-396. doi:10.1097/01.mco.0000172578.56396.9e
Kalantar-Zadeh, K., Stenvinkel, P., Pillon, L., & Kopple, J. D. (2003). Inflammation and Nutrition in Renal Insufficiency. Advances in Renal Replacement Therapy, 10(3), 155-169. doi:10.1053/j.arrt.2003.08.008
Kalil, R. S., Carpenter, M. A., Ivanova, A., Gravens-Mueller, L., John, A. A., Weir, M. R., . . . Hunsicker, L. G. (2017). Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study. Am J Kidney Dis, 70(6), 762-769. doi:10.1053/j.ajkd.2017.06.013
Kalim, H., Kusworini, H., Gunawan, A., Wahono, C. S., & Hasanah, D. (2015). Lupus in developing country: Indonesian's patients profile and the risk of lupus nephritis. International Journal of Rheumatic Diseases, 18, 9. 
Kallianpur, A. R. (2005). Genomic screening and complications of hematopoietic stem cell transplantation: Has the time come? Bone Marrow Transplantation, 35(1), 1-16. doi:10.1038/sj.bmt.1704716
Kalra, O. P., Jat, S. L., Ranga, G. S., Mehrotra, G., & Sharma, S. B. (2012). Serum homocysteine level as a risk factor for carotid atherosclerosis in patients with chronic kidney disease and the effect of hemodialysis. Hemodialysis International, 16(1), 147. doi:10.1111/j.1542-4758.2011.00651.x
Kamath, S., Landray, M. J., & Lip, G. Y. H. (2001). Folic acid for all - Is the time right yet? British Journal of Cardiology, 8(1), 9+11. 
Kanbay, M., Afsar, B., Gusbeth-Tatomir, P., & Covic, A. (2010). Arterial stiffness in dialysis patients: Where are we now? International Urology and Nephrology, 42(3), 741-752. doi:10.1007/s11255-009-9675-1
Kanemaru, K., Kanemaru, A., & Murayama, S. (2016). Association between renal functions and CSF biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 12(7), P665. 
Kang, H. G., Lee, B. S., Hahn, H., Lee, J. H., Ha, I. S., Cheong, H. I., & Choi, Y. (2002). Reduction of plasma homocystein by folic acid in children with chronic renal failure. Pediatric Nephrology, 17(7), 511-514. doi:10.1007/s00467-002-0864-8
Kang, H. G., Lee, B. S., Hahn, H., Lee, J. H., Ha, I. S., Cheong, H. I., & Choi, Y. (2002). Reduction of plasma homocysteine by folic acid in children with chronic renal failure. Pediatr Nephrol, 17(7), 511-514. doi:10.1007/s00467-002-0864-8
Kannampuzha, J., Donnelly, S. M., McFarlane, P. A., Chan, C. T., House, J. D., Pencharz, P. B., & Darling, P. B. (2010). Glutathione and Riboflavin Status in Supplemented Patients Undergoing Home Nocturnal Hemodialysis versus Standard Hemodialysis. Journal of Renal Nutrition, 20(3), 199-208. doi:10.1053/j.jrn.2009.09.002
Kao, J. H. (2019). Highlights. Journal of the Formosan Medical Association, 118(10), 1379-1382. doi:10.1016/j.jfma.2019.09.001
Kao, J. H. (2021). Highlights. Journal of the Formosan Medical Association, 120(12), 2051-2054. doi:10.1016/j.jfma.2021.11.008
Kaplan, L. N., Mamer, O. A., & Hoffer, L. J. (2001). Parenteral vitamin B12 reduces hyperhomocysteinemia in end-stage renal disease. Clin Invest Med, 24(1), 5-11. 
Kar, Y. D., Özdemir, Z. C., Çarman, K. B., Yarar, C., Tekin, N., & Bör, Ö. (2021). Cerebral sinovenous thrombosis in children: clinical presentation, locations, and acquired and inherited prothrombotic risk factors. Turkish Journal of Pediatrics, 63(6), 1028-1037. doi:10.24953/turkjped.2021.06.011
Karakitsos, D., Patrianakos, A. P., Parthenakis, F. I., Malliaraki, N., Nikitovic, D., Kyriazis, J., . . . Vardas, P. E. (2007). Altered proximal aortic stiffness and endothelin plasma levels in diabetic patients with end-stage renal disease. Asaio j, 53(3), 343-350. doi:10.1097/MAT.0b013e318050d607
Karbasi-Afshar, R., Saburi, A., & Taheri, S. (2013). Clinical associations between renal dysfunction and vascular events: A literature review. ARYA Atherosclerosis, 9(3), 203-209. 
Karmin, O., & Siow, Y. L. (2018). Metabolic Imbalance of homocysteine and hydrogen sulfide in kidney disease. Current Medicinal Chemistry, 25(3), 367-377. doi:10.2174/0929867324666170509145240
Kárpáti, I., Balla, J., Szóke, G., Bereczky, Z., Páll, D., Ben, T., . . . Muszbek, L. (2002). Frequency of hyperhomocysteinemia in hemodialysis patients with folic acid supplementation. Orvosi hetilap, 143(27), 1635-1640. 
Karst, M., Hollenhorst, J., & Achenbach, J. (2020). Life-threatening course in coronavirus disease 2019 (COVID-19): Is there a link to methylenetetrahydrofolic acid reductase (MTHFR) polymorphism and hyperhomocysteinemia? Medical Hypotheses, 144. doi:10.1016/j.mehy.2020.110234
Kasiske, B. L., Anderson-Haag, T., Ibrahim, H. N., Pesavento, T. E., Weir, M. R., Nogueira, J. M., . . . Steffes, M. W. (2013). A prospective controlled study of kidney donors: Baseline and 6-month follow-up. American Journal of Kidney Diseases, 62(3), 577-586. doi:10.1053/j.ajkd.2013.01.027
Kasiske, B. L., Anderson-Haag, T., Israni, A. K., Kalil, R. S., Kimmel, P. L., Kraus, E. S., . . . Weir, M. R. (2015). A prospective controlled study of living kidney donors: Three-year follow-up. American Journal of Kidney Diseases, 66(1), 114-124. doi:10.1053/j.ajkd.2015.01.019
Kaskel, F. J., & Bamgbola, O. F. (2008). Validation of a Composite Scoring Scheme in the Diagnosis of Folate Deficiency in a Pediatric and Adolescent Dialysis Cohort. Journal of Renal Nutrition, 18(5), 430-439. doi:10.1053/j.jrn.2008.05.009
Katsiki, N., Perez-Martinez, P., & Mikhailidis, D. P. (2017). Homocysteine and Non-Cardiac Vascular Disease. Current Pharmaceutical Design, 23(22), 3224-3232. doi:10.2174/1381612823666170317124913
Katsiki, N., Tziomalos, K., & Mikhailidis, D. P. (2014). Alcohol and the cardiovascular system: A double-edged sword. Current Pharmaceutical Design, 20(40), 6276-6288. doi:10.2174/1381612820666140620125741
Katsimardou, A., Stavropoulos, K., Imprialos, K., Doumas, M., & Athyros, V. G. (2019). Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo? Journal of Clinical Hypertension, 21(10), 1578-1579. doi:10.1111/jch.13676
Kavey, R. E. W., Allada, V., Daniels, S. R., Hayman, L. L., McCrindle, B. W., Newburger, J. W., . . . Steinberger, J. (2006). Cardiovascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association expert panel on population and prevention science; the councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing, and the kidney in heart disease. Circulation, 114(24), 2710-2738. doi:10.1161/CIRCULATIONAHA.106.179568
Kavousi, M., Elias-Smale, S., Rutten, J. H. W., Leening, M. J. G., Vliegenthart, R., Verwoert, G. C., . . . Witteman, J. C. M. (2012). Evaluation of newer risk markers for coronary heart disease risk classification: A cohort study. Annals of Internal Medicine, 156(6), 438-444. doi:10.7326/0003-4819-156-6-201203200-00006
Kavousi, M., Elias-Smale, S., Rutten, J. H. W., Vliegenthart, R., Oudkerk, M., Hofman, A., . . . Witteman, J. C. M. (2012). Global cardiovascular risk assessment beyond traditional risk factors; the Rotterdam Study. European Journal of Preventive Cardiology, 19(1), S85. doi:10.1177/2047487312448008
Kawada, T. (2016). Plasma homocysteine level, serum leptin and estimated glomerular filtration rate with special emphasis on sex difference. Clinical Nutrition, 35(2), 541. doi:10.1016/j.clnu.2015.11.014
Kayadibi, H., Sertoglu, E., & Uyanik, M. (2014). Important issues in studies dealing with total homocysteine. Transplantation, 98(11), e89. doi:10.1097/tp.0000000000000492
Keddis, M. T., Bhutani, G., & El-Zoghby, Z. M. (2014). Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant. Cardiovascular and Hematological Disorders - Drug Targets, 14(3), 185-194. doi:10.2174/1871529X14666140401112654
Kelly, J. J., & Kohlhagen, J. (2004). Atherosclerosis and Folic Acid Supplementation Trial: Untangling the web of cardiac risk in chronic kidney disease. Nephrology, 9(3), 112-113. doi:10.1111/j.1440-1797.2004.00253.x
Kendrick, E. (2001). Cardiovascular disease and the renal transplant recipient. Am J Kidney Dis, 38(6 Suppl 6), S36-43. doi:10.1053/ajkd.2001.28924
Kennedy, R., Case, C., Fathi, R., Johnson, D., Isbel, N., & Marwick, T. H. (2001). Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease? Am J Med, 110(3), 198-204. doi:10.1016/s0002-9343(00)00695-1
Kerkeni, M., Letaief, A., Achour, A., Miled, A., Trivin, F., & Maaroufi, K. (2009). Hyperhomocysteinemia, paraoxonase concentration and cardiovascular complications in Tunisian patients with nondiabetic renal disease. Clinical Biochemistry, 42(9), 777-782. doi:10.1016/j.clinbiochem.2009.02.009
Kerkvliet, S. P., Rheault, M. N., & Berry, S. A. (2021). Liver transplant as a curative treatment in a pediatric patient with classic homocystinuria: A case report. American Journal of Medical Genetics, Part A, 185(4), 1247-1250. doi:10.1002/ajmg.a.62076
Kern, I., Bonafé, L., Bourquin, V., Girardin, E., Boulat, O., Baumgartner, M. R., . . . Hadaya, K. (2010). End-stage renal failure in ayoung adult: An unusual prese ntationof late-onset cobalamin C disease. Journal of Inherited Metabolic Disease, 33, S33. doi:10.1007/s10545-010-9163-x
Kes, P. (2000). Hyperhomocysteinemia in end-stage renal failure. Acta Med Croatica, 54(4-5), 175-181. 
Kessler, M. (2000). Atherosclerosis and hemodialysis. Nephrologie, 21(7), 349-350. 
Kessler, M. (2002). Epidemiology of cardiovascular disease in end-stage renal failure. Nephrologie, 23(7), 361-365. 
Khan, N. A., Saini, H., Mawari, G., Kumar, S., Hira, H. S., & Daga, M. K. (2016). The effect of folic acid supplementation on hyperhomocysteinemia and pulmonary function parameters in chronic obstructive pulmonary disease: a pilot study. Journal of clinical and diagnostic research, 10(11), OC17‐OC21. doi:10.7860/JCDR/2016/21322.8927
Khandekar, A., & Khandge, J. (2012). Incidence of Cardiovascular Disease (CVD) in chronic kidney disease subjects (PRE-DIALYSIS): The role of plasma high sensitivity C-reactive protein (HS-CRP), homocysteine (HCY), carotid intima media thickness (CIMT) and left ventricular hypertrophy (LVH). Nephrology Dialysis Transplantation, 27, ii246. doi:10.1093/ndt/gfs225
Khasanova, Y. V., Nelayeva, A. A., Galkina, A. B., & Medvedeva, I. V. (2012). The role of coagulation and inflammation in the development of diabetic nephropathy in patients with diabetes mellitus type 2. Diabetes Mellitus, 15(1), 31-34. doi:10.14341/2072-0351-5976
Khatri, M., Wright, C. B., Nickolas, T. L., Yoshita, M., Paik, M. C., Kranwinkel, G., . . . Decarli, C. (2007). Chronic kidney disease is associated with white matter hyperintensity volume: The Northern Manhattan Study (NOMAS). Stroke, 38(12), 3121-3126. doi:10.1161/STROKEAHA.107.493593
Kheir, F., & Haddad, R. (2010). Anemia in the elderly. Disease-a-Month, 56(8), 456-467. doi:10.1016/j.disamonth.2010.03.006
Khosroshahi, H. T., Dehgan, R., Asl, B. H., Safaian, A., Panahi, F., Estakhri, R., & Purasgar, B. (2013). Effect of omega-3 supplementation on serum level of homocysteine in hemodialysis patients. Iranian Journal of Kidney Diseases, 7(6), 479-484. 
Khrulev, A. E., Nikitina, A. A., & Khruleva, N. S. (2019). Specific risk factors for cerebrovascular disorders in patients with chronic kidney disease in the pre-dialysis period. Cardiovascular Therapy and Prevention (Russian Federation), 18(3), 88-93. doi:10.15829/1728-8800-2019-3-88-93
Kielstein, J. T., Bode-Böger, S. M., Frölich, J. C., Haller, H., & Böger, R. H. (2001). Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney International, Supplement, 59(78), S9-S13. doi:10.1046/j.1523-1755.2001.59780009.x
Kielstein, J. T., Böger, R. H., Bode-Böger, S. M., Frölich, J. C., Haller, H., Ritz, E., & Fliser, D. (2002). Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. Journal of the American Society of Nephrology, 13(1), 170-176. 
Kielstein, J. T., Tsikas, D., & Fliser, D. (2006). Effects of asymmetric dimethylarginine (ADMA) infusion in humans. European Journal of Clinical Pharmacology, 62(SUPPL. 1), 39-44. doi:10.1007/s00228-005-0010-1
Kim, H. J., Jeong, H., Park, K. M., & Yang, D. H. (2012). Relationship between serum leptin level and cardiovascular, nutrtional risk factors in non-diabetic hemodialysis. Kidney Research and Clinical Practice, 31(2), A45. doi:10.1016/j.krcp.2012.04.440
Kim, J., Kim, H., Roh, H., & Kwon, Y. (2018). Causes of hyperhomocysteinemia and its pathological significance. Archives of Pharmacal Research, 41(4), 372-383. doi:10.1007/s12272-018-1016-4
Kim, J. I., Cho, J., & Kim, M. (2017). Coagulation profile in patients with chronic kidney disease before and after kidney transplantation. Transplant International, 30, 98. doi:10.1111/tri.13051
Kim, J. S., Choi, S. T., Song, J. S., Kang, E. J., Lee, K. H., & Ha, Y. J. (2013). Elevated serum homocysteine levels in gouty patients were related not with serum uric acid levels but with decreased renal function. Annals of the Rheumatic Diseases, 72. doi:10.1136/annrheumdis-2013-eular.2099
Kim, M. K., Yun, K. J., Chun, H. J., Jang, E. H., Han, K. D., Park, Y. M., . . . Kwon, H. S. (2014). Clinical utility of serum beta-2-microglobulin as a predictor of diabetic complications in patients with type 2 diabetes without renal impairment. Diabetes and Metabolism, 40(6), 459-465. doi:10.1016/j.diabet.2014.08.002
Kim, S. J., & Bang, O. Y. (2013). Antiplatelet therapy for preventing stroke in patients with chronic kidney disease. In Contributions to Nephrology (Vol. 179, pp. 119-129).
Kimura, H., Gejyo, F., Suzuki, S., & Miyazaki, R. (2000). The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. Journal of the American Society of Nephrology, 11(5), 885-893. 
Kimura, H., Gejyo, F., Suzuki, S., Takeda, T., Miyazaki, R., & Yoshida, H. (2000). A C677T mutation in the methylenetetrahydrofolate reductase gene modifies serum cysteine in dialysis patients. Am J Kidney Dis, 36(5), 925-933. doi:10.1053/ajkd.2000.19085
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., . . . Yokote, K. (2018). Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. Journal of Atherosclerosis and Thrombosis, 25(9), 846-984. doi:10.5551/jat.GL2017
Kirschbaum, B. (1998). Effect of hemodialysis on the hypersulfatemia of chronic renal failure. Asaio j, 44(4), 314-318. doi:10.1097/00002480-199807000-00014
Kisialiou, A., Grella, R., Carrizzo, A., Pelone, G., Bartolo, M., Zucchella, C., . . . Vecchione, C. (2014). Risk factors and acute ischemic stroke subtypes. Journal of the Neurological Sciences, 339(1-2), 41-46. doi:10.1016/j.jns.2014.01.014
Kitiyakara, C., Gonin, J., Massy, Z., & Wilcox, C. S. (2000). Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidate stress and hyperhomocysteinemia. Curr Opin Nephrol Hypertens, 9(5), 477-487. doi:10.1097/00041552-200009000-00004
Klemm, A., Franke, C., Busch, M., Müller, A., Franke, S., Lang, D., . . . Stein, G. (2004). Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites. Clinical nephrology, 61(3), 191‐197. doi:10.5414/cnp61191
Klusmann, A., Ivens, K., Schadewaldt, P., Grabensee, B., & Heering, P. (2000). [Is homocysteine a risk factor for coronary heart disease in patients with terminal renal failure?]. Med Klin (Munich), 95(4), 189-194. doi:10.1007/pl00002105
Klykov, C. M., & Lentz, S. R. (2013). Trends in clinical laboratory homocysteine testing from 1997 to 2010: The impact of evidence on clinical practice at a single institution. Clinical Chemistry and Laboratory Medicine, 51(3), 671-675. doi:10.1515/cclm-2012-0637
Kobayashi, S., Ikeda, T., Moriya, H., Ohtake, T., & Kumagai, H. (2004). Asymptomatic cerebral lacunae in patients with chronic kidney disease. American Journal of Kidney Diseases, 44(1), 35-41. doi:10.1053/j.ajkd.2004.03.026
Koenig, J. C., Rutsch, F., Bockmeyer, C., Baumgartner, M., Beck, B. B., Kranz, B., & Konrad, M. (2015). Nephrotic syndrome and thrombotic microangiopathy caused by cobalamin C deficiency. Pediatric Nephrology, 30(7), 1203-1206. doi:10.1007/s00467-015-3110-x
Kohlhagen, J., & Kelly, J. (2005). Vascular disease and risk factors in chronic kidney disease. Vascular Disease Prevention, 2(4), 321-331. doi:10.2174/156727005774329645
Kokot, F., Chudek, J., Łysiak-SzydŁowska, W., Domagała, B., Adamczak, M., Ignacy, W., . . . Wiecek, A. (2001). Levels of carnitine and homocysteine in plasma of long-term hemodialysis patients with chronic renal failure. Polskie archiwum medycyny wewntrznej, 106(6), 1131-1136. 
Koktasoglu, F., Gul, A. Z., Demirel, M., Ariş, Ö., Elçioǧlu, Ö. C., & Selek, Ş. (2021). Metabolic profiling study in serum of patients with polycystic kidney disease and chronic kidney disease based on 1 h NMR spectroscopy. Clinical Chemistry and Laboratory Medicine, 59(SUPPL 1), S516. doi:10.1515/cclm-2021-5024
Kolarz, M., Głowacki, R., Stompór, T., Wyroślak, J., & Undas, A. (2012). Elevated levels of Nε-homocysteinyl-lysine isopeptide in patients on long-term hemodialysis. Clinical Chemistry and Laboratory Medicine, 50(8), 1373-1378. doi:10.1515/cclm-2011-0716
Kolarz, M., Wyroślak, J., Zbróg, Z., Kraśniak, A., Rogulska, J., & Padjas, A. (2010). Antibodies against N-homocysteinylated proteins and their determinants in patients on long-term hemodialysis. Pol Arch Med Wewn, 120(6), 223-230. 
Koloverou, E., & Panagiotakos, D. B. (2016). Macronutrient composition and management of non-insulin-dependent diabetes mellitus (NIDDM): A new paradigm for individualized nutritional therapy in diabetes patients. Review of Diabetic Studies, 13(1), 6-16. doi:10.1900/RDS.2016.13.6
Kong, X., Ma, X., Zhang, C., Su, H., & Xu, D. (2017). Hyperhomocysteinemia increases the risk of chronic kidney disease in a Chinese middle-aged and elderly population-based cohort. International Urology and Nephrology, 49(4), 661-667. doi:10.1007/s11255-016-1452-3
Koning, A. M., Frenay, A. R. S., Leuvenink, H. G. D., & Van Goor, H. (2015). Hydrogen sulfide in renal physiology, disease and transplantation - The smell of renal protection. Nitric Oxide - Biology and Chemistry, 46, 37-49. doi:10.1016/j.niox.2015.01.005
Kopple, J. D. (2005). The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. American Journal of Clinical Nutrition, 81(6), 1257-1266. doi:10.1093/ajcn/81.6.1257
Kos-Kudła, B., & Staszewicz, P. (2003). The role of hormone replacement therapy in the treatment of women with complicated chronic renal failure. Polski Merkuriusz Lekarski, 14(80), 163-167. 
Kosmas, C. E., Silverio, D., Tsomidou, C., Salcedo, M. D., Montan, P. D., & Guzman, E. (2018). The Impact of Insulin Resistance and Chronic Kidney Disease on Inflammation and Cardiovascular Disease. Clinical Medicine Insights: Endocrinology and Diabetes, 11. doi:10.1177/1179551418792257
Koulouridis, E., Tzilianos, M., Katsarou, A., Costimba, I., Klonou, E., Panagiotaki, E., . . . Kaliolia, I. (2001). Homocysteine and C-reactive protein levels in haemodialysis patients. Int Urol Nephrol, 33(2), 207-215. doi:10.1023/a:1015254315839
Kousios, A., Kouis, P., Hadjivasilis, A., & Panayiotou, A. (2020). Cardiovascular Risk Assessment Using Ultrasonographic Surrogate Markers of Atherosclerosis and Arterial Stiffness in Patients With Chronic Renal Impairment: A Narrative Review of the Evidence and a Critical View of Their Utility in Clinical Practice. Canadian Journal of Kidney Health and Disease, 7. doi:10.1177/2054358120954939
Kovács, K. R., Czuriga, D., Bereczki, D., Bornstein, N. M., & Csiba, L. (2013). Silent brain infarction - a review of recent observations. International Journal of Stroke, 8(5), 334-347. doi:10.1111/j.1747-4949.2012.00851.x
Koyama, K. (2012). Reduced remethylation in patients with Chronic Kidney Disease (CKD) induces vitamin B6 deficiency by enhanced trans-sulfuration activity. Clinical Chemistry and Laboratory Medicine, 50(2), A32. doi:10.1515/cclm-2012-0032
Koyama, K., Ito, A., Yamamoto, J., Nishio, T., Kajikuri, J., Dohi, Y., . . . et al. (2010). Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis. American journal of kidney diseases, 55(6), 1069‐1078. doi:10.1053/j.ajkd.2009.12.035
Koyama, K., Ito, A., Yamamoto, J., Nishio, T., Kajikuri, J., Dohi, Y., . . . Itoh, T. (2010). Randomized Controlled Trial of the Effect of Short-term Coadministration of Methylcobalamin and Folate on Serum ADMA Concentration in Patients Receiving Long-term Hemodialysis. American Journal of Kidney Diseases, 55(6), 1069-1078. doi:10.1053/j.ajkd.2009.12.035
Koyama, K., Usami, T., Takeuchi, O., Morozumi, K., & Kimura, G. (2002). Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation. Nephrology Dialysis Transplantation, 17(5), 916-922. doi:10.1093/ndt/17.5.916
Kozłowska, I. (2004). The effect of lowering plasma homocysteine levels on some parameters of thrombotic activity in haemodialyzed patients with chronic renal failure. Annales Academiae Medicae Stetinensis, 50(1), 87-95. 
Krajnc, M., Pečovnik-Balon, B., Hojs, R., & Rupreht, M. (2011). Comparison of coronary artery calcification and some coronary artery calcification risk factors in patients on haemodialysis and in patients with type 2 diabetes. Journal of International Medical Research, 39(3), 1006-1015. doi:10.1177/147323001103900336
Krane, V., & Wanner, C. (2001). Cardiovascular disease and predisposing factors in chronic renal failure. Journal of Clinical and Basic Cardiology, 4(2), 97-100. 
Kraśniak, A., Drozdz, M., Pasowicz, M., Chmiel, G., Michałek, M., Szumilak, D., . . . Sułowicz, W. (2007). Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrology Dialysis Transplantation, 22(2), 515-521. doi:10.1093/ndt/gfl564
Kronenberg, F. (1998). Homocysteine, lipoprotein(a) and fibrinogen: Metabolic risk factors for cardiovascular complications of chronic renal disease. Current Opinion in Nephrology and Hypertension, 7(3), 271-278. doi:10.1097/00041552-199805000-00006
Kruglova, M. P., Grachev, S. V., Bulgakova, P. O., Ivanov, A. V., Virus, E. D., Nikiforova, K. A., . . . Kubatiev, A. A. (2020). Low S-adenosylmethionine/ S-adenosylhomocysteine Ratio in Urine is Associated with Chronic Kidney Disease. Lab Med, 51(1), 80-85. doi:10.1093/labmed/lmz035
Kruglova, M. P., Grachev, S. V., Bulgakova, P. O., Ivanov, A. V., Virus, E. D., Nikiforova, K. A., . . . Kubatiev, A. A. (2021). Low S-adenosylmethionine/S-adenosylhomocysteine ratio in urine is associated with chronic kidney disease. Lab Medicine, 51(1), 80-85. doi:10.1093/LABMED/LMZ035
Kruglova, M. P., Ivanov, A. V., Virus, E. D., Bulgakova, P. O., Samokhin, A. S., Fedoseev, A. N., . . . Kubatiev, A. A. (2021). Urine S-Adenosylmethionine are Related to Degree of Renal Insufficiency in Patients with Chronic Kidney Disease. Lab Medicine, 52(1), 47-56. doi:10.1093/LABMED/LMAA034
Krummel, T., & Hannedouche, T. (2013). Clinical potentials of adsorptive dialysis membranes. Blood Purification, 35(SUPPL.2), 1-4. doi:10.1159/000350835
Krzesinski, J. M., Dubois, B., & Rorive, G. (2003). Prevention of chronic renal failure in the adult. Revue Medicale de Liege, 58(6), 369-377. 
Kuang, Q., Xue, N., Chen, J., Shen, Z., Cui, X., Fang, Y., & Ding, X. (2018). Low Plasma Hydrogen Sulfide Is Associated with Impaired Renal Function and Cardiac Dysfunction. American Journal of Nephrology, 47(5), 361-371. doi:10.1159/000489606
Kubo, M., Kiyohara, Y., Kato, I., Tanizaki, Y., Katafuchi, R., Hirakata, H., . . . Iida, M. (2003). Risk factors for renal glomerular and vascular changes in an autopsy-based population survey: the Hisayama study. Kidney Int, 63(4), 1508-1515. doi:10.1046/j.1523-1755.2003.00886.x
Kumagai, H., Sakurai, M., Takita, T., Maruyama, Y., Uno, S., Ikegaya, N., . . . Hishida, A. (2006). Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Am J Kidney Dis, 48(5), 797-805. doi:10.1053/j.ajkd.2006.08.003
Kumar, J., & Shah, S. V. (2005). Kidney disease as an independent risk factor for cardiovascular events. J Ren Nutr, 15(1), 99-104. doi:10.1053/j.jrn.2004.09.032
Kumchev, E., Taralov, Z., Stoianova, L., & Dimitrakov, D. (2001). Assessment of the serum homocysteine as a risk factor for accelerated cardiovascular pathology in predialysis patients with chronic renal failure. Nephrology, Hemodialysis and Transplantation, 7(1-2), 45-49. 
Kundhal, K., Pierratos, A., & Chan, C. T. (2005). Newer paradigms in renal replacement therapy: will they alter cardiovascular outcomes? Cardiol Clin, 23(3), 385-391. doi:10.1016/j.ccl.2005.03.001
Kurowska, E. M. (2002). Nitric oxide therapies in vascular diseases. Current Pharmaceutical Design, 8(3), 155-166. doi:10.2174/1381612023396429
Lacey, B., Herrington, W. G., Preiss, D., Lewington, S., & Armitage, J. (2017). The Role of Emerging Risk Factors in Cardiovascular Outcomes. Current Atherosclerosis Reports, 19(6). doi:10.1007/s11883-017-0661-2
LaCroix, A. Z., Lee, J. S., Wu, L., Cauley, J. A., Shlipak, M. G., Ott, S. M., . . . Cummings, S. R. (2008). Cystatin-C, renal function, and incidence of hip fracture in postmenopausal women. Journal of the American Geriatrics Society, 56(8), 1434-1441. doi:10.1111/j.1532-5415.2008.01807.x
Laguna, P., Robles, N. R., Lopez Gomez, J., Barroso, S., & Collado, G. (2018). Lack of Correlation of Carotid Intima-Media Index and Peripheral Artery Disease. High Blood Pressure and Cardiovascular Prevention, 25(4), 379-383. doi:10.1007/s40292-018-0282-z
Lai, C. L., Xing, J. P., Liu, X. H., Qi, J., Zhao, J. Q., Ji, Y. R., . . . Ruan, L. F. (2017). Relationships of inflammatory factors and risk factors with different target organ damage in essential hypertension patients. Chinese Medical Journal, 130(11), 1296-1302. doi:10.4103/0366-6999.206343
Lai, S., Dimko, M., Galani, A., Coppola, B., Innico, G., Frassetti, N., . . . Mariotti, A. (2015). Early markers of cardiovascular risk in chronic kidney disease. Renal Failure, 37(2), 254-261. doi:10.3109/0886022X.2014.982489
Lai, S., Mariotti, A., Coppola, B., Lai, C., Aceto, P., Dimko, M., . . . Cianci, R. (2014). Uricemia and homocysteinemia: Nontraditional risk factors in the early stages of chronic kidney disease - Preliminary data. European Review for Medical and Pharmacological Sciences, 18(7), 1010-1017. 
Lai, S., Mariotti, A., Coppola, B., Lai, C., Aceto, P., Dimko, M., . . . Cianci, R. (2014). Uricemia and homocysteinemia: nontraditional risk factors in the early stages of chronic kidney disease--preliminary data. Eur Rev Med Pharmacol Sci, 18(7), 1010-1017. 
Lai, S., Mazzaferro, S., Muscaritoli, M., Mastroluca, D., Testorio, M., Perrotta, A., . . . Molfino, A. (2020). Prebiotic therapy with inulin associated with low protein diet in chronic kidney disease patients: Evaluation of nutritional, cardiovascular and psychocognitive parameters. Toxins, 12(6). doi:10.3390/toxins12060381
Lai, S., Tsai, Y., & Chang, S. (2017). Association of weight status, hyperhomocysteinemia and risk of chronic kidney disease in a Taiwanese adult population. Obesity Facts, 10, 161. doi:10.1159/000468958
Lai, S. H., Tsai, Y. W., Chen, Y. C., & Chang, S. S. (2018). Obesity, hyperhomocysteinaemia and risk of chronic kidney disease: A population-based study. Family Practice, 35(3), 259-265. doi:10.1093/fampra/cmx110
Laight, D. (2019). Cardiovascular risk prediction for primary prevention. Prescriber, 30(3), 25-29. doi:10.1002/psb.1747
Lameire, N., Vanholder, R., & De Smet, R. (2001). Uremic toxins and peritoneal dialysis. Kidney International, Supplement, 59(78), S292-S297. doi:10.1046/j.1523-1755.2001.59780292.x
Landray, M. J., Thambyrajah, J., McGlynn, F. J., Jones, H. J., Baigent, C., Kendall, M. J., . . . Wheeler, D. C. (2001). Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. American Journal of Kidney Diseases, 38(3), 537-546. 
Landray, M. J., Townend, J. N., Martin, S., Martin, U., & Wheeler, D. C. (1999). Lipid-lowering drugs and homocysteine. Lancet, 353(9168), 1974-1975. doi:10.1016/s0140-6736(05)77189-0
Landray, M. J., Townend, J. N., Martin, S., Martin, U., & Wheeler, D. C. (1999). Lipid-lowering drugs and homocysteine [9]. Lancet, 353(9168), 1974-1975. doi:10.1016/S0140-6736(05)77189-0
Lane, J. S., Vittinghoff, E., Lane, K. T., Hiramoto, J. S., & Messina, L. M. (2006). Risk factors for premature peripheral vascular disease: Results for the National Health and Nutritional Survey, 1999-2002. Journal of Vascular Surgery, 44(2), 319-325. doi:10.1016/j.jvs.2006.04.015
Lara-Prado, J. I., Pazos-Pérez, F., Méndez-Landa, C. E., Grajales-García, D. P., Feria-Ramírez, J. A., Salazar-González, J. J., . . . Treviño-Becerra, A. (2021). Acute kidney injury and organ dysfunction: What is the role of uremic toxins? Toxins, 13(8). doi:10.3390/toxins13080551
Lau, J. F., Weinberg, M. D., & Olin, J. W. (2011). Peripheral artery disease. Part 1: Clinical evaluation and noninvasive diagnosis. Nature Reviews Cardiology, 8(7), 405-418. doi:10.1038/nrcardio.2011.66
Lau, Y. W., Resontoc, L. P., Than, M., Ng, K. H., Gong, L. L., Chan, Y. H., . . . Yap, H. K. (2013). GDF-15 and ST2 are useful predictors of arteriopathy in pre-dialysis and dialysis children. Pediatric Nephrology, 28(8), 1375. doi:10.1007/s00467-013-2521-9
Lavori, P. W., Wilt, T. J., & Sugarman, J. (2007). Quality assurance questionnaire for professionals fails to improve the quality of informed consent. Clinical Trials, 4(6), 638-649. doi:10.1177/1740774507085144
Leblanc, M., Pichette, V., Geadah, D., & Ouimet, D. (2000). Folic acid and pyridoxal-5'-phosphate losses during high-efficiency hemodialysis in patients without hydrosoluble vitamin supplementation. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 10(4), 196-201. 
Lee, H. A., Choi, J. S., Ha, K. S., Yang, D. H., Chang, S. K., & Hong, S. Y. (1999). Influence of 5,10-methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine concentration in patients with end-stage renal disease. Am J Kidney Dis, 34(2), 259-263. doi:10.1016/s0272-6386(99)70353-7
Lee, H. A., Park, E. A., Cho, S. J., Kim, H. S., Kim, Y. J., Lee, H., . . . Park, H. (2013). Mendelian randomization analysis of the effect of maternal homocysteine during pregnancy, as represented by maternal MTHFR C677T genotype, on birth weight. Journal of Epidemiology, 23(5), 371-375. doi:10.2188/jea.JE20120219
Lee, M., Hong, K. S., Chang, S. C., & Saver, J. L. (2010). Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: A meta-analysis. Stroke, 41(6), 1205-1212. doi:10.1161/STROKEAHA.109.573410
Leening, M. J. G., Kavousi, M., Steyerberg, E. W., Hofman, A., De Maat, M. P. M., Oudkerk, M., . . . Witteman, J. C. M. (2013). Evaluation of newer risk markers for coronary heart disease: The Rotterdam study. Nederlands Tijdschrift voor Geneeskunde, 157(30). 
Lerman, A., Toya, T., Sara, J. D. S., Lerman, B., Ahmad, A., Corban, M., & Lerman, L. (2020). PLASMA HOMOCYSTEINE LEVEL IS ASSOCIATED WITH PERIPHERAL MICROVASCULAR ENDOTHELIAL DYSFUNCTION. Journal of the American College of Cardiology, 75(11), 2270. doi:10.1016/S0735-1097(20)32897-7
Leskinen, Y., Lehtimäki, T., Loimaala, A., Huhtala, H., Salenius, J. P., Oja, S. S., & Saha, H. (2004). Homocysteine and carotid atherosclerosis in chronic renal failure - The confounding effect of renal function. Atherosclerosis, 175(2), 315-323. doi:10.1016/j.atherosclerosis.2004.04.002
Leskinen, Y., Lehtimäki, T., Loimaala, A., Huhtala, H., Salenius, J. P., Oja, S. S., & Saha, H. (2004). Homocysteine and carotid atherosclerosis in chronic renal failure--the confounding effect of renal function. Atherosclerosis, 175(2), 315-323. doi:10.1016/j.atherosclerosis.2004.04.002
Levey, A. S., Coresh, J., Tighiouart, H., Greene, T., & Inker, L. A. (2020). Measured and estimated glomerular filtration rate: current status and future directions. Nat Rev Nephrol, 16(1), 51-64. doi:10.1038/s41581-019-0191-y
Levi, A., Cohen, E., Levi, M., Goldberg, E., Garty, M., & Krause, I. (2014). Elevated serum homocysteine is a predictor of accelerated decline in renal function and chronic kidney disease: A historical prospective study. European Journal of Internal Medicine, 25(10), 951-955. doi:10.1016/j.ejim.2014.10.014
Levin, A., Lancashire, W., & Fassett, R. G. (2013). Targets, trends, excesses, and deficiencies: Refocusing clinical investigation to improve patient outcomes. Kidney International, 83(6), 1001-1009. doi:10.1038/ki.2013.91
Li, C., Cheng, G., Sha, T., Cheng, W., & Yan, Y. (2020). The Relationships between Screen Use and Health Indicators among Infants, Toddlers, and Preschoolers: A Meta-Analysis and Systematic Review. Int J Environ Res Public Health, 17(19). doi:10.3390/ijerph17197324
Li, G., Kidd, J., & Li, P. L. (2020). Podocyte lysosome dysfunction in chronic glomerular diseases. International Journal of Molecular Sciences, 21(5). doi:10.3390/ijms21051559
Li, H., & Goligorsky, M. S. (2002). Endothelial gene responses to homocysteine: Relation to atherosclerosis. Experimental Nephrology, 10(2), 164-169. doi:10.1159/000049911
Li, L., Hasegawa, H., Inaba, N., Yoshioka, W., Chang, D., Liu, J., & Ichida, K. (2018). Diet-induced hyperhomocysteinemia impairs vasodilation in 5/6-nephrectomized rats. Amino Acids, 50(10), 1485-1494. doi:10.1007/s00726-018-2626-3
Li, L., Hasegawa, H., Inaba, N., Yoshioka, W., Chang, D., Liu, J. X., & Ichida, K. (2018). Diet-induced hyperhomocysteinemia impairs vasodilation in 5/6-nephrectomized rats. Amino Acids, 50(10), 1485-1494. doi:10.1007/s00726-018-2626-3
Li, L., Tang, W., & Yi, F. (2019). Role of Inflammasome in Chronic Kidney Disease. In (Vol. 1165, pp. 407-421).
Li, L., Yang, C., Zhao, Y., Zeng, X., Liu, F., & Fu, P. (2014). Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol, 15, 122. doi:10.1186/1471-2369-15-122
Li, M., Hu, L., Hu, L., Huang, X., Liu, X., Zhou, W., . . . Cheng, X. (2021). Visceral Adiposity Index Is Inversely Associated with Renal Function in Normal-Weight Adults with Hypertension: The China H-Type Hypertension Registry Study. Journal of Nutrition, 151(6), 1394-1400. doi:10.1093/jn/nxab022
Li, N., Zhou, G., Zheng, Y., Zhou, E., He, W., Sun, W., & Zhang, L. (2022). Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease. Renal Failure, 44(1), 241-249. doi:10.1080/0886022X.2022.2032744
Li, P. K. T. (2010). Endotoxemia, inflammation and cv disease in dialysis. Nephrology, 15, 7. doi:10.1111/j.1440-1797.2010.01335.x
Li, S., Qiu, B., Lu, H., Lai, Y., Liu, J., Luo, J., . . . Nie, J. (2019). Hyperhomocysteinemia Accelerates Acute Kidney Injury to Chronic Kidney Disease Progression by Downregulating Heme Oxygenase-1 Expression. Antioxidants and Redox Signaling, 30(13), 1635-1650. doi:10.1089/ars.2017.7397
Li, Y., Spence, J. D., Wang, X., Huo, Y., Xu, X., & Qin, X. (2020). Effect of Vitamin B12 Levels on the Association Between Folic Acid Treatment and CKD Progression: A Post Hoc Analysis of a Folic Acid Interventional Trial. American Journal of Kidney Diseases, 75(3), 325-332. doi:10.1053/j.ajkd.2019.07.020
Liakopoulos, V., Georgianos, P. I., Eleftheriadis, T., & Sarafidis, P. A. (2011). Epigenetic mechanisms and kidney diseases. Current Medicinal Chemistry, 18(12), 1733-1739. doi:10.2174/092986711795496827
Liang, S., Wang, W. L., Zhu, F. L., Duan, S. W., Sun, X. F., Chen, X. M., & Cai, G. Y. (2018). Chinese observational prospective study of ageing population with chronic kidney disease (C-OPTION): A study protocol. BMJ Open, 8(2). doi:10.1136/bmjopen-2017-019457
Liang, Y., Yang, Z., Yang, Z., Hansen, B., Gong, L., & Zeng, W. (2017). GFR and biomarkers of CKD in diabetic and prediabetic rhesus monkeys. Journal of the American Society of Nephrology, 28, 1149. 
Libetta, C., Sepe, V., Esposito, P., Galli, F., & Dal Canton, A. (2011). Oxidative stress and inflammation: Implications in uremia and hemodialysis. Clinical Biochemistry, 44(14-15), 1189-1198. doi:10.1016/j.clinbiochem.2011.06.988
Lilien, M., Duran, M., Van Hoeck, K., Poll-The, B. T., & Schröder, C. (1999). Hyperhomocyst(e)inaemia in children with chronic renal failure. Nephrology Dialysis Transplantation, 14(2), 366-368. doi:10.1093/ndt/14.2.366
Lim, P. S., Hung, W. R., & Wei, Y. H. (2001). Polymorphism in methylenetetrahydrofolate reductase gene: its impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving hemodialysis. Nephron, 87(3), 249-256. doi:10.1159/000045922
Lin, J., Xu, R., Yun, L., Hou, Y., Li, C., Lian, Y., & Zheng, F. (2019). A risk prediction model for renal damage in a hypertensive Chinese Han population. Clinical and Experimental Hypertension, 41(6), 552-557. doi:10.1080/10641963.2018.1523913
Lin, T. J., Hsu, B. G., Wang, J. H., Lai, Y. H., Dongoran, R. A., & Liu, C. H. (2020). Serum indoxyl sulfate as a potential biomarker of aortic arterial stiffness in coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases, 30(12), 2320-2327. doi:10.1016/j.numecd.2020.07.035
Lin, Y. H., Pao, K. Y., Wu, V. C., Lin, Y. L., Chien, Y. F., Hung, C. S., . . . Hwang, J. J. (2007). The influence of estimated creatinine clearance on plasma homocysteine in hypertensive patients with normal serum creatinine. Clinical Biochemistry, 40(3-4), 230-234. doi:10.1016/j.clinbiochem.2006.11.010
Lindner, A., Bankson, D. D., Stehman-Breen, C., Mahuren, J. D., & Coburn, S. P. (2002). Vitamin B6 metabolism and homocysteine in end-stage renal disease and chronic renal insufficiency. American Journal of Kidney Diseases, 39(1), 134-145. 
Lippi, G., Tessitore, N., Gammaro, L., Rugiu, C., Maschio, G., & Guidi, G. (2001). Cardiovascular risk factors in patients with chronic renal failure maintained on hemodialysis or continuous ambulatory peritoneal dialysis [2]. Thrombosis Research, 101(6), 517-519. doi:10.1016/S0049-3848(00)00426-6
Litwin, M., Abuauba, M., Wawer, Z. T., Grenda, R., Kurył, T., & Pietraszek, E. (2000). Sulphur amino acids, vitamin B12 and folic acid in children with chronic renal failure. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 8(46), 268-269. 
Litwin, M., Abuauba, M., Wawer, Z. T., Grenda, R., Kuryt, T., & Pietraszek, E. (2001). Folate, vitamin B12, and sulfur amino acid levels in patients with renal failure. Pediatric Nephrology, 16(2), 127-132. doi:10.1007/s004670000524
Litwin, M., Grenda, R., Lukasiewicz, H., Kuryl, T., & Teklinska, E. (1999). Hyperhomocysteinemia in children with chronic renal failure - Effect of folic acid treatment and activity of natural coagulation inhibitors. Pediatria Polska, 74(9), 865-872. 
Liu, C., Lin, L., & Xu, R. (2020). Elevated homocysteine and differential risks of the renal function decline in hypertensive patients. Clinical and Experimental Hypertension, 42(6), 565-570. doi:10.1080/10641963.2020.1739698
Liu, D., Ding, H., Liu, S., & Shen, J. (2012). Estimated glomerular filtration rate decline in 567 patients with acute stroke. Scandinavian Journal of Urology and Nephrology, 46(2), 142-147. doi:10.3109/00365599.2011.639032
Liu, I. D., Chaturvedi, S., Lau, Y. W. P., Resontoc, L. P., Than, M., Ng, K. H., . . . Yap, H. K. (2014). A composite risk score of novel biomarkers predicts arteriopathy in predialysis and dialysis children. Annals of the Academy of Medicine Singapore, 43(9), S19. 
Liu, J., Peng, Y., Zhou, N., Liu, X., Meng, Q., Xu, H., & Zhao, S. (2017). Combined methylmalonic acidemia and homocysteinemia presenting predominantly with late-onset diffuse lung disease: a case series of four patients. Orphanet Journal of Rare Diseases, 12(1). doi:10.1186/s13023-017-0610-8
Liu, L. (2010). Micronutrients, inflammatory biomarkers, and risk of cardiovascular disease and all-cause mortality in the United States: Implications for a healthier diet and longevity. Circulation, 122(2), e85-e86. doi:10.1161/CIRCULATIONAHA.110.192773
Liu, M., Kong, W., Yu, X., & Dai, M. (2020). The study of tongfu xiezhuo recipe on regulating intestinal barrier function in chronic kidney disease. International Journal of Clinical and Experimental Medicine, 13(6), 4553-4562. 
Liu, P. T., & Chen, J. D. (2021). Synergistic association of hyperuricemia and hyperhomocysteinemia with chronic kidney disease in middle-Aged adults and the elderly population. Medicine (United States), 100(37). doi:10.1097/MD.0000000000027202
Liu, X., Guo, Y., Wu, J., Yao, N., Wang, H., & Li, B. (2020). Discrimination of chronic kidney disease and diabetic nephropathy and analysis of their related influencing factors. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 5085-5096. doi:10.2147/DMSO.S275398
Liu, Y. H., Lu, M., & Bian, J. S. (2011). Hydrogen sulfide and renal ischemia. Expert Review of Clinical Pharmacology, 4(1), 49-61. doi:10.1586/ecp.10.127
Liyanage, T., Toyama, T., Hockham, C., Ninomiya, T., Perkovic, V., Woodward, M., . . . Jun, M. (2022). Prevalence of chronic kidney disease in Asia: a systematic review and analysis. BMJ Glob Health, 7(1). doi:10.1136/bmjgh-2021-007525
Lobb, I., Sonke, E., Aboalsamh, G., & Sener, A. (2015). Hydrogen sulphide and the kidney: Important roles in renal physiology and pathogenesis and treatment of kidney injury and disease. Nitric Oxide - Biology and Chemistry, 46, 55-65. doi:10.1016/j.niox.2014.10.004
Locatelli, F., Bommer, J., London, G. M., Martín-Malo, A., Wanner, C., Yaqoob, M., & Zoccali, C. (2001). Cardiovascular disease determinants in chronic renal failure: Clinical approach and treatment. Nephrology Dialysis Transplantation, 16(3), 459-468. doi:10.1093/ndt/16.3.459
Locatelli, F., Canaud, B., Eckardt, K. U., Stenvinkel, P., Wanner, C., & Zoccali, C. (2003). The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant, 18(9), 1716-1725. doi:10.1093/ndt/gfg288
Locatelli, F., Marcelli, D., Conte, F., D'Amico, M., Del Vecchio, L., Limido, A., . . . Spotti, D. (2000). Cardiovascular disease in chronic renal failure: The challenge continues. Nephrology Dialysis Transplantation, 15(SUPPL. 5), 69-80. 
Locsey, L., Seres, I., Kovács, D., Asztalos, L., & Paragh, G. (2013). Relationship between lipid peroxidation and arterial stiffness in renal transplanted patients. Nephrology Dialysis Transplantation, 28, i283. doi:10.1093/ndt/gft123
Lõcsey, L., Seres, I., Kovács, D., Asztalos, L., & Paragh, G. (2013). Connection between arterial stiffness and lipid peroxidation change in renal transplanted patients. Transplant International, 26, 248. doi:10.1111/tri.12214
Locsey, L., Szegedi, J., Dán, A., Görögh, S., & Tóths, E. (2001). Homocysteine and cystatin C level changes in haemodialysed patients and connection with cerebro- and cardiovascular complications. Acta physiologica Hungarica, 88(3-4), 293-299. 
Lócsey, L., Szlanka, B., Borbás, B., Szabó, L., Dán, A., Asztalos, L., . . . Lörincz, I. (2010). Arterial stiffness in chronic renal failure and after renal transplantation. Transplantation Proceedings, 42(6), 2299-2303. doi:10.1016/j.transproceed.2010.05.017
Löcsey, L., Szlanka, B., Borbás, B., Szabó, L., Dán, A., Asztalos, L., . . . Lörincz, I. (2010). Arterial stiffness in chronic renal failure and after renal transplantation. Transplant Proc, 42(6), 2299-2303. doi:10.1016/j.transproceed.2010.05.017
Loehrer, F. M., Angst, C. P., Brunner, F. P., Haefeli, W. E., & Fowler, B. (1998). Evidence for disturbed S-adenosylmethionine : S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions? Nephrol Dial Transplant, 13(3), 656-661. doi:10.1093/ndt/13.3.656
Logar, C. M., Herzog, C. A., & Beddhu, S. (2003). Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations. American Journal of the Medical Sciences, 325(4), 214-227. doi:10.1097/00000441-200304000-00008
Loi, M., Zaliani, A., Abbamonte, M., Ferrari, E. P., Maestri, R., Trojano, L., & Balbi, P. (2020). Milestones and timescale of poststroke recovery: A cohort study. Behavioural Neurology, 2020. doi:10.1155/2020/8216758
Loitsch, S. M., Reuter, K. C., Oremek, G. M., Wetzstein, R., Stangl, K., Armbruster, F. P., . . . Stein, J. (2014). Comparison of a new microbiological assay with a standard high-performance liquid chromatographic method for determination of vitamin B6in serum. Clinical Laboratory, 60(6), 1035-1041. doi:10.7754/Clin.Lab.2014.140101
Long, Y., Zhen, X., Zhu, F., Hu, Z., Lei, W., Li, S., . . . Nie, J. (2017). Hyperhomocysteinemia Exacerbates Cisplatin-induced Acute Kidney Injury. International journal of biological sciences, 13(2), 219-231. doi:10.7150/ijbs.16725
Lorenzen, J., Krämer, R., Kliem, V., Bode-Boeger, S. M., Veldink, H., Haller, H., . . . Kielstein, J. T. (2010). Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. European Journal of Clinical Investigation, 40(4), 294-300. doi:10.1111/j.1365-2362.2010.02271.x
Lotfollahi, L., Ossareh, S., & Neyestani, T. R. (2021). Evaluation of 25-hydroxy vitamin d and 1,25-dihydroxy vitamin d levels in maintenance hemodialysis patients. Iranian Journal of Kidney Diseases, 15(1), 31-37. 
Lottermoser, K., Petras, S., Pöge, U., Fimmers, R., Hertfelder, H. J., Schiermeyer, B., . . . Düsing, R. (2001). The fibrinolytic system in chronic renal failure. European journal of medical research, 6(9), 372-376. 
Lovcić, V., Kes, P., & Reiner, Z. (2006). [Characteristics of hyperhomocysteinemia in dialysis patients]. Acta Med Croatica, 60(1), 21-26. 
Lovcić, V., Kes, P., Zeljko, R., & Kusec, V. (2006). [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?]. Acta Med Croatica, 60(3), 201-208. 
Lu, K. C., Yang, H. Y., & Su, S. L. (2013). Effect of folic acid supplementation on cardiovascular events in non-diabetic chronic kidney diseases: Meta-analysis of randomized controlled trials. Nephrology Dialysis Transplantation, 28, i475. doi:10.1093/ndt/gft151
Łubińska, M., Kazimierska, E., & Sworczak, K. (2006). Hyperhomocysteinemia as a new risk factor for different diseases. Advances in Clinical and Experimental Medicine, 15(5), 897-903. 
Lubomirova, M., Tzoncheva, A., Petrova, J., & Kiperova, B. (2007). Homocystein and carotid atherosclerosis in chronic renal failure. Hippokratia, 11(4), 205-209. 
Lubomirova, M., Tzontcheva, A., Petrova, J., & Kiperova, B. (2009). Homocysteine is an important cardiovascular risk factor in chronic renal failure. Acta Medica Bulgarica, 36(2), 43-51. 
Luke, J. N., Schmidt, D. F., Ritte, R., O'Dea, K., Brown, A., Piers, L. S., . . . Rowley, K. G. (2016). Nutritional predictors of chronic disease in a Central Australian Aboriginal cohort: A multi-mixture modelling analysis. Nutrition, Metabolism and Cardiovascular Diseases, 26(2), 162-168. doi:10.1016/j.numecd.2015.11.009
Luo, D., Wan, X., Liu, J., & Tong, T. (2018). Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res, 27(6), 1785-1805. doi:10.1177/0962280216669183
Luo, D., Zhong, Z., Qiu, Y., Wang, Y., Li, H., Lin, J., . . . Mao, H. (2021). Abnormal iron status is associated with an increased risk of mortality in patients on peritoneal dialysis. Nutrition, Metabolism and Cardiovascular Diseases, 31(4), 1148-1155. doi:10.1016/j.numecd.2020.12.018
Lv, J. C., & Zhang, L. X. (2019). Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol, 1165, 3-15. doi:10.1007/978-981-13-8871-2_1
Ma, T., & Ding, G. (2013). Effects of residual renal function on left ventricle and analysis of related factors in patients with hemodialysis. Ren Fail, 35(2), 198-203. doi:10.3109/0886022x.2012.745153
Ma, X., Zhang, J., Zhang, C., Yang, X., Yu, A., Huang, Y., . . . Ouyang, G. (2021). Targeting Enrichment and Correlation Studies of Glutathione and Homocysteine in IgAVN Patient Urine Based on a Core-Shell Zr-Based Metal-Organic Framework. ACS applied materials & interfaces, 13(33), 40070-40078. doi:10.1021/acsami.1c09967
Maas, R. (2005). Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med, 10 Suppl 1, S49-57. doi:10.1191/1358863x05vm605oa
Machowska, A., Qureshi, A. R., Isoyama, N., Leurs, P., Anderstam, B., Heimburger, O., . . . Lindholm, B. (2014). Plasma pentosidine, malnutrition and all-cause mortality in CKD stage 5 patients. International Journal of Artificial Organs, 37(8), 607. doi:10.5301/ijao.5000346
Mactier, R., Davies, S., Dudley, C., Harden, P., Jones, C., Kanagasundaram, S., . . . Wright, M. (2011). Summary of the 5th edition of the renal association clinical practice guidelines (2009-2012). Nephron - Clinical Practice, 118(SUPPL. 1), c27-c70. doi:10.1159/000328060
Madkour, M. E., Bekheet, I. W., Abdel-Ghaffar, N., Waked, E., & Younes, K. (2006). Independent, non-traditional risk factors for cardiovascular events and atherothrombosis in chronic kidney disease and in hemodialysis-dependent patients. Journal of Medical Sciences, 6(3), 484-491. 
Maesato, K., Ohtake, T., Mochida, Y., Ishioka, K., Oka, M., Moriya, H., . . . Kobayashi, S. (2017). Correlation of hippocampal atrophy with hyperhomocysteinemia in hemodialysis patients: An exploratory pilot study. PLoS ONE, 12(4). doi:10.1371/journal.pone.0175102
Mafra, D., Borges, N., Alvarenga, L., Esgalhado, M., Cardozo, L., Lindholm, B., & Stenvinkel, P. (2019). Dietary components that may influence the disturbed gut microbiota in chronic kidney disease. Nutrients, 11(3). doi:10.3390/nu11030496
Magott, M. (1998). Homocysteine as a nonlipid factor in the pathogenesis of atherosclerosis. Postpy higieny i medycyny doświadczalnej, 52(3), 259-267. 
Mahrooz, A., Zargari, M., Sedighi, O., Shaygani, H., & Gohari, G. (2012). Increased oxidized-LDL levels and arylesterase activity/HDL ratio in ESRD patients treated with hemodialysis. Clinical and investigative medicine. Médecine clinique et experimentale, 35(3), E144-151. 
Maisel, A. S., Katz, N., Hillege, H. L., Shaw, A., Zanco, P., Bellomo, R., . . . Ronco, C. (2011). Biomarkers in kidney and heart disease. Nephrology Dialysis Transplantation, 26(1), 62-74. doi:10.1093/ndt/gfq647
Majumder, S., Ren, L., Pushpakumar, S., & Sen, U. (2019). Hydrogen sulphide mitigates homocysteine-induced apoptosis and matrix remodelling in mesangial cells through Akt/FOXO1 signalling cascade. Cellular Signalling, 61, 66-77. doi:10.1016/j.cellsig.2019.05.003
Mäki-Petäjä, K. M., & Wilkinson, I. B. (2010). Arterial stiffness and inflammation - A potential target for a drug therapy. Artery Research, 4(4), 99-107. doi:10.1016/j.artres.2010.10.002
Makita, Y., Moczulski, D. K., Bochenski, J., Smiles, A. M., Warram, J. H., & Krolewski, A. S. (2003). Methylenetetrahydrofolate reductase gene polymorphism and susceptibility to diabetic nephropathy in type 1 diabetes. Am J Kidney Dis, 41(6), 1189-1194. doi:10.1016/s0272-6386(03)00350-0
Makulska, I., Szczepańska, M., Drozdz, D., Polak-Jonkisz, D., & Zwolińska, D. (2013). Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease. Pediatric Nephrology, 28(1), 121-128. doi:10.1007/s00467-012-2280-z
Makulska, I., Szczepańska, M., Drozdz, D., & Zwolnska, D. (2012). Skin autofluorescence (SAF) as a new noninvasive marker of cardiovascular damage in children with Chronic Kidney Disease (CKD). Nephrology Dialysis Transplantation, 27, ii543. doi:10.1093/ndt/gfs250
Małecki, R. (2000). Hyperhomocysteinemia as a risk factor for cardiovascular diseases in patients with chronic renal failure. Polskie archiwum medycyny wewntrznej, 104(4), 695-701. 
Mallamaci, F., Bonanno, G., Seminara, G., Rapisarda, F., Fatuzzo, P., Candela, V., . . . Zoccali, C. (2005). Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis, 45(4), 702-707. doi:10.1053/j.ajkd.2005.01.004
Mallamaci, F., Zoccali, C., Tripepi, G., Fermo, I., Benedetto, F. A., Cataliotti, A., . . . Soldarini, A. (2002). Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int, 61(2), 609-614. doi:10.1046/j.1523-1755.2002.00144.x
Malyszko, J., Malyszko, J. S., & Bachorzewska-Gajewska, H. (2005). Cardiovascular risk in chronic renal disease and transplantation prevention and management. Expert Opinion on Pharmacotherapy, 6(6), 929-943. doi:10.1517/14656566.6.6.929
Mann, J. F., Sheridan, P., McQueen, M. J., Held, C., Arnold, J. M., Fodor, G., . . . Lonn, E. M. (2008). Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. Nephrology, dialysis, transplantation, 23(2), 645‐653. doi:10.1093/ndt/gfm485
Mann, J. F. E., & Lonn, E. M. (2008). Reply. Nephrology Dialysis Transplantation, 23(7), 2429-2430. doi:10.1093/ndt/gfn106
Mann, J. F. E., Sheridan, P., McQueen, M. J., Held, C., Arnold, J. M. O., Fodor, G., . . . Lonn, E. M. (2008). Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease - Results of the renal Hope-2 study. Nephrology Dialysis Transplantation, 23(2), 645-653. doi:10.1093/ndt/gfm485
Manns, B. J., Burgess, E. D., Hyndman, M. E., Parsons, H. G., Schaefer, J. P., & Scott-Douglas, N. W. (1999). Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis, 34(4), 669-677. doi:10.1016/s0272-6386(99)70392-6
Manns, B. J., Burgess, E. D., Parsons, H. G., Schaefer, J. P., Hyndman, M. E., & Scott-Douglas, N. W. (1999). Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int, 55(1), 315-320. doi:10.1046/j.1523-1755.1999.00258.x
Manolov, V., Petrova, J., Bogov, B., Hadjidekova, S., Vasilev, V., Yonova, D., . . . Traykov, L. (2017). Evaluation of hepcidin and atherosclerosis in dialysis patients. Clinical Laboratory, 63(11-12), 1787-1792. doi:10.7754/Clin.Lab.2017.170336
Marcelino, M. C. D. S., Magalhães, W. V., Fonseca, F. L. A., Nucci, R. A. B., & Maifrino, L. B. M. (2020). Effects of resistance training on kidney morphology of aged ovariectomized rats. Acta Histochemica, 122(7). doi:10.1016/j.acthis.2020.151613
Marcén, R. (2006). Cardiovascular risk factors in renal transplantation - Current controversies. Nephrology Dialysis Transplantation, 21(SUPPL. 3), iii3-iii8. doi:10.1093/ndt/gfl298
Marchi, G., Busti, F., Zidanes, A. L., Vianello, A., & Girelli, D. (2020). Cobalamin deficiency in the elderly. Mediterranean Journal of Hematology and Infectious Diseases, 12(1). doi:10.4084/MJHID.2020.043
Marcucci, R., Zanazzi, M., Bertoni, E., Rosati, A., Fedi, S., Lenti, M., . . . Salvadori, M. (2005). Homocysteine-lowering therapy and carotid intima-media thickness in renal transplant recipients. Transplantation proceedings, 37(6), 2491‐2492. doi:10.1016/j.transproceed.2005.06.101
Marcus, J., Sarnak, M. J., & Menon, V. (2007). Homocysteine lowering and cardiovascular disease risk: Lost in translation. Canadian Journal of Cardiology, 23(9), 707-710. doi:10.1016/S0828-282X(07)70814-0
Marin Conesa, E., García Medina, A. M., Pellicer Espinosa, I., Gómez López, E., Martínez Zarco, M., Morales De la Prida, M., . . . Iniesta Valera, J. A. (2020). Superior ophtalmic vein thrombosis. European Journal of Neurology, 27, 740. 
Maróti, Z., Németh, I., Túri, S., Karg, E., Ugocsai, P., & Endreffy, E. (2004). Heme oxygenase 1 expression in young uremic patients on hemodialysis. Pediatr Nephrol, 19(4), 426-431. doi:10.1007/s00467-003-1384-x
Marouga, A., Dalamaga, M., Kastania, A. N., Antonakos, G., Thrasyvoulides, A., Kontelia, G., . . . Vlahakos, D. V. (2013). Correlates of serum resistin in elderly, non-diabetic patients with chronic kidney disease. Clinical Laboratory, 59(9-10), 1121-1128. doi:10.7754/Clin.Lab.2012.121112
Marsch, W. C., Komatsuzaki, S., Mueller, A., Hagemann, M., Lange, D., Maemecke, L., . . . Hoffmann, K. (2019). Livedoid vasculopathy: does hyperhomocysteinaemia play an aetiological role? European Journal of Dermatology, 29(3), 287-293. doi:10.1684/ejd.2019.3554
Martínez I Camps, E. (2004). Medical treatment of chronic kidney failure. Anales de Cirugia Cardiaca y Vascular, 10(1), 21-23+26. 
Massara, M., Stilo, F., Benedetto, F., De Caridi, G., & Spinelli, F. (2012). Carotid restenosis: Incidence and role of risk factors. European Surgical Research, 49(3-4), 180-181. doi:10.1159/0000341743
Massimetti, C., Cardello, P., Brescia, F., Imperato, G., & Feriozzi, S. (2016). Association between low serum magnesium levels and the extent of abdominal aortic calcification in renal transplant patients. Nephrology Dialysis Transplantation, 31, i319-i320. doi:10.1093/ndt/gfw178.34
Massimetti, C., Imperato, G., De Spirito, S., Pifferi, B., & Feriozzi, S. (2016). Changes in left ventricular hypertrophy after renal transplantation. Nephrology Dialysis Transplantation, 31, i575. doi:10.1093/ndt/gfw200.33
Massimetti, C., Imperato, G., Zampi, G., De Vincenzi, A., Fabbri, G. D. D., Brescia, F., & Feriozzi, S. (2014). Effects of renal transplantation on cardiac structure and function. Nephrology Dialysis Transplantation, 29, iii318. doi:10.1093/ndt/gfu160
Massy, Z. A. (1999). Reversal of hyperhomocyst(e)inaemia in chronic renal failure - Is folic or folinic acid the answer? Nephrology Dialysis Transplantation, 14(12), 2810-2812. doi:10.1093/ndt/14.12.2810
Massy, Z. A. (2000). Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients. Nephrology Dialysis Transplantation, 15(SUPPL. 5), 81-91. doi:10.1093/ndt/15.suppl_5.81
Massy, Z. A. (2003). Potential strategies to normalize the levels of homocysteine in chronic renal failure patients. Kidney International, Supplement, 63(84), S134-S136. doi:10.1046/j.1523-1755.63.s84.28.x
Massy, Z. A. (2006). Therapy of hyperhomocysteinemia in chronic kidney disease. Seminars in Nephrology, 26(1), 24-27. doi:10.1016/j.semnephrol.2005.06.006
Massy, Z. A., Ceballos, I., Chadefaux-Vekemens, B., Nguyen-Khoa, T., Descamps-Latscha, B., Drüeke, T. B., & Jungers, P. (2001). Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. Kidney International, Supplement, 59(78), S243-S245. 
Massy, Z. A., Chadefaux-Vekemans, B., Chevalier, A., Bader, C. A., Drüeke, T. B., Legendre, C., . . . Kreis, H. (1994). Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant, 9(8), 1103-1108. doi:10.1093/ndt/9.8.1103
Massy, Z. A., Khoa, T. N., Lacour, B., Descamps-Latscha, B., Man, N. K., & Jungers, P. (1999). Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrology Dialysis Transplantation, 14(10), 2392-2397. doi:10.1093/ndt/14.10.2392
Matsumoto, A. K., Maes, M., Michelin, A. P., Soares, A. E., de Oliveira Semeão, L., Godeny, P., . . . Alvares Delfino, V. D. (2020). Vitamin D deficiency is not associated with increased oxidative stress in chronic kidney disease pre-dialysis patients. Jornal Brasileiro de Nefrologia, 42(4), 420-428. doi:10.1590/2175-8239-JBN-2019-0156
Matsumoto, A. K., Maes, M., Michelin, A. P., Soares, A. E., Semeão, L. O., Godeny, P., . . . Delfino, V. D. A. (2020). Vitamin D deficiency is not associated with increased oxidative stress in chronic kidney disease pre-dialysis patients. Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia, 42(4), 420-428. doi:10.1590/2175-8239-JBN-2019-0156
Matsumoto, A. K., Michelin, A. P., de Oliveira Semeao, L., Sepulveda-Loyolaa, W., de Lima Pedrao, J. V., Porto, G. M., . . . Barbosa, D. S. (2021). A randomized trial of short-term treatment with folic acid to reduce the oxidative stress of patients with chronic kidney disease. Current drug metabolism. doi:10.2174/1389200222666211210153145
Matsumoto, A. K., Michelin, A. P., Semeão, L. O., Sepúlveda-Loyola, W., de Lima Pedrão, J. V., Porto, G. M., . . . Barbosa, D. S. (2021). A Randomized Trial of Short-term Treatment with Folic Acid to Reduce the Oxidative Stress of Patients with Chronic Kidney Disease. Current drug metabolism, 22(14), 1139‐1150. doi:10.2174/1389200222666211210153145
Matsumoto, A. K., Michelin, A. P., Semeão, L. O., Sepúlveda-Loyola, W., Pedrão, J. V. L., Porto, G. M., . . . Barbosa, D. S. (2021). A Randomized Trial of Short-term Treatment with Folic Acid to Reduce the Oxidative Stress of Patients with Chronic Kidney Disease. Current Drug Metabolism, 22(14), 1139-1150. doi:10.2174/1389200222666211210153145
McCarley, P. B., & Salai, P. B. (2005). Cardiovascular disease in chronic kidney disease. American Journal of Nursing, 105(4), 40-53. 
McCarty, M. F. (2004). Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine - An explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction. Medical Hypotheses, 63(4), 699-708. doi:10.1016/j.mehy.2002.11.008
McCullough, P. A. (2003). Beyond serum creatinine: Defining the patient with renal insufficiency and why? Reviews in Cardiovascular Medicine, 4(SUPPL. 1), S2-S6. 
McCullough, P. A. (2003). Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? Journal of the American College of Cardiology, 41(5), 725-728. doi:10.1016/S0735-1097(02)02955-8
McCullough, P. A., & Fallahzadeh, M. K. (2016). Nutritional deficiencies and sarcopenia in heart failure: A therapeutic opportunity to reduce hospitalization and death. Reviews in Cardiovascular Medicine, 17, S30-S39. doi:10.3909/ricm17S1S004
McCullough, P. A., & Lepor, N. E. (2005). Piecing together the evidence on anemia: The link between chronic kidney disease and cardiovascular disease. Reviews in Cardiovascular Medicine, 6(SUPPL. 3), S4-S12. 
McDonald, S. P., Whiting, M. J., Tallis, G. A., & Barbara, J. A. (2001). Relationships between homocysteine and related amino acids in chronic hemodialysis patients. Clin Nephrol, 55(6), 465-470. 
McGregor, D., Shand, B., & Lynn, K. (2000). A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease. Nephron, 85(3), 215‐220. doi:10.1159/000045664
McGregor, D. O., Dellow, W. J., Lever, M., George, P. M., Robson, R. A., & Chambers, S. T. (2001). Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int, 59(6), 2267-2272. doi:10.1046/j.1523-1755.2001.00743.x
McGregor, D. O., Dellow, W. J., Robson, R. A., Lever, M., George, P. M., & Chambers, S. T. (2002). Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. Kidney International, 61(3), 1040-1046. doi:10.1046/j.1523-1755.2002.00199.x
McPherson, R., Frohlich, J., Fodor, G., & Genest, J. (2006). Canadian Cardiovascular Society position statement - Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Canadian Journal of Cardiology, 22(11), 913-927. doi:10.1016/S0828-282X(06)70310-5
Mehra, M. R. (2006). Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. American Journal of Transplantation, 6(6), 1248-1256. doi:10.1111/j.1600-6143.2006.01314.x
Mehta, P. K., & Wenger, N. K. (2007). Coronary heart disease in women: Battle is won, but the war remains. Minerva Medica, 98(5), 459-478. 
Meier, P., Saudan, P., Burnier, M., & Martin, P. Y. (2003). Comorbidity and cardiovascular risk factors related to chronic renal failure. Medecine et Hygiene, 61(2426), 441-450. 
Melero-Rubio, E., Párraga-Díaz, M., Gómez-Sánchez, M. P., Pellicer-Villaescusa, S., & Merchán-Mayado, E. (2009). Observational study on markers of cardiovascular risk in renal patient: conventional hemodialysis vs. haemofiltration online. Journal of renal care, 35(4), 201-204. 
Memon, L., Spasojevic-Kalimanovska, V., Stanojevic, N. B., Kotur-Stevuljevic, J., Simic-Ogrizovic, S., Giga, V., . . . Spasic, S. (2013). Are levels of NT-proBNP and SDMA useful to determine diastolic dysfunction in chronic kidney disease and renal transplant patients? Journal of Clinical Laboratory Analysis, 27(6), 461-470. doi:10.1002/jcla.21628
Menezes, F. L., Leite, H. P., Massaoka, H., Do Val, M. L. M., Monteiro, M. L. R., Reis, M., . . . Koch Nogueira, P. C. (2016). Vascular repercussion in children with end stage renal disease. Pediatric Nephrology, 31(10), 1950. doi:10.1007/s00467-016-3467-5
Menon, V., Gul, A., & Sarnak, M. J. (2005). Cardiovascular risk factors in chronic kidney disease. Kidney International, 68(4), 1413-1418. doi:10.1111/j.1523-1755.2005.00551.x
Menon, V., Sarnak, M. J., Greene, T., Wang, X., Pereira, A. A., Beck, G. J., . . . et al. (2006). Relationship between homocysteine and mortality in chronic kidney disease. Circulation, 113(12), 1572‐1577. doi:10.1161/CIRCULATIONAHA.105.570127
Menon, V., Sarnak, M. J., Greene, T., Wang, X., Pereira, A. A., Beck, G. J., . . . Shlipak, M. G. (2006). Relationship between homocysteine and mortality in chronic kidney disease. Circulation, 113(12), 1572-1577. doi:10.1161/CIRCULATIONAHA.105.570127
Menon, V., Sarnak, M. J., Pereira, A. A., Levey, A. S., Greene, T., Wang, X., . . . Shlipak, M. G. (2006). Response to letter regarding article, "Relationship between homocysteine and mortality in chronic kidney disease" [2]. Circulation, 114(16), e548. doi:10.1161/CIRCULATIONAHA.106.644674
Menon, V., Wang, X., Greene, T., Beck, G. J., Kusek, J. W., Selhub, J., . . . Sarnak, M. J. (2005). Homocysteine in chronic kidney disease: Effect of low protein diet and repletion with B vitamins. Kidney International, 67(4), 1539-1546. doi:10.1111/j.1523-1755.2005.00234.x
Merhi, B., Shireman, T., Carpenter, M. A., Kusek, J. W., Jacques, P., Pfeffer, M., . . . Bostom, A. (2017). Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort. American Journal of Kidney Diseases, 70(3), 377-385. doi:10.1053/j.ajkd.2017.04.014
Merouani, A., Delvin, E. E., Genest, J., Jr., Rozen, R., & Lambert, M. (2002). Plasma homocysteine concentration changes after renal transplantation in children. Pediatr Nephrol, 17(7), 520-523. doi:10.1007/s00467-002-0868-4
Merouani, A., Genest, J., Jr., Rozen, R., Lambert, M., Mitchell, G. A., Dubois, J., & Robitaille, P. (1999). Cerebral vascular complication and hyperhomocysteinemia in a cystinotic uremic child. Pediatr Nephrol, 13(1), 73-76. doi:10.1007/s004670050567
Merouani, A., Lambert, M., Delvin, E. E., Genest J, Jr., Robitaille, P., & Rozen, R. (2001). Plasma homocysteine concentration in children with chronic renal failure. Pediatric Nephrology, 16(10), 805-811. doi:10.1007/s004670100648
Merouani, A., Lambert, M., Delvin, E. E., Genest, J., Jr., Robitaille, P., & Rozen, R. (2001). Plasma homocysteine concentration in children with chronic renal failure. Pediatr Nephrol, 16(10), 805-811. doi:10.1007/s004670100648
Merouani, A., Rozen, R., Clermont, M. J., & Genest, J. (2002). Renal function, homocysteine, and other plasma thiol concentrations during the postrenal transplant period. Transplant Proc, 34(4), 1159-1160. doi:10.1016/s0041-1345(02)02771-9
Mezzano, D., Pais, E. O., Aranda, E., Panes, O., Downey, P., Ortiz, M., . . . Pereira, J. (2001). Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney International, 60(5), 1844-1850. doi:10.1046/j.1523-1755.2001.00998.x
Miao, X. H., Wang, C. G., Hu, B. Q., Li, A., Chen, C. B., & Song, W. Q. (2010). TGF-β1 immunohistochemistry and promoter methylation in chronic renal failure rats treated with uremic clearance granules. Folia Histochemica et Cytobiologica, 48(2), 284-291. doi:10.2478/v10042-010-0001-7
Miarka, P., Grabowska, B., Skowron, M., Pietrzycka, A., & Sliwka, I. (2017). The new, volatile biomarkers of chronic kidney disease and coexisting type 2 diabetes. Diabetologia, 60(1), S489. doi:10.1007/s00125-017-4350-z
Migliacci, R., Falcinelli, F., Imperiali, P., Floridi, A., Nenci, G. G., & Gresele, P. (2004). Endothelial dysfunction in patients with kidney failure and vascular risk factors: Acute effects of hemodialysis. Italian Heart Journal, 5(5), 371-377. 
Milani, R. V., & Lavie, C. J. (2008). Homocysteine: The Rubik's cube of cardiovascular risk factors. Mayo Clinic Proceedings, 83(11), 1200-1202. doi:10.4065/83.11.1200
Millan, I., & De Alvaro, F. (1998). Homocystein and endothelial disfunction in patients with diabetes mellitus, chronic renal failure, dialysis and transplantation. Nefrologia, 18(3), 186-195. 
Mimura, I., & Nangaku, M. (2010). The suffocating kidney: Tubulointerstitial hypoxia in end-stage renal disease. Nature Reviews Nephrology, 6(11), 667-678. doi:10.1038/nrneph.2010.124
Min, S. Y., Park, D. W., Lee, J. Y., Kim, W. J., Lee, S. W., Kim, Y. H., . . . Park, S. J. (2009). The value of preprocedural levels of plasma homocysteine for the prediction of periprocedural myocardial infarction and long-term clinical outcomes after successful coronary stenting. American Journal of Cardiology, 103(9), 81B. 
Misra, M. (2005). Preface. Hemodialysis International, 9(SUPPL. 1), S1. doi:10.1111/j.1542-4758.2005.01162.x
Mitrovic, J. S., & Lezaic, V. (2010). Comments on in patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney International, 78(10), 1049. doi:10.1038/ki.2010.300
Mitsnefes, M., Kartal, J., Khoury, P., & Daniels, S. (2007). Adiponectin in children with chronic kidney disease: Role of adiposity and kidney dysfunction. Clinical Journal of the American Society of Nephrology, 2(1), 46-50. doi:10.2215/CJN.02790806
Miyamoto, T., Qureshi, A. R., Shah, V., Maynard, S., Guo, Q. Y., Carrero, J. J., . . . Dominic, R. S. C. (2009). Modulators of angiogenesis, PIGF and sFlt-1, predict mortality in prevalent hemodialysis patients. Blood Purification, 28(4), 295. doi:10.1159/000235632
Miyata, Y., Obata, Y., Mochizuki, Y., Kitamura, M., Mitsunari, K., Matsuo, T., . . . Sakai, H. (2019). Periodontal disease in patients receiving dialysis. International Journal of Molecular Sciences, 20(15). doi:10.3390/ijms20153805
Moczulski, D., Fojcik, H., Zukowska-Szczechowska, E., Szydlowska, I., & Grzeszczak, W. (2003). Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrology Dialysis Transplantation, 18(8), 1535-1540. doi:10.1093/ndt/gfg211
Mojiminiyi, O. A., Al Mohammedi, H., Al Rammah, T., Pinto, C., & Abdella, N. (2011). Putative mechanisms that link cystatin-C with development of coronary heart disease in patients with type 2 diabetes mellitus. Clinical Chemistry, 57(10), A184. 
Mok, C. C. (2006). Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 35(2), 85-95. doi:10.1080/03009740600601526
Molina de Salazar, D. I., & Muñoz-Gómez, D. (2018). Metabolic syndrome in women. Revista Colombiana de Cardiologia, 25, 21-29. doi:10.1016/j.rccar.2017.12.006
Monfared, A., Azimi, S. Z., Kazemnezhad, E., Khosravi, M., Lebadi, M., Mirzajani, E., & Ashtiani, M. N. (2014). The authors' reply. Transplantation, 98(11), e89-90. doi:10.1097/tp.0000000000000494
Monfared, A., Azimi, S. Z., Kazemnezhad, E., Khosravi, M., Lebadi, M., Mirzajani, E., & Ashtiani, M. N. (2014). Hyperhomocysteinemia and assessment of its associated factors in renal transplant recipients: a single-center study in northern Iran. Transplantation, 98(1), 66-71. doi:10.1097/01.TP.0000443222.82207.3d
Montgomery, J. E., & Brown, J. R. (2013). Metabolic biomarkers for predicting cardiovascular disease. Vascular Health and Risk Management, 9(1), 37-45. doi:10.2147/VHRM.S30378
Moon, H., Ko, H. J., & Kim, A. S. (2020). Hyperhomocysteinemia concurrent with metabolic syndrome is independently associated with chronic kidney disease among community-dwelling adults in an urban korean population. International Journal of Environmental Research and Public Health, 17(18), 1-15. doi:10.3390/ijerph17186810
Moore, S. A., Mittal, M. K., & Rabinstein, A. A. (2013). Duret hemorrhage following subdural hematoma evacuation. JAMA Neurology, 70(4), 518. doi:10.1001/jamaneurol.2013.614
Morena, M., Patrier, L., Jaussent, I., Bargnoux, A. S., Dupuy, A. M., Badiou, S., . . . Cristol, J. P. (2011). Reduced glomerular filtration rate, inflammation and HDL cholesterol as main determinants of superoxide production in non-dialysis chronic kidney disease patients. Free Radical Research, 45(6), 735-745. doi:10.3109/10715762.2011.574291
Moreso, F., & Grinyo, J. M. (2007). Graft dysfunction and cardiovascular risk - An unholy alliance. Nephrology Dialysis Transplantation, 22(3), 699-702. doi:10.1093/ndt/gfl657
Morimoto, K., Haneda, T., Okamoto, K., Ishida, H., & Kikuchi, K. (2002). Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients. Nephron, 90(1), 43-50. doi:10.1159/000046313
Morris, S. T., & Jardine, A. G. (2000). The vascular endothelium in chronic renal failure. Journal of Nephrology, 13(2), 96-105. 
Mosteanu, D., Wang, X., Kimpel, D., & Lewis, J. (2016). Cardiovascular risk and lipid screening in rheumatoid arthritis patients in a university rheumatology practice: Quality improvement project. Arthritis and Rheumatology, 68, 552. doi:10.1002/art.39977
Moustapha, A., Gupta, A., Robinson, K., Arheart, K., Jacobsen, D. W., Schreiber, M. J., & Dennis, V. W. (1999). Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int, 55(4), 1470-1475. doi:10.1046/j.1523-1755.1999.00378.x
Moustapha, A., Naso, A., Nahlawi, M., Gupta, A., Arheart, K. L., Jacobsen, D. W., . . . Dennis, V. W. (1998). Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation, 97(2), 138-141. doi:10.1161/01.cir.97.2.138
Movilli, E. (2007). Homocysteine and reverse epidemiology. Nephrol Dial Transplant, 22(7), 2093; author reply 2093. doi:10.1093/ndt/gfm186
Mudge, D. W., Rogers, R., Hollett, P., Law, B., Reiger, K., Petrie, J. J., . . . et al. (2005). Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance. Nephrology, dialysis, transplantation, 20(10), 2178‐2185. doi:10.1093/ndt/gfh987
Mudge, D. W., Rogers, R., Hollett, P., Law, B., Reiger, K., Petrie, J. J., . . . Hawley, C. M. (2005). Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance. Nephrol Dial Transplant, 20(10), 2178-2185. doi:10.1093/ndt/gfh987
Muijsers, H. E. C., Roeleveld, N., van der Heijden, O. W. H., & Maas, A. H. E. M. (2019). Consider Preeclampsia as a First Cardiovascular Event. Current Cardiovascular Risk Reports, 13(7). doi:10.1007/s12170-019-0614-0
Muntner, P., Hamm, L. L., Kusek, J. W., Chen, J., Whelton, P. K., & He, J. (2004). The Prevalence of Nontraditional Risk Factors for Coronary Heart Disease in Patients with Chronic Kidney Disease. Annals of Internal Medicine, 140(1), 9-17+I25. doi:10.7326/0003-4819-140-1-200401060-00006
Muntner, P., Vupputuri, S., Coresh, J., Uribarri, J., & Fox, C. S. (2009). Metabolic abnormalities are present in adults with elevated serum cystatin C. Kidney Int, 76(1), 81-88. doi:10.1038/ki.2009.76
Mureddu, G. F., Brandimarte, F., Faggiano, P., Rigo, F., & Nixdorff, U. (2013). Between risk charts and imaging: How should we stratify cardiovascular risk in clinical practice? European Heart Journal Cardiovascular Imaging, 14(5), 401-416. doi:10.1093/ehjci/jes297
Murphy, D., & Drawz, P. E. (2019). Blood pressure variability in CKD: Treatable or hypertension’s homocysteine? Clinical Journal of the American Society of Nephrology, 14(2), 175-177. doi:10.2215/CJN.14991218
Muscheites, J., Meyer, A. A., Drueckler, E., Wigger, M., Fischer, D. C., Kundt, G., . . . Haffner, D. (2008). Assessment of the cardiovascular system in pediatric chronic kidney disease: A pilot study. Pediatric Nephrology, 23(12), 2233-2239. doi:10.1007/s00467-008-0906-y
Musikhina, N., Kostousova, A., Petelina, T., & Gorbatenko, E. (2021). Factors influencing the survival rate of patients after acute coronary syndrome and percutaneous coronary intervention, 5-year follow-up. European Heart Journal: Acute Cardiovascular Care, 10(SUPPL 1), i97. doi:10.1093/ehjacc/zuab020.086
Mwasongwe, S. E., Young, B., Bidulescu, A., Sims, M., Correa, A., & Musani, S. K. (2018). Relation of multi-marker panel to incident chronic kidney disease and rapid kidney function decline in African Americans: The Jackson Heart Study. BMC Nephrology, 19(1). doi:10.1186/s12882-018-1026-y
Myrvang, H. (2011). Risk factors: Lowering homocysteine levels may have no 'FAVORITable' effect on cardiovascular outcomes. Nature Reviews Nephrology, 7(6), 304. doi:10.1038/nrneph.2011.45
Naderi, N., Abcede, H., Al-Khoury, L., Mozaffar, T., & Jain, V. (2013). Predictive risk factors of in-hospital mortality following acute stroke in the United States: Data from the nationwide inpatient database, 2006-2010. Neurology, 80(1). 
Nafar, M., Khatami, F., Kardavani, B., Farjad, R., Pour-Reza-Gholi, F., Firouzan, A., . . . Einollahi, B. (2009). Role of folic acid in atherosclerosis after kidney transplant: a double-blind, randomized, placebo-controlled clinical trial. Experimental and clinical transplantation, 7(1), 33‐39. 
Nagane, N. S., Ganu, J. V., & Gandhi, R. (2009). Oxidative stress, serum homocysteine and serum nitric oxide in different stages of chronic renal failure. Biomedical Research, 20(1), 71-74. 
Nagane, N. S., Ganu, J. V., & Jagtap, P. E. (2013). Study of oxidative stress in pre- and post-hemodialysis in chronic renal failure patients. Biomedical Research (India), 24(4), 498-502. 
Naicker, S. (2011). Biomarkers of renal disease. Southern African Journal of Anaesthesia and Analgesia, 17(1), 118-119. doi:10.1080/22201173.2011.10872753
Nair, A. P., Nemirovsky, D., Kim, M., Geer, E. B., Farkouh, M. E., Winston, J., . . . Robbins, M. J. (2005). Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med, 72(6), 365-373. 
Najim, M. K., Maatook, M. A., & Abbas, H. J. (2020). IRISIN LEVELS AS BIOMARKER IN THYROID DISEASES AND THE CORRELATION WITH ATHEROSCLEROSIS AND MYOPATHY RISK FACTORS. Biochemical and Cellular Archives, 20(2), 5793-5796. 
Nakamura, T., Saionji, K., Hiejima, Y., Hirayama, H., Tago, K., Takano, H., . . . Hata, A. (2002). Methylenetetrahydrofolate reductase genotype, vitamin B12, and folate influence plasma homocysteine in hemodialysis patients. Am J Kidney Dis, 39(5), 1032-1039. doi:10.1053/ajkd.2002.32779
Nakanishi, T., Hasuike, Y., Otaki, Y., Hama, Y., Nanami, M., Miyagawa, K., . . . Takamitsu, Y. (2003). Free cysteine is increased in plasma from hemodialysis patients. Kidney International, 63(3), 1137-1140. doi:10.1046/j.1523-1755.2003.00808.x
Nakanishi, T., Ishigami, Y., Otaki, Y., Izumi, M., Hiraoka, K., Inoue, T., & Takamitsu, Y. (2002). Impairment of vascular responses to reactive hyperemia and nitric oxide in chronic renal failure. Nephron, 92(3), 529-535. doi:10.1159/000064078
Nakanishi, T., Otaki, Y., Hasuike, Y., Nanami, M., Itahana, R., Miyagawa, K., . . . Takamitsu, Y. (2002). Association of hyperhomocysteinemia with plasma sulfate and urine sulfate excretion in patients with progressive renal disease. Am J Kidney Dis, 40(5), 909-915. doi:10.1053/ajkd.2002.36320
Namikoshi, T., Tomita, N., Satoh, M., Sakuta, T., Kuwabara, A., Nagasu, H., . . . Kashihara, N. (2009). High dietary protein intake induces endothelial dysfunction in uninephrectomized rats. Molecular Medicine Reports, 2(3), 429-434. doi:10.3892/mmr-00000117
Nanayakkara, P. W., Kiefte-de Jong, J. C., Stehouwer, C. D., van Ittersum, F. J., Olthof, M. R., Kok, R. M., . . . Smulders, Y. M. (2008). Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease. Nephrology, dialysis, transplantation, 23(8), 2586‐2592. doi:10.1093/ndt/gfn040
Nanayakkara, P. W., Kiefte-de Jong, J. C., ter Wee, P. M., Stehouwer, C. D., van Ittersum, F. J., Olthof, M. R., . . . Smulders, Y. M. (2009). Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. American journal of kidney diseases, 53(1), 41‐50. doi:10.1053/j.ajkd.2008.06.016
Nanayakkara, P. W., Teerlink, T., Stehouwer, C. D., Allajar, D., Spijkerman, A., Schalkwijk, C., . . . van Guldener, C. (2005). Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney international, 68(5), 2230‐2236. doi:10.1111/j.1523-1755.2005.00680.x
Nanayakkara, P. W., van Guldener, C., ter Wee, P. M., Scheffer, P. G., van Ittersum, F. J., Twisk, J. W., . . . Stehouwer, C. D. (2007). Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Archives of internal medicine, 167(12), 1262‐1270. doi:10.1001/archinte.167.12.1262
Nanayakkara, P. W. B., & Gaillard, C. A. J. M. (2010). Vascular disease and chronic renal failure: New insights. Netherlands Journal of Medicine, 68(1), 5-14. 
Nanayakkara, P. W. B., Kiefte-De Jong, J. C., Stehouwer, C. D. A., Van Ittersum, F. J., Olthof, M. R., Kok, R. M., . . . Smulders, Y. M. (2008). Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease. Nephrology Dialysis Transplantation, 23(8), 2586-2592. doi:10.1093/ndt/gfn040
Nanayakkara, P. W. B., Kiefte-de Jong, J. C., ter Wee, P. M., Stehouwer, C. D. A., van Ittersum, F. J., Olthof, M. R., . . . Smulders, Y. M. (2009). Randomized Placebo-Controlled Trial Assessing a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Plasma Asymmetric Dimethylarginine Concentration in Mild to Moderate CKD. American Journal of Kidney Diseases, 53(1), 41-50. doi:10.1053/j.ajkd.2008.06.016
Nanayakkara, P. W. B., Le Poole, C. Y., Fouque, D., van Guldener, C., Stehouwer, C. D. A., Smulders, Y. M., . . . ter Wee, P. M. (2009). Plasma adiponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3 - 5 chronic kidney disease. Clinical Nephrology, 72(1), 21-30. doi:10.5414/cnp72021
Nanayakkara, P. W. B., Teerlink, T., Stehouwer, C. D. A., Allajar, D., Spijkerman, A., Schalkwijk, C., . . . Van Guldener, C. (2005). Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney International, 68(5), 2230-2236. doi:10.1111/j.1523-1755.2005.00680.x
Nanayakkara, P. W. B., Van Guldener, C., Ter Wee, P. M., Scheffer, P. G., Van Ittersum, F. J., Twisk, J. W., . . . Stehouwer, C. D. A. (2007). Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: Results from the anti-oxidant therapy in chronic renal insufficiency (ATIC) study. Archives of Internal Medicine, 167(12), 1262-1270. doi:10.1001/archinte.167.12.1262
Nand, N. (2013). Relationship of cardiovascular mortality & homocysteine levels in chronic kidney disease. Cardiology (Switzerland), 125, 185. doi:10.1159/000354059
Nand, N., Sharma, M., & Mittal, N. (2013). Prevalence of hyperhomocysteinaemia in chronic kidney disease and effect of supplementation of folic acid and vitamin B12 on cardiovascular mortality. Journal, Indian Academy of Clinical Medicine, 14(1), 33-36. 
Naono, S., Tamura, A., & Kadota, J. (2009). Plasma homocysteine level is unrelated to long-term cardiovascular events in patients with previous percutaneous coronary intervention. Journal of Cardiology, 54(1), 21-28. doi:10.1016/j.jjcc.2009.02.007
Narayanaswamy, A. G., Meenakshi, K., Porchelvan, S., Harsha Nair, H., Akshaya, S., Roshini Priya, V., . . . Tamil Selvan, S. (2020). Knowledge about risk factors, symptoms and diet pertaining to cardiac disease among rural population of Tamil Nadu. International Journal of Research in Pharmaceutical Sciences, 11(Special Issue 2), 319-325. doi:10.26452/ijrps.v11iSPL2.3548
Nardin, M., Verdoia, M., Gioscia, R., Negro, F., & De Luca, G. (2021). Impact of renin angiotensin system inhibitors on homocysteine levels and platelets reactivity in patients on dual antiplatelet therapy. Nutrition, Metabolism and Cardiovascular Diseases, 31(4), 1276-1285. doi:10.1016/j.numecd.2020.12.004
Naruszewicz, M., Klinke, M., Dziewanowski, K., Staniewicz, A., & Bukowska, H. (2001). Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin. Metabolism: Clinical and Experimental, 50(2), 131-134. doi:10.1053/meta.2001.20174
Nascimento, M. M., Suliman, M. E., Silva, M., Chinaglia, T., Marchioro, J., Hayashi, S. Y., . . . Anderstam, B. (2010). Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: A placebo-controlled study. Peritoneal Dialysis International, 30(3), 336-342. doi:10.3747/pdi.2009.00073
Naseri, M., Shahri, H. M. M., Horri, M., Salehi, M., Salemian, F., Moeenolroayaa, G., & Pourhasan, M. (2013). Hyperhomocysteinemia in chronic kidney diseases stage v: Is there any predicting factor? Pediatric Nephrology, 28(8), 1645-1646. doi:10.1007/s00467-013-2523-7
Nasri, H. (2006). A positive correlation of serum homocysteine with leptin in maintenance hemodialysis patients. Archives of Medical Science, 2(3), 185-189. 
Nathan, D. P., & Tang, G. L. (2014). The impact of chronic renal insufficiency on vascular surgery patient outcomes. Seminars in Vascular Surgery, 27(3-4), 162-169. doi:10.1053/j.semvascsurg.2015.01.006
Navarro, J. F., Mora, C., Muros, M., & García-Idoate, G. (2003). Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron. Clinical practice, 95(4), c128-135. 
Nct. (2005). Treatment of Acute Schizophrenia With Vitamin Therapy. https://clinicaltrials.gov/show/NCT00140166. 
Nct. (2006). Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events. https://clinicaltrials.gov/show/NCT00317005. 
Nct. (2007). Effects of Mesna on Homocysteine in Kidney Failure. https://clinicaltrials.gov/show/NCT00524199. 
Nct. (2013). CSPPT- Chronic Kidney Diseases Study. https://clinicaltrials.gov/show/NCT01871740. 
Nechiporuk, V., Nebesna, Z., Didyk, N., Mazur, O., & Korda, M. (2022). MICROSCOPIC CHANGES OF THE KIDNEY IN EXPERIMENTAL HYPERHOMOCYSTEINEMIA ON THE BACKGROUND OF HYPER- AND HYPOTHYROIDISM. Georgian medical news(323), 116-122. 
Nedelcu, C., Ionescu, M., Pantea-Stoian, A., Niţǎ, D., Petcu, L., Mazilu, L., . . . Parepa, I. R. (2021). Correlation between plasma homocysteine and first myocardial infarction in young patients: Case-control study in Constanta County, Romania. Experimental and Therapeutic Medicine, 21(1). doi:10.3892/etm.2020.9533
Nerbass, F. B., Draibe, S. A., & Cuppari, L. (2005). Hyperhomocysteinemia in chronic renal failure. Revista de Nutricao, 18(2), 239-249. doi:10.1590/s1415-52732005000200008
Nerbass, F. B., Draibe, S. A., Feiten, S. F., Chiarello, P. G., Vannucchi, H., & Cuppari, L. (2006). Homocysteine and its determinants in nondialyzed chronic kidney disease patients. Journal of the American Dietetic Association, 106(2), 267-270. doi:10.1016/j.jada.2005.10.035
Nesrallah, G., Suri, R., Moist, L., Kortas, C., & Lindsay, R. M. (2003). Volume control and blood pressure management in patients undergoing quotidian hemodialysis. American journal of kidney diseases, 42(1 Suppl), 13‐17. doi:10.1016/s0272-6386(03)00532-8
Neugarten, J., & Golestaneh, L. (2013). Gender and the prevalence and progression of renal disease. Adv Chronic Kidney Dis, 20(5), 390-395. doi:10.1053/j.ackd.2013.05.004
Ngowi, E. E., Sarfraz, M., Afzal, A., Khan, N. H., Khattak, S., Zhang, X., . . . Wu, D. D. (2020). Roles of Hydrogen Sulfide Donors in Common Kidney Diseases. Frontiers in Pharmacology, 11. doi:10.3389/fphar.2020.564281
Nicoll, R., Howard, J. M., & Henein, M. Y. (2015). A review of the effect of diet on cardiovascular calcification. International Journal of Molecular Sciences, 16(4), 8861-8883. doi:10.3390/ijms16048861
Nigwekar, S. U., Kang, A., Zoungas, S., Cass, A., Gallagher, M. P., Kulshrestha, S., . . . Jardine, M. J. (2016). Interventions for lowering plasma homocysteine levels in dialysis patients. Cochrane Database Syst Rev, 2016(5), Cd004683. doi:10.1002/14651858.CD004683.pub4
Ninomiya, T. (2013). Risk of stroke in kidney disease. In Contributions to Nephrology (Vol. 179, pp. 58-66).
Ninomiya, T., Kiyohara, Y., Kubo, M., Tanizaki, Y., Tanaka, K., Okubo, K., . . . Iida, M. (2004). Hyperhomocysteinemia and the development of chronic kidney disease in a general population: The Hisayama study. American Journal of Kidney Diseases, 44(3), 437-445. doi:10.1053/j.ajkd.2004.05.024
Nishizawa, Y., Shoji, T., Ishimura, E., Inaba, M., & Morii, H. (2001). Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis, 38(4 Suppl 1), S4-7. doi:10.1053/ajkd.2001.27380
Niwa, T. (2009). Recent progress in the analysis of uremic toxins by mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 877(25), 2600-2606. doi:10.1016/j.jchromb.2008.11.032
Noce, A., Dessì, M., Durante, O., Manca Di Villahermosa, S., Canale, M. P., & Di Daniele, N. (2013). Influence of continuous erythropoietin receptor activator on markers of cardiovascular risk in chronic kidney disease patients. International Journal of Cardiology, 167(6), 3070-3072. doi:10.1016/j.ijcard.2012.11.073
Noce, A., Durante, O., Di Villahermosa, S. M., Taccone-Gallucci, M., Dessì, M., Di Daniele, N., & Tozzo, C. (2010). Influence of treatment with continuous erythropoietin receptor activator on markers of cardiovascular risk in chronic kidney disease patients. NDT Plus, 3, iii66. 
Noce, A., Fabrini, R., Dessì, M., Bocedi, A., Santini, S., Rovella, V., . . . Ricci, G. (2014). Erythrocyte glutathione transferase activity: A possible early biomarker for blood toxicity in uremic diabetic patients. Acta Diabetologica, 51(2), 219-224. doi:10.1007/s00592-013-0497-3
Nolan, C. R. (2005). Phosphate binder therapy for attainment of K/DOQI™ bone metabolism guidelines. Kidney International, Supplement, 68(96), S7-S14. doi:10.1111/j.1523-1755.2005.00449.x
Nolin, T. D., McMenamin, M. E., & Himmelfarb, J. (2007). Simultaneous determination of total homocysteine, cysteine, cysteinylglycine, and glutathione in human plasma by high-performance liquid chromatography: Application to studies of oxidative stress. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 852(1-2), 554-561. doi:10.1016/j.jchromb.2007.02.024
Nolin, T. D., Ouseph, R., Himmelfarb, J., McMenamin, M. E., & Ward, R. A. (2010). Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clinical journal of the American Society of Nephrology, 5(9), 1588‐1594. doi:10.2215/CJN.00210110
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007). Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of Vascular Surgery, 45(1 SUPPL.), S5-S67. doi:10.1016/j.jvs.2006.12.037
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., Fowkes, F. G. R., & Rutherford, R. B. (2007). Inter-Society Consensus for the management of peripheral arterial disease (TASC II). International Angiology, 26(2), 82-157. 
Novak, J. E., Inrig, J. K., Patel, U. D., Califf, R. M., & Szczech, L. A. (2008). Negative trials in nephrology: What can we learn? Kidney International, 74(9), 1121-1127. doi:10.1038/ki.2008.286
Novobílský, K., Kaučák, V., Bárta, J., Kryza, R., & Dvořáčková, J. (2014). Native aortic valve thrombus as a source of embolisation into the coronary artery. Cor et Vasa, 56(5), e413-e416. doi:10.1016/j.crvasa.2013.09.005
Nowroozpoor, A., Gutterman, D., & Safdar, B. (2021). Is microvascular dysfunction a systemic disorder with common biomarkers found in the heart, brain, and kidneys? — A scoping review. Microvascular Research, 134. doi:10.1016/j.mvr.2020.104123
Nurmohamed, S. A., & Nubé, M. J. (2005). Reverse epidemiology: Paradoxical observations in haemodialysis patients. Netherlands Journal of Medicine, 63(10), 376-381. 
Nursalim, A., Siregar, P., & Widyahening, I. S. (2013). Effect of folic acid, vitamin B6 and vitamin B12 supplementation on mortality and cardiovascular complication among patients with chronic kidney disease: an evidence-based case report. Acta medica Indonesiana, 45(2), 150-156. 
Obeid, R., Kuhlmann, M., Kirsch, C. M., & Herrmann, W. (2005). Cellular uptake of vitamin B12 in patients with chronic renal failure. Nephron - Clinical Practice, 99(2), c42-c48. doi:10.1159/000083132
Obeid, R., Kuhlmann, M. K., Köhler, H., & Herrmann, W. (2005). Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients. Clin Chem, 51(1), 196-201. doi:10.1373/clinchem.2004.041210
Ochodnicky, P., Vettoretti, S., Henning, R. H., Buikema, H., & Van Dokkum, P. E. (2006). Endothelial dysfunction in chronic kidney disease: Determinant of susceptibility to end-organ damage and therapeutic response. Journal of Nephrology, 19(3), 246-258. 
Ohkuma, T., Minagawa, T., Takada, N., Ohno, M., Oda, H., & Ohashi, H. (2003). C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients. Am J Kidney Dis, 42(2), 355-361. doi:10.1016/s0272-6386(03)00675-9
Ohta, H. (2014). Updates on Lifestyle-Related Diseases and Bone Metabolism. Efficacy of selective estrogen receptor modulators (SERMs) in lifestyle-related osteoporosis. Clinical calcium, 24(11), 1679-1687. 
Oishi, K., Nagake, Y., Yamasaki, H., Fukuda, S., Ichikawa, H., Ota, K., & Makino, H. (2000). The significance of atherogenic indices in patients on hemodialysis. Am J Nephrol, 20(2), 107-115. doi:10.1159/000013566
Oishi, K., Nagake, Y., Yamasaki, H., Fukuda, S., Ichikawa, H., Ota, K., & Makino, H. (2000). The significance of serum homocysteine levels in diabetic patients on haemodialysis. Nephrol Dial Transplant, 15(6), 851-855. doi:10.1093/ndt/15.6.851
Okubo, K., Hayashi, K., Wakino, S., Matsuda, H., Kubota, E., Honda, M., . . . Saruta, T. (2005). Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertension Research, 28(2), 181-189. doi:10.1291/hypres.28.181
Olaru-Lego, G., Predescu, L., Achim, C., Radu, D. N., Ginghina, C., & Enache, R. (2020). When the easiest answer is the right one. European Heart Journal Cardiovascular Imaging, 21, i1110. doi:10.1093/ehjci/jez319.1050
Oliva-Damaso, E., Oliva-Damaso, N., Rodriguez-Esparragon, F., Payan, J., Baamonde-Laborda, E., Gonzalez-Cabrera, F., . . . Rodriguez-Perez, J. C. (2019). Asymmetric (ADMA) and symmetric (SDMA) dimethylarginines in chronic kidney disease: A clinical approach. International Journal of Molecular Sciences, 20(15). doi:10.3390/ijms20153668
Omezzine, A., Ben Rejeb, N., Nabli, N., Abroug, S., Harbi, A., & Bouslama, A. (2003). Homocysteine and antioxidant status in pediatric hemodialysis. Immuno-Analyse et Biologie Specialisee, 18(3), 158-161. doi:10.1016/S0923-2532(03)00049-8
Opatrný Jr, K., Zemanová, P., Mareš, J., Vít, L., Opatrná, S., Šefrna, F., . . . Massry, S. G. (2002). Fibrinolysis defect in long-term hemodialysis patients with type 2 diabetes mellitus and its relation to metabolic disorders. American Journal of Nephrology, 22(5-6), 429-436. doi:10.1159/000065270
Opatrný Jr, K., Zemanová, P., Opatrná, S., Šefrna, F., & Vít, L. (2004). Plasma concentrations of von Willebrand factor in peritoneal dialysis patients. Nieren- und Hochdruckkrankheiten, 33(4), 177-183. doi:10.5414/nhp33177
Opatrný, K., Jr., Zemanová, P., Mares, J., Vít, L., Opatrná, S., Sefrna, F., . . . Massry, S. G. (2002). Fibrinolysis defect in long-term hemodialysis patients with type 2 diabetes mellitus and its relation to metabolic disorders. Am J Nephrol, 22(5-6), 429-436. doi:10.1159/000065270
O'Riordan, E., Chen, J., Brodsky, S. V., Smirnova, I., Li, H., & Goligorsky, M. S. (2005). Endothelial cell dysfunction: The syndrome in making. Kidney International, 67(5), 1654-1658. doi:10.1111/j.1523-1755.2005.00256.x
Osorio, A., Ortega, E., De Haro, T., Torres, J. M., Sánchez, P., & Ruiz-Requena, E. (2011). Lipid profiles and oxidative stress parameters in male and female hemodialysis patients. Molecular and Cellular Biochemistry, 353(1-2), 59-63. doi:10.1007/s11010-011-0774-9
Ossareh, S., Shayan-Moghaddam, H., Salimi, A., Asgari, M., & Farrokhi, F. (2009). Different doses of oral folic acid for homocysteine-lowering therapy in patients on hemodialysis: a randomized controlled trial. Iranian journal of kidney diseases, 3(4), 227‐233. 
Ossi, E., Mioni, G., D'Angelo, A., Lupo, A., Valvo, E., & Maschio, G. (1974). Aspects of water and electrolyte metabolism investigated by means of muscle biopsy. Giornale di Clinica Medica, 55(2), 131-144. 
Ostojic, S. M. (2019). Benefits and drawbacks of guanidinoacetic acid as a possible treatment to replenish cerebral creatine in AGAT deficiency. Nutritional Neuroscience, 22(5), 302-305. doi:10.1080/1028415X.2017.1385176
Ostrakhovitch, E. A., & Tabibzadeh, S. (2015). Homocysteine in Chronic Kidney Disease. Advances in clinical chemistry, 72, 77-106. doi:10.1016/bs.acc.2015.07.002
Ostrakhovitch, E. A., & Tabibzadeh, S. (2019). Homocysteine and age-associated disorders. Ageing Research Reviews, 49, 144-164. doi:10.1016/j.arr.2018.10.010
Ottosson, P., Attman, P. O., Knight, C., Samuelsson, O., Weiss, L., & Alaupovic, P. (2001). Do high-flux dialysis membranes affect renal dyslipidemia? ASAIO journal (American Society for Artificial Internal Organs : 1992), 47(3), 229‐234. doi:10.1097/00002480-200105000-00014
Özdem, S., Fevzi Ersoy, F., Yilmaz, V., Dönmez, L., Boz, A., Çolak, D., & Süleymanlar, G. (2010). Possible role of homocysteine in osteoporosis in patients with terminal renal failure. Turkish Journal of Biochemistry, 35. 
Ozdemir, K., Yilmaz, E., Dincel, N., Bozabali, S., Apaydin, S., Gun, Z. H., . . . Mir, S. (2017). Association of clearance of middle- and large-molecular-weight substance with arterial stiffness and left ventricular mass in children receiving renal replacement therapy. Minerva Pediatrica, 69(6), 495-502. doi:10.23736/S0026-4946.16.04253-5
Özdemir, K., Yilmaz, E., Dincel, N., Bozabali, S., Apaydin, S., Gun, Z. H., . . . Mir, S. (2017). Association of clearance of middle- and large-molecular-weight substance with arterial stiffness and left ventricular mass in children receiving renal replacement therapy. Minerva Pediatr, 69(6), 495-502. doi:10.23736/s0026-4946.16.04253-5
Pachaly, M. A., do Nascimento, M. M., Suliman, M. E., Hayashi, S. Y., Riella, M. C., Manfro, R. C., . . . Lindholm, B. (2008). Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients. Blood Purif, 26(2), 204-210. doi:10.1159/000117438
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., . . . Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj, 372, n71. doi:10.1136/bmj.n71
Pakfetrat, M., Shahroodi, J. R., Zolgadr, A. A., Larie, H. A., Nikoo, M. H., & Malekmakan, L. (2013). Effects of zinc supplement on plasma homocysteine level in end-stage renal disease patients: a double-blind randomized clinical trial. Biological trace element research, 153(1‐3), 11‐15. doi:10.1007/s12011-013-9639-2
Palit, S., Chonchol, M., Cheung, A. K., Kaufman, J., Smits, G., & Kendrick, J. (2015). Association of BP with death, cardiovascular events, and progression to chronic dialysis in patients with advanced kidney disease. Clinical Journal of the American Society of Nephrology, 10(6), 934-940. doi:10.2215/CJN.08620814
Palleschi, S., De Angelis, S., Rossi, B., Diana, L., Papa, V., Severini, G., & Splendiani, G. (2008). Homocysteinemia correlates with plasma thiol redox status in patients with end-stage renal disease. Nephron Clin Pract, 108(2), c106-112. doi:10.1159/000113527
Pan, Y., Guo, L. L., Cai, L. L., Zhu, X. J., Shu, J. L., Liu, X. L., & Jin, H. M. (2012). Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: A meta-analysis of randomised, controlled trials. British Journal of Nutrition, 108(3), 400-407. doi:10.1017/S0007114511007033
Paniagua, R., Frías, Y., de Ventura, M. J., Rodríguez, E., Hurtado, M. E., Alcántara, G., . . . Amato, D. (2003). C-reactive protein and anti-Chlamydia pneumoniae antibodies as risk factors of cardiovascular death in incident patients on peritoneal dialysis. Perit Dial Int, 23(2), 132-137. 
Panuccio, V., Tripepi, R., Tripepi, G., Mallamaci, F., Benedetto, F. A., Cataliotti, A., . . . Zoccali, C. (2004). Heart Valve Calcifications, Survival, and Cardiovascular Risk in Hemodialysis Patients. American Journal of Kidney Diseases, 43(3), 479-484. doi:10.1053/j.ajkd.2003.11.009
Papademetriou, V., Katsiki, N., Doumas, M., & Faselis, C. (2014). Halting arterial aging in patients with cardiovascular disease: Hypolipidemic and antihypertensive therapy. Current Pharmaceutical Design, 20(40), 6339-6349. doi:10.2174/1381612820666140620162157
Paparello, J., Kshirsagar, A., & Batlle, D. (2002). Comorbidity and cardiovascular risk factors in patients with chronic kidney disease. Semin Nephrol, 22(6), 494-506. doi:10.1053/snep.2002.35969
Parajuli, S., Lockridge, J. B., Langewisch, E. D., Norman, D. J., & Kujovich, J. L. (2016). Hypercoagulability in kidney transplant recipients. Transplantation, 100(4), 719-726. doi:10.1097/TP.0000000000000887
Paraskevas, K. I., Mikhailidis, D. P., & Thompson, C. S. (2008). Editorial: Experimental models for the study of drugs used to prevent and treat vascular diseases. Current Pharmaceutical Design, 14(4), 306-308. doi:10.2174/138161208783497732
Park, E. H., Choi, S. T., & Srong, J. S. (2014). The relationship between serum homocysteine, uric acid and renal function in chronic gouty patients: 2 year follow-up results. Arthritis and Rheumatology, 66, S533. doi:10.1002/art.38914
Park, J. S., Jung, H. H., Yang, W. S., Kim, S. B., Min, W. K., & Chi, H. S. (2000). Effects of hormonal replacement therapy on lipid and haemostatic factors in post-menopausal ESRD patients. Nephrology, dialysis, transplantation, 15(11), 1835‐1840. doi:10.1093/ndt/15.11.1835
Park, S., Lee, S., Kim, Y., Cho, S., Kim, K., Kim, Y. C., . . . Kim, D. K. (2021). Causal effects of homocysteine, folate, and cobalamin on kidney function: A mendelian randomization study. Nutrients, 13(3), 1-10. doi:10.3390/nu13030906
Parnetti, L., Bottiglieri, T., & Lowenthal, D. (1997). Role of homocysteine in age-related vascular and non-vascular diseases. Aging (Milano), 9(4), 241-257. doi:10.1007/bf03341827
Parsons, D. S., Reaveley, D. A., Pavitt, D. V., & Brown, E. A. (2002). Relationship of renal function to homocysteine and lipoprotein(a) levels: The frequency of the combination of both risk factors in chronic renal impairment. American Journal of Kidney Diseases, 40(5), 916-923. doi:10.1053/ajkd.2002.36321
Paschalis, E. (2012). Molecular mechanisms of homocysteine effects on bone cells. Clinical Chemistry and Laboratory Medicine, 50(2), A15. doi:10.1515/cclm-2012-0032
Pastore, A., De Angelis, S., Casciani, S., Ruggia, R., Di Giovamberardino, G., Noce, A., . . . Dessi, M. (2006). Effects of folic acid before and after vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with known MTHFR genotypes. Clinical chemistry, 52(1), 145‐148. doi:10.1373/clinchem.2005.056119
Pastore, A., Noce, A., Di Giovamberardino, G., De Stefano, A., Callà, C., Zenobi, R., . . . Di Daniele, N. (2015). Homocysteine, cysteine, folate and vitamin B12 status in type 2 diabetic patients with chronic kidney disease. Journal of Nephrology, 28(5), 571-576. doi:10.1007/s40620-014-0126-4
Pastore, A., Noce, A., Di Giovamberardino, G., De Stefano, A., Callà, C., Zenobi, R., . . . Di Daniele, N. (2015). Homocysteine, cysteine, folate and vitamin B₁₂ status in type 2 diabetic patients with chronic kidney disease. J Nephrol, 28(5), 571-576. doi:10.1007/s40620-014-0126-4
Pastore, A., Noce, A., Di Giovamberardino, G., De Stefano, A., Callà, C., Zenobi, R., . . . Di Daniele, N. (2015). Homocysteine, cysteine, folate and vitamin B₁₂ status in type 2 diabetic patients with chronic kidney disease. J Nephrol, 28(5), 571-576. doi:10.1007/s40620-014-0126-4
Pastore, A., Noce, A., Di Giovamberardino, G., Di Stefano, A., Di Daniele, N., Dessí, M., & Callà, C. (2012). Homocysteine, folate and vitamin B12 levels in type 2 diabetic patiens with various stage of chronic kidney disease. Clinical Chemistry and Laboratory Medicine, 50(2), A48. doi:10.1515/cclm-2012-0032
Patsouras, M. D., & Vlachoyiannopoulos, P. G. (2019). Evidence of epigenetic alterations in thrombosis and coagulation: A systematic review. Journal of Autoimmunity, 104. doi:10.1016/j.jaut.2019.102347
Paul, E. A., Guttenberg, M., Kaplan, P., Watkins, D., Rosenblatt, D. S., Treat, J. R., & Kaplan, B. S. (2013). Atypical glomerulopathy associated with the cblE inborn error of vitamin B12 metabolism. Pediatric Nephrology, 28(7), 1135-1139. doi:10.1007/s00467-013-2443-6
Paul, E. A., Guttenberg, M., Kaplan, P., Watkins, D., Rosenblatt, D. S., Treat, J. R., & Kaplan, B. S. (2013). Atypical glomerulopathy associated with the cblE inborn error of vitamin B₁₂ metabolism. Pediatr Nephrol, 28(7), 1135-1139. doi:10.1007/s00467-013-2443-6
Peach, G., & Loftus, I. M. (2013). Acute and chronic lower limb ischaemia. Surgery (United Kingdom), 31(5), 229-235. doi:10.1016/j.mpsur.2013.03.004
Pecchini, P., Malberti, F., Mieth, M., Quinn, R., Tripepi, G., Mallamaci, F., . . . Ravani, P. (2012). Measuring asymmetric dimethylarginine (ADMA) in CKD: A comparison between enzyme-linked immunosorbent assay and liquid chromatographyelectrospray tandem mass spectrometry. Journal of Nephrology, 25(6), 1016-1022. doi:10.5301/jn.5000085
Pečovnik-Balon, B. (2005). Cardiovascular calcification in patients with end-stage renal disease. Therapeutic Apheresis and Dialysis, 9(3), 208-210. doi:10.1111/j.1774-9987.2005.00255.x
Pedone, C., & Incalzi, R. A. (2017). The nephroprotective effect of folic acid-only a matter of homocysteine? [1]. JAMA Internal Medicine, 177(2), 285-286. doi:10.1001/jamainternmed.2016.8580
Pelikant-Malecka, I., Sielicka, A., Kaniewska, E., Smolenski, R. T., & Slominska, E. M. (2015). Endothelial toxicity of unusual nucleotide metabolites. Pharmacological Reports, 67(4), 818-822. doi:10.1016/j.pharep.2015.03.020
Pellino, M. L., Maiorana, C. A., Lares, M., Arana, D. C., & Arana, D. G. (2012). Effect cardiac, inflamatory and endothelial of transplanted patients, with renal chronic disease. Series cases. Revista Latinoamericana de Hipertension, 7(3), 48-52. 
Peña, J., & Claro, J. C. (2014). Is folic acid effective for the prevention of cardiovascular events in patients with advanced or terminal chronic kidney disease? Revista Medica de Chile, 142(5), 636-645. doi:10.4067/S0034-98872014000500013
Peng, Y., Liu, H., Liu, F., Wang, H., Liu, Y., & Duan, S. (2005). Inhibitory effect of PPAR-gamma activator on IL-6 and mPGES protein expression in PBMC induced by homocysteine. Hemodial Int, 9 Suppl 1, S15-20. doi:10.1111/j.1542-4758.2005.01165.x
Pépion, C., Jacob, L., & Samama, C. M. (2003). Chronic renal failure and thrombosis. Sang Thrombose Vaisseaux, 15(4), 193-201. 
Pereira, A. A., Weiner, D. E., Scott, T., & Sarnak, M. J. (2005). Cognitive function in dialysis patients. Am J Kidney Dis, 45(3), 448-462. doi:10.1053/j.ajkd.2004.10.024
Pérez Flores, I., & Luño, J. (2002). Renal insufficiency is an important cardiovascular risk factor. Nefrología : publicación oficial de la Sociedad Española Nefrologia, 22(4), 306-309. 
Perez, O., Stern, E., & Ferris, L. (2010). Diffuse dermal angiomatosis versus microvenular hemangiomas. Journal of the American Academy of Dermatology, 62(3), AB53. doi:10.1016/j.jaad.2009.11.258
Perła-Kaján, J., & Jakubowski, H. (2012). Paraoxonase 1 and homocysteine metabolism. Amino Acids, 43(4), 1405-1417. doi:10.1007/s00726-012-1321-z
Perlstein, T. S., Pande, R. L., Beckman, J. A., & Creager, M. A. (2008). Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(1), 166-172. doi:10.1161/ATVBAHA.107.153262
Perna, A. F., Acanfora, F., Satta, E., Lombardi, C., Capasso, R., Ingrosso, D., & De Santo, N. G. (2007). L-propionyl carnitine, homocysteine and S-adenosylhomocysteine in hemodialysis. Journal of Nephrology, 20(1), 63-65. 
Perna, A. F., Acanfora, F., Satta, E., Lombardi, C., Ingrosso, D., & De Santo, N. G. (2004). Hyperhomocysteinemia and cardiovascular disease in uremia: the newest evidence in epidemiology and mechanisms of action. Semin Nephrol, 24(5), 426-430. doi:10.1016/j.semnephrol.2004.06.019
Perna, A. F., Capasso, R., Acanfora, F., Satta, E., Lombardi, C., Ingrosso, D., . . . De Santo, N. G. (2006). Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: Cardiovascular and metabolic consequences. Seminars in Nephrology, 26(1), 20-23. doi:10.1016/j.semnephrol.2005.06.005
Perna, A. F., Capasso, R., Lombardi, C., Acanfora, F., Satta, E., & Ingrosso, D. (2005). Hyperhomocysteinemia and macromolecule modifications in uremic patients. Clinical Chemistry and Laboratory Medicine, 43(10), 1032-1038. doi:10.1515/CCLM.2005.181
Perna, A. F., Castaldo, P., De Santo, N. G., Galletti, P., & Ingrosso, D. (1999). Homocysteine and chronic renal failure. Mineral and Electrolyte Metabolism, 25(4-6), 279-285. doi:10.1159/000057460
Perna, A. F., Castaldo, P., Ingrosso, D., & De Santo, N. G. (1999). Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. Journal of Nephrology, 12(4), 230-240. 
Perna, A. F., De Santo, N. G., & Ingrosso, D. (1997). Adverse effects of hyperhomocysteinemia and their management by folic acid. Mineral and Electrolyte Metabolism, 23(3-6), 174-178. 
Perna, A. F., Glorieux, G., Zacchia, M., Trepiccione, F., Capolongo, G., Vigorito, C., . . . Ingrosso, D. (2019). The role of the intestinal microbiota in uremic solute accumulation: a focus on sulfur compounds. Journal of Nephrology, 32(5), 733-740. doi:10.1007/s40620-019-00589-z
Perna, A. F., & Ingrosso, D. (2012). Low hydrogen sulphide and chronic kidney disease: A dangerous liaison. Nephrology Dialysis Transplantation, 27(2), 486-493. doi:10.1093/ndt/gfr737
Perna, A. F., & Ingrosso, D. (2016). Atherosclerosis determinants in renal disease: How much is homocysteine involved? Nephrology Dialysis Transplantation, 31(6), 860-863. doi:10.1093/ndt/gfv409
Perna, A. F., & Ingrosso, D. (2019). Homocysteine and chronic kidney disease: an ongoing narrative. J Nephrol, 32(5), 673-675. doi:10.1007/s40620-019-00622-1
Perna, A. F., Ingrosso, D., Castaldo, P., De Santo, N. G., Galletti, P., & Zappia, V. (1999). Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications. Miner Electrolyte Metab, 25(1-2), 95-99. doi:10.1159/000057428
Perna, A. F., Ingrosso, D., Castaldo, P., Galletti, P., & De Santo, N. G. (2001). Homocysteine and transmethylations in uremia. Kidney International, Supplement, 59(78), S230-S233. doi:10.1046/j.1523-1755.2001.59780230.x
Perna, A. F., Ingrosso, D., & De Santo, N. G. (2003). Homocysteine and oxidative stress. Amino Acids, 25(3-4), 409-417. doi:10.1007/s00726-003-0026-8
Perna, A. F., Ingrosso, D., De Santo, N. G., Galletti, P., & Zappia, V. (1995). Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney International, 47(1), 247-253. doi:10.1038/ki.1995.31
Perna, A. F., Ingrosso, D., Galletti, P., Zappia, V., & De Santo, N. G. (1996). Membrane protein damage and methylation reactions in chronic renal failure. Kidney International, 50(2), 358-366. doi:10.1038/ki.1996.324
Perna, A. F., Ingrosso, D., Lombardi, C., Acanfora, F., Satta, E., Cesare, C. M., . . . De Santo, N. G. (2003). Possible mechanisms of homocysteine toxicity. Kidney International, Supplement, 63(84), S137-S140. doi:10.1046/j.1523-1755.63.s84.33.x
Perna, A. F., Ingrosso, D., Lombardi, C., Cesare, C. M., Acantora, F., Satta, E., & De Santo, N. G. (2003). Homocysteine in uremia. American Journal of Kidney Diseases, 41(3 SUPPL. 1), S123-S126. doi:10.1053/ajkd.2003.50100
Perna, A. F., Ingrosso, D., Molino, D., Galletti, P., Montini, G., Zacchello, G., . . . De Santo, N. G. (2003). Hyperhomocysteinemia and protein damage in chronic renal failure and kidney transplant pediatric patients - Italian initiative on uremic hyperhomocysteinemia (IIUH). Journal of Nephrology, 16(4), 516-521. 
Perna, A. F., Ingrosso, D., Molino, D., Galletti, P., Montini, G., Zacchello, G., . . . De Santo, N. G. (2003). Hyperhomocysteinemia and protein damage in chronic renal failure and kidney transplant pediatric patients--Italian initiative on uremic hyperhomocysteinemia (IIUH). J Nephrol, 16(4), 516-521. 
Perna, A. F., Ingrosso, D., Satta, E., Romano, M., Cimmino, A., Galletti, P., . . . De Santo, N. G. (2001). Metabolic consequences of hyperhomocysteinemia in uremia. American Journal of Kidney Diseases, 38(4 SUPPL. 1), S85-S90. doi:10.1053/ajkd.2001.27411
Perna, A. F., Ingrosso, D., Violetti, E., Luciano, M. G., Sepe, I., Lanza, D., . . . De Santo, N. G. (2009). Hyperhomocysteinemia in uremia - A red flag in a disrupted circuit. Seminars in Dialysis, 22(4), 351-356. doi:10.1111/j.1525-139X.2009.00579.x
Perna, A. F., Ingrosso, D., Violetti, E., Luciano, M. G., Sepe, I., Lanza, D., . . . De Santo, N. G. (2009). Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit. Semin Dial, 22(4), 351-356. doi:10.1111/j.1525-139X.2009.00579.x
Perna, A. F., Ingrosso, D., Zappia, V., Galletti, P., Capasso, G., & De Santo, N. G. (1993). Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest, 91(6), 2497-2503. doi:10.1172/jci116485
Perna, A. F., Lanza, D., Sepe, I., Conzo, G., Altucci, L., & Ingrosso, D. (2013). Altered folate receptor 2 expression in uraemic patients on haemodialysis: Implications for folate resistance. Nephrology Dialysis Transplantation, 28(5), 1214-1224. doi:10.1093/ndt/gfs510
Perna, A. F., Lanza, D., Sepe, I., Di Nunzio, A., Conzo, G., Satta, E., . . . Ingrosso, D. (2013). Vasodilatation caused by endogenous hydrogen sulfide in chronic renal failure. Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, 30(2). 
Perna, A. F., Luciano, M. G., Ingrosso, D., Pulzella, P., Sepe, I., Lanza, D., . . . De Santo, N. G. (2009). Hydrogen sulphide-generating pathways in haemodialysis patients: A study on relevant metabolites and transcriptional regulation of genes encoding for key enzymes. Nephrology Dialysis Transplantation, 24(12), 3756-3763. doi:10.1093/ndt/gfp378
Perna, A. F., Luciano, M. G., Ingrosso, D., Raiola, I., Pulzella, P., Sepe, I., . . . De Santo, N. G. (2010). Hydrogen sulfide, the third gaseous signaling molecule with cardiovascular properties, is decreased in hemodialysis patients. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 20(5 Suppl), S11-14. 
Perna, A. F., Luciano, M. G., Pulzella, P., Satta, E., Capasso, R., Lombardi, C., . . . De Santo, N. G. (2008). Is Homocysteine Toxic in Uremia? Journal of Renal Nutrition, 18(1), 12-17. doi:10.1053/j.jrn.2007.10.005
Perna, A. F., Pane, F., Sepe, N., Fontanarosa, C., Pinto, G., Zacchia, M., . . . Amoresano, A. (2019). Lanthionine and other relevant sulfur amino acid metabolites: Detection of prospective uremic toxins in serum by multiple reaction monitoring tandem mass spectrometry. In Methods in Molecular Biology (Vol. 2007, pp. 9-17).
Perna, A. F., Satta, E., Lombardi, C., Acanfora, F., Ingrosso, D., & De Santo, N. G. (2004). Hyperhomocysteinemia and the cardiovascular disease of uremia. Nutrition Research, 24(10), 839-849. doi:10.1016/j.nutres.2004.04.009
Perna, A. F., Sepe, I., Lanza, D., Pollastro, R. M., De Santo, N. G., & Ingrosso, D. (2012). Hyperhomocysteinemia in Chronic Renal Failure: Alternative Therapeutic Strategies. Journal of Renal Nutrition, 22(1), 191-194. doi:10.1053/j.jrn.2011.10.008
Perna, A. F., Violetti, E., Lanza, D., Sepe, I., Bellinghieri, G., Savica, V., . . . De Santo, N. G. (2012). Therapy of Hyperhomocysteinemia in Hemodialysis Patients: Effects of Folates and N-Acetylcysteine. Journal of Renal Nutrition, 22(5), 507-514.e501. doi:10.1053/j.jrn.2011.10.007
Pernod, G., Bosson, J. L., Golshayan, D., Barro, C., Alloatti, S., Turc-Baron, C., . . . Wauters, J. P. (2004). The Diamant Alpin Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients. J Nephrol, 17(1), 66-75. 
Peters, B. A., Hall, M. N., Liu, X., Neugut, Y. D., Pilsner, J. R., Levy, D., . . . Gamble, M. V. (2014). Creatinine, arsenic metabolism, and renal function in an arsenic-exposed population in Bangladesh. PLoS ONE, 9(12). doi:10.1371/journal.pone.0113760
Petropoulos, T. E., Ramirez, M. E., Granton, J., Licht, C., John, R., Moayedi, Y., . . . McQuillan, R. F. (2018). Renal thrombotic microangiopathy and pulmonary arterial hypertension in a patient with late-onset cobalamin C deficiency. Clinical Kidney Journal, 11(3), 310-314. doi:10.1093/ckj/sfx119
Pettitt, R. M., Brumbaugh, A. P., Gartman, M. F., & Jackson, A. M. (2020). Chronic kidney disease: Detection and evaluation. Osteopathic Family Physician, 12(1), 14-19. doi:10.33181/12011
Pezzati, P., Balboni, F., & Graziani, M. S. (2010). Hyperhomocysteinemia and cardiovascular risk: State of the art. Biochimica Clinica, 34(3), 173-186. 
Pfeiffer, C. M., Osterloh, J. D., Kennedy-Stephenson, J., Picciano, M. F., Yetley, E. A., Rader, J. I., & Johnson, C. L. (2008). Trends in circulating concentrations of total homocysteine among US adolescents and adults: Findings from the 1991-1994 and 1999-2004 National Health and Nutrition Examination Surveys. Clinical Chemistry, 54(5), 801-813. doi:10.1373/clinchem.2007.100214
Pinzon, R. T., Antonius, R. A., Veronica, V., & Parianto, Y. P. (2020). The impacts of parenteral vitamin B1, B6, B12 on hemoglobin levels in chronic kidney disease patients undergoing hemodialysis. International Journal of Research in Pharmaceutical Sciences, 11(4), 5426-5430. doi:10.26452/ijrps.v11i4.3171
Pinzon, R. T., Veronica, V., Dian Christi, Y. R. T., & Pradani, R. A. (2020). The effects of Vitamin B combination injection on lymphocyte count in chronic kidney failure patients. Biomedical and Pharmacology Journal, 13(4), 2081-2085. doi:10.13005/BPJ/2088
Piroddi, M., Bartolini, D., Ciffolilli, S., & Galli, F. (2013). Nondialyzable uremic toxins. Blood Purification, 35(SUPPL.2), 30-41. doi:10.1159/000350846
Pisanu, E., Sanna, M., Scanu, B., E. Satta, A., Deiana, L., & Zinellu, A. (2012). Lipid lowering therapy decreases LDL-S-homocysteinilation levels in chronic kidney desease patients. FEBS Journal, 279, 104. doi:10.1111/j.1742-4658.2010.08705.x
Pita-Fernández, S., Chouciño-Fernández, T., Juega-Puig, J., Seoane-Pillado, T., Lõpez-Calviño, B., Pértega-Díaz, S., . . . Gil-Guillén, V. (2014). A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia. International Journal of Clinical Practice, 68(10), 1231-1238. doi:10.1111/ijcp.12475
Pizzolo, F., Blom, H. J., Choi, S. W., Girelli, D., Guarini, P., Martinelli, N., . . . Friso, S. (2011). Folic acid effects on s-adenosylmethionine, s-adenosylhomocysteine, and DNA methylation in patients with intermediate hyperhomocysteinemia. J Am Coll Nutr, 30(1), 11-18. doi:10.1080/07315724.2011.10719939
Pöge, U., Look, M., Gerhardt, T., Klehr, H. U., Sauerbruch, T., & Woitas, R. P. (2004). Intravenous treatment of hyperhomocysteinemia in patients on chronic hemodialysis--a pilot study. Ren Fail, 26(6), 703-708. doi:10.1081/jdi-200037108
Poli, A., Schmitt, C., Moulouel, B., Mirmiran, A., Talbi, N., Rivière, S., . . . Gouya, L. (2022). Givosiran in acute intermittent porphyria: A personalized medicine approach. Molecular Genetics and Metabolism, 135(3), 206-214. doi:10.1016/j.ymgme.2022.01.002
Polkinghorne, K. R., Zoungas, S., Branley, P., Villanueva, E., McNeil, J. J., Atkins, R. C., . . . Kerr, P. G. (2003). Randomized, placebo-controlled trial of intramuscular vitamin B 12 for the treatment of hyperhomocysteinaemia in dialysis patients. Internal Medicine Journal, 33(11), 489-494. doi:10.1046/j.1445-5994.2003.00420.x
Ponte, B., Pruijm, M., Marques-Vidal, P., Martin, P. Y., Burnier, M., Paccaud, F., . . . Bochud, M. (2013). Determinants and burden of chronic kidney disease in the population-based CoLaus study: A cross-sectional analysis. Nephrology Dialysis Transplantation, 28(9), 2329-2339. doi:10.1093/ndt/gft206
Popolo, A., Autore, G., Pinto, A., & Marzocco, S. (2013). Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radical Research, 47(5), 346-356. doi:10.3109/10715762.2013.779373
Poyrazoǧlu, H. M., Düşünsel, R., Narin, F., Gündüz, Z., Narin, N., Karakükçü, M., & Tahan, F. (2004). Homocysteine and left ventricular hypertrophy in children with chronic renal failure. Pediatric Nephrology, 19(2), 193-198. doi:10.1007/s00467-003-1351-6
Prabhu, M. V., Santosh Pai, B. H., Reddy, S., & Kodan, P. (2013). Cardiovascular disease in peritoneal dialysis: A review. Clinical Queries: Nephrology, 2(4), 152-155. doi:10.1016/j.cqn.2013.11.001
Prasad, K. (2021). Current Status of Primary, Secondary, and Tertiary Prevention of Coronary Artery Disease. International Journal of Angiology, 30(3), 177-186. doi:10.1055/s-0041-1731273
Pratap, B., Gupta, P., Kumar, P., Abraham, G., & Santhanam, R. (2007). Multiple myeloma and hypercoagulability leading to internal jugular vein thrombosis in a dialysis patient. Hemodialysis International, 11(1), 35-37. doi:10.1111/j.1542-4758.2007.00150.x
Preston, E., Ellis, M. R., Kulinskaya, E., Davies, A. H., & Brown, E. A. (2005). Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD. American Journal of Kidney Diseases, 46(5), 856-862. doi:10.1053/j.ajkd.2005.07.048
Prichard, S. (1999). Major and minor risk factors for cardiovascular disease in continuous ambulatory peritoneal dialysis patients. Perit Dial Int, 19 Suppl 2, S133-137. 
Proesmans, W., van de Wijdeven, P., & Van Geet, C. (2005). Thrombophilia in neonatal renal venous and arterial thrombosis [3]. Pediatric Nephrology, 20(2), 241-242. doi:10.1007/s00467-004-1677-8
Przemysław, W., Piotr, K., Grazyna, C., Danuta, K. P., Małgorzata, I., Bernadeta, M., . . . Witold, S. (2011). Total, free, and protein-bound thiols in plasma of peritoneal dialysis and predialysis patients. International Urology and Nephrology, 43(4), 1201-1209. doi:10.1007/s11255-011-9905-1
Przemysław, W., Piotr, K., Grażyna, C., Danuta, K. P., Małgorzata, I., Bernadeta, M., . . . Witold, S. (2011). Total, free, and protein-bound thiols in plasma of peritoneal dialysis and predialysis patients. Int Urol Nephrol, 43(4), 1201-1209. doi:10.1007/s11255-011-9905-1
Pushpakumar, S., Kundu, S., Narayanan, N., & Sen, U. (2015). DNA hypermethylation in hyperhomocysteinemia contributes to abnormal extracellular matrix metabolism in the kidney. FASEB Journal, 29(11), 4713-4725. doi:10.1096/fj.15-272443
Pushpakumar, S., Ren, L., Biswas, R., & Sen, U. (2016). Epigenetic regulation of macrophage polarization and renal inflammation. FASEB Journal, 30. 
Qin, X., Huo, Y., Langman, C. B., Hou, F., Chen, Y., Matossian, D., . . . Wang, X. (2011). Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: A meta-analysis. Clinical Journal of the American Society of Nephrology, 6(3), 482-488. doi:10.2215/CJN.05310610
Qin, X., Huo, Y., Xie, D., Hou, F., Xu, X., & Wang, X. (2013). Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: A meta-analysis of randomized controlled trials. Clinical Nutrition, 32(5), 722-727. doi:10.1016/j.clnu.2012.12.009
Qin, X., Xu, M., Zhang, Y., Li, J., Xu, X., Wang, X., . . . Huo, Y. (2012). Effect of folic acid supplementation on the progression of carotid intima-media thickness: A meta-analysis of randomised controlled trials. Heart, 98, E277. doi:10.1136/heartjnl-2012-302920w.3
Qin, X., Xu, M., Zhang, Y., Li, J., Xu, X., Wang, X., . . . Huo, Y. (2012). Effect of folic acid supplementation on the progression of carotid intima-media thickness: A meta-analysis of randomized controlled trials. Atherosclerosis, 222(2), 307-313. doi:10.1016/j.atherosclerosis.2011.12.007
Qu, N., Chen, L., Liang, S., Wei, M., Sun, L., He, Q., . . . Liu, H. (2022). Roxadustat Attenuates the Disruption of Epithelial Tight Junction in Caco2 Cells and a Rat Model of CKD Through MicroRNA-223. Frontiers in Medicine, 9. doi:10.3389/fmed.2022.850966
Querfeld, U. (2001). Undertreatment of cardiac risk factors in adolescents with renal failure. Peritoneal Dialysis International, 21(SUPPL. 3), S285-S289. doi:10.1177/089686080102103s50
Quero Alfonso, A. I., Fernández Castillo, R., Fernández Gallegos, R., & Gomez Jimenez, F. J. (2014). [Study of serum albumin and BMI as nutritional markers in hemodialysis patients]. Nutr Hosp, 31(3), 1317-1322. doi:10.3305/nh.2015.31.3.8084
Quero Alfonso, A. I., Fernández Castillo, R., Fernández Gallegos, R., & Gomez Jimenez, F. J. (2015). Study of serum albumin and BMI as nutritional markers in hemodialysis patients. Nutrición hospitalaria, 31(3), 1317-1322. doi:10.3305/nh.2015.31.3.8084
Quiroga, I., Morris-Stiff, G., Baboo, R., Darby, C. R., Lord, R. H., & Jurewicz, W. A. (2001). Differential homocysteine levels in renal transplant patients receiving neoral versus tacrolimus. Transplantation proceedings, 33(1‐2), 1209‐1210. doi:10.1016/s0041-1345(00)02389-7
Rafeq, Z., Roh, J. D., Guarino, P., Kaufman, J., & Joseph, J. (2013). Adverse myocardial effects of B-vitamin therapy in subjects with chronic kidney disease and hyperhomocysteinaemia. Nutrition, Metabolism and Cardiovascular Diseases, 23(9), 836-842. doi:10.1016/j.numecd.2012.07.002
Rakhit, D. J., Marwick, T. H., Armstrong, K. A., Johnson, D. W., Leano, R., & Isbel, N. M. (2006). Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart, 92(10), 1402-1408. doi:10.1136/hrt.2005.074393
Ramanathan, G., Harichandana, B., Kannan, S., Elumalai, R., & Sfd, P. (2019). Association between end-stage diabetic nephropathy and MTHFR (C677T and A1298C) gene polymorphisms. Nephrology, 24(2), 155-159. doi:10.1111/nep.13208
Ramos, N., Carnicer, C., Segarra, A., Chacon, P., & Seron, D. (2010). Analysis of variables associated to cardiovascular disease in patients suffering from chronic kidney disease according to affected vascular territory. NDT Plus, 3, iii59-iii60. 
Ramos, N., Carnicer, C., Segarra, A., Chacon, P., & Seron, D. (2010). Relationship of serum levels of metalloproteinases (MMP) clinical outcomes and biomarkers of endothelial dysfunction in patients with chronic kidney disease (CKD). NDT Plus, 3, iii70. 
Rangaswami, J., Mathew, R. O., Parasuraman, R., Tantisattamo, E., Lubetzky, M., Rao, S., . . . Dadhania, D. M. (2019). Cardiovascular disease in the kidney transplant recipient: Epidemiology, diagnosis and management strategies. Nephrology Dialysis Transplantation, 34(5), 760-773. doi:10.1093/ndt/gfz053
Rao, M., Jaber, B. L., & Balakrishnan, V. S. (2005). Gene polymorphism association studies in dialysis: Cardiovascular disease. Seminars in Dialysis, 18(3), 217-225. doi:10.1111/j.1525-139X.2005.18316.x
Rao, N., & Juneja, R. (2018). Neurological manifestations of renal disease. Neurology India, 66(1), 53-54. doi:10.4103/0028-3886.222825
Rao, P., Reddy, G. C., & Kanagasabapathy, A. S. (2008). Malnutrition- inflammation- atherosclerosis syndrome in chronic kidney disease. Indian Journal of Clinical Biochemistry, 23(3), 209-217. doi:10.1007/s12291-008-0048-9
Rapp, N., Evenepoel, P., Stenvinkel, P., & Schurgers, L. (2020). Uremic toxins and vascular calcification-missing the forest for all the trees. Toxins, 12(10). doi:10.3390/toxins12100624
Rasmussen, L. E., Svensson, M., Jørgensen, K. A., Schmidt, E. B., & Christensen, J. H. (2010). The content of docosahexaenoic acid in serum phospholipid is inversely correlated with plasma homocysteine levels in patients with end-stage renal disease. Nutrition research (New York, N.Y.), 30(8), 535‐540. doi:10.1016/j.nutres.2010.07.004
Rasouli, M. L., Nasir, K., Blumenthal, R. S., Park, R., Aziz, D. C., & Budoff, M. J. (2005). Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis, 181(1), 159-165. doi:10.1016/j.atherosclerosis.2005.01.001
Ratan, D. G., Rahman, M., Ahasan, H. N., Alam, M. B., Miah, M. T., Kabir, A., . . . Khan, M. A. I. (2010). Non-traditional cardiovascular risk factors in chronic kidney disease (CKD) and haemodialysis dependent patients - A case control study. Journal of Medicine, 11(2), 108-114. 
Ratto, E., Leoncini, G., Viazzi, F., & Pontremoli, R. (2008). Glomerular filtration rate and cardiovascular risk: prognostic and therapeutic implications. Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, 25(1), 21-31. 
Ravani, P., Tripepi, G., Malberti, F., Testa, S., Mallamaci, F., & Zoccali, C. (2005). Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. Journal of the American Society of Nephrology, 16(8), 2449-2455. doi:10.1681/ASN.2005010076
Rayasam, V., Hooks, B., Gadre, A., Mehta, A., & Kumar, D. (2021). Hyperhomocysteinemia with concurrent venous and arterial thromboses. American Journal of Respiratory and Critical Care Medicine, 203(9). doi:10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A3547
Regmi, P., Gyawali, P., Sigdel, M., Malla, B., Shah, D. S., Khanal, M. P., & Jha, B. (2012). Assessment of cardiovascular risk in Nepalese individuals with chronic kidney disease. Clinical Chemistry, 58(10), A234. 
Regmi, P., Malla, B., Gyawali, P., Sigdel, M., Shah, D. S., & Khanal, M. P. (2013). Product of serum calcium and phosphorus (ca x po4) as predictor of cardiovascular risk in predialysis patients. Clinical Chemistry, 59(10), A240-A241. 
Regmi, P., Malla, B., Gyawali, P., Sigdel, M., Shrestha, R., Shah, D. S., & Khanal, M. P. (2014). Product of serum calcium and phosphorus (Ca × PO4) as predictor of cardiovascular disease risk in predialysis patients. Clinical Biochemistry, 47(1-2), 77-81. doi:10.1016/j.clinbiochem.2013.09.012
Renjen, P., Chaudhari, D., Sagar, G., & Jasuja, S. (2018). Neurology of renal disorders. Neurology India, 66(1), 163-167. doi:10.4103/0028-3886.222815
Renke, M., Tylicki, L., Rutkowski, P., Larczynski, W., Neuwelt, A., Aleksandrowicz, E., . . . Rutkowski, B. (2010). The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: a placebo-controlled, randomized, cross-over study. Medical science monitor, 16(7), PI13‐18. 
Renke, M., Tylicki, L., Rutkowski, P., Larczynski, W., Neuwelt, A., Aleksandrowicz, E., . . . Rutkowski, B. (2010). The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: A placebo-cotrolled, randomized, cross-over study. Medical Science Monitor, 16(7), 13-18. 
Resanović, I., Zarić, B., Radovanović, J., Sudar-Milovanović, E., Gluvić, Z., Jevremović, D., & Isenović, E. R. (2020). Hyperbaric Oxygen Therapy and Vascular Complications in Diabetes Mellitus. Angiology, 71(10), 876-885. doi:10.1177/0003319720936925
Restrepo, C., Saling, M., Ames, D., Bush, A., Faux, N., Martins, R., . . . Ellis, K. (2013). The effect of vascular risk factors on the rate of cognitive change in older adults: Data from the australian imaging biomarkers and lifestyle (AIBL) flagship study. Alzheimer's and Dementia, 9(4), P454-P455. doi:10.1016/j.jalz.2013.05.911
Restrepo, C., Saling, M., Lim, Y. Y., Harrington, K., Maruff, P., Ames, D., . . . Ellis, K. A. (2016). Difference in the rate of cognitive change between individuals with and without vascular risk factors: A longitudinal study. Alzheimer's and Dementia, 12(7), P766-P767. 
Restrepo, C., Saling, M., Yates, P., Villemagne, V., Ames, D., Bush, A., . . . Ellis, K. (2012). The effect of vascular risk factors on cognition in older adults: Data from the aibl study. Alzheimer's and Dementia, 8(4), P635. doi:10.1016/j.jalz.2012.05.1693
Reszke, R., Kiliś-Pstrusińska, K., & Szepietowski, J. C. (2021). Chronic kidney disease-associated itch (CKD-aI) in children—A narrative review. Toxins, 13(7). doi:10.3390/toxins13070450
Ricciardi, C. A., Lacquaniti, A., De gregrorio, F., Bruzzese, A., Visconti, L., Lacava, V., . . . Buemi, M. (2016). Predicting progression in CKD: Corin balances heart and renal systems. Nephrology Dialysis Transplantation, 31, i176. doi:10.1093/ndt/gfw164.10
Rifkin, D. E., & Sarnak, M. J. (2009). Does Inflammation Fuel the Fire in CKD? American Journal of Kidney Diseases, 53(4), 572-575. doi:10.1053/j.ajkd.2009.01.001
Righetti, M. (2008). Folate metabolism dysfunction. Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, 25(1), 32-41. 
Righetti, M. (2008). Hopeful for a second HOPE-2 post hoc analysis. Nephrology Dialysis Transplantation, 23(7), 2428-2429. doi:10.1093/ndt/gfn066
Righetti, M. (2009). Protective effect of vitamin B therapy on bone and cardiovascular disease. Recent Pat Cardiovasc Drug Discov, 4(1), 37-44. doi:10.2174/157489009787260061
Righetti, M. (2012). Cardio-renal-anemia syndrome: A link between erythropoietin, dimethylarginine and homocysteine. Current Medicinal Chemistry, 19(21), 3502-3507. doi:10.2174/092986712801323261
Righetti, M., Ferrario, G. M., Milani, S., Serbelloni, P., La Rosa, L., Uccellini, M., & Sessa, A. (2003). Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Medical science monitor, 9(4), PI19‐24. 
Righetti, M., Ferrario, G. M., Serbelloni, P., Milani, S., & Tommasi, A. (2006). Homocysteine reduction rate in internal haemodiafiltration-a comparison with other mixed dialysis therapies. Nephrol Dial Transplant, 21(7), 2034-2035. doi:10.1093/ndt/gfl077
Righetti, M., Serbelloni, P., Milani, S., & Ferrario, G. (2006). Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood purification, 24(4), 379‐386. doi:10.1159/000093680
Righetti, M., Tommasi, A., Lagona, C., La Rosa, L., Uccellini, M., & Sessa, A. (2004). Effective homocysteine-lowering vitamin B treatment in peritoneal dialysis patients. Perit Dial Int, 24(4), 373-377. 
Rinat, C., Becker-Cohen, R., Nir, A., Feinstein, S., Shemesh, D., Algur, N., . . . Frishberg, Y. (2010). A comprehensive study of cardiovascular risk factors, cardiac function and vascular disease in children with chronic renal failure. Nephrology Dialysis Transplantation, 25(3), 785-793. doi:10.1093/ndt/gfp570
Ritter, J. K., Li, G., Xia, M., & Boini, K. (2016). Anandamide and its metabolites: What are their roles in the kidney? Frontiers in Bioscience - Scholar, 8(2), 264-277. doi:10.2741/S461
Rizzo, M. A., Frediani, F., Granata, A., Ravasi, B., Cusi, D., & Gallieni, M. (2012). Neurological complications of hemodialysis: State of the art. Journal of Nephrology, 25(2), 170-182. doi:10.5301/jn.5000087
Roberts, M. A., Hare, D. L., Ratnaike, S., & Ierino, F. L. (2006). Cardiovascular Biomarkers in CKD: Pathophysiology and Implications for Clinical Management of Cardiac Disease. American Journal of Kidney Diseases, 48(3), 341-360. doi:10.1161/01.HYP.0000205123.40068.84
Robins, A. J., Milewczyk, B. K., Booth, E. M., & Mallick, N. P. (1972). Plasma amino acid abnormalities in chronic renal failure. Clinica chimica acta; international journal of clinical chemistry, 42(1), 215-217. 
Robinson, K. (2004). Renal Disease, Homocysteine, and Cardiovascular Complications. Circulation, 109(3), 294-295. doi:10.1161/01.CIR.0000114133.99074.96
Robinson, K., Gupta, A., Dennis, V., Arheart, K., Chaudhary, D., Green, R., . . . Jacobsen, D. W. (1996). Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation, 94(11), 2743-2748. doi:10.1161/01.cir.94.11.2743
Robitaille, R., Lafrance, J. P., & Leblanc, M. (2006). Altered laboratory findings associated with end-stage renal disease. Seminars in Dialysis, 19(5), 373-380. doi:10.1111/j.1525-139X.2006.00192.x
Robles, N. R., Romero, J., Gomez Casero, L., Escola, J. M., Ramos, J. L., & Sánchez Casado, E. (2005). Hyperhomocysteinemia in patients with mild chronic renal failure. European Journal of Internal Medicine, 16(5), 334-338. doi:10.1016/j.ejim.2005.06.006
Robles, N. R., Sanchez Munoz-Torrero, J. F., Garcia Gallego, F., Velasco Gemio, J., & Escola, J. M. (2008). Homocysteinemia in hypertensive patients with renal target organ damage (mild renal dysfunction). Eur J Med Res, 13(5), 196-199. 
Robles, N. R., Sánchez Muñoz-Torrero, J. F., Garcia Gallego, F., Velasco Gemio, J., & Escola, J. M. (2008). Homocysteinemia in hypertensive patients with renal target organ damage (Mild Renal Dysfunction). European Journal of Medical Research, 13(5), 196-199. 
Rodriguez-Iturbe, B., & Correa-Rotter, R. (2010). Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease. Expert Opinion on Pharmacotherapy, 11(16), 2687-2698. doi:10.1517/14656561003796570
Rodríguez-Ribera, L., Pastor, S., Corredor, Z., Silva, I., Diaz, J. M., Ballarin, J., . . . Coll, E. (2016). Genetic damage in patients moving from hemodialysis to online hemodiafiltration. Mutagenesis, 31(2), 131-135. doi:10.1093/mutage/gev063
Rogacev, K., Seiler, S., Zawada, A., Reichart, B., Roth, D., Ulrich, C., . . . Heine, G. (2010). CD14++16+ monocytes: Independent predictors of cardiovascular outcome in patients with chronic kidney disease. NDT Plus, 3, iii81-iii82. 
Romanelli, P., & Bouzari, N. (2006). New clinical syndromes in dermatology. Semin Cutan Med Surg, 25(2), 79-86. doi:10.1016/j.sder.2006.05.001
Román-García, P., Rodríguez-García, M., Cabezas-Rodríguez, I., López-Ongil, S., Díaz-López, B., & Cannata-Andía, J. B. (2011). Vascular calcification in patients with chronic kidney disease: Types, clinical impact and pathogenesis. Medical Principles and Practice, 20(3), 203-212. doi:10.1159/000323434
Ronco, C., Haapio, M., House, A. A., Anavekar, N., & Bellomo, R. (2008). Cardiorenal Syndrome. Journal of the American College of Cardiology, 52(19), 1527-1539. doi:10.1016/j.jacc.2008.07.051
Rosendorff, C., & Jogendra, M. R. (2013). Uric Acid: Where Are We? Journal of Clinical Hypertension, 15(1), 5-6. doi:10.1111/jch.12034
Rosing, K., Fobker, M., & Voss, R. (2011). NGAL: Is there a diagnostic value for decreasing renal function of heart transplant patients receiving different immunosuppressant regimen? Therapeutic Drug Monitoring, 33(4), 546. doi:10.1097/01.ftd.0000400651.94145.ba
Ross, L., & Banerjee, D. (2013). Cardiovascular complications of chronic kidney disease. International Journal of Clinical Practice, 67(1), 4-5. doi:10.1111/ijcp.12069
Rossi, G., Giordano, A., Breda, S., Lisi, C., Roura, X., Zatelli, A., & Paltrinieri, S. (2013). Big-endothelin 1 (big ET-1) and homocysteine in the serum of dogs with chronic kidney disease. Veterinary Journal, 198(1), 109-115. doi:10.1016/j.tvjl.2013.06.022
Rossi, G. P., Seccia, T. M., Barton, M., Danser, A. H. J., De Leeuw, P. W., Dhaun, N., . . . Webb, D. J. (2018). Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: Role in disease conditions: A joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension. Journal of Hypertension, 36(3), 462-471. doi:10.1097/HJH.0000000000001600
Rostand, S. G. (2000). Coronary heart disease in chronic renal insufficiency: Some management considerations. Journal of the American Society of Nephrology, 11(10), 1948-1956. 
Rovella, V., Ferrannini, M., Tesauro, M., Marrone, G., Busca, A., Sorge, R., . . . Noce, A. (2019). Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease. Journal of Nephrology, 32(1), 75-81. doi:10.1007/s40620-018-0496-0
Rucker, D., & Tonelli, M. (2009). Cardiovascular risk and management in chronic kidney disease. Nature Reviews Nephrology, 5(5), 287-296. doi:10.1038/nrneph.2009.42
Russo, D., Morrone, L., Di Iorio, B., Andreucci, M., De Gregorio, M. G., Errichiello, C., . . . Locatelli, F. (2015). Parathyroid hormone may be an early predictor of low serum hemoglobin concentration in patients with not advanced stages of chronic kidney disease. Journal of Nephrology, 28(6), 701-708. doi:10.1007/s40620-014-0129-1
Russo, D., Morrone, L. F., Brancaccio, S., Napolitano, P., Salvatore, E., Spadola, R., . . . Andreucci, V. E. (2009). Pulse pressure and presence of coronary artery calcification. Clinical Journal of the American Society of Nephrology, 4(2), 316-322. doi:10.2215/CJN.02580508
Russo, L., Battaglia, Y., Capasso, G. B., D'Esposito, V., Di Iorio, B., Di Lullo, L., . . . Russo, D. (2016). Inflammation but not deranged mineral metabolism may explain the progression of coronary artery calcification in CKD patients not on dialysis. Nephrology Dialysis Transplantation, 31, i464-i465. doi:10.1093/ndt/gfw190.31
Sadaria, R. G., & Vasava, S. N. (2021). Thyroid profile and its correlation with serum creatinine ichronic kidney disease patients in tertiary care hospital. Indian Journal of Forensic Medicine and Toxicology, 15(2), 681-685. doi:10.37506/ijfmt.v15i2.14390
Safder, O., Al Sharif, S., & Kari, J. A. (2014). Pediatric CKD and cardivascular disease. Cardiovascular and Hematological Disorders - Drug Targets, 14(3), 177-184. doi:10.2174/1871529X14666140401112335
Sagheb, M. M., Ostovan, M. A., Sohrabi, Z., Atabati, E., Raisjalai, G. A., & Roozbeh, J. (2010). Hyperhomocysteinemia and cardiovascular risks in hemodialysis patients. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 21(5), 863-866. 
Sahakyan, K., Klein, B. E., Myers, C. E., Tsai, M. Y., & Klein, R. (2010). Novel risk factors in long-term hypertension incidence in type 1 diabetes mellitus. Am Heart J, 159(6), 1074-1080. doi:10.1016/j.ahj.2010.03.023
Sahakyan, K., Klein, B. E. K., Myers, C. E., Tsai, M. Y., & Klein, R. (2010). Novel risk factors in long-term hypertension incidence in type 1 diabetes mellitus. American Heart Journal, 159(6), 1074-1080. doi:10.1016/j.ahj.2010.03.023
Sahinarslan, A., Güz, G., Okyay, K., Mutluay, R., Yalçin, R., Bali, M., . . . Cengel, A. (2008). Prognostic value of troponin T and homocysteine in patients with end-stage renal disease. Türk Kardiyoloji Derneǧi arşivi : Türk Kardiyoloji Derneǧinin yayin organidir, 36(6), 382-387. 
Saifan, C., El-Charabaty, E., & El-Sayegh, S. (2013). Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study. Vasc Health Risk Manag, 9, 361-364. doi:10.2147/vhrm.S47255
Saito, M., & Marumo, K. (2010). CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Bone quality in chronic kidney disease : enzymatic and non-enzymatic glycation or oxidation induced cross-links in bone. Clinical calcium, 20(7), 1068-1076. 
Saito, M., & Marumo, K. (2015). Effects of Collagen Crosslinking on Bone Material Properties in Health and Disease. Calcified Tissue International, 97(3), 242-261. doi:10.1007/s00223-015-9985-5
Salma Mahaboob, R., & Prabhakar Reddy, E. (2018). Nitric oxide levels in chronic renal failure patients and maintenance hemodialysis in comparison to healthy controls. Indian Journal of Public Health Research and Development, 9(8), 210-214. doi:10.5958/0976-5506.2018.00722.2
Samodelov, S. L., Gai, Z., Kullak-Ublick, G. A., & Visentin, M. (2019). Renal reabsorption of folates: Pharmacological and toxicological snapshots. Nutrients, 11(10). doi:10.3390/nu11102353
Samuelsson, O., Lee, D. M., Attman, P. O., Knight-Gibson, C., Mullen, J. K., Larsson, R., . . . Alaupovic, P. (1999). The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression. Nephron, 82(4), 306-311. doi:10.1159/000045445
Sánchez Alvarez, J. E., Pérez Tamajón, L., Hernández, D., Alvarez González, A., Delgado, P., & Lorenzo, V. (2005). Efficacy and safety of two vitamin supplement regimens on homocysteine levels in hemodialysis patients. Prospective, randomized clinical trial. Nefrología : publicación oficial de la Sociedad Española Nefrologia, 25(3), 288-296. 
Sánchez, C., Aranda, P., Planells, E., Galindo, P., Pérez de la Cruz, A., Larrubia, M., & Llopis, J. (2010). Influence of low-protein dietetic foods consumption on quality of life and levels of B vitamins and homocysteine in patients with chronic renal failure. Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral, 25(2), 238-244. 
Sánchez, C., Planells, E., Aranda, P., de la Cruz, A. P., Asensio, C., Mataix, J., & Llopis, J. (2007). [Vitamin B complex and homocysteine in chronic renal failure]. Nutr Hosp, 22(6), 661-671. 
Sánchez González, C., Planells, E., Aranda, P., Pérez De La Cruz, A., Asensio, C., Mataix, J., & Llopis, J. (2007). Vitamin B complex and homocysteine in chronic renal failure. Nutricion Hospitalaria, 22(6), 661-671. 
Santoro, A., & Bainotti, A. (2005). Arterial hypertension and cardiovascular risk in patients with nephropathy. Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, 22 Suppl 31, S56-59. 
Santos, P. W., & Wetmore, J. B. (2021). Sequential Bone Scintigraphy and the Evolution of Warfarin-Mediated Calcific Uremic Arteriolopathy. Case Reports in Nephrology and Dialysis, 11(1), 78-86. doi:10.1159/000512611
Sarkar, P. K., & Lambert, L. A. (2001). Aetiology and treatment of hyperhomocysteinaemia causing ischaemic stroke. International Journal of Clinical Practice, 55(4), 262-268. 
Sarnak, M. J., & Levey, A. S. (2000). Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. Journal of Thrombosis and Thrombolysis, 10(2), 169-180. doi:10.1023/A:1018718727634
Sashi Papu John, A. M., & Sen, U. (2019). GYY4137 Modulates Renal Remodeling in Hyperhomocysteinemia. FASEB Journal, 33(SUPPL 1), 570.573. doi:10.1096/fasebj.2019.33.1_supplement.570.3
Satoh, M. (2022). Elevated albumin-to-creatinine ratio as a risk factor for stroke and homocysteine as an effect modifier in hypertensive Asian individuals. Hypertension Research, 45(1), 170-171. doi:10.1038/s41440-021-00794-z
Satta, E., Perna, A. F., Lombardi, C., Acanfora, F., Violetti, E., Romano, M. M., . . . De Santo, N. G. (2006). Hyperhomocysteinemia in chronic renal failure. Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, 23(5), 480-489. 
Satyan, S., & Rocher, L. L. (2004). Impact of kidney transplantation on the progression of cardiovascular disease. Advances in Chronic Kidney Disease, 11(3), 274-293. doi:10.1053/j.arrt.2004.04.010
Savaj, S. (2013). Omega-3 and serum homocysteine level in hemodialysis patients. Iran J Kidney Dis, 7(6), 421-422. 
Scalais, E., Osterheld, E., Geron, C., Pierron, C., Chafai, R., Schlesser, V., . . . De Meirleir, L. (2019). Parenteral hydroxocobalamin dose intensification in five patients with different types of early onset intracellular cobalamin defects: Clinical and biochemical responses. In (Vol. 49, pp. 70-79).
Schaefer, R. M., Teschner, M., & Kosch, M. (2002). Folate metabolism in renal failure. Nephrology Dialysis Transplantation, 17(SUPPL. 5), 24-27. doi:10.1093/ndt/17.suppl_5.24
Schiel, R., Franke, S., Busch, M., Müller, A., Fleck, C., Müller, U. A., . . . Stein, G. (2003). Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency. European journal of medical research, 8(7), 283-291. 
Scholze, A., Rinder, C., Beige, J., Riezler, R., Zidek, W., & Tepel, M. (2004). Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation, 109(3), 369‐374. doi:10.1161/01.CIR.0000109492.65802.AD
Schröder, C. H., de Boer, A. W., Giesen, A. M., Monnens, L. A., & Blom, H. (1999). Treatment of hyperhomocysteinemia in children on dialysis by folic acid. Pediatr Nephrol, 13(7), 583-585. doi:10.1007/s004670050748
Schupp, N., Stopper, H., Rutkowski, P., Kobras, K., Nebel, M., Bahner, U., . . . Heidland, A. (2006). Effect of different hemodialysis regimens on genomic damage in end-stage renal failure. Seminars in Nephrology, 26(1), 28-32. doi:10.1016/j.semnephrol.2005.06.007
Schwedhelm, E., & Böger, R. H. (2011). The role of asymmetric and symmetric dimethylarginines in renal disease. Nature Reviews Nephrology, 7(5), 275-285. doi:10.1038/nrneph.2011.31
Schwedhelm, E., Xanthakis, V., Maas, R., Sullivan, L. M., Atzler, D., Lüneburg, N., . . . Böger, R. H. (2011). Plasma symmetric dimethylarginine reference limits from the Framingham offspring cohort. Clin Chem Lab Med, 49(11), 1907-1910. doi:10.1515/cclm.2011.679
Scott, D., & Ebeling, P. R. (2019). Vitamin D and public health. International Journal of Environmental Research and Public Health, 16(5). doi:10.3390/ijerph16050848
Seiki, S., Chonchol, M., Cheung, A. K., Kaufman, J. S., Greene, T., Roberts, W. L., . . . Kendrick, J. (2012). 25-hydroxyvitamin D deficiency is associated with an increased risk of metabolic syndrome in patients with non-diabetic chronic kidney disease. Clinical Nephrology, 78(6), 432-441. doi:10.5414/CN107498
Semple, D., Smith, K., Bhandari, S., & Seymour, A. M. L. (2011). Uremic cardiomyopathy and insulin resistance: A critical role for Akt? Journal of the American Society of Nephrology, 22(2), 207-215. doi:10.1681/ASN.2009090900
Sen, U., Basu, P., Abe, O. A., Givvimani, S., Tyagi, N., Metreveli, N., . . . Tyagi, S. C. (2009). Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. American Journal of Physiology - Renal Physiology, 297(2), F410-F419. doi:10.1152/ajprenal.00145.2009
Sen, U., Givvimani, S., Abe, O. A., Lederer, E. D., & Tyagi, S. C. (2011). Cystathionine β-synthase and cystathionine γ-lyase double gene transfer ameliorate homocysteine-mediated mesangial inflammation through hydrogen sulfide generation. American Journal of Physiology - Cell Physiology, 300(1), C155-C163. doi:10.1152/ajpcell.00143.2010
Sepe, V., Adamo, G., Giuliano, M. G., Libetta, C., & Dal Canton, A. (2007). Folic acid for stroke prevention. Lancet, 370(9588), 651; author reply 651. doi:10.1016/s0140-6736(07)61328-2
Sepe, V., Libetta, C., Rossi, N., Guidetti, C., & Dal Canton, A. (2003). Inverse association between homocysteine and vascular endothelial growth factor receptor 2 serum levels in hemodialyzed and kidney transplanted patients. Kidney Int, 64(5), 1922. doi:10.1046/j.1523-1755.2003.t01-1-00296.x
Sepe, V., Libetta, C., Villa, G., Zucchi, M., Gori, E., Pisacco, P., & Dal Canton, A. (2002). Correlation between hyperhomocysteinemia and interleukin-18 serum levels in maintenance hemodialyzed patients. Kidney Int, 62(5), 1900. doi:10.1046/j.1523-1755.2002.00643.x
Sethi, S., Sethi, N., Sandhu, J. S., Makkar, V., Kaur, S., Sohal, P. M., & Mehta, S. (2021). Changing spectrum of mineral bone disorder in chronic kidney disease stage 3 to 5 d and its associated factors, a prospective cross-sectional study from tertiary care hospital in northern India. Iranian Journal of Kidney Diseases, 15(3), 199-205. 
Shah, B., Jagtap, P., Sarmah, D., Datta, A., Raut, S., Sarkar, A., . . . Bhattacharya, P. (2021). Cerebro-renal interaction and stroke. European Journal of Neuroscience, 53(4), 1279-1299. doi:10.1111/ejn.14983
Shaidullov, I., Khaertdinov, N., Garanina, E., Rizvanov, A., & Sitdikova, G. (2019). Cytokines levels in rats with prenatal hyperhomocysteinemia. European Journal of Clinical Investigation, 49, 175-176. doi:10.1111/eci.13109
Shakeri, A., Abdi, M., Khosroshahi, H. T., & Fouladi, R. F. (2011). Common Carotid Artery Intima-Media Thickness and atherosclerotic plaques in carotid bulb in patients with Chronic Kidney Disease on hemodialysis: A Case-control study. Pakistan Journal of Biological Sciences, 14(17), 844-848. doi:10.3923/pjbs.2011.844.848
Shankar, A., Wang, J. J., Chua, B., Rochtchina, E., Flood, V., & Mitchell, P. (2008). Positive association between plasma homocysteine level and chronic kidney disease. Kidney and Blood Pressure Research, 31(1), 55-62. doi:10.1159/000114300
Shantouf, R. S., Budoff, M. J., Ahmadi, N., Ghaffari, A., Flores, F., Gopal, A., . . . Kalantar-Zadeh, K. (2010). Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. American Journal of Nephrology, 31(5), 419-425. doi:10.1159/000294405
Shastri, S., & Sarnak, M. J. (2010). Cardiovascular disease and CKD: Core curriculum 2010. American Journal of Kidney Diseases, 56(2), 399-417. doi:10.1053/j.ajkd.2010.03.019
Shastry, S., Ingram, A. J., Scholey, J. W., & James, L. R. (2007). Homocysteine induces mesangial cell apoptosis via activation of p38-mitogen-activated protein kinase. Kidney International, 71(4), 304-311. doi:10.1038/sj.ki.5002031
Shawon, J., Rahman, M. M., Nahar, Z., & Kabir, Y. (2021). Glutathione S -transferase (M1 and T1) and angiotensin-converting enzyme gene polymorphisms and chronic kidney disease in Bangladeshi population. Meta Gene, 30. doi:10.1016/j.mgene.2021.100981
Sheidaee, N., Nakanishi, R., Ceponiene, I., Yang, W., & Budoff, M. (2017). Relationship of thoracic aortic calcification with cardiovascular risk factors in patients with impaired renal function. Journal of Cardiovascular Computed Tomography, 11(4), S53-S54. 
Shemin, D., Bostom, A. G., & Selhub, J. (2001). Treatment of hyperhomocysteinemia in end-stage renal disease. American Journal of Kidney Diseases, 38(4 SUPPL. 1), S91-S94. doi:10.1053/ajkd.2001.27412
Shen, Z., Zhang, Z., & Zhao, W. (2022). Relationship between plasma homocysteine and chronic kidney disease in US patients with type 2 diabetes mellitus: a cross-sectional study. BMC Nephrol, 23(1), 419. doi:10.1186/s12882-022-03045-6
Shevchuk, S. V., Postovitenko, K. P., Iliuk, I. A., Bezsmertna, H. V., Bezsmertnyi, Y. O., Kurylenko, I. V., . . . Baranova, I. V. (2019). The relationship between homocysteine level and vitamins B12, B9 and B6 status in patients with chronic kidney disease. Wiadomosci lekarskie (Warsaw, Poland : 1960), 72(4), 532-538. 
Shi, W., Zhou, Y., Wang, H., Sun, Y., & Chen, Y. (2019). Synergistic interaction of hypertension and hyperhomocysteinemia on chronic kidney disease: Findings from the National Health and Nutrition Examination Survey 1999-2006. Journal of Clinical Hypertension, 21(10), 1567-1577. doi:10.1111/jch.13673
Shi, Y., Ding, C., Hu, L., Li, M., Huang, X., Zhou, W., . . . Cheng, X. (2021). Saturation Effects of Plasma Homocysteine on Chronic Kidney Disease in Chinese Adults With H-type Hypertension: A Cross-sectional Study. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 31(5), 459-466. doi:10.1053/j.jrn.2020.09.002
Shi, Y., Liu, Z., Shen, Y., & Zhu, H. (2018). A novel perspective linkage between kidney function and alzheimer’s disease. Frontiers in Cellular Neuroscience, 12. doi:10.3389/fncel.2018.00384
Shields, R. C. (2010). Medical management of carotid stenosis. Perspectives in Vascular Surgery and Endovascular Therapy, 22(1), 18-27. doi:10.1177/1531003510380929
Shishehbor, M. H., Oliveira, L. P., Lauer, M. S., Sprecher, D. L., Wolski, K., Cho, L., . . . Hazen, S. L. (2008). Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol, 101(12), 1741-1746. doi:10.1016/j.amjcard.2008.02.060
Shishehbor, M. H., Oliveira, L. P. J., Lauer, M. S., Sprecher, D. L., Wolski, K., Cho, L., . . . Hazen, S. L. (2008). Emerging Cardiovascular Risk Factors That Account for a Significant Portion of Attributable Mortality Risk in Chronic Kidney Disease. American Journal of Cardiology, 101(12), 1741-1746. doi:10.1016/j.amjcard.2008.02.060
Shlipak, M. G., & Day, E. C. (2013). Biomarkers for incident CKD: A new framework for interpreting the literature. Nature Reviews Nephrology, 9(8), 478-483. doi:10.1038/nrneph.2013.108
Shojaei, M. H., Djalali, M., Siassi, F., Khatami, M. R., Boroumand, M. A., & Eshragian, M. R. (2009). Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid. Iran J Kidney Dis, 3(3), 141-144. 
Shoji, T., Abe, T., Matsuo, H., Egusa, G., Yamasaki, Y., Kashihara, N., . . . Kashiwagi, A. (2012). Chronic kidney disease, Dyslipidemia, and atherosclerosis. Journal of Atherosclerosis and Thrombosis, 19(4), 229-315. doi:10.5551/jat.10454
Shroff, R. (2021). Reducing the burden of cardiovascular disease in children with chronic kidney disease: prevention vs. damage limitation. Pediatric Nephrology, 36(8), 2537-2544. doi:10.1007/s00467-021-05102-y
Siasos, G., Tousoulis, D., Michalea, S., Oikonomou, E., Kolia, C., Kioufis, S., . . . StefanadisC. (2012). Biomarkers determining cardiovascular risk in patients with kidney disease. Current Medicinal Chemistry, 19(16), 2555-2571. doi:10.2174/092986712800492986
Siems, W., Quast, S., Carluccio, F., Wiswedel, I., Hirsch, D., Augustin, W., . . . Sommerburg, O. (2002). Oxidative stress in chronic renal failure as cardiovascular risk factor. Nieren- und Hochdruckkrankheiten, 31(SUPPL. 1), S13-S21. 
Siems, W., Quast, S., Carluccio, F., Wiswedel, I., Hirsch, D., Augustin, W., . . . Sommerburg, O. (2003). Oxidative stress in cardio renal anemia syndrome: Correlations and therapeutic possibilities. Clinical Nephrology, 60(SUPPL.1), S22-S30. 
Sigit, J. I., Hages, M., Brensing, K. A., Frotscher, U., Pietrzik, K., von Bergmann, K., & Lütjohann, D. (2001). Total plasma homocysteine and related amino acids in end-stage renal disease (ESRD) patients measured by gas chromatography-mass spectrometry--comparison with the Abbott IMx homocysteine assay and the HPLC method. Clin Chem Lab Med, 39(8), 681-690. doi:10.1515/cclm.2001.112
Signorelli, S. S., Fatuzzo, P., Rapisarda, F., Neri, S., Ferrante, M., Conti, G. O., . . . Anzaldi, M. (2006). Propionyl-L-carnitine therapy: Effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney and Blood Pressure Research, 29(2), 100-107. doi:10.1159/000094363
Signorelli, S. S., Fatuzzo, P., Rapisarda, F., Neri, S., Ferrante, M., Oliveri Conti, G., . . . Anzaldi, M. (2006). Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney Blood Press Res, 29(2), 100-107. doi:10.1159/000094363
Signorelli, S. S., Fatuzzo, P., Rapisarda, F., Neri, S., Ferrante, M., Oliveri Conti, G., . . . et al. (2006). Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney & blood pressure research, 29(2), 100‐107. doi:10.1159/000094363
Silva de Almeida, C. C., Guerra, D. C., Vannucchi, M. T., Geleilete, T. J., Vannucchi, H., & Chiarello, P. G. (2011). What is the meaning of homocysteine in patients on dialysis? J Ren Nutr, 21(5), 394-400. doi:10.1053/j.jrn.2010.12.005
Silva de Almeida, C. C., Guerra, D. C., Vannucchi, M. T. I., Geleilete, T. J. M., Vannucchi, H., & Chiarello, P. G. (2011). What Is the Meaning of Homocysteine in Patients on Dialysis? Journal of Renal Nutrition, 21(5), 394-400. doi:10.1053/j.jrn.2010.12.005
Silva, E. H., Wickramatilake, C. M., Lekamwasam, S., Mudduwa, L. K. B., & Ubayasiri, R. A. (2019). Vascular dysfunction and atherosclerosis in chronic kidney disease; a distinct entity. Journal of Nephropathology, 8(2). doi:10.15171/jnp.2019.17
Silverberg, D. S., & Schwartz, D. (2012). The role of Iron, omega-3 fatty acids, and vitamins in heart failure. Current Treatment Options in Cardiovascular Medicine, 14(4), 328-341. doi:10.1007/s11936-012-0188-3
Simeone, P., Boccatonda, A., Liani, R., & Santilli, F. (2018). Significance of urinary 11-dehydro-thromboxane B2 in age-related diseases: Focus on atherothrombosis. Ageing Research Reviews, 48, 51-78. doi:10.1016/j.arr.2018.09.004
Simic-Ogrizovic, S., Stosovic, M., Novakovic, I., Pejanovic, S., Jemcov, T., Radovic, M., & Djukanovic, L. (2006). Fuzzy role of hyperhomocysteinemia in hemodialysis patients' mortality. Biomed Pharmacother, 60(4), 200-207. doi:10.1016/j.biopha.2006.03.008
Sindhav, J. B., Comp, P. C., & Chandrasekaran, K. (1999). Hyperhomocysteinemia, aortic thrombus, and peripheral arterial emboli - A case report. Angiology, 50(7), 599-603. doi:10.1177/000331979905000710
Singh, R. G., Rathore, S. S., Kumar, R., Agarwal, A., & Dubey, G. P. (2010). Nephroprotective role of salacia chinensis in diabetic CKD patients: a pilot study. Indian J Med Sci, 64(8), 378-384. 
Singh, R. G., Rathore, S. S., Kumar, R., Usha, Agarwal, A., & Dubey, G. P. (2010). Nephroprotective role of salacia chinensis in diabetic CKD patients: A pilot study. Indian Journal of Medical Sciences, 64(8), 378-384. doi:10.4103/0019-5359.100341
Singh, S. (2014). Cardiovascular disease in chronic kidney disease. Clinical Queries: Nephrology, 3(1), 20-29. doi:10.1016/j.cqn.2014.03.006
Sipovskiĭ, V. G., Nepovorotin, A. I., Smirtnov, A. V., Dobronravov, V. A., Khokhlov, S. E., Petrishchev, N. N., . . . Borisova, E. A. (2006). [Renal tubular epithelocytic changes in hypercysteinemia and experimental chronic renal failure]. Arkh Patol, 68(6), 29-31. 
Sipovsky, V. G., Nevorotin, A. I., Smirnov, A. V., Dobronravov, V. A., Khokhlov, S. E., Petrishchev, N. N., . . . Borisova, E. A. (2006). Renal tubular epithelocytic changes in hypercysteinemia and experimental chronic renal failure. Arkhiv Patologii, 68(6), 29-31. 
Sircana, A., De Michieli, F., Parente, R., Framarin, L., Leone, N., Berrutti, M., . . . Musso, G. (2019). Gut microbiota, hypertension and chronic kidney disease: Recent advances. Pharmacological Research, 144, 390-408. doi:10.1016/j.phrs.2018.01.013
Sirvent, A. E., González, C., Enríquez, R., Fernández, J., Millán, I., Barber, X., & Amorós, F. (2010). Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease. Journal of Nephrology, 23(3), 282-290. 
Sjöberg, B., Anderstam, B., Suliman, M., & Alvestrand, A. (2006). Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD. American Journal of Kidney Diseases, 47(1), 60-71. doi:10.1053/j.ajkd.2005.09.032
Skamra, C., & Ramsey-Goldman, R. (2010). Management of cardiovascular complications in systemic lupus erythematosus. International Journal of Clinical Rheumatology, 5(1), 75-100. doi:10.2217/ijr.09.73
Skoupy, S., Födinger, M., Veitl, M., Perschl, A., Puttinger, H., Röhrer, C., . . . Sunder-Plassmann, G. (2002). Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients. J Am Soc Nephrol, 13(5), 1331-1337. doi:10.1097/01.asn.0000013299.11876.f6
Škovierová, H., Vidomanová, E., Mahmood, S., Sopková, J., Drgová, A., Červeňová, T., . . . Lehotský, J. (2016). The molecular and cellular effect of homocysteine metabolism imbalance on human health. International Journal of Molecular Sciences, 17(10). doi:10.3390/ijms17101733
Sladen, R. N. (2011). Chronic kidney disease: The silent enemy? Anesthesia and Analgesia, 112(6), 1277-1279. doi:10.1213/ANE.0b013e318217f828
Slow, S., McGregor, D. O., Lever, M., Lee, M. B., George, P. M., & Chambers, S. T. (2004). Dimethylglycine supplementation does not affect plasma homocysteine concentrations in pre-dialysis chronic renal failure patients. Clinical Biochemistry, 37(11), 974-976. doi:10.1016/j.clinbiochem.2004.07.005
Slow, S., Vasudevamurthy, M., Fraser, R., McEntyre, C., Lever, M., Chambers, S., & George, P. (2007). Dimethylthetin treatment causes diffuse alveolar lung damage: a pilot study in a sheep model of Continuous Ambulatory Peritoneal Dialysis (CAPD). Exp Toxicol Pathol, 58(5), 285-290. doi:10.1016/j.etp.2006.10.004
Smirnov, A. V., Petrischev, N. N., Mnuskina, M. M., Panina, I. Y., Pumyantsev, A. S., Vasina, E. Y., . . . Menshutina, M. A. (2012). Endothelial dysfunction and apoptosis at early stage of chronic kidney disease. Terapevticheskii Arkhiv, 84(6), 9-15. 
Smirnov, A. V., Petrischev, N. N., Panina, I. Y., Rumyantsev, A. S., Degtyareva, O. A., Tugusheva, F. A., & Menshutina, M. A. (2007). Glomerular filtration rate is an indicator of endothelial function at early stages of chronic kidney disease. Terapevticheskii Arkhiv, 79(6), 25-30. 
Smirnov, A. V., Petrishchev, N. N., Mnuskina, M. M., Panina, I., Rumiantsev, A., Vasina, E., . . . Menshutina, M. A. (2012). [Endothelial dysfunction and apoptosis at early stage of chronic kidney disease]. Ter Arkh, 84(6), 9-15. 
Smirnov, A. V., Petrishchev, N. N., Panina, I., Rumiantsev, A., Degtereva, O. A., Tugusheva, F. A., & Menshutina, M. A. (2007). [Glomerular filtration rate is an indicator of endothelial function at early stages of chronic kidney disease]. Ter Arkh, 79(6), 25-30. 
Smith, A. D., & Refsum, H. (2021). Homocysteine - from disease biomarker to disease prevention. J Intern Med, 290(4), 826-854. doi:10.1111/joim.13279
Smith, C. L., & Vallance, P. (2005). Cardiovascular tests: Use & limits of biochemical markers - Therapeutic measurements of ADMA involved in cardiovascular disorders. Current Pharmaceutical Design, 11(17), 2177-2185. doi:10.2174/1381612054367364
Snavely, J. (2002). Hyperhomocysteinemia in end stage renal disease: is treatment necessary? Nephrology nursing journal : journal of the American Nephrology Nurses' Association, 29(2), 155-160; quiz 161-162. 
Sobrin, L., & Seddon, J. M. (2014). Nature and nurture- genes and environment- predict onset and progression of macular degeneration. Progress in Retinal and Eye Research, 40, 1-15. doi:10.1016/j.preteyeres.2013.12.004
Socha, M. W., Polakowska, M. J., Socha-Urbanek, K., & Fiedor, P. (1999). Hyperhomocysteinemia as a risk factor for cardiovascular diseases. The association of hyperhomocysteinemia with diabetes mellitus and renal transplant recipients. Annals of transplantation : quarterly of the Polish Transplantation Society, 4(1), 11-19. 
Söderström, E., Blind, R., Wennberg, P., Andersson, J., Söderberg, S., Nilsson, T. K., & Hultdin, J. (2021). Mild impairment of renal function (shrunken pore syndrome) is associated with increased risk of a future first-ever myocardial infarction in women. Scandinavian Journal of Clinical and Laboratory Investigation, 81(6), 438-445. doi:10.1080/00365513.2021.1941235
Solecki, M. (2015). Is venous thromboembolism prophylaxis necessary during laparoscopic procedures? A commentary to SAGES guidelines - Guidelines for deep venous thrombosis prophylaxis during laparoscopic surgery. Current Gynecologic Oncology, 13(4), 269-276. doi:10.15557/CGO.2015.0030
Soleimani, A. (2010). Comparison the efficacy of oral folic acid and folinic acid on the blood homocysteine level of hemodialysis patients. Nephrology, 15, 109. doi:10.1111/j.1440-1797.2010.01337.x
Soleimani, A., Usefzadeh, M., Mianehsaz, E., Foroozanfard, F., Nikoueinejad, H., Moraveji, S. A., . . . Rajali, M. (2011). Comparison of oral folic acid and folinic acid on blood homocysteine level of patients on hemodialysis. Iranian Journal of Kidney Diseases, 5(1), 45-49. 
Sombolos, K., Fragia, T., Natse, T., Bartholomatos, G., Karagianni, A., Katsaris, G., . . . Papagalanis, N. (2002). The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on serum homocysteine in hemodialysis patients. J Nephrol, 15(6), 671-675. 
Song, J. S., Choi, S. T., & Park, E. H. (2015). Two-year follow-up study of the relationship between serum homocysteine, uric acid and renal function in gouty patients. Annals of the Rheumatic Diseases, 74, 775-776. doi:10.1136/annrheumdis-2015-eular.3222
Song, J. S., Kim, J. S., & Choi, S. T. (2013). Elevated serum homocysteine levels in gouty patients were related not with serum uric acid levels but with decreased renal function. International Journal of Rheumatic Diseases, 16, 72. 
Song, J. S., Kim, J. S., & Choi, S. T. (2013). Serum homocysteine related to decreased renal function in chronic gouty patients. Arthritis and Rheumatism, 65, S851. doi:10.1002/art.38216
Soran, H., Schofield, J. D., & Durrington, P. N. (2015). Antioxidant properties of HDL. Frontiers in Pharmacology, 6(OCT), 222. doi:10.3389/fphar.2015.00222
Soria, C., Chadefaux, B., Coude, M., Gaillard, O., & Kamoun, P. (1990). Concentrations of total homocysteine in plasma in chronic renal failure. Clinical Chemistry, 36(12), 2137-2138. doi:10.1093/clinchem/36.12.2137
Soria, C., Chadefaux, B., Coudé, M., Gaillard, O., & Kamoun, P. (1990). Concentrations of total homocysteine in plasma in chronic renal failure. Clin Chem, 36(12), 2137-2138. 
Soveri, I., Lind, L., Wikström, B., Zilmer, M., Zilmer, K., & Fellström, B. (2007). Improvement in central arterial pressure waveform during hemodialysis is related to a reduction in asymmetric dimethylarginine (ADMA) levels. Nephron - Clinical Practice, 106(4), c180-c186. doi:10.1159/000104429
Spence, J. D. (2020). Impaired Renal Function and Cerebrovascular Disease. Angiology, 71(6), 489-490. doi:10.1177/0003319720916295
Spence, J. D., Cordy, P., Kortas, C., & Freeman, D. (1999). Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: No difference between 1 and 5 mg daily. American Journal of Nephrology, 19(3), 405-410. doi:10.1159/000013486
Spence, J. D., Urquhart, B. L., & Bang, H. (2016). Effect of renal impairment on atherosclerosis: Only partially mediated by homocysteine. Nephrology Dialysis Transplantation, 31(6), 937-944. doi:10.1093/ndt/gfv380
Spence, J. D., Yi, Q., & Hankey, G. J. (2017). B vitamins in stroke prevention: time to reconsider. The Lancet Neurology, 16(9), 750-760. doi:10.1016/S1474-4422(17)30180-1
Spinneker, A., Sola, R., Lemmen, V., Castillo, M. J., Pietrzik, K., & González-Gross, M. (2007). Vitamin B6 status, deficiency and its consequences - An overview. Nutricion Hospitalaria, 22(1), 7-24. 
Splendiani, G., De Angelis, S., Tullio, T., Ferranini, M., Dessì, M. R., Pastore, A., . . . Cortese, C. (2004). Selective adsorption of homocysteine using an HFR-ON LINE technique. Artif Organs, 28(6), 592-595. doi:10.1111/j.1525-1594.2004.00053.x
Stabler, S. P. (2020). Alterations in sulfur amino acids as biomarkers of disease. Journal of Nutrition, 150, 2532S-2537S. doi:10.1093/jn/nxaa118
Stabler, S. P., Lindenbaum, J., & Allen, R. H. (1996). The use of homocysteine and other metabolites in the specific diagnosis of vitamin B-12 deficiency. Journal of Nutrition, 126(4 SUPPL.), 1266S-1272S. doi:10.1093/jn/126.suppl_4.1266s
Stam, F., van Guldener, C., Schalkwijk, C. G., ter Wee, P. M., Donker, A. J., & Stehouwer, C. D. (2003). Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant, 18(5), 892-898. doi:10.1093/ndt/gfg080
Stam, F., van Guldener, C., Schalkwijk, C. G., ter Wee, P. M., Donker, A. J. M., & Stehouwer, C. D. A. (2003). Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrology Dialysis Transplantation, 18(5), 892-898. doi:10.1093/ndt/gfg080
Stam, F., van Guldener, C., Ter Wee, P. M., Jakobs, C., de Meer, K., & Stehouwer, C. D. (2005). Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease. Kidney Int, 67(1), 259-264. doi:10.1111/j.1523-1755.2005.00076.x
Stam, F., van Guldener, C., ter Wee, P. M., Kulik, W., Smith, D. E., Jakobs, C., . . . de Meer, K. (2004). Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine. Am J Physiol Renal Physiol, 287(2), F215-223. doi:10.1152/ajprenal.00376.2003
Stanciu, G. D., Ababei, D. C., Bild, V., Bild, W., Paduraru, L., Gutu, M. M., & Tamba, B. I. (2020). Renal contributions in the pathophysiology and neuropathological substrates shared by chronic kidney disease and alzheimer’s disease. Brain Sciences, 10(8), 1-20. doi:10.3390/brainsci10080563
Stanford, J. L., Molina, H., Phillips, J., Kohlman-Trigoboff, D., Moore, J., & Smith, B. M. (2000). Oral folate reduces plasma homocyst(e)ine levels in hemodialysis patients with cardiovascular disease. Cardiovasc Surg, 8(7), 567-571. doi:10.1016/s0967-2109(00)00062-4
Stehouwer, C. D. A. (2000). Clinical relevance of hyperhomocysteinaemia in atherothrombotic disease. Drugs and Aging, 16(4), 251-260. doi:10.2165/00002512-200016040-00001
Steiber, A. L., & Kopple, J. D. (2011). Vitamin Status and Needs for People with Stages 3-5 Chronic Kidney Disease. Journal of Renal Nutrition, 21(5), 355-368. doi:10.1053/j.jrn.2010.12.004
Stenvinkel, P., & Ekström, T. J. (2008). Epigenetics - A helpful tool to better understand processes in clinical nephrology? Nephrology Dialysis Transplantation, 23(5), 1493-1496. doi:10.1093/ndt/gfn056
Stenvinkel, P., Karimi, M., Johansson, S., Axelsson, J., Suliman, M., Lindholm, B., . . . Schalling, M. (2007). Impact of inflammation on epigenetic DNA methylation - A novel risk factor for cardiovascular disease? Journal of Internal Medicine, 261(5), 488-499. doi:10.1111/j.1365-2796.2007.01777.x
Stępniewska, J., Gołembiewska, E., Dołęgowska, B., Domański, M., & Ciechanowski, K. (2015). Oxidative stress and antioxidative enzyme activities in chronic kidney disease and different types of renal replacement therapy. Current Protein and Peptide Science, 16(3), 243-248. doi:10.2174/1389203716666150224150508
Stilo, F., Massara, M., Macrì, I., Atteritano, M., La Spada, M., De Caridi, G., . . . Spinelli, F. (2014). The role of hyperhomocysteinemia and elevated serum levels of C reactive protein on carotid restenois. Italian Journal of Vascular and Endovascular Surgery, 21(1), 25-29. 
Stinghen, A. E. M., & Pecoits-Filho, R. (2011). Vascular damage in kidney disease: Beyond hypertension. International Journal of Hypertension, 2011. doi:10.4061/2011/232683
Stopper, H., Treutlein, A. T., Bahner, U., Schupp, N., Schmid, U., Brink, A., . . . Heidland, A. (2008). Reduction of the genomic damage level in haemodialysis patients by folic acid and vitamin B12 supplementation. Nephrol Dial Transplant, 23(10), 3272-3279. doi:10.1093/ndt/gfn254
Stover, P. J., Berry, R. J., & Field, M. S. (2016). Time to think about nutrient needs in chronic disease. JAMA Internal Medicine, 176(10), 1451-1452. doi:10.1001/jamainternmed.2016.4699
Stoyioglou, A., & Jaff, M. R. (2004). Medical treatment of peripheral arterial disease: A comprehensive review. Journal of Vascular and Interventional Radiology, 15(11), 1197-1207. doi:10.1097/01.RVI.0000137978.15352.C6
Strada, E., & Savazzi, G. (2011). From kidney disease to ischemic heart disease. Recenti Progressi in Medicina, 102(4), 166-171. doi:10.1701/624.7289
Strasser, E. F., Burghardt, F., Weiss, D., Strobel, J., Zimmermann, R., & Eckstein, R. (2012). Frequency of phospholipid inhibitors in CRF patients with VTE or bleeding history. Hamostaseologie, 32(1), A32. 
Stringer, S., Sharma, P., Dutton, M., Jesky, M., Ng, K., Kaur, O., . . . Cockwell, P. (2013). The natural history of, and risk factors for, progressive Chronic Kidney Disease (CKD): The Renal Impairment in Secondary care (RIISC) study; Rationale and protocol. BMC Nephrology, 14(1). doi:10.1186/1471-2369-14-95
Subhapriya, S., Tomi, L., & Padmanaban, V. C. (2013). Atherosclerosis: Critical role of oxidation and inflammation. International Journal of Pharmacy and Pharmaceutical Sciences, 5(SUPPL.4), 6-8. 
Suliman, M., Stenvinkel, P., Qureshi, A. R., Kalantar-Zadeh, K., Bárány, P., Heimbürger, O., . . . Lindholm, B. (2007). The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant, 22(1), 209-217. doi:10.1093/ndt/gfl510
Suliman, M. E., Lindholm, B., Bárány, P., & Bergström, J. (2001). Hyperhomocysteinemia in chronic renal failure patients: Relation to nutritional status and cardiovascular disease. Clinical Chemistry and Laboratory Medicine, 39(8), 734-738. doi:10.1515/CCLM.2001.122
Suliman, M. E., Lindholm, B., Bárány, P., Qureshi, A. R., & Stenvinkel, P. (2007). Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. Seminars in Dialysis, 20(6), 523-529. doi:10.1111/j.1525-139X.2007.00336.x
Suliman, M. E., Qureshi, A. R., Bárány, P., Stenvinkel, P., Filho, J. C., Anderstam, B., . . . Bergström, J. (2000). Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int, 57(4), 1727-1735. doi:10.1046/j.1523-1755.2000.00018.x
Suliman, M. E., Stenvinkel, P., Bárány, P., Heimbürger, O., Anderstam, B., & Lindholm, B. (2003). Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. Am J Kidney Dis, 41(3 Suppl 1), S89-95. doi:10.1053/ajkd.2003.50093
Suliman, M. E., Stenvinkel, P., Bárány, P., Rashid Qureshi, A., & Lindholm, B. (2006). Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients. Seminars in Nephrology, 26(1), 14-19. doi:10.1016/j.semnephrol.2005.06.004
Suliman, M. E., Stenvinkel, P., Heimbürger, O., Bàràny, P., Lindholm, B., & Bergström, J. (2002). Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. American Journal of Kidney Diseases, 40(3), 480-488. doi:10.1053/ajkd.2002.34887
Suliman, M. E., Stenvinkel, P., Jogestrand, T., Maruyama, Y., Qureshi, A. R., Bárány, P., . . . Lindholm, B. (2006). Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clinical Nephrology, 66(6), 418-425. doi:10.5414/cnp66418
Suliman, M. E., Stenvinkel, P., & Lindholm, B. (2005). Is hyperhomocysteinemia a contributor to atherosclerosis in chronic kidney disease patients? Nephron. Clinical practice, 101(4), c187-189. 
Suliman, M. E., Stenvinkel, P., Qureshi, A. R., Bárány, P., Heimburger, O., Anderstam, B., . . . Lindholm, B. (2004). Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. Am J Kidney Dis, 44(3), 455-465. 
Suliman, M. E., Stenvinkel, P., Qureshi, A. R., Bárány, P., Heimbürger, O., Anderstam, B., . . . Lindholm, B. (2004). Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. American Journal of Kidney Diseases, 44(3), 455-465. doi:10.1053/j.ajkd.2004.04.049
Suliman, M. E., Stenvinkel, P., Qureshi, A. R., Kalantar-Zadeh, K., & Lindholm, B. (2007). Reply [2]. Nephrology Dialysis Transplantation, 22(7), 2093. doi:10.1093/ndt/gfm235
Šulović, L. S. (2017). Risk factors for cardiovascular disease in children on chronic hemodialysis – Uremia-related (Non-traditional) risk factors, part II. Vojnosanitetski Pregled, 74(1), 54-58. doi:10.2298/VSP150418144S
Sun, Y. H., Yang, X. L., Li, F., Song, L. J., & Li, J. (2015). Effect of anti-helicobacter pylori treatment on early diabetic kidney disease. World Chinese Journal of Digestology, 23(7), 1202-1207. doi:10.11569/wcjd.v23.i7.1202
Sunder-Plassmann, G., Födinger, M., Buchmayer, H., Papagiannopoulos, M., Wojcik, J., Kletzmayr, J., . . . Hörl, W. H. (2000). Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol, 11(6), 1106-1116. doi:10.1681/asn.V1161106
Sunder-Plassmann, G., Födinger, M., Buchmayer, H., Papagiannopoulos, M., Wojcik, J., Kletzmayr, J., . . . et al. (2000). Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. Journal of the American Society of Nephrology : JASN, 11(6), 1106‐1116. doi:10.1681/ASN.V1161106
Sunder-Plassmann, G., Födinger, M., & Säemann, M. D. (2012). Cardiovascular disease mortality in kidney transplant recipients: No light at the end of the tunnel? American Journal of Kidney Diseases, 59(6), 754-757. doi:10.1053/j.ajkd.2011.11.022
Sunder-Plassmann, G., & Hörl, W. H. (2001). Proceedings of the Fourth International Congress on Uremic Toxicity-Vienna, Austria-November 20-23, 1999: Introduction. Kidney International, Supplement, 59(78), S1. 
Sunder-Plassmann, G., Winkelmayer, W. C., & Fodinger, M. (2000). Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease. Expert Opinion on Investigational Drugs, 9(11), 2637-2652. doi:10.1517/13543784.9.11.2637
Sunder-Plassmann, G., Winkelmayer, W. C., & Födinger, M. (2000). Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease. Expert Opin Investig Drugs, 9(11), 2637-2651. doi:10.1517/13543784.9.11.2637
Sunder-Plassmann, G., Winkelmayer, W. C., & Födinger, M. (2006). Genetic aspects of hyperhomocysteinemia in chronic kidney disease. Seminars in Nephrology, 26(1), 8-13. doi:10.1016/j.semnephrol.2005.06.003
Sunder-Plassmann, G., Winkelmayer, W. C., & Födinger, M. (2008). Approaching the End of the Homocysteine Hype? American Journal of Kidney Diseases, 51(4), 549-553. doi:10.1053/j.ajkd.2008.01.007
Sung, C. C., Hsu, Y. C., Chen, C. C., Lin, Y. F., & Wu, C. C. (2013). Oxidative stress and nucleic acid oxidation in patients with chronic kidney disease. Oxidative Medicine and Cellular Longevity. doi:10.1155/2013/301982
Susantitaphong, P., & Jaber, B. L. (2014). Understanding discordant meta-analyses of convective dialytic therapies for chronic kidney failure. American Journal of Kidney Diseases, 63(6), 888-891. doi:10.1053/j.ajkd.2014.03.005
Susantitaphong, P., Siribamrungwong, M., & Jaber, B. L. (2013). Convective therapies versus low-flux hemodialysis for chronic kidney failure: A meta-analysis of randomized controlled trials. Nephrology Dialysis Transplantation, 28(11), 2859-2874. doi:10.1093/ndt/gft396
Suwelack, B., Gerhardt, U., Witta, J., Rahn, K. H., & Hohage, H. (2000). Effect of homocysteine on carotid intima-media thickness after renal transplantation. Clinical Transplantation, 14(6), 555-560. doi:10.1034/j.1399-0012.2000.140607.x
Suzuki, Y., Aoki, Y., Matsuyama, Y., Hasegawa, H., Shinohara, Y., Hashimoto, T., . . . Soejima, A. (2008). Clinical evaluation of serum albumin reductivity in patients with renal dysfunction: A comparison between conservative renal failure patients and hemodialysis patients. Japanese Journal of Nephrology, 50(4), 513-520. 
Suzuki, Y., Suda, K., Matsuyama, Y., Era, S., & Soejima, A. (2014). Close relationship between redox state of human serum albumin and serum cysteine levels in non-diabetic CKD patients with various degrees of renal function. Clinical Nephrology, 82(5), 320-325. doi:10.5414/CN108040
Svetkey, L. P. (2005). Management of prehypertension. Hypertension, 45(6), 1056-1061. doi:10.1161/01.HYP.0000167152.98618.4b
Sydor, A., Drozdz, M., Kraśniak, A., Miłkowski, A., Chmiel, G., Małczak, J., . . . Sułowicz, W. (2002). Hyperhomocysteinemia and advancement of atherosclerosis in patients with chronic renal failure on maintenance hemodialysis. Przegla̧d lekarski, 59(12), 962-967. 
Sydor, A., & Sułowicz, W. (1999). Hyperhomocysteinemia in chronic renal failure. Przegla̧d lekarski, 56(7-8), 520-524. 
Szabó, A. J., Tulassay, T., Melegh, B., Szabó, T., Szabó, A., Vannay, A., . . . Reusz, G. S. (2001). Hyperhomocysteinaemia and MTHFR C677T gene polymorphism in renal transplant recipients. Archives of disease in childhood, 85(1), 47-49. 
Taes, Y. E., Delanghe, J. R., De Bacquer, D., Langlois, M., Stevens, L., Geerolf, I., . . . De Vriese, A. S. (2004). Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients. Kidney international, 66(6), 2422-2428. doi:10.1111/j.1523-1755.2004.66019.x
Taes, Y. E. C., Bernard, D. R., & Delanghe, J. R. (2003). Homocysteine and methionine transamination [2]. American Journal of Kidney Diseases, 41(4), 898-899. doi:10.1016/S0272-6386(03)00257-9
Tahar, A., Zerdoumi, F., Saidani, M., Griene, L., & Koceir, E. A. (2018). Effects of oral vitamin D3 supplementation in stage 3 chronic kidney disease subjects: Insulin resistance syndrome and hormonal disturb interactions. Annales de Biologie Clinique, 76(3), 313-325. doi:10.1684/abc.2018.1342
Tain, Y. L. (2007). Endothelial dysfunction links cardiovascular disease to pediatric chronic kidney disease: The role of nitric oxide deficiency. Acta Paediatrica Taiwanica, 48(5), 246-250. 
Tain, Y. L., & Hsu, C. N. (2015). Aminothiols in homocysteine metabolic cycle are associated with cardiovascular outcomes in children with chronic kidney disease. Nephrology Dialysis Transplantation, 30, iii667. doi:10.1093/ndt/gfv203.17
Tak, Y. J., Jeong, D. W., Kim, Y. J., Lee, S. Y., Lee, J. G., Song, S. H., . . . Kang, Y. H. (2016). Hyperhomocysteinaemia as a potential marker of early renal function decline in middle-aged Asian people without chronic kidney disease. International Urology and Nephrology, 48(2), 239-248. doi:10.1007/s11255-015-1180-0
Takamitsu, Y., & Nakanishi, T. (2001). Association of endothelial dysfunction with sulfur amino acid metabolism in chronic renal failure. American Journal of Kidney Diseases, 38(4 SUPPL. 1), S95-S99. doi:10.1053/ajkd.2001.27413
Tamadon, M. R., Jamshidi, L., Soliemani, A., Ghorbani, R., Malek, F., & Malek, M. (2011). Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis. Iranian journal of kidney diseases, 5(2), 93‐96. 
Tamura, M. K., Xie, D., Yaffe, K., Cohen, D. L., Teal, V., Kasner, S. E., . . . Go, A. S. (2011). Vascular risk factors and cognitive impairment in chronic kidney disease: The Chronic Renal Insufficiency Cohort (CRIC) study. Clinical Journal of the American Society of Nephrology, 6(2), 248-256. doi:10.2215/CJN.02660310
Tamura, T., Bergman, S. M., & Morgan, S. L. (1998). Hyperhomocysteinemia as a cause of vascular occlusion in end-stage-renal disease. Int J Artif Organs, 21(2), 72-74. 
Tamura, T., Johnston, K. E., & Bergman, S. M. (1996). Homocysteine and folate concentrations in blood from patients treated with hemodialysis. J Am Soc Nephrol, 7(11), 2414-2418. doi:10.1681/asn.V7112414
Tamura, Y., & Araki, A. (2015). Diabetes mellitus and white matter hyperintensity. Geriatrics and Gerontology International, 15, 34-42. doi:10.1111/ggi.12666
Tanaka, M., Nakamura, Y., Itoh, S., & Kato, Y. (2017). Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study. Osteoporosis and Sarcopenia, 3(1), 37-44. doi:10.1016/j.afos.2016.12.002
Tangalos, E. G., Hoggard, J. G., Murray, A. M., & Thomas, D. R. (2004). Treatment of kidney disease and anemia in elderly, long-term care residents. Journal of the American Medical Directors Association, 5(4 SUPPL.), H1-H6. doi:10.1016/S1525-8610(04)70140-1
Tariq, A., Mansoor, M. A., Marti, H. P., Jonsson, G., Slettan, A., Weeraman, P., & Apeland, T. (2018). Systemic redox biomarkers and their relationship to prognostic risk markers in autosomal dominant polycystic kidney disease and IgA nephropathy. Clinical Biochemistry, 56, 33-40. doi:10.1016/j.clinbiochem.2018.04.010
Taruangsri, P., Ong-Ajyooth, L., Ong-Ajyooth, S., Chaiyasoot, W., Leowattana, W., Sritippayawan, S., . . . Vanichakarn, S. (2005). Relationship between hyperhomocysteinemia and atherosclerosis in chronic hemodialysis patients. J Med Assoc Thai, 88(10), 1373-1381. 
Taskapan, H., Senel, S., Ulutas, O., Taskapan, M. C., Aksoy, Y., Kosar, F., . . . Sahin, I. (2006). Platelet activity and serum homocysteine levels in patients with end-stage renal failure with regard to dialysis modality. Ren Fail, 28(4), 303-308. doi:10.1080/08860220600599019
Tayebi, A., Biniaz, V., Savari, S., Ebadi, A., Shermeh, M. S., Einollahi, B., & Rahimi, A. (2016). Effect of Vitamin B12 supplementation on serum homocysteine in patients undergoing hemodialysis: A randomized controlled trial. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 27(2), 256-262. doi:10.4103/1319-2442.178255
Tayebi-Khosroshahi, H., Dehgan, R., Habibi Asl, B., Safaian, A., Panahi, F., Estakhri, R., & Purasgar, B. (2013). Effect of omega-3 supplementation on serum level of homocysteine in hemodialysis patients. Iranian journal of kidney diseases, 7(6), 479‐484. 
Tbahriti, H. F., Meknassi, D., Chellouai, Z., Moussaoui, R., Messaoudi, A., Kaddous, A., . . . Mekki, K. (2013). Effect of hemodialysis and peritoneal dialysis on malnutrition, inflammation and atherosclerosis (MIA) syndrome in chronic renal failure patients. Annals of Nutrition and Metabolism, 63, 294. doi:10.1159/000354245
Tbahriti, H. F., Messaoudi, A., Kaddous, A., Bouchenak, M., & Mekki, K. (2014). The degree of chronic renal failure is associated with the rate of pro-inflammatory cytokines, hyperhomocysteinemia and with oxidative stress. Annales de Cardiologie et d'Angeiologie, 63(3), 135-139. doi:10.1016/j.ancard.2014.04.016
Teerlink, T., Luo, Z., Palm, F., & Wilcox, C. S. (2009). Cellular ADMA: Regulation and action. Pharmacological Research, 60(6), 448-460. doi:10.1016/j.phrs.2009.08.002
Tepel, M., & Zidek, W. (2004). N-Acetylcysteine in nephrology; contrast nephropathy and beyond. Curr Opin Nephrol Hypertens, 13(6), 649-654. doi:10.1097/00041552-200411000-00011
Teplan, V., Schück, O., Stollová, M., & Vítko, S. (2003). Obesity and hyperhomocysteinaemia after kidney transplantation. Nephrol Dial Transplant, 18 Suppl 5, v71-73. doi:10.1093/ndt/gfg1053
Ter Wee, P. M., & Jorna, A. T. M. (2004). Treatment of patients with chronic renal insufficiency; a guideline for internists. Nederlands Tijdschrift voor Geneeskunde, 148(15), 719-724. 
Teramoto, T., Sasaki, J., Ishibashi, S., Birou, S., Daida, H., Dohi, S., . . . Yokote, K. (2013). Cardiovascular disease risk factors other than dyslipidemia executive summary of the Japan atherosclerosis society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version. Journal of Atherosclerosis and Thrombosis, 20(10), 733-742. doi:10.5551/jat.17368
Thaha, M., Yogiantoro, M., & Tomino, Y. (2006). Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease. Clinical drug investigation, 26(4), 195‐202. doi:10.2165/00044011-200626040-00003
Thambyrajah, J., Landray, M. J., McGlynn, F. J., Jones, H. J., Wheeler, D. C., & Townend, J. N. (2000). Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation, 102(8), 871-875. doi:10.1161/01.CIR.102.8.871
Thilo, F., Liu, Y., Krueger, K., Förste, N., Wittstock, A., Scholze, A., & Tepel, M. (2012). Do cysteine residues regulate transient receptor potential canonical type 6 channel protein expression? Antioxidants and Redox Signaling, 16(5), 452-457. doi:10.1089/ars.2011.4343
Tomas, P., Gonzalez, M. A., Torregrosa, I., Gorriz, J. L., Saez, G., Tormos, M., . . . Puchades, M. J. (2019). Oxidative stress and chronic kidney disease: Travelling companions. Nephrology Dialysis Transplantation, 34, a495. doi:10.1093/ndt/gfz103.SP404
Tomić, M., Vrabec, R., Ljubić, S., Bulum, T., & Rahelić, D. (2022). Plasma homocysteine is associated with nonproliferative retinopathy in patients with type 2 diabetes without renal disease. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 16(1). doi:10.1016/j.dsx.2021.102355
Tomlinson, D. R., Lang, D., & Lewis, M. J. (2006). Homocysteine, B vitamins, and cardiovascular disease [9]. New England Journal of Medicine, 355(2), 209. 
Tonbul, H. Z., Demir, M., Altintepe, L., Güney, I., Yeter, E., Türk, S., . . . Yildiz, A. (2006). Malnutrition-inflammation-atherosclerosis (MIA) syndrome components in hemodialysis and peritoneal dialysis patients. Ren Fail, 28(4), 287-294. doi:10.1080/08860220600583625
Tonelli, M., & Pfeffer, M. A. (2007). Kidney disease and cardiovascular risk. In Annual Review of Medicine (Vol. 58, pp. 123-139).
Torres, N., Torre-Villalvazo, I., & Tovar, A. R. (2006). Regulation of lipid metabolism by soy protein and its implication in diseases mediated by lipid disorders. Journal of Nutritional Biochemistry, 17(6), 365-373. doi:10.1016/j.jnutbio.2005.11.005
Touam, M., Zingraff, J., Jungers, P., Chadefaux-Vekemans, B., Drüeke, T., & Massy, Z. A. (1999). Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int, 56(6), 2292-2296. doi:10.1046/j.1523-1755.1999.00792.x
Tousoulis, D., Georgakis, M. K., Oikonomou, E., Papageorgiou, N., Zaromitidou, M., Latsios, G., . . . Siasos, G. (2015). Asymmetric dimethylarginine: Clinical significance and novel therapeutic approaches. Current Medicinal Chemistry, 22(24), 2871-2901. doi:10.2174/0929867322666150625095046
Trakarnvanich, T., Ingsathit, A., Chaipresert, A., Thirakupt, P., & Sirivongs, D. (2018). Prevalence of hyperhomocysteinemia in thai CKD patients and relationship to cardiovascular events: Subgroup analysis from thai SEEK study. Journal of the Medical Association of Thailand, 101(8), S61-S67. 
Trakarnvanich, T., Prommool, S., Kurathong, S., Teepprasan, T., & Wang, Y. (2017). Associations Among Cardio-Ankle Vascular Index, Carotid Intima-Media Thickness, and Fibroblast Growth Factor-21 Levels in Kidney Transplant Patients. Transplantation Proceedings, 49(8), 1791-1796. doi:10.1016/j.transproceed.2017.06.038
Tremblay, R., Bonnardeaux, A., Geadah, D., Busque, L., Lebrun, M., Ouimet, D., & Leblanc, M. (2000). Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney international, 58(2), 851‐858. doi:10.1046/j.1523-1755.2000.00234.x
Trimarchi, H., Forrester, M., Schropp, J., Pereyra, H., & Freixas, E. A. (2004). Low initial vitamin B12 levels in Helicobacter pylori--positive patients on chronic hemodialysis. Nephron Clin Pract, 96(1), c28-32. doi:10.1159/000075569
Trimarchi, H., Genoud, V., Schiel, A., Castañon, M., Freixas, E., Diaz, M. L., . . . Kordich, L. (2002). The C677T thermolabile variant of methylene tetrahydrofolate reductase on homocysteine, folate and vitamin B12 in a hemodialysis center. Medicina (B Aires), 62(2), 149-153. 
Trimarchi, H., Schiel, A., Freixas, E., & Díaz, M. (2002). Randomized trial of methylcobalamin and folate effects on homocysteine in hemodialysis patients. Nephron, 91(1), 58-63. doi:10.1159/000057605
Trimarchi, H., Young, P., Díaz, M. L., Schropp, J., Forrester, M., & Freixas, E. (2005). [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients]. Medicina (B Aires), 65(6), 513-517. 
Tripathi, G., Sankhwar, S. N., Sharma, R. K., Baburaj, V. P., & Agrawal, S. (2010). Role of thrombotic risk factors in end-stage renal disease. Clin Appl Thromb Hemost, 16(2), 132-140. doi:10.1177/1076029609335911
Tsai, J. C., Kuo, H. T., Chiu, Y. W., Hwang, S. J., Chuang, H. Y., Chang, J. M., . . . Lai, Y. H. (2005). Correlation of plasma homocysteine level with arterial stiffness and pulse pressure in hemodialysis patients. Atherosclerosis, 182(1), 121-127. doi:10.1016/j.atherosclerosis.2005.01.038
Tsai, M. H., Chang, C. H., Liou, H. H., & Fang, Y. W. (2021). Inverted u-curve association between serum indoxyl sulfate levels and cardiovascular events in patients on chronic hemodialysis. Journal of Clinical Medicine, 10(4), 1-10. doi:10.3390/jcm10040744
Tsai, M. Y., Aras, O., Sozen, H., Hanson, N. Q., Woll, P. S., Arends, V. L., . . . Matas, A. J. (2004). Plasma homocysteine levels in living kidney donors before and after uninephrectomy. J Lab Clin Med, 143(6), 340-343. doi:10.1016/j.lab.2004.03.001
Tsimihodimos, V., Mikhailidis, D. P., & Elisaf, M. (2013). Summarizing the FIELD study: Lessons from a 'negative' trial. Expert Opinion on Pharmacotherapy, 14(18), 2601-2610. doi:10.1517/14656566.2013.850075
Tucker, P. S., Dalbo, V. J., Han, T., & Kingsley, M. I. (2013). Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers, 18(2), 103-115. doi:10.3109/1354750X.2012.749302
Tunçay, S. C., Doğan, E., Hakverdi, G., Tutar, Z. Ü., & Mir, S. (2021). Interleukin-8 is increased in chronic kidney disease in children, but not related to cardiovascular disease. Jornal Brasileiro de Nefrologia, 43(3), 359-364. doi:10.1590/2175-8239-JBN-2020-0225
Tungkasereerak, P., Ong-ajyooth, L., Chaiyasoot, W., Ong-ajyooth, S., Leowattana, W., Vasuvattakul, S., . . . Sritippayawan, S. (2006). Effect of short-term folate and vitamin B supplementation on blood homocysteine level and carotid artery wall thickness in chronic hemodialysis patients. Chotmaihet thangphaet [Journal of the Medical Association of Thailand], 89(8), 1187‐1193. 
Tylicki, L., Födinger, M., Puttinger, H., Rutkowski, P., Strozecki, P., Tyszko, S., . . . Hörl, W. H. (2005). Methylenetetrahydrofolate reductase gene polymorphisms in essential hypertension: Relation with the development of hypertensive end-stage renal disease. American Journal of Hypertension, 18(11), 1442-1448. doi:10.1016/j.amjhyper.2005.05.012
Tzavara, V., Pamfil, C., Boumpas, D. T., & Bertsias, G. K. (2013). An update on the management of comorbid conditions in lupus nephritis. Clinical Investigation, 3(3), 281-293. doi:10.4155/cli.13.2
Ueland, P. M., Refsum, H., Beresford, S. A. A., & Vollset, S. E. (2000). The controversy over homocysteine and cardiovascular risk. American Journal of Clinical Nutrition, 72(2), 324-332. doi:10.1093/ajcn/72.2.324
Undas, A., & Jakubowski, H. (2006). Letter by Undas and Jakubowski regarding article, "Relationship between homocysteine and mortality in chronic kidney disease". Circulation, 114(16), e547; author reply e548. doi:10.1161/circulationaha.106.634691
Undas, A., & Jakubowski, H. (2006). Letter by Undas and Jakubowski regarding article, "Relationship between homocysteine and mortality in chronic kidney disease" [1]. Circulation, 114(16), e547. doi:10.1161/CIRCULATIONAHA.106.634691
Ureña Torres, P. A. (2009). Origin of the mediacalcosis in kidney failure. Journal des Maladies Vasculaires, 34(3), 204-210. doi:10.1016/j.jmv.2009.02.002
Urquhart, B. L., Freeman, D. J., Cutler, M. J., Mainra, R., Spence, J. D., & House, A. A. (2008). Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: A placebo-controlled, double-blind, randomized trial. Clinical Journal of the American Society of Nephrology, 3(4), 1041-1047. doi:10.2215/CJN.04771107
Urquhart, B. L., Freeman, D. J., Spence, J. D., & House, A. A. (2007). The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. Am J Kidney Dis, 49(1), 109-117. doi:10.1053/j.ajkd.2006.10.002
Urquhart, B. L., & House, A. A. (2007). Assessing plasma total homocysteine in patients with end-stage renal disease. Perit Dial Int, 27(5), 476-488. 
Urso, S., Garozzo, M., Milone, F., & Battaglia, G. (2004). Cardiovascular risk markers in hemodialysis patients. Int J Artif Organs, 27(12), 1083-1090. doi:10.1177/039139880402701212
Usta, M. F., & Sari, E. (2017). The association between erectile dysfunction and hyperhomocysteinemia in men with end stage renal disase. European Urology, Supplements, 16(13), e3029. 
Valli, A., Carrero, J. J., Qureshi, A. R., Garibotto, G., Bárány, P., Axelsson, J., . . . Suliman, M. E. (2008). Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. Clinica Chimica Acta, 395(1-2), 106-110. doi:10.1016/j.cca.2008.05.018
Vallianou, N. G., Mitesh, S., Gkogkou, A., & Geladari, E. (2019). Chronic kidney disease and cardiovascular disease: Is there any relationship? Current Cardiology Reviews, 15(1), 55-63. doi:10.2174/1573403X14666180711124825
Valočiková, I. (2006). Cardiac biomarkers and kidney diseases. Lekarsky Obzor, 55(11), 479-482. 
Valocikova, I., Kristofova, B., & Valocik, G. (2008). Cardiac biomarkers and chronic renal diseases. Bratislava Medical Journal, 109(8), 341-344. 
van Guldener, C. (2005). Homocysteine and the kidney. Current Drug Metabolism, 6(1), 23-26. doi:10.2174/1389200052997410
van Guldener, C. (2006). Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrology Dialysis Transplantation, 21(5), 1161-1166. doi:10.1093/ndt/gfl044
van Guldener, C. (2008). Homocysteine lowering and severe kidney disease. Jama, 299(3), 287-288; author reply 288. doi:10.1001/jama.299.3.287-b
Van Guldener, C. (2008). Homocysteine lowering and severe kidney disease [6]. JAMA - Journal of the American Medical Association, 299(3), 287-288. 
van Guldener, C., Donker, A. J., Jakobs, C., Teerlink, T., de Meer, K., & Stehouwer, C. D. (1998). No net renal extraction of homocysteine in fasting humans. Kidney Int, 54(1), 166-169. doi:10.1046/j.1523-1755.1998.00983.x
Van Guldener, C., Donker, A. J. M., Jakobs, C., Teerlink, T., De Meer, K., & Stehouwer, C. D. A. (1998). No net renal extraction of homocysteine in fasting humans. Kidney International, 54(1), 166-169. doi:10.1046/j.1523-1755.1998.00983.x
van Guldener, C., Janssen, M. J., de Meer, K., Donker, A. J., & Stehouwer, C. D. (1999). Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. Journal of internal medicine, 245(2), 175‐183. doi:10.1046/j.1365-2796.1999.00430.x
van Guldener, C., Janssen, M. J., Lambert, J., Steyn, M., Donker, A. J., & Stehouwer, C. D. (1998). Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant, 13(7), 1782-1786. doi:10.1093/ndt/13.7.1782
van Guldener, C., Janssen, M. J., Lambert, J., ter Wee, P. M., Donker, A. J., & Stehouwer, C. D. (1998). Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Peritoneal dialysis international, 18(3), 282‐289. 
van Guldener, C., Janssen, M. J., Stehouwer, C. D., Jakobs, C., Bronzwaer, J. G., Surachno, J., & Donker, A. J. (1998). The effect of renal transplantation on hyperhomocysteinaemia in dialysis patients, and the estimation of renal homocysteine extraction in patients with normal renal function. Neth J Med, 52(2), 58-64. doi:10.1016/s0300-2977(97)00069-7
Van Guldener, C., Janssen, M. J. F. M., Lambert, J., Steyn, M., Donker, A. J. M., & Stehouwer, C. D. A. (1998). Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 13(7), 1782-1786. doi:10.1093/ndt/13.7.1782
Van Guldener, C., Janssen, M. J. F. M., Stehouwer, C. D. A., Jakobs, C., Bronzwaer, J. G. F., Surachno, J., & Donker, A. J. M. (1998). The effect of renal transplantation on hyperhomocysteinaemia in dialysis patients, and the estimation of renal homocysteine extraction in patients with normal renal function. Netherlands Journal of Medicine, 52(2), 58-64. doi:10.1016/S0300-2977(97)00069-7
van Guldener, C., Kulik, W., Berger, R., Dijkstra, D. A., Jakobs, C., Reijngoud, D. J., . . . De Meer, K. (1999). Homocysteine and methionine metabolism in ESRD: A stable isotope study. Kidney Int, 56(3), 1064-1071. doi:10.1046/j.1523-1755.1999.00624.x
Van Guldener, C., Lambert, J., Janssen, M. J. F. M., Donker, A. J. M., & Stehouwer, C. D. A. (1997). Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 12(SUPPL. 2), 14-18. 
van Guldener, C., Lambert, J., ter Wee, P. M., Donker, A. J., & Stehouwer, C. D. (2000). Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy. Clinical nephrology, 53(1), 33‐41. 
van Guldener, C., Nanayakkara, P. W., & Stehouwer, C. D. (2007). Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med, 45(12), 1683-1687. doi:10.1515/cclm.2007.340
Van Guldener, C., Nanayakkara, P. W. B., & Stehouwer, C. D. A. (2007). Homocysteine and asymmetric dimethylarginine (ADMA): Biochemically linked but differently related to vascular disease in chronic kidney disease. Clinical Chemistry and Laboratory Medicine, 45(12), 1683-1687. doi:10.1515/CCLM.2007.340
van Guldener, C., & Robinson, K. (2000). Homocysteine and renal disease. Semin Thromb Hemost, 26(3), 313-324. doi:10.1055/s-2000-8407
van Guldener, C., Stam, F., & Stehouwer, C. D. (2001). Homocysteine metabolism in renal failure. Kidney Int Suppl, 78, S234-237. doi:10.1046/j.1523-1755.2001.59780234.x
van Guldener, C., Stam, F., & Stehouwer, C. D. (2005). Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation. Clin Chem Lab Med, 43(10), 1026-1031. doi:10.1515/cclm.2005.180
Van Guldener, C., Stam, F., & Stehouwer, C. D. A. (2001). Homocysteine metabolism in renal failure. Kidney International, Supplement, 59(78), S234-S237. doi:10.1046/j.1523-1755.2001.59780234.x
van Guldener, C., Stam, F., & Stehouwer, C. D. A. (2005). Hyperhomocysteinaemia in chronic kidney disease: Focus on transmethylation. Clinical Chemistry and Laboratory Medicine, 43(10), 1026-1031. doi:10.1515/CCLM.2005.180
van Guldener, C., & Stehouwer, C. D. (2000). Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost, 26(3), 281-289. doi:10.1055/s-2000-8472
van Guldener, C., & Stehouwer, C. D. (2003). Homocysteine metabolism in renal disease. Clin Chem Lab Med, 41(11), 1412-1417. doi:10.1515/cclm.2003.217
van Guldener, C., & Stehouwer, C. D. (2003). Hyperhomocysteinaemia and vascular disease--a role for DNA hypomethylation? Lancet, 361(9370), 1668-1669. doi:10.1016/s0140-6736(03)13380-6
van Guldener, C., & Stehouwer, C. D. (2005). Homocysteine and methionine metabolism in renal failure. Semin Vasc Med, 5(2), 201-208. doi:10.1055/s-2005-872405
van Guldener, C., & Stehouwer, C. D. A. (2003). Homocysteine metabolism in renal disease. Clinical Chemistry and Laboratory Medicine, 41(11), 1412-1417. doi:10.1515/CCLM.2003.217
Van Sandwijk, M. S., Berge, I. J. M. T., Majoie, C. B. L. M., Caan, M. W. A., De Sonneville, L. M. J., Van Gool, W. A., & Bemelman, F. J. (2016). Cognitive changes in chronic kidney disease and after transplantation. Transplantation, 100(4), 734-742. doi:10.1097/TP.0000000000000968
Vanholder, R. (2018). Introduction to the toxins special issue on “novel issues in uremic toxicity”. Toxins, 10(10). doi:10.3390/toxins10100388
Vanholder, R., Pletinck, A., Schepers, E., & Glorieux, G. (2018). Biochemical and clinical impact of organic uremic retention solutes: A comprehensive update. Toxins, 10(1). doi:10.3390/toxins10010033
Vanholder, R., Van Laecke, S., Verbeke, F., Glorieux, G., & Van Biesen, W. (2008). Uraemic toxins and cardiovascular disease: In vitro research versus clinical outcome studies. NDT Plus, 1(1), 2-10. doi:10.1093/ndtplus/sfm024
Varga, E., Seres, I., Harangi, M., Sztanek, F., Asztalos, L., Lcsey, L., . . . Paragh, G. (2009). Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients. Disease Markers, 26(3), 141-148. doi:10.3233/DMA-2009-0624
Varma, R., Garrick, R., McClung, J., & Frishman, W. H. (2005). Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease. Cardiology in Review, 13(2), 98-107. doi:10.1097/01.crd.0000132600.45876.d0
Vassiliou, D., & Sardh, E. (2021). Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta-synthase. Journal of Internal Medicine, 290(4), 928-930. doi:10.1111/joim.13341
Vega De Ceniga, M., Esteban, M., Barba, A., Estallo, L., Blanco-Colio, L. M., & Martin-Ventura, J. L. (2014). Assessment of biomarkers and predictive model for short-term prospective abdominal aortic aneurysm growth - A pilot study. Annals of Vascular Surgery, 28(7), 1642-1648. doi:10.1016/j.avsg.2014.02.025
Vega De Ceniga, M., Esteban, M., Barba, A., Martín-Ventura, J. L., & Estallo, L. (2015). Biomarkers and predictive models for abdominal aortic aneurysm growth. Angiologia, 67(6), 454-463. doi:10.1016/j.angio.2015.01.004
Veitch, D. P., Friedl, K. E., & Weiner, M. W. (2013). Military risk factors for cognitive decline, dementia and Alzheimer's disease. Current Alzheimer Research, 10(9), 907-930. doi:10.2174/15672050113109990142
Vemuri, C., Ram, R., Suchitra, M. M., Harini Devi, N., Vijaya Lakshmi, B., & Siva Kumar, V. (2017). A study on relationship between osteopontin and cardiovascular risk factors and carotid intimamedia thickness in chronic kidney disease. Nephrology Dialysis Transplantation, 32, iii560. doi:10.1093/ndt/gfx169
Verbeelen, D. L. (2006). The challenge of the unacceptable high mortality in end-stage kidney disease: is folic acid the answer? Blood Purif, 24(4), 377-378. doi:10.1159/000093679
Veringa, S. J., Nanayakkara, P. W., van Ittersum, F. J., Vegting, I. L., van Guldener, C., Smulders, Y. M., . . . Stehouwer, C. D. (2012). Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on arterial compliance and distensibility in patients with mild-to-moderate chronic kidney disease. Clinical nephrology, 78(4), 263‐272. doi:10.5414/cn107439
Vianna, A. C., Mocelin, A. J., Matsuo, T., Morais-Filho, D., Largura, A., Delfino, V. A., . . . Matni, A. M. (2007). Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodialysis international. International Symposium on Home Hemodialysis, 11(2), 210‐216. doi:10.1111/j.1542-4758.2007.00171.x
Vítek, L., & Schwertner, H. A. (2008). Protective effects of serum bilirubin on peripheral vascular disease. Annals of Hepatology, 7(1), 94-95. doi:10.1016/s1665-2681(19)31897-6
Vlachopanou, A., Nikolopoulos, P., Bampali, T., Foulidis, V., Katopodis, K., & Gouva, C. (2014). Effect of intravenous ferric carboxymaltose in the management of iron deficiency anemia, homocysteine (HCY) levels and cardiac function in patientswith chronic kidney disease (CKD). Nephrology Dialysis Transplantation, 29, iii22. doi:10.1093/ndt/gfu117
Vlagopoulos, P. T., & Sarnak, M. J. (2005). Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. Medical Clinics of North America, 89(3), 587-611. doi:10.1016/j.mcna.2004.11.003
Vojtková, J., Motyková, K., & Bánovčin, P. (2020). Possible association between haemostasis dysfunction and early onset of microvascular complications in patients with type 1 diabetes. Pediatric Endocrinology, Diabetes and Metabolism, 26(2), 89-96. doi:10.5114/pedm.2020.95623
Volpe, D., Tobin, G. A., Tavakkoli, F., Dowling, T. C., & Parker, R. J. (2012). Effect of uremic serum and uremic toxin on in vitro microsomal metabolism. Drug Metabolism Reviews, 44, 57-58. doi:10.3109/03602532.2012.744573
Volpe, D. A., Tobin, G. A., Tavakkoli, F., Dowling, T. C., Light, P. D., & Parker, R. J. (2014). Effect of uremic serum and uremic toxins on drug metabolism in human microsomes. Regulatory Toxicology and Pharmacology, 68(2), 297-303. doi:10.1016/j.yrtph.2013.10.006
Vrentzos, G. E., Papadakis, J. A., Vardakis, K. E., Maliaraki, N., Stilianou, K., Arvanitis, A., . . . Ganotakis, E. S. (2003). Intravenous administration of vitamin B12 in the treatment of hyperhomocysteinemia associated with end-stage renal disease. J Nephrol, 16(4), 535-539. 
Vychytil, A., Födinger, M., Papagiannopoulos, M., Wölfl, G., Hörl, W. H., & Sunder-Plassmann, G. (1999). Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Kidney Int, 55(5), 2054-2061. doi:10.1046/j.1523-1755.1999.00437.x
Vychytil, A., Födinger, M., Pleiner, J., Müllner, M., Konner, P., Skoupy, S., . . . Sunder-Plassmann, G. (2003). Acute effect of amino acid peritoneal dialysis solution on vascular function. American journal of clinical nutrition, 78(5), 1039‐1045. doi:10.1093/ajcn/78.5.1039
Waddington, F., Naunton, M., & Thomas, J. (2015). Paracetamol and analgesic nephropathy: Are you kidneying me? International Medical Case Reports Journal, 8. doi:10.2147/IMCRJ.S71471
Wadia, R., Ghiya, S., Singh, J., Sontakke, S., Bharadwaj, V., Sonawane, R., . . . Nadkarni, N. (2016). Clinical correlates of leukoaraiosis: A study of 175 patients. Annals of Indian Academy of Neurology, 19(4), 478-481. doi:10.4103/0972-2327.194425
Wallimann, T., Riek, U., & Möddel, M. (2017). Intradialytic creatine supplementation: A scientific rationale for improving the health and quality of life of dialysis patients. Medical Hypotheses, 99, 1-14. doi:10.1016/j.mehy.2016.12.002
Wan, C., Su, H., & Zhang, C. (2016). Role of NADPH Oxidase in Metabolic Disease-Related Renal Injury: An Update. Oxidative Medicine and Cellular Longevity, 2016. doi:10.1155/2016/7813072
Wang, A. Y., Lam, C. W., Wang, M., Woo, J., Chan, I. H., Lui, S. F., . . . Li, P. K. (2005). Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am J Kidney Dis, 45(4), 715-729. doi:10.1053/j.ajkd.2004.12.012
Wang, A. Y. M. (2020). Does Vitamin B12 Delay CKD Progression? American Journal of Kidney Diseases, 75(3), 317-319. doi:10.1053/j.ajkd.2019.10.003
Wang, H., Li, Z., Guo, X., Chen, Y., Chen, S., Tian, Y., & Sun, Y. (2018). Contribution of non-traditional lipid profiles to reduced glomerular filtration rate in H-type hypertension population of rural China. Annals of Medicine, 50(3), 249-259. doi:10.1080/07853890.2018.1445277
Wang, H. T., Peng, Y. M., & Liu, H. (2003). Alteration of homocysteine before and after hemodialysis in chronic hemodialysis patients. Bulletin of Hunan Medical University, 28(3), 266-268. 
Wang, Y., Zheng, Y., Chen, P., Liang, S., He, P., Shao, X., . . . Chen, X. (2021). The weak correlation between serum vitamin levels and chronic kidney disease in hospitalized patients: a cross-sectional study. BMC Nephrology, 22(1). doi:10.1186/s12882-021-02498-5
Wang, Y. N., Xia, H., Song, Z. R., Zhou, X. J., & Zhang, H. (2022). Plasma Homocysteine as a Potential Marker of Early Renal Function Decline in IgA Nephropathy. Frontiers in Medicine, 9. doi:10.3389/fmed.2022.812552
Wanner, C., & Zimmermann, J. (1998). Causes of coronary heart disease in patients on renal replacement therapy. Kidney Blood Press Res, 21(2-4), 287-289. doi:10.1159/000025881
Ward, R. A. (2005). Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol, 16(8), 2421-2430. doi:10.1681/asn.2005010070
Wasilewska, A., Narkiewicz, M., Rutkowski, B., & Łysiak-Szydłowska, W. (2003). Is there any relationship between lipids and vitamin B levels in persons with elevated risk of atherosclerosis? Med Sci Monit, 9(3), Cr147-151. 
Wasilewska, A., Narklewicz, M., Rutkowski, B., & Łysiak-Szydłowska, W. (2003). Is there any relationship between lipids and vitamin B levels in persons with elevated risk of atherosclerosis? Medical Science Monitor, 9(3), CR147-CR151. 
Watanabe, K., Watanabe, T., & Nakayama, M. (2014). Cerebro-renal interactions: Impact of uremic toxins on cognitive function. NeuroToxicology, 44, 184-193. doi:10.1016/j.neuro.2014.06.014
Waters, H. M., & Seal, L. H. (2001). A systematic approach to the assessment of erythropoiesis. Clinical and Laboratory Haematology, 23(5), 271-283. doi:10.1046/j.1365-2257.2001.00406.x
Weekley, C. C., & Peralta, C. A. (2012). Advances in the use of multimarker panels for renal risk stratification. Current Opinion in Nephrology and Hypertension, 21(3), 301-308. doi:10.1097/MNH.0b013e328352132d
Weiner, D. E., Carpenter, M. A., Levey, A. S., Ivanova, A., Cole, E. H., Hunsicker, L., . . . Bostom, A. G. (2012). Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: The FAVORIT trial. American Journal of Transplantation, 12(9), 2437-2445. doi:10.1111/j.1600-6143.2012.04101.x
Weiner, D. E., Park, M., Tighiouart, H., Joseph, A. A., Carpenter, M. A., Goyal, N., . . . Bostom, A. G. (2019). Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. American Journal of Kidney Diseases, 73(1), 51-61. doi:10.1053/j.ajkd.2018.05.015
Weinrauch, L. A., Liu, J., Claggett, B., Finn, P. V., Weir, M. R., & D’Elia, J. A. (2018). Calcium channel blockade and survival in recipients of successful renal transplant: An analysis of the FAVORIT trial results. International Journal of Nephrology and Renovascular Disease, 11, 1-7. doi:10.2147/IJNRD.S148517
Wells G. (2014). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. Ottawa, ON, Canada, Ottawa Health Research Institute. 
Weng, H., Li, Y., Fan, F., Yang, H., Zhou, G., Sun, P., . . . Li, J. (2020). The association between total homocysteine and blood pressure in two independent Chinese populations. Journal of Human Hypertension, 34(9), 657-665. doi:10.1038/s41371-019-0288-6
Wesseling, S., Koeners, M. P., & Joles, J. A. (2009). Taurine red bull or red herring? Hypertension, 53(6), 909-911. doi:10.1161/HYPERTENSIONAHA.109.130427
Wheeler, D. C., Townend, J. N., & Landray, M. J. (2003). Cardiovascular risk factors in predialysis patients: Baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. Kidney International, Supplement, 63(84), S201-S203. doi:10.1046/j.1523-1755.63.s84.45.x
Widiana, I. G., & Suwitra, K. (2004). Relationship between creatinine clearance and plasma homocysteine levels in predialytic chronic renal failure patients. Acta medica Indonesiana, 36(1), 15-18. 
Wilcken, D. E., Dudman, N. P., Tyrrell, P. A., & Robertson, M. R. (1988). Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism, 37(7), 697-701. doi:10.1016/0026-0495(88)90093-5
Wilcken, D. E., & Gupta, V. J. (1979). Sulphr containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest, 9(4), 301-307. doi:10.1111/j.1365-2362.1979.tb00888.x
Wilcken, D. E., Gupta, V. J., & Reddy, S. G. (1980). Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. Clin Sci (Lond), 58(5), 427-430. doi:10.1042/cs0580427
Wilcken, D. E. L. (1998). Novel risk factors for vascular disease: The homocysteine hypothesis of cardiovascular disease. Journal of Cardiovascular Risk, 5(4), 217-221. doi:10.1097/00043798-199808000-00002
Wilcken, D. E. L., Dudman, N. P. B., Tyrrell, P. A., & Robertson, M. R. (1988). Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism, 37(7), 697-701. doi:10.1016/0026-0495(88)90093-5
Wilcox, C. S. (2002). Randomized study of folic acid therapy for hyperhomocysteinemia in patients with end stage renal disease receiving hemodialysis. Www.clinicaltrials.gov/ct2/show/nct00004495. 
Wilcox, C. S. (2010). Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacology and Therapeutics, 126(2), 119-145. doi:10.1016/j.pharmthera.2010.01.003
Willoughby, M. L. (1980). [Congenital and acquired thrombocyte function disorders]. Kinderarztl Prax, 48(7), 337-351. 
Winkelmayer, W. C., Kramar, R., Curhan, G. C., Chandraker, A., Endler, G., Födinger, M., . . . Sunder-Plassmann, G. (2005). Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol, 16(1), 255-260. doi:10.1681/asn.2004070576
Winkelmayer, W. C., Skoupy, S., Eberle, C., Födinger, M., & Sunder-Plassmann, G. (2004). Effects of TCN2 776C>G on vitamin B12, folate, and total homocysteine levels in kidney transplant patients. Kidney International, 65(5), 1877-1881. doi:10.1111/j.1523-1755.2004.00592.x
Witasp, A., Van Craenenbroeck, A. H., Shiels, P. G., Ekström, T. J., Stenvinkel, P., & Nordfors, L. (2017). Current epigenetic aspects the clinical kidney researcher should embrace. Clinical Science, 131(14), 1649-1667. doi:10.1042/CS20160596
Wolff, F., Gausset, P., & Vanderpas, J. (2005). Better stability of total homocysteine measurement with sodium fluoride than with EDTA. Clin Lab, 51(5-6), 275-278. 
Wooley, A. C., & Kerr, J. L. (2018). Monitoring Patients on Metformin: Recent Changes and Rationales. Journal of Pharmacy Technology, 34(1), 28-36. doi:10.1177/8755122517747295
Wright, J., & Hutchison, A. (2009). Cardiovascular disease in patients with chronic kidney disease. Vascular Health and Risk Management, 5, 713-722. 
Wrone, E. M., Hornberger, J. M., Zehnder, J. L., McCann, L. M., Coplon, N. S., & Fortmann, S. P. (2004). Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. Journal of the American Society of Nephrology : JASN, 15(2), 420‐426. doi:10.1097/01.asn.0000110181.64655.6c
Wrone, E. M., Zehnder, J. L., Hornberger, J. M., McCann, L. M., Coplon, N. S., & Fortmann, S. P. (2001). An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int, 60(3), 1106-1113. doi:10.1046/j.1523-1755.2001.0600031106.x
Wu, C. C., Zheng, C. M., Lin, Y. F., Lo, L., Liao, M. T., & Lu, K. C. (2012). Role of homocysteine in end-stage renal disease. Clinical Biochemistry, 45(16-17), 1286-1294. doi:10.1016/j.clinbiochem.2012.05.031
Wu, F., & Yu, L. (2007). Changes in the atherosclerosis-associated indexes during hemodialysis in patients with terminal renal failure. Journal of Clinical Rehabilitative Tissue Engineering Research, 11(25), 4960-4962. 
Wu, H. H. L., & Wang, A. Y. (2022). Vitamin B12 and chronic kidney disease. Vitam Horm, 119, 325-353. doi:10.1016/bs.vh.2022.01.011
Wu, H. H. L., & Wang, A. Y. M. (2022). Vitamin B12 and chronic kidney disease. Vitamins and hormones, 119, 325-353. doi:10.1016/bs.vh.2022.01.011
Wu, H. H. L., & Wang, A. Y. M. (2022). Vitamin B12 and chronic kidney disease. In Vitamins and Hormones (Vol. 119, pp. 325-353).
Wu, J., Liu, D., Yang, L., & Liu, J. (2022). Association Between Serum Homocysteine Levels and Severity of Diabetic Kidney Disease in 489 Patients with Type 2 Diabetes Mellitus: A Single-Center Study. Med Sci Monit, 28, e936323. doi:10.12659/msm.936323
Wu, Q., Zhang, H., Ding, J. R., Hong, Z. Y., Wu, H., Zhu, Z. Y., . . . Chai, Y. F. (2018). UPLC-QTOF MS-Based Serum Metabolomic Profiling Analysis Reveals the Molecular Perturbations Underlying Uremic Pruritus. BioMed Research International, 2018. doi:10.1155/2018/4351674
Wu, X., Lin, J., Xue, N., Teng, J., Wang, Y., Li, Y., . . . Fang, Y. (2021). Relationship Between Gene Polymorphism of Methylenetetrahydrofolate Reductase C677T and Left Ventricular Hypertrophy in Chinese Patients with Chronic Kidney Disease. Laboratory medicine, 52(6), 519-527. doi:10.1093/labmed/lmab004
Wu, Y., Hou, J., Li, J., Luo, Y., & Wu, S. (2016). Correlation between Carotid Intima-Media Thickness and Early-Stage Chronic Kidney Disease: Results from Asymptomatic Polyvascular Abnormalities in Community Study. Journal of Stroke and Cerebrovascular Diseases, 25(2), 259-265. doi:10.1016/j.jstrokecerebrovasdis.2015.09.026
Xiao, H., Xiong, C., Shao, X., Gao, P., Chen, H., Ning, J., . . . Zou, H. (2020). Visceral adiposity index and chronic kidney disease in a non-diabetic population: A cross-sectional study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 257-265. doi:10.2147/DMSO.S231656
Xiao, W., Wen, Y., Ye, P., Wang, F., Cao, R., Bai, Y., & Wu, H. (2020). Noninvasive central pulse pressure is an independent determinant of renal function. Journal of Clinical Hypertension, 22(2), 234-242. doi:10.1111/jch.13792
Xiao, W., Ye, P., Wang, F., Cao, R., Bai, Y., & Wang, X. (2021). Plasma Homocysteine Is a Predictive Factor for Accelerated Renal Function Decline and Chronic Kidney Disease in a Community-Dwelling Population. Kidney and Blood Pressure Research, 46(5), 541-549. doi:10.1159/000514360
Xidakis, D., Antonaki, E., Kostakis, K., Sfakianaki, M., & Papadogiannakis, A. (2015). Association between low grade inflammation and diastolic heart failure in predialysis patients. The effect of aldosterone blockade. Nephrology Dialysis Transplantation, 30, iii475-iii476. doi:10.1093/ndt/gfv191.10
Xie, D., Yuan, Y., Guo, J., Yang, S., Xu, X., Wang, Q., . . . Hou, F. (2015). Hyperhomocysteinemia predicts renal function decline: a prospective study in hypertensive adults. Scientific reports, 5, 16268. doi:10.1038/srep16268
Xie, L., Ma, S., Ding, N., Wang, Y., Lu, G., Xu, L., . . . Jiang, Y. (2021). Homocysteine induces podocyte apoptosis by regulating miR-1929-5p expression through c-Myc, DNMT1 and EZH2. Molecular Oncology, 15(11), 3203-3221. doi:10.1002/1878-0261.13032
Xu, X., Hu, J., Song, N., Chen, R., Zhang, T., & Ding, X. (2017). Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol, 18(1), 27. doi:10.1186/s12882-016-0433-1
Xu, X., Qin, X., Li, Y., Sun, D., Wang, J., Liang, M., . . . Hou, F. F. (2016). Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA internal medicine, 176(10), 1443‐1450. doi:10.1001/jamainternmed.2016.4687
Yamaguchi, Y., Zampino, M., Moaddel, R., Chen, T. K., Tian, Q., Ferrucci, L., & Semba, R. D. (2021). Plasma metabolites associated with chronic kidney disease and renal function in adults from the Baltimore Longitudinal Study of Aging. Metabolomics, 17(1). doi:10.1007/s11306-020-01762-3
Yamamoto, K., Eguchi, K., Kaneko, I., Akiba, T., & Mineshima, M. (2013). Preliminary study for efficient removal of protein-bound toxins. Therapeutic Apheresis and Dialysis, 17(5), A14. doi:10.1111/1744-9987.12117
Yamamoto, K. I., Eguchi, K., Takagi, M., Kaneko, I., Akiba, T., Sakai, K., & Mineshima, M. (2012). Preliminary study on protein-bound toxin removal by dilution and pH change methods. Hemodialysis International, 16(1), 152. doi:10.1111/j.1542-4758.2011.00651.x
Yamamoto, S., & Fukagawa, M. (2017). Uremic Toxicity and Bone in CKD. Journal of Nephrology, 30(5), 623-627. doi:10.1007/s40620-017-0406-x
Yamamoto, T., Qureshi, A. R., Anderstam, B., Heimbürger, O., Bárány, P., Lindholm, B., . . . Axelsson, J. (2010). Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrology Dialysis Transplantation, 25(12), 4017-4023. doi:10.1093/ndt/gfq329
Yamauchi, M. (2016). The assessment of bone quality in lifestyle-related diseases. Clinical calcium, 26(1), 65-72. 
Yang, J., Choi, E. T., Kunapuli, S. P., Yang, X., & Wang, H. (2015). Hyperhomocysteinemia-mediated SCD40L induction and CD16+CD40+ monocyte differentiation in chronic kidney disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 35. 
Yang, J., Fang, P., Yu, D., Zhang, L., Zhang, D., Jiang, X., . . . Wang, H. (2016). Chronic Kidney Disease Induces Inflammatory CD40+ Monocyte Differentiation via Homocysteine Elevation and DNA Hypomethylation. Circulation Research, 119(11), 1226-1241. doi:10.1161/CIRCRESAHA.116.308750
Yang, J., Kolli, A. C., Choi, E. T., Yang, X. F., & Wang, H. (2014). Hyperhomocysteinemia induces cd40+ monocyte and inflammatory monocyte in chronic kidney disease subjects via DNA hypomethylation-related mechanism. Circulation, 130. 
Yang, J. J., Shu, X. O., Herrington, D. M., Moore, S. C., Meyer, K. A., Ose, J., . . . Yu, D. (2021). Circulating trimethylamine N-oxide in association with diet and cardiometabolic biomarkers: An international pooled analysis. American Journal of Clinical Nutrition, 113(5), 1145-1156. doi:10.1093/ajcn/nqaa430
Yang, S. Y., Huang, J. W., Shih, K. Y., Hsu, S. P., Chu, P. L., Chu, T. S., & Wu, K. D. (2005). Factors associated with increased plasma homocysteine in patients using an amino acid peritoneal dialysis fluid. Nephrol Dial Transplant, 20(1), 161-166. doi:10.1093/ndt/gfh554
Yao, Y., Liu, H., Zhang, X., & Duan, X. (2002). Methylenetetrahydrofolate reductase gene polymorphism and plasma homocysteine levels in hemodialysing patients. Zhonghua nei ke za zhi [Chinese journal of internal medicine], 41(8), 522-525. 
Yaqoob, M. M. (2002). Emerging cardiovascular risk factors in end-stage renal disease. J Nephrol, 15(2), 205-208. 
Yashu, L., Yang, X., Qijun, W., Qing, C., & Yuhong, Z. (2021). Associations between serum vitamins and serum uric acid in a population of Shenyang, China. Journal of Nutritional Science and Vitaminology, 67(2), 77-83. doi:10.3177/jnsv.67.77
Yavuz, F., & Kaplan, M. (2021). Association between serum elabela levels and chronic totally occlusion in patients with stable angina pectoris. Arquivos Brasileiros de Cardiologia, 117(3), 503-510. doi:10.36660/abc.20200492
Yavuz, S., Kilic, M., Kilic, T., Kanko, M., & Berki, T. (2010). Correlation between clinical-biochemical risk factors and the extent of saphenous vein graft disease in CABG patients. Interactive Cardiovascular and Thoracic Surgery, 10, S60. doi:10.1510/icvts.2010.0000S1
Ye, M., Lin, W., Zheng, J., & Lin, S. (2021). N-acetylcysteine for chronic kidney disease: A systematic review and meta-analysis. American Journal of Translational Research, 13(4), 2472-2485. 
Ye, Z., Wang, C., Zhang, Q., Li, Y., Zhang, J., Ma, X., . . . Lou, T. (2017). Prevalence of Homocysteine-Related Hypertension in Patients With Chronic Kidney Disease. Journal of Clinical Hypertension, 19(2), 151-160. doi:10.1111/jch.12881
Ye, Z., Zhang, Q., Li, Y., Wang, C., Zhang, J., Ma, X., . . . Lou, T. (2016). High prevalence of hyperhomocysteinemia and its association with target organ damage in chinese patients with chronic kidney disease. Nutrients, 8(10). doi:10.3390/nu8100645
Yeh, Y. C., Huang, M. F., Hwang, S. J., Tsai, J. C., Liu, T. L., Hsiao, S. M., . . . Chen, C. S. (2016). Association of homocysteine level and vascular burden and cognitive function in middle-aged and older adults with chronic kidney disease. International Journal of Geriatric Psychiatry, 31(7), 723-730. doi:10.1002/gps.4383
Yeh, Y. C., Kuo, M. C., Hwang, S. J., Hsioa, S. M., Tsai, J. C., Huang, M. F., & Chen, C. S. (2013). Homocysteine and cognitive impairment in chronic kidney disease. European Psychiatry, 28. 
Yeolekar, M. E., Bichile, S. K., & Shete, M. M. (2002). Hyperhomocysteinemia and vascular disease: role and implications. The Journal of the Association of Physicians of India, 50 Suppl, 5-8. 
Yerkey, M. W., Kernis, S. J., Franklin, B. A., Sandberg, K. R., & McCullough, P. A. (2004). Renal dysfunction and acceleration of coronary disease. Heart, 90(8), 961-966. doi:10.1136/hrt.2003.015503
Yerram, P., Karuparthi, P. R., Hesemann, L., Horst, J., & Whaley-Connell, A. (2007). Chronic kidney disease and cardiovascular risk. Journal of the American Society of Hypertension, 1(3), 178-184. doi:10.1016/j.jash.2007.01.010
Yeun, J. Y., & Kaysen, G. A. (2000). C-reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD. Curr Opin Nephrol Hypertens, 9(6), 621-630. doi:10.1097/00041552-200011000-00006
Yi, F., & Li, P. L. (2008). Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am J Nephrol, 28(2), 254-264. doi:10.1159/000110876
Yi, F., Xia, M., Li, N., Zhang, C., Tang, L., & Li, P. L. (2009). Contribution of guanine nucleotide exchange factor Vav2 to hyperhomocysteinemic glomerulosclerosis in rats. Hypertension, 53(1), 90-96. doi:10.1161/hypertensionaha.108.115675
Yilmaz, A., Gedikbasi, A., Karagoz, N., Sucu, A., Akinci, N., Pehlivanoglu, C., . . . Emre, S. (2013). Possible relationship between serum homocysteine level and cresent formation in children with IgA nephropathy. Pediatric Nephrology, 28(8), 1434. doi:10.1007/s00467-013-2518-4
Yonova, D. (2004). Serum homocysteine in patients with renal disease and chronic renal failure on conservative and dialysis treatment. Nephrology, Dialysis and Transplantation, 10(1-4), 34-36. 
Young, A., Boudville, N., Geddes, C., Gill, J., Jassal, V., Klarenbach, S., . . . Garg, A. X. (2010). Bone mineral metabolism and other biochemical measures after live donor nephrectomy. American Journal of Transplantation, 10, 180. doi:10.1111/j.1600-6143.2010.03107.x
Yu, Y., Hou, F., Zhou, H., Yang, Y., Zhang, X., Yang, L., & Hu, M. (2002). The role of hyperhomocysteinemia on atherosclerosis in patients with chronic renal failure. Zhonghua nei ke za zhi [Chinese journal of internal medicine], 41(8), 517-521. 
Yu, Y. M., Hou, F. F., Zhang, X., Zhou, H., & Liu, Z. Q. (2004). Hyperhomocysteinemia, oxidative stress and microinflammation in chronic renal failure: their roles in atherogene. Zhonghua nei ke za zhi [Chinese journal of internal medicine], 43(4), 292-295. 
Yuan, X., Zhang, J., Xie, F., Tan, W., Wang, S., Huang, L., . . . Yuan, Q. (2017). Loss of the protein cystathionine β-synthase during kidney injury promotes renal tubulointerstitial fibrosis. Kidney and Blood Pressure Research, 42(3), 428-443. doi:10.1159/000479295
Yuzawa, Y. (2012). [Role of hydrogen sulfide in chronic kidney disease and diabetic nephropathy]. Nihon Yakurigaku Zasshi, 139(1), 17-21. doi:10.1254/fpj.139.17
Zaidan, N., & Nazzal, L. (2022). The Microbiome and Uremic Solutes. Toxins, 14(4). doi:10.3390/toxins14040245
Zawada, A. M., Rogacev, K. S., & Heine, G. H. (2013). Clinical relevance of epigenetic dysregulation in chronic kidney disease-associated cardiovascular disease. Nephrology Dialysis Transplantation, 28(7), 1663-1671. doi:10.1093/ndt/gft042
Zawada, A. M., Rogacev, K. S., Hummel, B., Grün, O. S., Friedrich, A., Rotter, B., . . . Heine, G. H. (2012). SuperTAG methylation-specific digital karyotyping reveals uremia-induced epigenetic dysregulation of atherosclerosis-related genes. Circ Cardiovasc Genet, 5(6), 611-620. doi:10.1161/circgenetics.112.963207
Zawada, A. M., Schneider, J. S., Michel, A. I., Rogacev, K. S., Hummel, B., Krezdorn, N., . . . Heine, G. H. (2016). DNA methylation profiling reveals differences in the 3 human monocyte subsets and identifies uremia to induce DNA methylation changes during differentiation. Epigenetics, 11(4), 259-272. doi:10.1080/15592294.2016.1158363
Zeng, L., Ye, Z., Li, Y., Zhou, Y., Shi, Q., Hu, T., . . . Li, S. (2021). Different Lipid Parameters in Predicting Clinical Outcomes in Chinese Statin-Naïve Patients After Coronary Stent Implantation. Frontiers in Cardiovascular Medicine, 8. doi:10.3389/fcvm.2021.638663
Zeng, Y., Du, X., Yao, X., Qiu, Y., Jiang, W., Shen, J., . . . Liu, X. (2022). Mechanism of cell death of endothelial cells regulated by mechanical forces. Journal of Biomechanics, 131. doi:10.1016/j.jbiomech.2021.110917
Zhan, X. L., Yang, X. H., Gu, Y. H., Guo, L. L., & Jin, H. M. (2018). Epigallocatechin gallate protects against homocysteine-induced vascular smooth muscle cell proliferation. Molecular and Cellular Biochemistry, 439(1-2), 131-140. doi:10.1007/s11010-017-3142-6
Zhang, A., Deng, W., Zhang, B., Ren, M., Tian, L., Ge, J., . . . Cui, L. (2021). Association of lipid profiles with severity and outcome of acute ischemic stroke in patients with and without chronic kidney disease. Neurological Sciences, 42(6), 2371-2378. doi:10.1007/s10072-020-04791-x
Zhang, A., Sun, H., Qiu, S., & Wang, X. (2014). Metabolomics insights into pathophysiological mechanisms of nephrology. International Urology and Nephrology, 46(5), 1025-1030. doi:10.1007/s11255-013-0600-2
Zhang, C., Su, H., Wan, C., Lei, C. T., Zhang, C. Y., Ye, C., . . . Qiu, Y. (2018). Lipid deposition in kidney diseases: Interplay among redox, lipid mediators, and renal impairment. Antioxidants and Redox Signaling, 28(10), 1027-1043. doi:10.1089/ars.2017.7066
Zhang, J., Fuhrer, T., Ye, H., Kwan, B., Montemayor, D., Tumova, J., . . . Natarajan, L. (2022). High-Throughput Metabolomics and Diabetic Kidney Disease Progression: Evidence from the Chronic Renal Insufficiency (CRIC) Study. American Journal of Nephrology, 53(2-3), 215-225. doi:10.1159/000521940
Zhang, L., Wang, Y., Zhang, Z., Liang, H., Wu, L., Ni, L., . . . Xiao, J. (2021). Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study. BMC Cardiovascular Disorders, 21(1). doi:10.1186/s12872-021-02245-6
Zhang, S., Zhang, Y., Zhang, X., Luo, C., Cao, Y., Ji, D., . . . Wang, W. (2020). Nitrative Stress-Related Autophagic Insufficiency Participates in Hyperhomocysteinemia-Induced Renal Aging. Oxidative Medicine and Cellular Longevity, 2020. doi:10.1155/2020/4252047
Zhang, X., Li, H., Jin, H., Ebin, Z., Brodsky, S., & Goligorsky, M. S. (2000). Effects of homocysteine on endothelial nitric oxide production. American Journal of Physiology - Renal Physiology, 279(4 48-4), F671-F678. doi:10.1152/ajprenal.2000.279.4.f671
Zhang, Y. F., & Ning, G. (2008). Mecobalamin. Expert Opin Investig Drugs, 17(6), 953-964. doi:10.1517/13543784.17.6.953
Zhang, Y. M., Zhou, X. J., Shi, S. F., Liu, L. J., Lyu, J. C., Zhang, H., & Lyu, P. (2020). Homocysteine and IgA nephropathy: Observational and Mendelian randomization analyses. Chinese Medical Journal, 133(3), 277-284. doi:10.1097/CM9.0000000000000613
Zhang, Y. N., Pi, Y. L., Yan, X., Li, Y. Q., Qi, Z. J., & Zhang, H. F. (2020). Methylmalonic Acidemia Complicated by Homocystinuria Diseases: a Report of Three Cases. Adv Ther, 37(1), 630-636. doi:10.1007/s12325-019-01149-4
Zhang, Z., Cui, T., Cui, M., & Kong, X. (2020). High prevalence of chronic kidney disease among patients with diabetic foot: A cross-sectional study at a tertiary hospital in China. Nephrology, 25(2), 150-155. doi:10.1111/nep.13596
Zheng, C. M., Chiu, H. W., Lu, K. C., Lu, C. L., Wu, M. S., & Hsu, Y. H. (2020). Salubrinal improves osteoclast differentiation and vascular calcification in uremic millennium through inhibition of the endoplasmic reticulum (ER) stress condition. Nephrology Dialysis Transplantation, 35(SUPPL 3), iii1230. doi:10.1093/ndt/gfaa142.P0906
Zheng, H., Huang, X., Zhang, Q., & Katz, S. D. (2006). Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney International, 69(4), 679-684. doi:10.1038/sj.ki.5000046
Zhloba, A. A., & Subbotina, T. F. (2021). Тест на гомоаргинин для оценки метаболической дисфункции почки. Klinicheskaia laboratornaia diagnostika, 66(12), 709-717. doi:10.51620/0869-2084-2021-66-12-709-717
Zhou, M., Du, Y., Wu, Y., Zhang, P., Liu, P., & Li, J. (2021). Analysis of inflammatory factor levels in serum and risk factors in patients with chronic renal failure undergoing maintenance hemodialysis. American Journal of Translational Research, 13(6), 6994-7000. 
Zhou, Y. H., Tang, J. Y., Wu, M. J., Lu, J., Wei, X., Qin, Y. Y., . . . He, J. (2011). Effect of folic acid supplementation on cardiovascular outcomes: A systematic review and meta-analysis. PLoS ONE, 6(9). doi:10.1371/journal.pone.0025142
Zhu, B., Liu, W. H., Yu, D. R., Lin, Y., Li, Q., Tong, M. L., . . . Chen, H. Y. (2020). The Association of Low Hemoglobin Levels with IgA Nephropathy Progression: A Two-Center Cohort Study of 1,828 Cases. American Journal of Nephrology, 51(8), 624-634. doi:10.1159/000508770
Zhuravleva, N., Horoshev Anatolyevich, S., Mineeva Yurievna, N., & Tsauru Anatolyevich, G. (2022). POS-275 POLYMORPHISM OF THROMBOPHILIA GENES IN CHILDREN WITH STAGE V CKD. Kidney International Reports, 7(2), S121. doi:10.1016/j.ekir.2022.01.294
Ziada, K. M. (2007). Coronary revascularization in end-stage renal disease. Current Cardiology Reports, 9(5), 389-395. 
Ziaie, S., Moghaddam, M. P., Samadian, F., Sistanizad, M., Afzal, G., Saffaei, A., . . . Sabaghian, T. (2020). Omega-3 in patients undergoing continuous ambulatory peritoneal dialysis, effects on inflammatory markers and lipid profile. Iranian Journal of Kidney Diseases, 14(2), 119-125. 
Ziaie, S., Polroudi Moghaddam, M., Samadian, F., Sistanizad, M., Afzal, G., Saffaei, A., . . . Sabaghian, T. (2020). Omega-3 in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis, Effects on Inflammatory Markers and Lipid Profile. Iran J Kidney Dis, 14(2), 126-132. 
Ziakka, S., Rammos, G., Kountouris, S., Doulgerakis, C., Karakasis, P., Kourvelou, C., & Papagalanis, N. (2001). The effect of vitamin B6 and folate supplements on plasma homocysteine and serum lipids levels in patients on regular hemodialysis. Int Urol Nephrol, 33(3), 559-562. doi:10.1023/a:1019559328424
Zidek, W. (1997). Homocysteine - a new arteriosclerotic risk factor in end-stage renal failure. Nephron, 75(3), 249-250. doi:10.1159/000189544
Zietse, R., & Marrón, B. (2006). Reducing cardiovascular disease in patients on peritoneal dialysis - Is it possible? Nephrology Dialysis Transplantation, 21(SUPPL. 2), ii25-ii30. doi:10.1093/ndt/gfl140
Zinellu, A., Loriga, G., Sanna, M., Satta, A. E., Carboni, M., Deiana, L., & Carru, C. (2011). Low-density lipoprotein S-homocysteinylation degree in proteinuric chronic nephropat hy disease. Clinical Chemistry and Laboratory Medicine, 49, S295. doi:10.1515/CCLM.2011.508
Zinellu, A., Loriga, G., Satta, A. E., Deiana, L., & Carru, C. (2011). Increased levels of low-density lipoprotein S-homocysteinylation in chronic kidney disease (CKD). Atherosclerosis Supplements, 12(1), 57. 
Zinellu, A., Loriga, G., Scanu, B., Pisanu, E., Sanna, M., Deiana, L., . . . Carru, C. (2010). Increased low-density lipoprotein S-homocysteinylation in chronic kidney disease. American Journal of Nephrology, 32(3), 242-248. doi:10.1159/000319012
Zinellu, A., Sotgia, S., Loriga, G., Deiana, L., Satta, A. E., & Carru, C. (2012). Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy. Amino Acids, 43(4), 1499-1507. doi:10.1007/s00726-012-1223-0
Zinellu, A., Sotgia, S., Mangoni, A. A., Sotgiu, E., Ena, S., Arru, D., . . . Carru, C. (2016). Effects of ramipril and telmisartan on plasma concentrations of low molecular weight and protein thiols and carotid intima media thickness in patients with chronic kidney disease. Disease Markers, 2016. doi:10.1155/2016/1821596
Zinellu, A., Sotgia, S., Mangoni, A. A., Sotgiu, E., Ena, S., Satta, A. E., & Carru, C. (2016). Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of Pharmaceutical and Biomedical Analysis, 129, 383-388. doi:10.1016/j.jpba.2016.07.025
Zinellu, A., Sotgia, S., Pisanu, E., Loriga, G., Deiana, L., Satta, A. E., & Carru, C. (2012). LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. European Journal of Pharmaceutical Sciences, 47(1), 117-123. doi:10.1016/j.ejps.2012.05.006
Zittoun, J. (1998). Homocysteine and vascular diseases. Hematologie, 4(1), 7-16. 
Zizzi, C. F., Pellicano, R., & Biancone, L. (2021). The relationship between Helicobacter pylori and chronic kidney disease: Update 2020. Minerva Gastroenterologica e Dietologica, 66(4), 343-349. doi:10.23736/S1121-421X.20.02729-4
Zoccali, C. (2000). Cardiovascular risk in uraemic patients - Is it fully explained by classical risk factors? Nephrology Dialysis Transplantation, 15(4), 454-457. doi:10.1093/ndt/15.4.454
Zoccali, C. (2002). Cardiorenal risk as a new frontier of nephrology: Research needs and areas for intervention. Nephrology Dialysis Transplantation, 17(SUPPL. 11), 50-54. doi:10.1093/ndt/17.suppl_11.50
Zoccali, C. (2003). [Cardiovascular events in chronic advanced renal insufficiency. Current concepts]. Recenti Prog Med, 94(3), 125-130. 
Zoccali, C. (2005). Biomarkers in chronic kidney disease: Utility and issues towards better understanding. Current Opinion in Nephrology and Hypertension, 14(6), 532-537. doi:10.1097/01.mnh.0000185982.10201.a7
Zoccali, C. (2006). Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective. Kidney International, 70(1), 26-33. doi:10.1038/sj.ki.5000417
Zoccali, C., Benedetto, F. A., Mallamaci, F., Tripepi, G., Fermo, I., Focà, A., . . . Malatino, L. S. (2000). Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens, 18(9), 1207-1213. doi:10.1097/00004872-200018090-00006
Zoccali, C., Caridi, G., & Cambareri, F. (2007). The chronic renal failure epidemic: an underestimated public health problem. Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, 24 Suppl 38, 3-7. 
Zoccali, C., Enia, G., Tripepi, G., Panuccio, V., & Mallamaci, F. (2005). Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients. Peritoneal Dialysis International, 25(SUPPL. 3), S84-S87. doi:10.1177/089686080502503s21
Zoccali, C., & Jager, K. J. (2010). Hyperhomocysteinemia: a renal and cardiovascular risk factor? Nature reviews. Nephrology, 6(12), 695-696. 
Zoccali, C., & Mallamaci, F. (2006). Homocysteine and risk in end-stage renal disease: a matter of context. Kidney Int, 69(2), 204-206. doi:10.1038/sj.ki.5000078
Zoccali, C., Mallamaci, F., & Tripepi, G. (2003). Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl(85), S105-110. doi:10.1046/j.1523-1755.63.s85.25.x
Zoccali, C., Mallamaci, F., & Tripepi, G. (2007). It is important to lower homocysteine in dialysis patients. Seminars in Dialysis, 20(6), 530-533. doi:10.1111/j.1525-139X.2007.00345.x
Zoungas, S., Branley, P., Kerr, P. G., Ristevski, S., Muske, C., Demos, L., . . . McGrath, B. P. (2004). Atherosclerosis and folic acid supplementation trial in chronic renal failure: Baseline results. Nephrology, 9(3), 130-141. doi:10.1111/j.1440-1797.2004.00242.x
Zoungas, S., Kerr, P. G., Chadban, S., Muske, C., Ristevski, S., Atkins, R. C., . . . McGrath, B. P. (2004). Arterial function after successful renal transplantation. Kidney International, 65(5), 1882-1889. doi:10.1111/j.1523-1755.2004.00595.x
Zoungas, S., McGrath, B. P., Branley, P., Kerr, P. G., Muske, C., Wolfe, R., . . . et al. (2006). Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. Journal of the American College of Cardiology, 47(6), 1108‐1116. doi:10.1016/j.jacc.2005.10.064
Zoungas, S., McGrath, B. P., Branley, P., Kerr, P. G., Muske, C., Wolfe, R., . . . McNeil, J. J. (2006). Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: A multicenter, randomized, controlled trial. Journal of the American College of Cardiology, 47(6), 1108-1116. doi:10.1016/j.jacc.2005.10.064
Zoungas, S., Ristevski, S., Lightfoot, P., Liang, Y. L., Branley, P., Shiel, L. M., . . . McGrath, B. P. (2000). Carotid artery intima-medial thickness is increased in chronic renal failure. Clinical and Experimental Pharmacology and Physiology, 27(8), 639-641. doi:10.1046/j.1440-1681.2000.03301.x
Zuccala, A., Cinotti, G. A., Losito, A., Maggiore, Q., Mallamaci, F., Maschio, G., . . . Zucchelli, P. (1999). Renal insufficiency secondary to vascular damage: Is hypertension the only cause? Giornale Italiano di Nefrologia, 16(2), 199-209. 
Zucchelli, P. (2000). The careful correction of renal insufficiency abnormalities: early is good. Nephrol Dial Transplant, 15 Suppl 2, 2-6. doi:10.1093/ndt/15.suppl_1.2
Zychma, M. J., Gumprecht, J., Grzeszczak, W., & Zukowska-Szczechowska, E. (2002). Methylenetetrahydrofolate reductase gene C677T polymorphism, plasma homocysteine and folate in end-stage renal disease dialysis and non-dialysis patients. Nephron, 92(1), 235-239. doi:10.1159/000064458